0001144204-18-053676.txt : 20181012 0001144204-18-053676.hdr.sgml : 20181012 20181012170309 ACCESSION NUMBER: 0001144204-18-053676 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20181012 DATE AS OF CHANGE: 20181012 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACETO CORP CENTRAL INDEX KEY: 0000002034 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 111720520 STATE OF INCORPORATION: NY FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-04217 FILM NUMBER: 181120756 BUSINESS ADDRESS: STREET 1: 4 TRI HARBOR COURT CITY: PORT WASHINGTON STATE: NY ZIP: 11050 BUSINESS PHONE: 5166276000 MAIL ADDRESS: STREET 1: 4 TRI HARBOR COURT CITY: PORT WASHINGTON STATE: NY ZIP: 11050 FORMER COMPANY: FORMER CONFORMED NAME: ACETO CHEMICAL CO INC DATE OF NAME CHANGE: 19851203 10-Q/A 1 tv504330_10qa.htm 10-Q/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q-A

(Amendment No. 1)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2018

Commission file number 000-04217

 

ACETO CORPORATION

(Exact name of registrant as specified in its charter)

  

New York   11-1720520
(State or other jurisdiction of
incorporation or organization)		   (I.R.S. Employer Identification
Number)
     
4 Tri Harbor Court, Port Washington, NY 11050
(Address of principal executive offices) (Zip Code)

 

(516) 627-6000

(Registrant's telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every interactive data file required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act. Check one:

 

Large accelerated filer x   Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if a smaller reporting company)   Smaller reporting company ¨
      Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes ¨ No x

 

The registrant had 30,788,044 shares of common stock outstanding as of May 1, 2018.

 

 

 

 

  

Explanatory Note

(all dollar amounts in this Explanatory Note are expressed in thousands)

 

Aceto Corporation (the “Company”) is filing this Amendment No. 1 (“Amendment No. 1”) to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, which was filed with the Securities and Exchange Commission (“SEC”) on May 7, 2018 (the “Original Filing”), to amend and restate the Company’s unaudited consolidated condensed financial statements and related notes for the three and nine months ended March 31, 2018 and 2017, as discussed below and in Notes 2 and 12 to the accompanying restated consolidated condensed financial statements, as well as to amend certain other Items within the Original Filing as listed in “Items Amended in this Filing” below, as a result of the restatement of the Company’s consolidated condensed financial statements. Certain reclassifications between trade receivables and accrued expenses to the June 30, 2017 consolidated balance sheet, which have been reflected in the Company’s Annual Report on Form 10-K for the year ended June 30, 2018 are not reflected in the June 30, 2017 consolidated balance sheet presented herein.

 

Background of the Restatement

 

On September 26, 2018, the Audit Committee (the “Audit Committee”) of the Board of Directors of the Company, in consultation with management and the Company's independent registered public accounting firm, BDO USA, LLP (“BDO”), determined that the Company’s unaudited consolidated condensed financial statements for the three and nine months ended March 31, 2018 (the “Relevant Financial Statements”) incorrectly accounted for a valuation allowance related to deferred tax assets and should be restated to reflect this allowance (the “Restatement”). This incorrect valuation allowance has no effect on the Company's cash position or operating expenses and is solely related to the appropriate timing of the recording of a valuation allowance reserved against U.S. deferred tax assets.

 

At the time of the March 31, 2018 Form 10-Q filing, the Company believed that the carrying value of its deferred tax assets was appropriate based on its view that it was more likely than not that this deferred tax asset would be realized in future periods. In preparing its consolidated financial statements for the year ended June 30, 2018, the Company determined, in consultation with BDO, based on management's review of current and historical performance, internal projections and industry data and applicable accounting literature, that it should recognize a valuation allowance equal to the entire carrying value of the Company’s U.S. deferred tax assets. However, upon further review of the negative and positive objective evidence and applicable accounting literature, the Company determined, in consultation with BDO, that a full valuation allowance on domestic net deferred tax assets should have been recorded as of the end of its third fiscal quarter rather than as of the end of its fourth fiscal quarter. As a result, the Company has determined to record a valuation allowance of approximately $71,350 on its U.S. deferred tax assets at March 31, 2018.

 

The impact of this Restatement on the Company’s consolidated statements of operations for the three and nine months ended March 31, 2018 is to increase income tax expense and net loss by approximately $71,350.

 

   As reported   Adjustment   As restated 
For the quarter ended March 31, 2018            
Loss before income taxes  $(263,037)  $-   $(263,037)
Income tax (benefit) provision   (66,402)   71,350    4,948 
Net loss   (196,635)   (71,350)   (267,985)
Loss per diluted share  $(5.57)  $(2.02)  $(7.59)

 

   As reported   Adjustment   As restated 
For the nine months ended March 31, 2018      $     
Loss before income taxes  $(261,398)   -   $(261,398)
                
Income tax (benefit) provision   (51,353)   71,350    19,997 
Net loss   (210,045)   (71,350)   (281,395)
Loss per diluted share  $(5.97)  $(2.03)  $(8.00)

 

For additional information regarding the impact of the Restatement on the Company’s financial statements, see Note 2 of the notes to the Company’s consolidated financial statements.

 

 2 

 

 

On September 26, 2018, the Audit Committee concluded that the Relevant Financial Statements and related disclosures included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, should no longer be relied upon. This Amendment No. 1 reflects the Restatement. The Restatement has no effect on the Company’s consolidated balance sheet as of June 30, 2018 and consolidated statement of operations for the year ended June 30, 2018, which financial statements were filed on September 28, 2018 with the Company’s Annual Report on Form 10-K for the year ended June 30, 2018. The Annual Report reflected the results of the Restatement in Note 20 to the Company’s consolidated financial statements, entitled “Unaudited Quarterly Financial Data.”

 

Internal Control Considerations

 

The Company’s management determined that there was a control deficiency in its internal control that constitutes a material weakness, as discussed in Part I — Item 4 of this Amendment No. 1. A material weakness is a deficiency, or combination of control deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim consolidated financial statements will not be prevented or detected on a timely basis.

 

Items Amended in This Filing

 

For the convenience of the reader, this Amendment No. 1 sets forth the Original Filing, as modified and superseded where necessary to reflect the Restatement. The following items have been amended as a result of, and to reflect, the Restatement:

 

·Part I — Item 1. Financial Statements;

 

·Part I — Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations; and

 

·Part I — Item 4. Controls and Procedures.

 

In accordance with applicable SEC rules, this Amendment No. 1 includes new certifications required by Rule 13a-14 under the Securities and Exchange Act of 1934 (“Exchange Act”) from our Chief Executive Officer and Chief Financial Officer dated as of the date of filing of this Amendment No. 1.

 

Except for the items noted above, no other information included in the Original Filing is being amended or updated by this Amendment No. 1. This Amendment No. 1 continues to describe the conditions as of the date of the Original Filing, and, except as contained herein, the Company has not updated or modified the disclosures contained in the Original Filing. Accordingly, this Amendment No. 1 should be read in conjunction with the Company’s filings made with the SEC subsequent to the filing of the Original Filing, including the Company’s Annual Report on Form 10-K.

 

 3 

 

 

ACETO CORPORATION AND SUBSIDIARIES

QUARTERLY REPORT ON FORM 10Q-A FOR THE PERIOD ENDED MARCH 31, 2018

 

TABLE OF CONTENTS

 

PART I.  FINANCIAL INFORMATION 6
     
Item 1. Financial Statements 6
     
  Condensed Consolidated Balance Sheets – March 31, 2018 (as restated) (unaudited) and June 30, 2017 6
     
  Unaudited Condensed Consolidated Statements of Operations – Nine Months Ended March 31,  2018 (as restated) and 2017 7
     
  Unaudited Condensed Consolidated Statements of Operations – Three Months Ended March 31,  2018 (as restated) and 2017 8
     
  Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) –Three and Nine Months Ended March 31, 2018 (as restated) and 2017 9
     
  Unaudited Condensed Consolidated Statements of Cash Flows – Nine Months Ended March 31,   2018 (as restated) and 2017 10
     
  Notes to Unaudited Condensed Consolidated Financial Statements   11
     
  Report of Independent Registered Public Accounting Firm 30
     
Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations 31
     
Item 3.   Quantitative and Qualitative Disclosures about Market Risk 49
     
Item 4.   Controls and Procedures 50
     
PART II.  OTHER INFORMATION 50
     
Item 1. Legal Proceedings 50
     
Item 1A. Risk Factors 51
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 53
     
Item 3. Defaults Upon Senior Securities 53
     
Item 4. Mine Safety Disclosures 53
     
Item 5. Other Information 53
     
Item 6. Exhibits 54
     
Signatures   55
     
Exhibits    

 

 4 

 

 

CAUTIONARY STATEMENT RELATING TO THE SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

 

This Quarterly Report on Form 10-Q/A contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking statements contained in this Quarterly Report may not occur. Generally, these statements relate to our business plans or strategies, projected or anticipated benefits or other consequences of our plans or strategies, financing plans, projected or anticipated benefits from acquisitions that we may make, or projections involving anticipated revenues, earnings or other aspects of our operating results or financial position, and the outcome of any contingencies. Any such forward-looking statements are based on current expectations, estimates and projections of management. We intend for these forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements. Words such as “may,” “will,” “expect,” “believe,” “anticipate,” “project,” “plan,” “intend,” “estimate,” and “continue,” and their opposites and similar expressions are intended to identify forward-looking statements. We caution you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond our control, that may influence the accuracy of the statements and the projections upon which the statements are based. Factors that may affect our results include, but are not limited to the risks and uncertainties discussed in Item 1A of this Quarterly Report on Form 10-Q/A, the Company’s Annual Report on Form 10-K for the year ended June 30, 2017, as amended and other filings.

 

Any one or more of these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking statements made by us ultimately prove to be accurate. Our actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.

 

 5 

 

 

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

 

ACETO CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except per-share amounts)

 

  

March 31,

2018 (as
restated)

  

June 30,

2017

 
   (unaudited)     
ASSETS          
Current assets:          
Cash and cash equivalents  $62,032   $55,680 
Investments   3,059    2,046 
Trade receivables, less allowance for doubtful  accounts (March 31, 2018, $805; June 30, 2017, $485)   260,168    260,889 
Other receivables   15,771    12,066 
Inventory   141,669    136,387 
Prepaid expenses and other current assets   4,942    3,941 
Deferred income tax asset, net   -    546 
Total current assets   487,641    471,555 
           
Property and equipment, net   14,002    10,428 
Property held for sale   6,250    7,152 
Goodwill   1,939    236,970 
Intangible assets, net   241,513    285,081 
Deferred income tax asset, net   -    19,453 
Other assets   9,846    7,546 
           
TOTAL ASSETS  $761,191   $1,038,185 
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current liabilities:          
Current portion of long-term debt  $190,723   $14,466 
Accounts payable   125,083    90,011 
Accrued expenses   119,389    118,328 
Total current liabilities   435,195    222,805 
           
Long-term debt, net   128,697    339,200 
Long-term liabilities   63,623    61,449 
Environmental remediation liability   383    2,339 
Deferred income tax liability   1,261    7,325 
Total liabilities   629,159    633,118 
           
Commitments and contingencies (Note 8)          
           
Shareholders’ equity:          
Preferred stock, 2,000 shares authorized; no shares issued and outstanding   -    - 
Common stock, $.01 par value, 75,000 shares authorized; 30,839 and 30,094 shares issued and outstanding at March 31, 2018 and June 30, 2017, respectively   308    301 
Capital in excess of par value   221,253    214,198 
Retained (deficit) earnings   (91,704)   195,680 
Accumulated other comprehensive income (loss)   2,175    (5,112)
Total shareholders’ equity   132,032    405,067 
           
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY  $761,191   $1,038,185 

 

See accompanying notes to condensed consolidated financial statements and accountants’ review report.

 

 6 

 

 

ACETO CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited and in thousands, except per-share amounts)

 

   Nine months Ended 
   March 31, 
   2018   2017 
   (as restated)     
         
Net sales  $542,482   $443,698 
Cost of sales   440,833    339,735 
Gross profit   101,649    103,963 
           
Selling, general and administrative expenses   87,241    75,614 
Impairment charges   256,266    - 
Research and development expenses   6,208    4,998 
Operating (loss) income   (248,066)   23,351 
           
Other (expense) income:          
Interest expense   (15,443)   (10,223)
Interest and other income, net   2,111    1,230 
    (13,332)   (8,993)
           
(Loss) income before income taxes   (261,398)   14,358 
Income tax provision   19,997    4,949 
Net (loss) income  $(281,395)  $9,409 
           
Basic (loss) income per common share  $(8.00)  $0.30 
Diluted (loss) income per common share  $(8.00)  $0.30 
           
Weighted average shares outstanding:          
Basic   35,162    31,453 
Diluted   35,162    31,792 

 

See accompanying notes to condensed consolidated financial statements and accountants’ review report.

 

 7 

 

 

ACETO CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited and in thousands, except per-share amounts)

 

   Three months Ended 
   March 31, 
   2018   2017 
   (as restated)     
         
Net sales  $185,998   $190,128 
Cost of sales   158,302    147,809 
Gross profit   27,696    42,319 
           
Selling, general and administrative expenses   28,029    26,519 
Impairment charges   256,266    - 
Research and development expenses   2,471    2,607 
Operating (loss) income   (259,070)   13,193 
           
Other (expense) income:          
Interest expense   (5,040)   (5,321)
Interest and other income, net   1,073    640 
    (3,967)   (4,681)
           
(Loss) income before income taxes   (263,037)   8,512 
Income tax provision   4,948    2,924 
Net (loss) income  $(267,985)  $5,588 
           
Basic (loss) income per common share  $(7.59)  $0.16 
Diluted (loss) income per common share  $(7.59)  $0.16 
           
Weighted average shares outstanding:          
Basic   35,304    34,769 
Diluted   35,304    35,121 

 

See accompanying notes to condensed consolidated financial statements and accountants’ review report.

 

 8 

 

 

ACETO CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(unaudited and in thousands)

 

  

Nine months Ended

March 31,

  

Three months Ended

March 31,

 
   2018   2017   2018   2017 
   (as restated)       (as restated)     
                 
Net (loss) income  $(281,395)  $9,409   $(267,985)  $5,588 
                     
Other comprehensive (loss) income:                    
Foreign currency translation adjustments   5,167    (2,201)   1,941    947 
Change in fair value of interest rate swaps   2,120    (249)   1,138    (249)
Comprehensive (loss) income  $(274,108)  $6,959   $(264,906)  $6,286 

 

See accompanying notes to condensed consolidated financial statements and accountants’ review report.

 

 9 

 

 

ACETO CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited and in thousands)

 

  

Nine months Ended

March 31,

 
   2018   2017 
   (as restated)     
Operating activities:          
Net (loss) income  $(281,395)  $9,409 
Adjustments to reconcile net (loss) income to net cash provided by operating activities:          
Depreciation and amortization   24,608    15,301 
Amortization of debt issuance costs and debt discount   4,603    4,355 
Amortization of deferred financing costs   833    300 
Provision for doubtful accounts   305    (18)
Non-cash stock compensation   6,442    5,239 
Deferred income taxes   11,714    627 
Environmental charge   902    903 
Earnings on equity investment in joint venture   (1,990)   (1,558)
Contingent consideration   (2,505)   - 
Impairment charges   256,266    - 
Changes in assets and liabilities:          
 Trade accounts receivable   2,573    (14,839)
Other receivables   (3,662)   1,664 
Inventory   (3,102)   (3,778)
Prepaid expenses and other current assets   (927)   (424)
Other assets   (2,202)   215 
Accounts payable   34,224    18,857 
Accrued expenses and other liabilities   9,728    (4,702)
Net cash provided by operating activities   56,415    31,551 
           
Investing activities:          
 Payment for net assets of business acquired   -    (270,000)
 Purchases of investments   (2,880)   (1,824)
 Sales of investments   1,867    775 
 Payments for intangible assets   (779)   (3,077)
 Purchases of property and equipment, net   (4,677)   (1,386)
Net cash used in investing activities   (6,469)   (275,512)
           
Financing activities:          
 Payment of cash dividends   (5,924)   (5,944)
 Proceeds from exercise of stock options   595    550 
 Excess tax benefit on stock option exercises and restricted stock   -    551 
 Borrowings of bank loans   -    265,000 
 Payment for deferred financing costs   -    (5,407)
 Repayment of bank loans   (39,398)   (16,898)
Net cash (used in) provided by financing activities   (44,727)   237,852 
           
Effect of exchange rate changes on cash   1,133    (757)
           
Net increase (decrease) in cash   6,352    (6,866)
Cash and cash equivalents at beginning of period   55,680    66,828 
Cash and cash equivalents at end of period  $62,032   $59,962 

Non-Cash Item

 

In connection with the acquisition of certain products and related assets of entities referred to herein as Citron and Lucid, approximately 5,122 shares of Aceto common stock with a fair value of $90,400, to be issued beginning on December 21, 2019, is a non-cash item and is excluded from the Condensed Consolidated Statement of Cash Flows during the nine months ended March 31, 2017.

 

See accompanying notes to condensed consolidated financial statements and accountants’ review report

 

 10 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

(1) Basis of Presentation

 

The condensed consolidated financial statements of Aceto Corporation and subsidiaries (“Aceto” or the “Company”) included herein have been prepared by the Company and reflect all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for all periods presented. Interim results are not necessarily indicative of results which may be achieved for the full year.

 

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements and the disclosure of contingent assets and liabilities at the date of the financial statements. These judgments can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition; allowance for doubtful accounts; inventory; goodwill and other indefinite-life intangible assets; long-lived assets; environmental matters and other contingencies; income taxes; stock-based compensation; and purchase price allocation.

 

These condensed consolidated financial statements do not include all disclosures associated with consolidated financial statements prepared in accordance with GAAP. Accordingly, these statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended June 30, 2017, as amended (the “2017 10-K”).

 

(2) Restatement of Previously Issued Financial Statements

 

As previously disclosed, the Company determined that it incorrectly accounted for a valuation allowance related to U.S. net deferred tax assets. At the time of the March 31, 2018 Form 10-Q filing, the Company believed that the carrying value of its deferred tax assets was appropriate based on its view that it was more likely than not that this deferred tax asset would be realized in future periods. In preparing its consolidated financial statements for the year ended June 30, 2018, the Company determined, in consultation with BDO USA, LLP (“BDO”), based on management's review of current and historical performance, internal projections and industry data and applicable accounting literature, that it should recognize a valuation allowance equal to the entire carrying value of the Company’s U.S. deferred tax assets. However, upon further review of the negative and positive objective evidence and applicable accounting literature, the Company determined, in consultation with BDO, that a full valuation allowance on domestic net deferred tax assets should have been recorded as of the end of its third fiscal quarter rather than as of the end of its fourth fiscal quarter. As a result, the Company has determined to record a valuation allowance of approximately $71,350 on its U.S. deferred tax assets at March 31, 2018.

 

As a result, the Company is restating its condensed consolidated financial statements for the three and nine months ended March 31, 2018. The following financial tables reconcile the previously reported amounts to the restated amounts for each condensed consolidated financial statement.

 

The table below sets forth the condensed consolidated balance sheet, including the balances originally reported, corrections and the as restated balances for March 31, 2018 (in thousands):

 

 

   As Reported   Adjustment   As Restated 
Assets               
Deferred income tax asset, net  $70,089   $(70,089)  $- 
Total assets   831,280    (70,089)   761,191 
Liabilities and Shareholders’ Equity               
Deferred income tax liability   -    1,261    1,261 
Total liabilities   627,898    1,261    629,159 
Retained deficit   (20,354)   (71,350)   (91,704)
Total shareholders’ equity   203,382    (71,350)   132,032 
Total liabilities and shareholders’ equity  $831,280   $(70,089)  $761,191 

 

 11 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

The tables below set forth the condensed consolidated statements of loss, including the balances originally reported, corrections and the as restated balances for the three and nine months ended March 31, 2018 (in thousands, except per share data):

 

   As Reported   Adjustment   As Restated 
Three months ended March 31, 2018               
Income tax (benefit) provision  $(66,402)  $71,350   $4,948 
Net loss  $(196,635)  $(71,350)  $(267,985)
Basic loss per common share  $(5.57)  $(2.02)  $(7.59)
Diluted loss per common share  $(5.57)  $(2.02)  $(7.59)

 

   As Reported   Adjustment   As Restated 
Nine months ended March 31, 2018               
Income tax (benefit) provision  $(51,353)  $71,350   $19,997 
Net loss  $(210,045)  $(71,350)  $(281,395)
Basic loss per common share  $(5.97)  $(2.03)  $(8.00)
Diluted loss per common share  $(5.97)  $(2.03)  $(8.00)

 

The tables below set forth the condensed consolidated statements of comprehensive income, including the balances originally reported, corrections and the as restated balances for the three and nine months ended March 31, 2018 (in thousands):

 

   As Reported   Adjustment   As Restated 
Three months ended March 31, 2018               
Net loss  $(196,635)  $(71,350)  $(267,985)
Comprehensive loss  $(193,556)  $(71,350)  $(264,906)

 

   As Reported   Adjustment   As Restated 
Nine months ended March 31, 2018               
Net loss  $(210,045)  $(71,350)  $(281,395)
Comprehensive loss  $(202,758)  $(71,350)  $(274,108)

 

The table below sets forth the condensed consolidated statements of cash flows from operating activities, including the balances originally reported, corrections and the as restated balances for the nine months ended March 31, 2018 (in thousands):

 

   As Reported   Adjustment   As Restated 
Nine months ended March 31, 2018               
Net loss  $(210,045)  $(71,350)  $(281,395)
Deferred income taxes   (80,207)   91,921    11,714 
Accrued expenses and other liabilities   30,299    (20,571)   9,728 
Net cash provided by operating activities   56,415    -    56,415 

 

As indicated above, there was no impact on net cash provided by operating activities as the valuation allowance is a non-cash item. In addition, the restatement had no impact on cash flows from investing activities or financing activities.

 

 12 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

(3) Business Combinations

 

On December 21, 2016, wholly owned subsidiaries of Rising Pharmaceuticals, Inc. (“Rising”), a wholly owned subsidiary of Aceto, completed the acquisition of certain generic products and related assets of entities formerly known as Citron Pharma LLC (“Citron”) and its affiliate Lucid Pharma LLC (“Lucid”). Citron was a privately-held New Jersey-based pharmaceutical company focused on developing and marketing generic pharmaceutical products in partnership with leading generic pharmaceutical manufacturers based in India and the United States. Lucid was a privately-held New Jersey-based generic pharmaceutical distributor specializing in providing cost-effective products to various agencies of the U.S. Federal Government including the Veterans Administration and the Defense Logistics Agency. Lucid serviced 18 national contracts with the Federal Government, nearly all of which had 5-year terms.

 

Aceto and Citron possess complementary asset-light business models, drug development and manufacturing partnerships and product portfolios. The Company believes consistent with its strategy of expanding Rising’s portfolio of finished dosage form generic products through product development partnerships and acquisitions of late stage assets, abbreviated new drug applications (“ANDAs”) and complementary generic drug businesses, this transaction significantly expanded its roster of commercialized products and pipeline of products under development. In addition, the Company believes that this product acquisition greatly enhanced its size and stature within the generic pharmaceutical industry, expanded its partnership network and offers the Company opportunities to realize meaningful cost and tax efficiencies.

 

At closing, Aceto paid the sellers $270,000 in cash, committed to make a $50,000 unsecured deferred payment that will bear interest at a rate of 5% per annum to the sellers on December 21, 2021 and agreed to issue 5,122 shares of Aceto common stock beginning on December 21, 2019. The product purchase agreement also provides the sellers with a 5-year potential earn-out of up to an additional $50,000 in cash, based on the financial performance of four pre-specified pipeline products that are currently in development. In the third quarter of fiscal 2018, the Company reversed $2,505 of contingent consideration due to management’s evaluation and assessment of the financial performance of these products. As of March 31, 2018, the Company accrued $663 related to this contingent consideration.

 

Rising formed two subsidiaries to consummate the product acquisition – Rising Health, LLC (which acquired certain products and related assets of Citron) and Acetris Health, LLC (which acquired certain products and related assets of Lucid).

 

 13 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

(4) Stock-Based Compensation

 

Under the Aceto Corporation 2015 Equity Participation Plan (the “2015 Plan”), grants of stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards (“Stock Awards”) may be offered to employees, non-employee directors, consultants and advisors of the Company, including the chief executive officer, chief financial officer and other named executive officers. The maximum number of shares of common stock of the Company that may be issued pursuant to Stock Awards granted under the 2015 Plan will not exceed, in the aggregate, 4,250 shares. Performance-based awards may be granted, vested and paid based on the attainment of specified performance goals.

 

Under the Aceto Corporation 2010 Equity Participation Plan (as amended and restated in 2012, the “2010 Plan”), grants of stock options, restricted stock, restricted stock units, stock appreciation rights, and stock bonuses may be made to employees, non-employee directors and consultants of the Company. The maximum number of shares of common stock of the Company that may be issued pursuant to awards granted under the 2010 Plan will not exceed, in the aggregate, 5,250 shares. In addition, restricted stock may be granted to an eligible participant in lieu of a portion of any annual cash bonus earned by such participant. Such award may include additional shares of restricted stock (premium shares) greater than the portion of bonus paid in restricted stock. The restricted stock award is vested at issuance and the restrictions lapse ratably over a period of years as determined by the Board of Directors, generally three years. The premium shares vest when all the restrictions lapse, provided that the participant remains employed by the Company at that time.

 

During the nine months ended March 31, 2018, the Company granted 490 shares of restricted common stock to its employees that vest over three years and 27 shares of restricted stock to its non-employee directors, which vest over approximately one year. In addition, the Company also issued a target grant of 203 performance-vested restricted stock units, which grant could be as much as 355 units if certain performance criteria and market conditions are met. These performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.

 

During the year ended June 30, 2017, the Company granted 277 shares of restricted common stock to its employees that vest over three years and 22 shares of restricted common stock to its non-employee directors, which vest over approximately one year as well as 42 restricted stock units that have varying vest dates through July 2017. In addition, the Company also issued a target grant of 160 performance-vested restricted stock units, which grant could be as much as 280 if certain performance criteria and market conditions are met. These performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.

 

For the three and nine months ended March 31, 2018, the Company recorded stock-based compensation expense of approximately $1,931 and $6,426, respectively, related to restricted common stock and restricted stock units. Included in the $6,426 for the nine months ended March 31, 2018 is $431 in stock-based compensation expense associated with the retirement of a Chief Financial Officer in March 2018 and $2,017 in stock-based compensation expense associated with the separation of the Company’s former Chief Executive Officer in September 2017. For the three and nine months ended March 31, 2017, the Company recorded stock-based compensation expense of approximately $1,506 and $5,213, respectively, related to restricted common stock and restricted stock units. As of March 31, 2018, the total unrecognized stock-based compensation cost is approximately $7,864.

 

 14 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

(5) Capital Stock

 

On May 3, 2018, the Company’s Board of Directors declared a quarterly dividend of $0.01 per share which will be paid on June 22, 2018 to shareholders of record as of June 8, 2018.

 

On February 1, 2018, the Company’s Board of Directors declared a regular quarterly dividend of $0.065 per share which was paid on March 23, 2018 to shareholders of record as of March 9, 2018.

 

On December 7, 2017, the Company's Board of Directors declared a regular quarterly dividend of $0.065 per share which was paid on December 28, 2017 to shareholders of record as of December 18, 2017.

 

On August 24, 2017, the Company's Board of Directors declared a regular quarterly dividend of $0.065 per share which was paid on September 21, 2017 to shareholders of record as of September 8, 2017.

 

On May 4, 2017, the Board of Directors of the Company authorized the continuation of the Company’s stock repurchase program, expiring in May 2020. Under the stock repurchase program, the Company is authorized to purchase up to 5,000 shares of common stock in open market or private transactions, at prices not to exceed the market value of the common stock at the time of such purchase.

 

The Company is authorized to issue 75,000 shares of Common Stock and 2,000 shares of Preferred Stock. The Board of Directors has authority under the Company’s Restated Certificate of Incorporation to issue shares of preferred stock with voting and other relative rights to be determined by the Board of Directors.

 

(6) Net (Loss) Income Per Common Share

 

Basic income per common share is based on the weighted average number of common shares outstanding during the period. Diluted income per common share includes the dilutive effect of potential common shares outstanding. The following table sets forth the reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding:

 

  

Nine Months Ended

March 31,

  

Three Months Ended

March 31,

 
   2018   2017   2018   2017 
                 
Weighted average shares outstanding   35,162    31,453    35,304    34,769 
Dilutive effect of stock options and restricted stock awards and units   -    339    -    352 
                     
Diluted weighted average shares outstanding   35,162    31,792    35,304    35,121 

 

The effect of approximately 100 and 181 common equivalent shares for the three and nine months ended March 31, 2018, respectively, was excluded from the diluted weighted average shares outstanding due to a net loss for the periods. There were 170 and 143 common equivalent shares outstanding for the three and nine months ended March 31, 2018, respectively, that were not included in the calculation of diluted net income per common share because their effect would have been anti-dilutive.

 

The weighted average shares outstanding for the three and nine months ended March 31, 2018 includes the effect of 5,122 shares to be issued beginning on December 21, 2019 in connection with the acquisition of certain products and related assets from Citron and Lucid (see Note 3).

 

The Convertible Senior Notes (see Note 7) will only be included in the dilutive net income per share calculations using the treasury stock method during periods in which the average market price of Aceto’s common stock is above the applicable conversion price of the Convertible Senior Notes, or $33.215 per share, and the impact would not be anti-dilutive.

 

 15 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

(7) Debt

 

Long-term debt

 

   March 31,
2018		  

June 30,

2017

 
         
Convertible Senior Notes, net  $126,279   $121,676 
Revolving Bank Loans   62,000    90,000 
Term Bank Loans   128,526    139,227 
Mortgage   2,615    2,763 
    319,420    353,666 
Less current portion   190,723    14,466 
   $128,697   $339,200 

 

Convertible Senior Notes

 

In November 2015, Aceto offered $125,000 aggregate principal amount of Convertible Senior Notes due 2020 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In addition, Aceto granted the initial purchasers for the offering an option to purchase up to an additional $18,750 aggregate principal amount pursuant to the initial purchasers’ option to purchase additional Notes, which was exercised in November 2015. Therefore, the total offering was $143,750 aggregate principal amount. The Notes are unsecured obligations of Aceto and rank senior in right of payment to any of Aceto’s subordinated indebtedness, equal in right of payment to all of Aceto’s unsecured indebtedness that is not subordinated, effectively junior in right of payment to any of Aceto’s secured indebtedness to the extent of the value of the assets securing such indebtedness and structurally junior in right of payment to all indebtedness and other liabilities (including trade payables) of Aceto’s subsidiaries. The Notes will be convertible into cash, shares of Aceto common stock or a combination thereof, at Aceto’s election, upon the satisfaction of specified conditions and during certain periods. The Notes will mature in November 2020. The Notes pay 2.0% interest semi-annually in arrears on May 1 and November 1 of each year, which commenced on May 1, 2016. The Notes are convertible into 4,328 shares of common stock, based on an initial conversion price of $33.215 per share.

 

Holders may convert all or any portion of their notes, in multiples of one thousand dollar principal amount, at their option at any time prior to the close of business on the business day immediately preceding May 1, 2020 only under the following circumstances: (i) during any calendar quarter (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the five consecutive business day period after any five consecutive trading day period (which is referred to as the “measurement period”) in which the trading price per one thousand dollar principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of Aceto’s common stock and the conversion rate on each such trading day; or (iii) upon the occurrence of specified corporate events.

 

Upon conversion by the holders, the Company may elect to settle such conversion in shares of its common stock, cash, or a combination thereof. As a result of its cash conversion option, the Company separately accounted for the value of the embedded conversion option as a debt discount (with an offset to capital in excess of par value). The debt discount is being amortized as additional non-cash interest expense using the effective interest method over the term of the Notes. Debt issuance costs are being amortized as additional non-cash interest expense. The Company presents debt issuance costs as a direct deduction from the carrying value of the debt liability rather than showing the debt issuance costs as a deferred charge on the balance sheet.

 

 16 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

In connection with the offering of the Notes, Aceto entered into privately negotiated convertible note hedge transactions with option counterparties, which are affiliates of certain of the initial purchasers. The convertible note hedge transactions are expected generally to reduce the potential dilution to Aceto’s common stock and/or offset any cash payments Aceto is required to make in excess of the principal amount of converted Notes upon any conversion of Notes. Aceto also entered into privately negotiated warrant transactions with the option counterparties. The warrant transactions could separately have a dilutive effect to the extent that the market price per share of Aceto’s common stock as measured over the applicable valuation period at the maturity of the warrants exceeds the applicable strike price of the warrants. By entering into these transactions with the option counterparties, the Company issued convertible debt and a freestanding “call-spread.”

 

The carrying value of the Notes is as follows:

 

  

March 31,

2018

  

June 30,

2017

 
         
Principal amount  $143,750   $143,750 
Unamortized debt discount   (15,278)   (19,255)
Unamortized debt issuance costs   (2,193)   (2,819)
Net carrying value  $126,279   $121,676 

 

The following table sets forth the components of total “interest expense” related to the Notes recognized in the accompanying consolidated statements of operations for the three and nine months ended March 31:

 

   Nine Months Ended
March 31, 2018		   Three Months Ended
March 31, 2018		 
         
Contractual coupon  $2,127   $709 
Amortization of debt discount   3,977    1,347 
Amortization of debt issuance costs   626    208 
   $6,730   $2,264 

 

Credit Facilities

 

On December 21, 2016 the Company entered into a Second Amended and Restated Credit Agreement (the “A&R Credit Agreement”), with eleven banks, which amended and restated in its entirety the Amended and Restated Credit Agreement, dated as of October 28, 2015, as amended by Amendment No. 1 to Amended and Restated Credit Agreement, dated as of November 10, 2015, and Amendment No. 2 to Amended and Restated Credit Agreement, dated as of August 26, 2016 (collectively, the “First Amended Credit Agreement”). The A&R Credit Agreement increased the aggregate available revolving commitment under the First Amended Credit Agreement from $150,000 to an initial aggregate available revolving commitment of $225,000 (the “Initial Revolving Commitment”). Under the A&R Credit Agreement, the Company may borrow, repay and reborrow from and as of December 21, 2016, to but excluding December 21, 2021 (the “Maturity Date”) provided, that if any of the Notes remain outstanding on the date that is 91 days prior to the maturity date of the Notes (the “2015 Convertible Maturity Date”), then the Maturity Date shall mean the date that is 91 days prior to the 2015 Convertible Maturity Date. The A&R Credit Agreement provides for (i) Eurodollar Loans (as such terms are defined in the A&R Credit Agreement), (ii) ABR Loans (as such terms are defined in the A&R Credit Agreement) or (iii) a combination thereof. As of March 31, 2018, the Company borrowed Revolving Loans (as defined under the A&R Credit Agreement) aggregating $62,000 which loans are Eurodollar Loans at interest rates ranging from 3.57% to 3.63% at March 31, 2018. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company’s senior secured net leverage ratio.

 

 17 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

Under the A&R Credit Agreement, the Company also borrowed $150,000 in term loans (the “Initial Term Loan). Subject to certain conditions, including obtaining commitments from existing or prospective lenders, the Company had the right to increase the amount of the Initial Revolving Commitment (each, a “Revolving Facility Increase” and, together with the Initial Revolving Commitment, the “Revolving Commitment”) and/or the Initial Term Loan in an aggregate amount not to exceed $100,000 pursuant to an incremental loan feature in the A&R Credit Agreement. As of March 31, 2018, the remaining amount outstanding under the Initial Term Loan was $131,250 and was payable as a Eurodollar Loan at an interest rate of 4.05%. The proceeds of the Initial Revolving Commitment and Initial Term Loan were used to partially finance the acquisition of generic products and related assets of Citron and its affiliate Lucid, and pay fees and expenses related thereto. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company’s senior secured net leverage ratio.

 

The Initial Term Loan is payable as to principal in nineteen consecutive, equal quarterly installments of $3,750, which commenced on March 31, 2017 and will continue each March 31, June 30, September 30 and December 31 thereafter. To the extent not previously paid, the final payment on the Term Loan Maturity Date (as defined in the A&R Credit Agreement) shall be in an amount equal to the then outstanding unpaid principal amount of the Initial Term Loan.

 

The A&R Credit Agreement provides that commercial letters of credit shall be issued to provide the primary payment mechanism in connection with the purchase of any materials, goods or services in the ordinary course of business. The Company had no open letters of credit at March 31, 2018 and June 30, 2017.

 

In accordance with generally accepted accounting principles, deferred financing costs associated with the Initial Term Loan are presented as a direct deduction from the carrying value of the debt liability rather than showing the deferred financing costs as a deferred charge on the balance sheet. In addition, deferred financing costs associated with the Revolving Commitment have been recorded as a deferred charge on the balance sheet.

 

The A&R Credit Agreement provides for a security interest in substantially all the personal property of the Company and certain of its subsidiaries. The A&R Credit Agreement contains several financial covenants including, among other things, maintaining a minimum level of debt service and certain leverage ratios. Under the A&R Credit Agreement, the Company and its subsidiaries are also subject to certain restrictive covenants, including, among other things, covenants governing liens, limitations on indebtedness, limitations on guarantees, limitations on sales of assets and sales of receivables, and limitations on loans and investments.

 

On December 13, 2017, the Company entered into a First Amendment to the Second Amended and Restated Credit Agreement (the “2017 Amendment”), which amended the A&R Credit Agreement. The 2017 Amendment, among other things, contained several amendments to the financial covenants in the A&R Credit Agreement.

 

As of March 31, 2018, the Company was in compliance with all of its financial covenants except for the maximum total net leverage ratio and the minimum debt service coverage ratio. On May 3, 2018, the Company entered into a Second Amendment and Waiver to the Second Amended and Restated Credit Agreement (the “2018 Amendment”). The 2018 Amendment, among other things, contains a waiver of any event of default under the A&R Credit Agreement arising as a result of the non-compliance by the Company with the Total Net Leverage Ratio and Debt Service Coverage Ratio financial covenants, in each case, solely for the fiscal quarter ended March 31, 2018. The Amendment also contains several amendments to the A&R Credit Agreement including, among other things, (a) reducing the available revolving commitment thereunder to $100,000, and (b) during the period commencing on the closing of the 2018 Amendment and ending on the date the Company demonstrates compliance with each financial covenant set forth in the A&R Credit Agreement for the fiscal quarter ending June 30, 2018 (the “Limitation Period”; provided that if the Company is not in compliance with any of the financial covenants set forth in the A&R Credit Agreement for the fiscal quarter ending June 30, 2018, then the Limitation Period shall continue indefinitely): (i) fixing the applicable margin with respect to all loans under the A&R Credit Agreement to the highest level provided under the A&R Credit Agreement, which is 1.50% in the case of ABR Loans (as defined in the A&R Credit Agreement) and 2.50% in the case of Eurodollar Loans (as defined in the A&R Credit Agreement), (ii) fixing the commitment fee on the undrawn revolving commitments under the A&R Credit Agreement to the highest level provided under the A&R Credit Agreement which is 0.40% per annum, (iii) requiring the prior written consent of the Required Lenders (as defined in the A&R Credit Agreement) as a condition precedent to the lenders extending any Loans (as defined in the A&R Credit Agreement) or the issuing banks issuing, amending, renewing or extending any Letter of Credit (as defined in the A&R Credit Agreement), (iv) restricting the amount of dividends or distributions the Company may make to its shareholders to no more than $0.01 per share for the fiscal quarter ending on June 30, 2018 and, during the Limitation Period, restricting the Company from making any other dividends or distributions to its shareholders thereafter and (v) restricting the incurrence of certain indebtedness, limiting acquisitions and other investments and imposing certain other restrictions.

 

 18 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

In accordance with GAAP, we have classified the indebtedness outstanding under the Company’s credit facility as a current liability as of March 31, 2018. This differs from the customary treatment heretofore applicable to indebtedness outstanding under the Company’s credit facility, in which only the portion of such indebtedness payable within one year from the balance sheet date has been recorded as a current liability.  The waiver that the Company has received from its lenders under the credit facility applies solely to the non-compliance with certain financial covenants as of March 31, 2018 and thus does not waive non-compliance with any financial covenants as of June 30, 2018. It is probable that the Company will not comply with certain financial covenants as of June 30, 2018 in the absence of a material change in the Company’s operating results.  That probability is the factor that has caused the Company to reclassify its indebtedness. The Company believes it will work cooperatively with its lenders over the next 120 days and anticipates that the financial covenants for the June 30, 2018 reporting date will be amended.

 

Mortgage

 

On June 30, 2011, the Company entered into a mortgage payable for $3,947 on its corporate headquarters, in Port Washington, New York. This mortgage payable is secured by the land and building and is being amortized over a period of 20 years. The mortgage payable, which was modified in October 2013, bears interest at 4.92% per annum as of March 31, 2018 and matures on June 30, 2021.

 

(8) Commitments, Contingencies and Other Matters

 

The Company and its subsidiaries are subject to various claims which have arisen in the normal course of business. The Company provides for costs related to contingencies when a loss from such claims is probable and the amount is reasonably determinable. In determining whether it is possible to provide an estimate of loss, or range of possible loss, the Company reviews and evaluates its litigation and regulatory matters on a quarterly basis in light of potentially relevant factual and legal developments. If the Company determines an unfavorable outcome is not probable or reasonably estimable, the Company does not accrue for a potential litigation loss. While the Company has determined that there is a reasonable possibility that a loss has been incurred, no amounts have been recognized in the financial statements, other than what has been discussed below, because the amount of the liability cannot be reasonably estimated at this time.

 

In fiscal years 2011, 2009, 2008 and 2007, the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State had begun administrative proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly contributed to the contamination of the environment and thus believes that, at most, it is a de minimis contributor to the site contamination. Accordingly, the Company believes that the settlement offer is unreasonable. Management believes that the ultimate outcome of this matter will not have a material adverse effect on the Company's financial condition or liquidity.

 

 19 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

The Company has environmental remediation obligations in connection with Arsynco, Inc. (“Arsynco”), a subsidiary formerly involved in manufacturing chemicals located in Carlstadt, New Jersey, which was closed in 1993 and is currently held for sale. Based on continued monitoring of the contamination at the site and the approved plan of remediation, Arsynco received an estimate from an environmental consultant stating that the costs of remediation could be between $21,500 and $23,300. Remediation commenced in fiscal 2010, and as of March 31, 2018 and June 30, 2017, a liability of $4,495 and $8,451, respectively, is included in the accompanying consolidated balance sheets for this matter. For the nine months ended March 31, 2018, the Company recorded an environmental charge of $902, which is included in selling, general and administrative expenses in the accompanying condensed consolidated statement of operations for the nine months ended March 31, 2018. In accordance with GAAP, management believes that the majority of costs incurred to remediate the site will be capitalized in preparing the property which is currently classified as held for sale. An estimate of the fair value of the property has been determined by a third party real estate professional and supports the assumption that the expected fair value after the remediation is in excess of the amount required to be capitalized. However, these matters, if resolved in a manner different from those assumed in current estimates, could have a material adverse effect on the Company’s financial condition, operating results and cash flows when resolved in a future reporting period.

 

In connection with the environmental remediation obligation for Arsynco, in July 2009, Arsynco entered into a settlement agreement with BASF Corporation (“BASF”), the former owners of the Arsynco property. In accordance with the settlement agreement, BASF paid for a portion of the prior remediation costs and going forward, will co-remediate the property with the Company. The contract requires that BASF pay $550 related to past response costs and pay a proportionate share of the future remediation costs. Accordingly, the Company had recorded a gain of $550 in fiscal 2009. This $550 gain relates to the partial reimbursement of costs of approximately $1,200 that the Company had previously expensed. The Company also recorded an additional receivable from BASF, with an offset against property held for sale, representing its estimated portion of the future remediation costs. The balance of this receivable for future remediation costs as of March 31, 2018 and June 30, 2017 is $2,023 and $3,803, respectively, which is included in the accompanying consolidated balance sheets.

 

In March 2006, Arsynco received notice from the EPA of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for a site described as the Berry’s Creek Study Area (“BCSA”). Arsynco is one of over 150 PRPs which have potential liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. In July 2014, Arsynco received notice from the U.S. Department of Interior (“USDOI”) regarding the USDOI’s intent to perform a Natural Resource Damage (NRD) Assessment at the BCSA. Arsynco has to date declined to participate in the development and performance of the NRD assessment process. Based on prior practice in similar situations, it is possible that the State may assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State (or both) may assert claims against Arsynco for natural resource damages in connection with Berry's Creek; any such claim with respect to Berry's Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the former owners of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et al., Docket No. ESX-L-9868-05 (the "NJDEP Litigation") and were considering impleading Arsynco into the same proceeding. Arsynco entered into an agreement to avoid impleader. Pursuant to the agreement, Arsynco agreed to (1) a tolling period that would not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation; (2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against Arsynco. In July 2015, Arsynco was contacted by an allocation consultant retained by a group of the named PRPs, inviting Arsynco to participate in the allocation among the PRPs’ investigation and remediation costs relating to the BCSA. Arsynco declined that invitation. Since an amount of the liability cannot be reasonably estimated at this time, no accrual is recorded for these potential future costs. The impact of the resolution of this matter on the Company’s results of operations in a particular reporting period is not currently known.

 

A subsidiary of the Company markets certain agricultural protection products which are subject to the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). FIFRA requires that test data be provided to the EPA to register, obtain and maintain approved labels for pesticide products. The EPA requires that follow-on registrants of these products compensate the initial registrant for the cost of producing the necessary test data on a basis prescribed in the FIFRA regulations. Follow-on registrants do not themselves generate or contract for the data. However, when FIFRA requirements mandate that new test data be generated to enable all registrants to continue marketing a pesticide product, often both the initial and follow-on registrants establish a task force to jointly undertake the testing effort. The Company is presently a member of several such task force groups, which requires payments for such memberships. In addition, in connection with our agricultural protection business, the Company plans to acquire product registrations and related data filed with the United States Environmental Protection Agency to support such registrations and other supporting data for several products. The acquisition of these product registrations and related data filed with the United States Environmental Protection Agency as well as payments to various task force groups could approximate $2,299 through the remainder of fiscal 2018.

 

 20 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

The Company has been notified by the U.S. government that 11 generic drug products it acquired through its Acetris Health subsidiary in a product purchase agreement with Lucid are not in compliance with the federal Trade Agreement Act (“TAA”) country-of-origin provisions of a clause contained in the government supply contracts acquired from Lucid (the “TAA Notification”). The 11 finished dosage form products purchased by the U.S. government are manufactured by Aurolife Pharma LLC which is located in Dayton, New Jersey using APIs sourced from India. In conjunction with this finding, the U.S. Department of Veterans Affairs (“VA”) requested that Aceto supply new TAA-compliant sources for the referenced products by March 9, 2018 and supply new TAA-compliant drugs to the government purchasers under the contracts by March 26, 2018. The Company was not able to meet these deadlines and thereafter Acetris and the government entered into agreements that provided for a no-cost termination of each of the 11 supply contracts.

 

Under current longstanding law, the government, under the Buy America Act, is permitted to buy domestic end products, including commercial off-the-shelf (“COTS”) products like generic drugs that are manufactured in the U.S. even if their components are not all manufactured in the US. The Company believes that the government was and is permitted to buy Acetris’ products, because they are COTS items manufactured in the U.S. As a result, the Company has disputed the determination that the 11 products sold pursuant to novated contracts with the VA originate in India rather than the United States and has appealed the decision that it is not currently compliant with contract sourcing requirements. To further pursue remedies, Aceto has asserted an indemnification claim against the sellers under the product purchase agreement dated December 21, 2016. In addition, the U.S. Defense Logistics Agency, by letter dated April 25, 2018 to Acetris, requested that Acetris seek a ruling from U.S. Customs and Border Protection that seven products specified therein, each of which have APIs sourced from India, are TAA compliant.

 

In March 2018, Sigmapharm Laboratories, LLC (“SigmaPharm”) commenced an action against Rising and the Company in the United States District Court for the Eastern District of Pennsylvania.  The complaint arises out of an agreement, effective as of June 22, 2006 (the “SigmaPharm Agreement”), pursuant to which SigmaPharm agreed to supply certain generic pharmaceutical products (the “Products”) to Rising, and Rising in turn agreed to market and distribute the Products in the United States and pay SigmaPharm a share of the profits pursuant to a formula specified in the Agreement.  The complaint alleges that Rising and Aceto breached the Agreement by failing to pay or timely make payments due under the Agreement and to disclose certain information to SigmaPharm.  The complaint seeks, among other relief, a declaration that the Agreement has been terminated and that SigmaPharm has exclusive marketing and distribution rights to the Products; injunctive relief; and an unspecified amount of damages.  The Company intends to vigorously defend the action and assert counterclaims against SigmaPharm in the course of this litigation.

 

(9) Fair Value Measurements

 

GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly fashion between market participants at the measurement date. GAAP establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s assumptions (unobservable inputs). The hierarchy consists of three levels:

 

Level 1 – Quoted market prices in active markets for identical assets or liabilities;

  

Level 2 – Inputs other than Level 1 inputs that are either directly or indirectly observable; and

 

 21 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

Level 3 – Unobservable inputs that are not corroborated by market data.

 

On a recurring basis, Aceto measures at fair value certain financial assets and liabilities, which consist of cash equivalents, investments and foreign currency contracts. The Company classifies cash equivalents and investments within Level 1 if quoted prices are available in active markets. Level 1 assets include instruments valued based on quoted market prices in active markets which generally include corporate equity securities publicly traded on major exchanges. Time deposits are very short-term in nature and are accordingly valued at cost plus accrued interest, which approximates fair value, and are classified within Level 2 of the valuation hierarchy. The Company uses foreign currency futures contracts to minimize the risk caused by foreign currency fluctuation on its foreign currency receivables and payables by purchasing futures with one of its financial institutions. Futures are traded on regulated U.S. and international exchanges and represent commitments to purchase or sell a foreign currency at a future date and at a specific price. Aceto’s foreign currency derivative contracts are classified within Level 2 as the fair value of these hedges is primarily based on observable futures foreign exchange rates. At March 31, 2018, the Company had foreign currency contracts outstanding that had a notional amount of $62,350. Unrealized (losses) gains on hedging activities for the three and nine months ended March 31, 2018 was ($34) and $227, respectively. Unrealized gains (losses) on hedging activities for the three and nine months ended March 31, 2017 was $353 and ($230), respectively, and are included in interest and other income, net, in the consolidated statements of operations. The contracts have varying maturities of less than one year.

 

In conjunction with its existing credit agreement (see Note 7), the Company entered an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is December 21, 2021. The remaining notional balance of this derivative as of March 31, 2018 is $87,500. The unrealized gain to date associated with this derivative, which is recorded in accumulated other comprehensive income in the consolidated balance sheet at March 31, 2018, is $1,539. Aceto’s interest rate swaps are classified within Level 2 as the fair value of this hedge is primarily based on observable interest rates.

 

At March 31, 2018, the Company had accrued $752 of contingent consideration, $663 of which related to the acquisition of certain products and related assets of Citron and Lucid, which was completed in December 2016 (see Note 3) and $89 of contingent consideration related to a previously acquired company in France. At June 30, 2017, the Company had accrued $2,952 of contingent consideration, $2,807 of which related to the acquisition of certain products and related assets of Citron and Lucid and $145 of contingent consideration related to a previously acquired company in France. The contingent consideration was calculated using the present value of a probability weighted income approach.

 

The Company accounts for goodwill and intangible assets in accordance with ASC 350, Intangibles – Goodwill and Other (“ASC 350”). ASC 350 requires that goodwill and other intangibles with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value. During the third quarter of fiscal 2018, the Company’s Rising Pharmaceuticals reporting unit (which is part of the Human Health segment) had a decline in actual and forecasted revenue and earnings due to the persistent adverse conditions in the generics market. In addition, as noted above, the Company was notified by the U.S. government that 11 generic drug products it acquired through its Acetris Health subsidiary (part of the Rising reporting unit which is part of the Human Health segment) in a product purchase agreement with an entity formerly known as Lucid Pharma LLC are not in compliance with the federal Trade Agreement Act country-of-origin provisions of a clause contained in the government supply contracts acquired from Lucid. Based on these indicators, the Company determined that it was necessary to perform an interim goodwill impairment analysis at March 31, 2018 for its Rising reporting unit. The Company elected to early adopt Accounting Standards Update (“ASU”) 2017-04, Intangibles- Goodwill and Other (Topic 350), during the third quarter of fiscal 2018 which eliminated the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, the amount of an impairment charge is recognized if the carrying amount of a reporting unit is greater than its fair value. The fair value of the Rising reporting unit was estimated using many assumptions and estimates and a market participant approach that directly impacts the results of the testing. In making these assumptions and estimates, the Company used industry accepted valuation models and set criteria that were reviewed and approved by various levels of management. Accordingly, with respect to the third quarter of fiscal 2018, the Company recognized a pre-tax non-cash goodwill impairment charge of $235,110 related to the Rising reporting unit.

 

 22 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

Long-lived assets and certain identifiable intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  If it is determined such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization periods, their carrying values are reduced to estimated fair value.  Measurements based on undiscounted cash flows are Level 3 inputs.  As noted above, during the third quarter of fiscal 2018, the Company’s Rising Pharmaceuticals subsidiary had a decline in actual and forecasted revenue and earnings and therefore the Company performed an impairment test on the related intangibles. The projected undiscounted cash flows for certain intangibles were determined to be less than the carrying value, and as a result, the Company recognized an impairment charge of $5,745 in the third quarter of fiscal 2018. Additionally, as noted above, the Company was notified by the U.S. government that 11 generic drug products it acquired through its Acetris Health subsidiary in a product purchase agreement with an entity formerly known as Lucid Pharma LLC are not in compliance with the federal Trade Agreement Act country-of-origin provisions of a clause contained in the government supply contracts acquired from Lucid. Based on this, the Company performed an impairment test on the related intangible asset and recognized an impairment charge of $15,411 on the customer relationships intangible asset in the third quarter of fiscal 2018.

 

The total impairment charges for goodwill and intangibles recorded in the third quarter of fiscal 2018 was $256,266, all of which related to the Rising reporting unit which is part of the Human Health segment.

 

In connection with the acquisition of certain products and related assets of Citron and Lucid (see Note 3), the Company will issue 5,122 shares of Aceto common stock beginning on December 21, 2019. The preliminary fair value of the future issuance of these shares was determined to be $90,400 at the time of the product acquisition after taking into effect that the shares won’t be issued until the third and fourth anniversary of the closing and the present value calculation of dividends.

 

In November 2015, the Company issued $143,750 aggregate principal amount of Notes (see Note 7). Since Aceto has the option to settle the potential conversion of the Notes in cash, the Company separated the embedded conversion option feature from the debt feature and accounts for each component separately, based on the fair value of the debt component assuming no conversion option. The calculation of the fair value of the debt component required the use of Level 3 inputs, and was determined by calculating the fair value of similar non-convertible debt, using a theoretical borrowing rate of 6.5%. The value of the embedded conversion option was determined using an expected present value technique (income approach) to estimate the fair value of similar non-convertible debt and included utilization of convertible investors’ credit assumptions and high yield bond indices. The Notes approximate a full fair value of $126,600 at March 31, 2018 giving effect to certain factors, including the term of the Notes, current stock price of Aceto stock and effective interest rate.

 

The carrying values of all financial instruments classified as a current asset or current liability are deemed to approximate fair value because of the short maturity of these instruments. The fair values of the Company’s notes receivable and short-term and long-term bank loans were based upon current rates offered for similar financial instruments to the Company.

 

 23 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

The following tables summarize the valuation of the Company’s financial assets and liabilities which were determined by using the following inputs at March 31, 2018 and June 30, 2017:

 

   Fair Value Measurements at March 31, 2018 Using 
   Quoted Prices
in Active
Markets
(Level 1)		   Significant
Other
Observable
Inputs (Level 2)		   Significant
Unobservable
Inputs
 (Level 3)		   Total 
                 
Cash equivalents:                    
 Time deposits   -   $2,746    -   $2,746 
                     
Investments:                    
 Time deposits   -    3,059    -    3,059 
                     
Foreign currency contracts-assets (1)   -    285    -    285 
Foreign currency contracts-liabilities (2)   -    318    -    318 
Derivative asset for interest rate swap (3)   -    1,539    -    1,539 
Contingent consideration (4)   -    -   $752    752 

 

(1)Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.
(2)Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.
(3)Included in “Other assets” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.
(4)$89 included in “Accrued expenses” and $663 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.

 

   Fair Value Measurements at June 30, 2017 Using 
   Quoted Prices
in Active
Markets
(Level 1)		   Significant
Other
Observable
Inputs (Level 2)		   Significant
Unobservable
Inputs
(Level 3)		   Total 
                 
Cash equivalents:                    
Time deposits   -   $5,781    -   $5,781 
                     
Investments:                    
Time deposits   -    2,046    -    2,046 
                     
Foreign currency contracts-assets (5)   -    486    -    486 
Foreign currency contracts-liabilities (6)   -    137    -    137 
Derivative liability for interest rate swap (7)   -    581    -    581 
Contingent consideration (8)   -    -   $2,952    2,952 

 

(5)Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.
(6)Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.
(7)Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.
(8)$145 included in “Accrued expenses” and $2,807 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.

 

 24 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

(10) Recent Accounting Pronouncements

 

In February 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which gives entities the option to reclassify the disproportionate income tax effects ("stranded tax effects") caused by the newly-enacted U.S. Tax Cuts and Jobs Act from accumulated other comprehensive income to retained earnings. The update also requires new disclosures, some of which are applicable for all entities. The guidance in ASU 2018-02 is effective for annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact of the provisions of ASU 2018-02.

 

In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which has the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. In addition to that main objective, the amendments in ASU 2017-12 make certain targeted improvements to simplify the application of the hedge accounting guidance in current GAAP. The amendments in ASU 2017-12 are effective for public business entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of the provisions of ASU 2017-12.

 

In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company does not believe this new accounting standard update will have a material impact on its consolidated financial statements.

 

In January 2017, the FASB issued ASU 2017-01 Business Combinations (Topic 805): Clarifying the Definition of a Business, with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU 2017-01 is effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated financial statements.

 

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which addresses eight specific cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact of the provisions of ASU 2016-15.

 

In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which changes certain aspects of accounting for share-based payments to employees. The Company adopted ASU 2016-09 as of July 1, 2017. ASU 2016-09 requires that all tax benefits and deficiencies related to share-based payments be recognized and recorded through the statement of income for all awards settled or expiring after the adoption of ASU 2016-09. Under prior guidance, tax benefits in excess of compensation costs ("windfalls") were recorded in equity, and any tax deficiencies ("shortfalls") were recorded in equity to the extent of previous windfalls and then to the statement of income. For the three months and nine months ended March 31, 2018, the Company recorded additional tax expense of $420 and $1,521, respectively, associated with net tax deficiencies. ASU 2016-09 also requires, either prospectively or retrospectively, that all tax-related cash flows resulting from share-based payments be reported as operating activities on the statement of cash flows, a change from prior guidance that required windfall tax benefits to be presented as an inflow from financing activities and an outflow from operating activities on the statement of cash flows. The Company has elected to adopt such presentation on a prospective basis. Additionally, ASU 2016-09 allows entities to make an accounting policy election for the impact of most types of forfeitures on the recognition of expense for share-based payment awards by allowing the forfeitures to be either estimated, as was required under prior guidance, or recognized when they actually occur. Under ASU 2016-09, the Company recognizes forfeitures when they occur.

 

 25 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) that replaces existing lease guidance. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. ASU 2016-02 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2018. The Company is currently evaluating the impact of the provisions of ASU 2016-02.

 

In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Assets. This ASU is intended to simplify the presentation of deferred taxes on the balance sheet and requires an entity to present all deferred tax assets and deferred tax liabilities as non-current on the balance sheet. Under the prior guidance, entities were required to separately present deferred taxes as current or non-current. Netting deferred tax assets and deferred tax liabilities by tax jurisdiction will still be required under the new guidance. The Company prospectively adopted the provisions of ASU 2015-17, as of July 1, 2017. The Company's prospective adoption of ASU 2015-17 impacts the classification of deferred tax assets and liabilities on any balance sheet that reports the Company's financial position for any date after June 30, 2017. Balance sheets for prior periods have not been adjusted. The adoption of ASU 2015-17 has no impact on the Company's results of operations or cash flows.

 

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. This ASU requires that an entity measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted this standard in the first quarter of fiscal year 2018. The adoption of this standard did not have any impact on the condensed consolidated financial statements of the Company.

 

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which is the new comprehensive revenue recognition standard that will supersede all existing revenue recognition guidance under U.S. GAAP. The standard's core principle is that a company will recognize revenue when it transfers promised goods or services to a customer in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB subsequently issued ASU 2015-14, Revenue from Contracts with Customers - Deferral of the Effective Date, which approved a one-year deferral of ASU 2014-09 for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. In March 2016 and April 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers - Principal versus Agent Considerations (Reporting Revenue Gross versus Net), and ASU 2016-10, Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing, respectively, which further clarify the guidance related to those specific topics within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients, to reduce the risk of diversity in practice for certain aspects in ASU 2014-09, including collectibility, noncash consideration, presentation of sales tax and transition. Additionally, in December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers. ASU 2016-20 makes minor corrections or minor improvements to the standard that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. The Company has made progress in its evaluation of the amended guidance, including identification of revenue streams. The Company recognizes revenue from product sales at the time of shipment and passage of title and risk of loss and control of the goods is transferred to the customer. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to its customers. Although the Company is continuing to assess the impact of the amended guidance, Aceto generally anticipates that the timing of recognition of revenue will be substantially unchanged under the amended guidance. The amended guidance will be effective for Aceto in the first quarter of fiscal 2019 and permits adoption under either the full retrospective approach (recognize effects of the amended guidance in each prior reporting period presented) or the modified retrospective approach (recognize the cumulative effect of adoption as an adjustment to retained earnings at the date of initial application). The Company anticipates adopting this amended standard on a modified retrospective basis.

 

 26 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

(11) Segment Information

 

The Company's business is organized along product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.

 

Human Health - includes finished dosage form generic drugs and nutraceutical products.

 

Pharmaceutical Ingredients – includes pharmaceutical intermediates and active pharmaceutical ingredients (“APIs”).

 

Performance Chemicals - The Performance Chemicals segment is made up of two product groups: Specialty Chemicals and Agricultural Protection Products. Specialty Chemicals include a variety of chemicals used in the manufacture of plastics, surface coatings, cosmetics and personal care, textiles, fuels and lubricants, perform to their designed capabilities. Dye and pigment intermediates are used in the color-producing industries such as textiles, inks, paper, and coatings. Organic intermediates are used in the production of agrochemicals.

 

Agricultural Protection Products include herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms that can severely damage plant growth.

 

The Company's chief operating decision maker evaluates performance of the segments based on net sales, gross profit and income before income taxes. Unallocated corporate amounts are deemed by the Company as administrative, oversight costs, not managed by the segment managers. The Company does not allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments' performance, as the assets are managed on an entity-wide basis. During all periods presented, our chief operating decision maker has been the Chief Executive Officer of the Company. In accordance with GAAP, the Company has aggregated certain operating segments into reportable segments because they have similar economic characteristics, and the operating segments are similar in all of the following areas: (a) the nature of the products and services; (b) the nature of the production processes; (c) the type or class of customer for their products and services; (d) the methods used to distribute their products or provide their services; and (e) the nature of the regulatory environment.

 

Nine months Ended March 31, 2018 and 2017:

 

   Human
Health		   Pharmaceutical
Ingredients		  

Performance

Chemicals

   Unallocated
Corporate		   Consolidated
Totals		 
2018                         
Net sales  $301,407   $113,406   $127,669   $-   $542,482 
Gross profit   57,080    17,259    27,310    -    101,649 
(Loss) income before income taxes   (258,172)*   5,795    14,121    (23,142)   (261,398)
                          
2017                         
Net sales  $201,686   $121,253   $120,759   $-   $443,698 
Gross profit   56,424    19,867    27,672    -    103,963 
Income (loss) before income taxes   13,912    7,299    13,599    (20,452)   14,358 

 

* Includes goodwill impairment charge of $235,110. See Note 9 Fair Value Measurements for details.

 

 27 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

Three months Ended March 31, 2018 and 2017:

 

  Human
Health		   Pharmaceutical
Ingredients		   Performance
Chemicals		   Unallocated
 Corporate 		   Consolidated
Totals		 
2018                         
Net sales  $91,926   $43,201   $50,871   $-   $185,998 
Gross profit   9,535    7,038    11,123    -    27,696 
(Loss) income before income taxes   (265,486)*   2,987    6,699    (7,237)   (263,037)
                          
2017                         
Net sales  $99,816   $43,821   $46,491   $-   $190,128 
Gross profit   25,300    7,255    9,764    -    42,319 
Income (loss) before income taxes   5,007    3,036    5,034    (4,565)   8,512 

 

* Includes goodwill impairment charge of $235,110. See Note 9 Fair Value Measurements for details.

 

(12) Income Taxes

 

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (“the TCJA”) was signed by the U.S. President, which enacted various changes to the U.S. corporate tax law. Some of the most significant provisions impacting corporations include a reduced U.S. corporate income tax rate from 35% to 21% effective in 2018, a one-time "deemed repatriation" tax on unremitted earnings accumulated in non-U.S. jurisdictions, limitation on deductibility of interest, the transition of U.S. international taxation from a worldwide tax system to a territorial tax system and other provisions. U.S. GAAP accounting for income taxes requires that Aceto record the impacts of any tax law change on the Company’s deferred income taxes in the quarter that the tax law change is enacted. Due to the complexities involved in accounting for the enactment of the TCJA, SEC Staff Accounting Bulletin (“SAB”) 118 allows Aceto to provide a provisional estimate of the impacts of the TCJA in its earnings for the fiscal year ended June 30, 2018. Accordingly, based on currently available information, the Company recorded additional income tax expense of $12,720 for the nine months ended March 31, 2018. This charge is comprised of $3,342 related to the remeasurement of Aceto’s deferred tax assets arising from a lower U.S. corporate tax rate, $7,012 related to the deemed repatriation of unremitted earnings of foreign subsidiaries and $2,366 related to deferred tax liabilities for local tax authorities as the Company no longer asserts permanent reinvestment of its undistributed non-U.S. subsidiaries' earnings. Additional impacts from the enactment of the TCJA will be recorded as they are identified during the measurement period ending no later than December 22, 2018 as provided for in SAB 118. The charge recorded in the nine months ended March 31, 2018 represents the Company’s best estimate of the impact of the TCJA. The Company will continue to evaluate the interpretations and assumptions made, guidance that may be issued and actions the Company may take as a result of the TCJA, which could materially change this estimate in 2018 as new information becomes available.

 

Deferred tax assets are recorded for net operating losses and temporary differences between the book and tax basis of assets and liabilities expected to produce tax deductions in future periods. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the tax periods in which those deferred tax assets would be deductible. A valuation allowance is taken when necessary to reduce deferred tax assets to the amount expected to be realized. When determining the amount of net deferred tax assets that are more likely than not to be realized, the Company assesses all available positive and negative evidence. This evidence includes, but is not limited to, scheduled reversal of deferred tax liabilities, prior earnings history, projected future earnings, carry-back and carry-forward periods and the feasibility of ongoing tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. The weight given to the positive and negative evidence is commensurate with the extent the evidence may be objectively verified. As such, it is generally difficult for positive evidence regarding projected future taxable income (exclusive of reversing taxable temporary differences and carryforwards) to outweigh objective negative evidence such as the Company’s recent financial reporting loss for the three and nine months ended March 31, 2018 that created a cumulative loss. Therefore, the Company recorded a valuation allowance of $71,350 against its net U.S. deferred tax assets during the three and nine months ended March 31, 2018.

 

 28 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited and in thousands, except per-share amounts)

 

(13) Subsequent Events

 

On April 18, 2018, the Company issued a press release announcing, among other things, that (i) it was negotiating with its bank lenders a waiver of its credit agreement with respect to its total net leverage and debt service coverage financial covenants in the fiscal third quarter, (ii) the financial guidance issued on February 1, 2018 should no longer be relied upon, (iii) the Company anticipated recording substantial non-cash intangible asset impairment charges as described herein and (iv) the resignation of Edward Borkowski as its chief financial officer. Subsequently, the market price of the Company’s common stock declined significantly and several law firms publicly announced that they were investigating alleged violations of law associated with the matters described in the Company’s press release. Thereafter, Aceto and certain related individuals have been named as defendants in civil lawsuits that allege, among other things, that Aceto made false and misleading statements to investors in public filings that preceded the April 18, 2018 press release. The Company is currently preparing its responses to these legal proceedings.

 

In connection with the Department of Justice’s ongoing investigation into marketing and pricing practices throughout the generic pharmaceutical industry, the Company has received a subpoena from the Antitrust Division of the U.S. Department of Justice (the “DOJ”). The Company is one of many operating companies in the generic pharmaceutical industry to receive a subpoena from the DOJ relating to its years-long investigation into the industry. The Company is currently preparing its response to the subpoena.

 

 29 

 

 

Report of Independent Registered Public Accounting Firm

 

 

 

Board of Directors and Shareholders

Aceto Corporation

Port Washington, NY

 

Results of Review of Interim Consolidated Financial Statements

 

We have reviewed the condensed consolidated balance sheet of Aceto Corporation and subsidiaries as of March 31, 2018 and related condensed consolidated statements of operations and comprehensive income (loss) for the three-month and nine-month periods ended March 31, 2018 and 2017, and cash flows for the nine-month periods ended March 31, 2018 and 2017 included in the accompanying Securities and Exchange Commission Form 10-Q for the period ended March 31, 2018. Based on our reviews, we are not aware of any material modifications that should be made to the condensed consolidated financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

 

We have previously audited, in accordance with standards of the Public Company Accounting Oversight Board, the consolidated balance sheet of Aceto Corporation and subsidiaries as of June 30, 2017, and the related consolidated statements of income, comprehensive income, shareholders’ equity and cash flows for the year then ended (not presented herein); and in our report dated August 25, 2017, except for Note 2 which is dated November 9, 2017, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of June 30, 2017, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

 

Basis for Review Results

 

These interim financial statements are the responsibility of the Company’s management. We conducted our reviews in accordance with standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

 

We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

Emphasis of Matter

 

As discussed in Note 2 to the condensed consolidated financial statements, the March 31, 2018 consolidated financial statements have been restated to correct a misstatement.

 

 

 

/s/ BDO USA, LLP

 

Melville, New York

May 4, 2018, except for Notes 2 and 12 which are October 12, 2018

 

 30 

 

 

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

 

CAUTIONARY STATEMENT RELATING TO THE SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

 

This Quarterly Report contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking statements contained in this Quarterly Report may not occur. Generally, these statements relate to our business plans or strategies, projected or anticipated benefits or other consequences of our plans or strategies, financing plans, projected or anticipated benefits from acquisitions that we may make, or projections involving anticipated revenues, earnings or other aspects of our operating results or financial position, and the outcome of any contingencies. Any such forward-looking statements are based on current expectations, estimates and projections of management. We intend for these forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements. Words such as “may,” “will,” “expect,” “believe,” “anticipate,” “project,” “plan,” “intend,” “estimate,” and “continue,” and their opposites and similar expressions are intended to identify forward-looking statements. We caution you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond our control that may influence the accuracy of the statements and the projections upon which the statements are based. Factors that could cause actual results to differ materially from those set forth or implied by any forward-looking statement include, but are not limited to, our ability to remain competitive with competitors, risks associated with the generic product industry, dependence on a limited number of suppliers, risks associated with healthcare reform and reductions in reimbursement rates, difficulty in predicting revenue stream and gross profit, industry and market changes, the effect of fluctuations in operating results on the trading price of our common stock, risks associated with holding a significant amount of debt, inventory levels, reliance on outside manufacturers, risks of incurring uninsured environmental and other industry specific liabilities, governmental approvals and regulations, risks associated with hazardous materials, potential violations of government regulations, product liability claims, reliance on Chinese suppliers, potential changes to Chinese laws and regulations, potential changes to laws governing our relationships in India, fluctuations in foreign currency exchange rates, tax assessments, changes in tax rules, global economic risks, risk of unsuccessful acquisitions, effect of acquisitions on earnings, indemnification liabilities, terrorist activities, reliance on key executives, litigation risks, volatility of the market price of our common stock, changes to estimates, judgments and assumptions used in preparing financial statements, failure to maintain effective internal controls, and compliance with changing regulations, as well as other risks and uncertainties discussed in our reports filed with the Securities and Exchange Commission, including, but not limited to this Quarterly Report on Form 10-Q, the Company’s Annual Report on Form 10-K for the year ended June 30, 2017, as amended (the “2017 10-K”) and other filings. Copies of these filings are available at www.sec.gov.

 

Any one or more of these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking statements made by us ultimately prove to be accurate. Our actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.

 

NOTE REGARDING DOLLAR AMOUNTS

 

In this quarterly report, all dollar amounts are expressed in thousands, except for per-share amounts.

 

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to provide the readers of our financial statements with a narrative discussion about our business. The MD&A is provided as a supplement to and should be read in conjunction with our financial statements and the accompanying notes.

 

 31 

 

 

Executive Summary

 

We are reporting net sales of $542,482 for the nine months ended March 31, 2018, which represents a 22.3% increase from the $443,698 reported in the comparable prior period. Gross profit for the nine months ended March 31, 2018 was $101,649 and our gross margin was 18.7% as compared to gross profit of $103,963 and gross margin of 23.4% in the comparable prior period. Our selling, general and administrative costs (“SG&A”) for the nine months ended March 31, 2018 was $87,241, an increase of $11,627 from what we reported in the prior period. On April 18, 2018, the Company issued a press release announcing that we intended to record substantial impairment charges, including goodwill, due to the persistent adverse conditions in the generics market. As set forth in Note 9 to the Company’s Condensed Consolidated Financial Statements, we recorded impairment charges of $256,266 during the three months ended March 31, 2018. In addition, as disclosed in Notes 2 and 12, we recorded a valuation allowance of $71,350 against our U.S. net deferred tax assets during the three and nine months ended March 31, 2018. We had a net loss of $281,395 or $8.00 per diluted share, for the nine months ended March 31, 2018, compared to net income of $9,409, or $0.30 per diluted share, in the prior period.

 

The Company is incurring substantial expenses to address the issues that led to the impairment charges taken as of March 31, 2018. As announced by the Company in its April 18, 2019 press release, the Company will pay a flat monthly fee of $250 for the services of its interim chief financial officer, Rebecca Roof. The Company has also retained financial and legal advisors to assist it in dealing with the various challenges that the Company is currently facing.

 

Included in the Company’s press release issued April 18, 2018, is the announcement that the Board of Directors has initiated a process to identify and evaluate a range of strategic alternatives. Strategic alternatives to be considered may include the sale of a key business segment(s), a merger or other business combination with another party, continuing as a standalone entity or other potential alternatives. The Company has retained a financial advisor to assist with the evaluation of these strategic alternatives. There can be no assurance that the strategic review process will result in any transaction.

 

As more fully described in the notes to our condensed consolidated financial statements, on December 22, 2017, the Tax Cuts and Jobs Act of 2017 (“TCJA”) was signed by the U.S. President. The TCJA significantly changes the income tax environment for U.S. multinational corporations and as such, the Company recorded additional income tax expense of $12,720 during the nine months ended March 31, 2018.

 

Despite the difficult generic pharmaceutical industry environment, our financial position as of March 31, 2018 remains strong, as we had cash and cash equivalents and short-term investments of $65,091 and working capital of $52,446.

 

Our business is separated into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.

 

Products that fall within the Human Health segment include finished dosage form generic drugs and nutraceutical products. Aceto sells generic prescription products and over-the-counter pharmaceutical products to leading wholesalers, chain drug stores, distributors and mass merchandisers. As previously mentioned, given continued headwinds in the generics market, the Company recorded a goodwill impairment charge of $235,110 in the Rising business segment in the third quarter of fiscal 2018.

 

On December 21, 2016, Rising completed the acquisition of certain generic products and related assets of entities formerly known as Citron Pharma LLC (“Citron”) and its affiliate Lucid Pharma LLC (“Lucid”). Rising formed two subsidiaries to consummate the product acquisition – Rising Health, LLC (which acquired certain products and related assets of Citron) and Acetris Health, LLC (which acquired certain products and related assets of Lucid). Citron was a privately-held New Jersey-based pharmaceutical company focused on developing and marketing generic pharmaceutical products in partnership with leading generic pharmaceutical manufacturers based in India and the U.S. Lucid was a privately-held New Jersey-based generic pharmaceutical distributor specializing in providing cost-effective products to various agencies of the U.S. Federal Government including the Veterans Administration and the Defense Logistics Agency. Lucid serviced 18 national contracts with the Federal Government, nearly all of which had 5-year terms. In February 2018, Aceto was notified by the U.S. government that 11 generic drug products are not in compliance with the federal Trade Agreement Act (“TAA”) country-of-origin provisions of a clause contained in the government supply contracts. See Note 8 to the Company’s Condensed Consolidated Financial Statements. The 11 finished dosage form products purchased by the U.S. government are manufactured by Aurolife Pharma LLC which is located in Dayton, New Jersey using APIs sourced from India. Based on this notification, the Company recorded an impairment charge of $15,411 on the customer relationships intangible asset in the third quarter of fiscal 2018.

 

 32 

 

 

The assets acquired in the product purchase transaction expanded, complemented, and strengthened our existing and future product offerings. In what has become a competitive generic drug business environment, one key for long-term success is having an ever-growing commercial portfolio of generic products, a strong internal drug development pipeline and capable, reliable manufacturing partners. This transaction added significantly to the Rising business platform in all three crucial areas. We believe that, consistent with our strategy of expanding our portfolio of finished dosage form generic products through product development partnerships and acquisitions of late stage assets, abbreviated new drug applications (“ANDAs”) and complementary generic drug businesses, this product acquisition significantly expanded our roster of commercialized products and pipeline of products under development.

 

Based on a report issued by IQVIA Institute on April 19, 2018, “Spending on medicines grew by 0.6% in 2017 after off-invoice discounts and rebates. This spending includes all types of medicines, including institutional use for inpatients and outpatients. Focusing only on retail and mail-order pharmacy distribution, net spending declined by 2.1%.”

 

Aceto supplies the raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds and biochemicals used in pharmaceutical and nutritional preparations.

 

The Pharmaceutical Ingredients segment has two product groups: Active Pharmaceutical Ingredients (APIs) and Pharmaceutical Intermediates.

 

We supply APIs to many of the major generic drug companies, who we believe view Aceto as a valued partner in their effort to develop and market generic drugs. The process of introducing a new API from pipeline to market spans a number of years and begins with Aceto partnering with a generic pharmaceutical manufacturer and jointly selecting an API, several years before the expiration of a composition of matter patent, for future genericizing. We then identify the appropriate supplier, and concurrently utilizing our global technical network, work to ensure they meet standards of quality to comply with regulations. Our client, the generic pharmaceutical company, will submit the ANDA for U.S. Food and Drug Administration (“FDA”) approval or European-equivalent approval. The introduction of the API to market occurs after all the development testing has been completed and the ANDA or European-equivalent is approved and the patent expires or is deemed invalid. Aceto, at all times, has a pipeline of APIs at various stages of development both in the United States and Europe. Additionally, as the pressure to lower the overall cost of healthcare increases, Aceto has focused on, and works very closely with our customers to develop new API opportunities to provide alternative, more economical, second-source options for existing generic drugs. By leveraging our worldwide sourcing, regulatory and quality assurance capabilities, we provide to generic drug manufacturers an alternative, economical source for existing API products.

 

Aceto has long been a supplier of pharmaceutical intermediates, the complex chemical compounds that are the building blocks used in producing APIs. These are the critical components of all drugs, whether they are already on the market or currently undergoing clinical trials. Faced with significant economic pressures as well as ever-increasing regulatory barriers, the innovative drug companies look to Aceto as a source for high quality intermediates.

 

Aceto employs, on occasion, the same second source strategy for our pharmaceutical intermediates business that we use in our API business. Historically, pharmaceutical manufacturers have had one source for the intermediates needed to produce their products. Utilizing our global sourcing, regulatory support and quality assurance network, Aceto works with the large, global pharmaceutical companies, sourcing lower cost, quality pharmaceutical intermediates that will meet the same high level standards that their current commercial products adhere to.

 

The Performance Chemicals segment includes specialty chemicals and agricultural protection products.

 

 33 

 

 

Aceto is a major supplier to many different industrial segments providing chemicals used in the manufacture of plastics, surface coatings, cosmetics and personal care, textiles, fuels and lubricants. The paint and coatings industry produces products that bring color, texture, and protection to houses, furniture, packaging, paper, and durable goods. Many of today's coatings are eco-friendly, by allowing inks and coatings to be cured by ultraviolet light instead of solvents, or allowing power coatings to be cured without solvents. These growing technologies are critical in protecting and enhancing the world's ecology and Aceto is focused on supplying the specialty additives that make modern coating techniques possible.

 

The chemistry that makes much of the modern world possible is often done by building up simple molecules to sophisticated compounds in step-by-step chemical processes. The products that are incorporated in each step are known as intermediates and they can be as varied as the end uses they serve, such as crop protection products, dyes and pigments, textiles, fuel additives, electronics - essentially all things chemical.

 

Aceto provides various specialty chemicals for the food, flavor, fragrance, paper and film industries. Aceto’s raw materials are also used in sophisticated technology products, such as high-end electronic parts used for photo tooling, circuit boards, production of computer chips, and in the production of many of today's modern gadgets.

 

According to an April 17, 2018 Federal Reserve Statistical Release, in the first quarter of calendar year 2018, the index for consumer durables, which impacts the Specialty Chemicals business of the Performance Chemicals segment, is expected to increase at an annual rate of 7.8%.

 

Aceto’s agricultural protection products include herbicides, fungicides and insecticides, which control weed growth as well as the spread of insects and microorganisms that can severely damage plant growth. One of Aceto's most widely used agricultural protection products is a sprout inhibitor that extends the storage life of potatoes. Utilizing our global sourcing and regulatory capabilities, we identify and qualify manufacturers either producing the product or with knowledge of the chemistry necessary to produce the product, and then file an application with the U.S. EPA for a product registration. Aceto has an ongoing working relationship with manufacturers in China and India to determine which of the non-patented or generic, agricultural protection products they produce can be effectively marketed in the Western world. We have successfully brought numerous products to market. We have a strong pipeline, which includes future additions to our product portfolio. The combination of our global sourcing and regulatory capabilities makes the generic agricultural market a niche for us and we will continue to offer new product additions in this market. In the National Agricultural Statistics Services release dated June 30, 2017, the total crop acreage planted in the United States in 2017 decreased by .3% to 318 million acres from 319 million acres in 2016. The number of peanut acres planted in 2017 increased 8.8% from 2016 levels while sugarcane acreage harvested decreased 3.4% from 2016. In addition, the potato acreage harvested in 2017 increased approximately .7% from the 2016 level.

 

We believe our main business strengths are sourcing, regulatory support, quality assurance, marketing and distribution. We distribute more than 1,100 chemical compounds used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical industries. With business operations in ten countries, we believe that our global reach is distinctive in the industry, enabling us to source and supply quality products on a worldwide basis. Leveraging local professionals, we source approximately two-thirds of our products from Asia, buying from approximately 500 companies in China and 200 in India.

 

In this MD&A, we explain our general financial condition and results of operations, including, among other things, the following:

 

·factors that affect our business
·our earnings and costs in the periods presented
·changes in earnings and costs between periods
·sources of earnings
·the impact of these factors on our overall financial condition

 

As you read this MD&A section, refer to the accompanying condensed consolidated statements of operations, which present the results of our operations for the three and nine months ended March 31, 2018 and 2017. We analyze and explain the differences between periods in the specific line items of the condensed consolidated statements of operations.

 

 34 

 

 

Critical Accounting Estimates and Policies

 

As disclosed in our 2017 10-K, the discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. In preparing these financial statements, we were required to make estimates and assumptions that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We regularly evaluate our estimates including those related to allowances for bad debts, revenue recognition, partnered products, inventories, goodwill and indefinite-life intangible assets, long-lived assets, environmental and other contingencies, income taxes, stock-based compensation and purchase price allocation. We base our estimates on various factors, including historical experience, advice from outside subject-matter experts, and various assumptions that we believe to be reasonable under the circumstances, which together form the basis for our making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Since June 30, 2017, there have been no significant changes to the assumptions and estimates related to those critical accounting estimates and policies. We are planning to implement a new enterprise resource planning (“ERP”) system at our Rising subsidiary during the fourth quarter of our current fiscal year. In automating processes that heretofore have been undertaken manually, we may be required to reassess certain of our estimates, especially with respect to our rebates, returns and chargebacks approaches.

 

 35 

 

 

RESULTS OF OPERATIONS

 

Nine Months Ended March 31, 2018 Compared to Nine Months Ended March 31, 2017

 

  

Net Sales by Segment

Nine months ended March 31,

 
           Comparison 2018 
   2018   2017   Over/(Under) 2017 
       % of       % of   $   % 
Segment  Net sales   Total   Net sales   Total   Change   Change 
                         
Human Health  $301,407    55.6%  $201,686    45.5%  $99,721    49.4%
Pharmaceutical Ingredients   113,406    20.9    121,253    27.3    (7,847)   (6.5)
Performance Chemicals   127,669    23.5    120,759    27.2    6,910    5.7 
                               
Net sales  $542,482    100.0%  $443,698    100.0%  $98,784    22.3%

 

  

Gross Profit by Segment

Nine months ended March 31,

 
           Comparison 2018 
   2018   2017   Over/(Under) 2017 
   Gross   % of   Gross   % of   $   % 
Segment  Profit   Sales   Profit   Sales   Change   Change 
                         
Human Health  $57,080    18.9%  $56,424    28.0%  $656    1.2%
Pharmaceutical Ingredients   17,259    15.2    19,867    16.4    (2,608)   (13.1)
Performance Chemicals   27,310    21.4    27,672    22.9    (362)   (1.3)
                               
Gross profit  $101,649    18.7%  $103,963    23.4%  $(2,314)   (2.2)%

 

Net Sales

 

Net sales increased $98,784, or 22.3%, to $542,482 for the nine months ended March 31, 2018, compared with $443,698 for the prior period. We reported sales increases in our Human Health and Performance Chemicals segments and a decrease in our Pharmaceutical Ingredients segment.

 

Human Health

 

Net sales for the Human Health segment increased by $99,721 for the nine months ended March 31, 2018, to $301,407, which represents a 49.4% increase over net sales of $201,686 for the prior period. The primary reason for the increase is due to the acquisition of certain products and related assets of Citron and Lucid. Sales from the product acquisition of $161,138 are included in the nine months ended March 31, 2018 compared to $57,134 included in the nine months ended March 31, 2017. In addition, there was a rise of $3,221 in sales of nutritional products, sold abroad, primarily by our German subsidiary. These increases in Human Health were offset in part, by a decline in sales of certain currently marketed and pipeline generic products as a result of continued pricing pressure, intense competition and related consolidation of customers and softer than expected contributions from new product launches. In addition, Rising incurred approximately $12,903 in failure to supply penalties primarily related to supply challenges with regards to products acquired from Citron and Lucid.

 

 36 

 

 

Pharmaceutical Ingredients

 

Net sales for the Pharmaceutical Ingredients segment decreased $7,847 or 6.5% to $113,406 when compared to the prior period net sales of $121,253. The decrease in sales for this segment was due primarily to a decline in sales of domestic APIs of $7,096, mainly due to reduced orders of a customer-launched API, timing of sales of three products that are expected to be shipped in the fourth quarter of fiscal year 2018, delayed customer launch of an API, competition on another API and the discontinuance of two finish dosage drugs sold by our API business unit. These decreases in domestic APIs were offset in part by an increase of $2,135 of APIs sold abroad, specifically in Germany. Sales of intermediates sold both domestically and abroad decreased $2,886 from the prior period primarily occurring in France, due to delays in shipments.

 

Performance Chemicals

 

Net sales for the Performance Chemicals segment was $127,669 for the nine months ended March 31, 2018, representing an increase of $6,910 or 5.7%, from net sales of $120,759 for the prior period. The Specialty Chemicals business experienced a rise in sales of $10,937 over the prior period. The rise in Specialty Chemicals sales is partly due to an increase in domestic sales of $6,765, primarily from increased sales of agricultural and miscellaneous intermediates as well as surface coatings. In addition, sales of specialty chemical products sold abroad, increased $4,172 over the prior period, predominantly at our subsidiaries in Germany and France. Performance Chemicals sales were impacted by a $4,027 drop in sales of our agricultural protection products, predominantly from a decline in sales of an herbicide used to treat weeds on vegetables. In addition, sales of an insecticide used on cotton has decreased as orders have been pushed to the fourth quarter of fiscal 2018 and the first quarter of fiscal 2019.

 

Gross Profit

 

Gross profit decreased $2,314 to $101,649 (18.7% of net sales) for the nine months ended March 31, 2018, as compared to $103,963 (23.4% of net sales) for the prior period.

 

Human Health

 

Human Health segment’s gross profit of $57,080 for the nine months ended March 31, 2018 increased $656, or 1.2%, over the prior period. The gross margin of 18.9% was lower than the prior period’s gross margin of 28.0%. The decline in gross margin is primarily driven by unfavorable product mix on certain Rising products, continued pricing pressure, intense competition and related consolidation of customers and failure to supply charges.

 

Pharmaceutical Ingredients

 

Pharmaceutical Ingredients’ gross profit of $17,259 for the nine months ended March 31, 2018 decreased $2,608, or 13.1%, over the prior period. The gross margin of 15.2% was lower than the prior period’s gross margin of 16.4%. The decrease in gross profit and gross margin was predominantly the result of the decrease in the sales volume of APIs sold domestically, as well as a drop in reorders of a certain API which typically yields a significantly higher gross margin. In addition, our international subsidiaries experienced an unfavorable product mix on API sales.

 

Performance Chemicals

 

Gross profit for the Performance Chemicals segment decreased to $27,310 for the nine months ended March 31, 2018, versus $27,672 for the prior year, a decrease of $362 or 1.3%. The gross margin at 21.4% for the nine months ended March 31, 2018 was lower than the prior year’s gross margin of 22.9%. The decrease in gross profit was due to a $1,858 decline in gross profit for the Agricultural Protection Products business, as a result of the sales volume decline, partially offset by an increase in gross profit of $1,496 on the sales volume increase of sales of Specialty Chemicals. The drop in gross margin from the prior period is a result of an unfavorable product mix on sales of specialty chemical products sold domestically.

 

 37 

 

 

Selling, General and Administrative Expenses

 

SG&A of $87,241 for the nine months ended March 31, 2018 increased $11,627 or 15.4% from $75,614 reported for the prior period. As a percentage of sales, SG&A decreased to 16.1% for the nine months ended March 31, 2018 versus 17.0% in the prior period. SG&A for the current period included $15,884 of amortization expense associated with the purchased intangible assets related to the product purchase compared to $6,030 in the prior period. In fiscal 2018, we recorded $4,064 of one-time costs associated with the separation of the Company’s former Chief Executive Officer, including $2,017 of stock-based compensation. The increase in SG&A is also due to an increase in consulting fees of $1,610 which includes consulting services provided by former Citron and Lucid employees in connection with the Transition Services Agreement associated with the product purchase agreement and outsourcing fees related to the accounting processes of Rising Health and Acetris Health. In addition, SG&A rose due to an increase in professional fees of $3,433 and an increase in payroll and related fringe benefits of $1,721, due primarily to annual merit increases as well as the hiring of certain key management personnel. The increase in SG&A was offset in part by a reduction of $2,505 in the contingent consideration liability related to the acquisition of certain assets of Citron. SG&A for the prior period included $8,818 of transaction costs related to the product purchase agreement.

 

Impairment Charges

 

During the nine months ended March 31, 2018, the Company recorded impairment charges of $256,266, all of which related to the Rising business segment. The impairment charges consisted of $235,110 of goodwill impairment charges and a $21,156 write-down of other identifiable intangible assets. For additional information regarding these impairment charges, see Note 9 to the Company’s Condensed Consolidated Financial Statements. There were no impairment charges recorded in the nine months ended March 31, 2017.

 

Research and Development Expenses

 

Research and development expenses (“R&D”) increased to $6,208 for the nine months ended March 31, 2018 compared to $4,998 for the prior period. R&D expenses represent investment in our generic finished dosage form product pipeline. The majority of the R&D expenses are milestone based, which was the primary cause for such increase and will likely cause fluctuation from quarter to quarter.

 

Operating (Loss) Income

 

For the nine months ended March 31, 2018, operating loss was $(248,066) compared to operating income of $23,351 in the prior period, a decrease of $271,417 primarily due to the impairment charges recorded in fiscal 2018.

 

Interest Expense

 

Interest expense was $15,443 for the nine months ended March 31, 2018, an increase of $5,220 or 51.1% from the prior period. The increase was primarily due to interest expense associated with the Second Amended and Restated Credit Agreement, which was entered on December 21, 2016 to help fund our product acquisition, as well as additional interest associated with the $50,000 unsecured deferred payment related to the product acquisition.

 

Interest and Other Income, Net

 

Interest and other income, net was $2,111 for the nine months ended March 31, 2018, an increase of $881 from the prior period, primarily due to increases in unrealized foreign exchange gains from mark-to-market valuation of foreign currency futures contracts and an increase in income related to a joint venture for one of our agricultural protection products.

 

 38 

 

 

Provision for Income Taxes

 

The effective tax rate for the nine months ended March 31, 2018 was (7.7)% compared to expense of 34.5% for the prior period. During the nine months ended March 31, 2018, the Company recorded a valuation allowance of $71,350 against its U.S. deferred tax assets. For additional information, see Notes 2 and 12 to the Company’s Condensed Consolidated Financial Statements. In accordance with the TCJA, for the nine months ended March 31, 2018, we recorded additional income tax expense of $12,720. In addition, we recorded $1,521 of additional income tax expense associated with net tax deficiencies under ASU 2016-09, which was adopted prospectively in the first quarter of fiscal 2018. We expect the substantially lower corporate tax rate reflected in the TCJA to benefit our financial results and cash flow in future periods.

 

 39 

 

 

Three Months Ended March 31, 2018 Compared to Three Months Ended March 31, 2017

 

  

Net Sales by Segment

Three months ended March 31,

 
           Comparison 2018 
   2018   2017   Over/(Under) 2017 
       % of       % of   $   % 
Segment  Net sales   Total   Net sales   Total   Change   Change 
                         
Human Health  $91,926    49.4%  $99,816    52.5%  $(7,890)   (7.9)%
Pharmaceutical Ingredients   43,201    23.2    43,821    23.0    (620)   (1.4)
Performance Chemicals   50,871    27.4    46,491    24.5    4,380    9.4 
                               
Net sales  $185,998    100.0%  $190,128    100.0%  $(4,130)   (2.2)%

 

  

Gross Profit by Segment

Three months ended March 31,

 
           Comparison 2018 
   2018   2017   Over/(Under) 2017 
   Gross   % of   Gross   % of   $   % 
Segment  Profit   Sales   Profit   Sales   Change   Change 
                         
Human Health  $9,535    10.4%  $25,300    25.3%  $(15,765)   (62.3)%
Pharmaceutical Ingredients   7,038    16.3    7,255    16.6    (217)   (3.0)
Performance Chemicals   11,123    21.9    9,764    21.0    1,359    13.9 
                               
Gross profit  $27,696    14.9%  $42,319    22.3%  $(14,623)   (34.6)%

 

Net Sales

 

Net sales decreased $4,130 or 2.2%, to $185,998 for the three months ended March 31, 2018, compared with $190,128 for the prior period. We reported a sales increase in our Performance Chemicals segment and decreases in our Pharmaceutical Ingredients and Human Health segments.

 

Human Health

 

Net sales for the Human Health segment decreased by $7,890 for the three months ended March 31, 2018, to $91,926, which represents a 7.9% decrease compared to net sales of $99,816 for the prior period. The primary reason for the decrease is due to $8,148 decline in sales of Rising products as a result of continued pricing pressure, intense competition and related consolidation of customers and softer than expected contributions from new product launches. We believe these generic industry headwinds will continue in the near term. In addition, Rising incurred approximately $10,132 in failure to supply penalties primarily related to supply challenges with regards to products acquired from Citron and Lucid.

 

 40 

 

 

Pharmaceutical Ingredients

 

Net sales for the Pharmaceutical Ingredients segment decreased $620 or 1.4% to $43,201 when compared to the prior period net sales of $43,821. The decrease in sales for this segment was due primarily to a decline in sales of intermediates of $1,091 sold domestically. This decline is partially offset by an increase in sales of APIs, mainly experienced by our German subsidiaries.

 

Performance Chemicals

 

Net sales for the Performance Chemicals segment was $50,871 for the three months ended March 31, 2018, representing an increase of $4,380 or 9.4%, from net sales of $46,491 for the prior period. Performance Chemicals sales were impacted by a $1,472 increase in sales of our agricultural protection products, predominantly from an increase in sales of a fungicide used to prevent disease on pecan crops. Performance Chemicals also experienced a rise of $2,908 in Specialty Chemicals sales predominantly due to increased sales of surface coatings of $1,178. In addition, sales of specialty chemical products sold abroad, increased $1,625 over the prior period, predominantly at our subsidiaries in Germany and France.

 

Gross Profit

 

Gross profit decreased $14,623 to $27,696 (14.9% of net sales) for the three months ended March 31, 2018, as compared to $42,319 (22.3% of net sales) for the prior period.

 

Human Health

 

Human Health segment’s gross profit of $9,535 for the three months ended March 31, 2018 decreased $15,765, or 62.3%, over the prior period. The gross margin of 10.4% was lower than the prior period’s gross margin of 25.3%. The decline in gross profit and gross margin was primarily driven by unfavorable product mix on certain Rising products, continued pricing pressure, intense competition and related consolidation of customers and failure to supply charges.

 

Pharmaceutical Ingredients

 

Pharmaceutical Ingredients’ gross profit of $7,038 for the three months ended March 31, 2018 was relatively flat compared to the prior period gross profit of $7,255. The gross margin of 16.3% was consistent to the prior period’s gross margin of 16.6%.

 

Performance Chemicals

 

Gross profit for the Performance Chemicals segment increased to $11,123 for the three months ended March 31, 2018, versus $9,764 for the prior year, an increase of $1,359 or 13.9%. The gross margin at 21.9% for the three months ended March 31, 2018 was higher than the prior year’s gross margin of 21.0%. The increase in gross profit was due to sales volume increases in both the Specialty Chemicals and Agricultural Protection Products businesses. The increase in gross margin from the prior period is a result of a favorable product mix on sales of specialty chemical products sold in Germany.

 

 41 

 

 

Selling, General and Administrative Expenses

 

SG&A of $28,029 for the three months ended March 31, 2018 increased $1,510 or 5.7% from $26,519 reported for the prior period. As a percentage of sales, SG&A increased to 15.1% for the three months ended March 31, 2018 versus 13.9% in the prior period. The increase in SG&A is primarily due to an increase in professional fees of $2,484, an increase in payroll and related fringe benefits of $1,801 due primarily to annual merit increases as well as the hiring of certain key management personnel offset by a reduction of $2,505 in the contingent consideration liability related to the acquisition of certain assets of Citron.

 

Impairment Charges

 

During the three months ended March 31, 2018, the Company recorded impairment charges of $256,266, all of which related to the Rising business segment. The impairment charges consisted of $235,110 of goodwill impairment charges and $21,156 write-down of other identifiable intangible assets. For additional information regarding these impairment charges, see Note 9 to the Company’s Condensed Consolidated Financial Statements. There were no impairment charges recorded in the three months ended March 31, 2017.

 

Research and Development Expenses

 

R&D expenses decreased to $2,471 for the three months ended March 31, 2018 compared to $2,607 for the prior period. The majority of the R&D expenses are milestone based, which was the primary cause for such decrease and will likely cause fluctuation from quarter to quarter.

 

Operating Income

 

For the three months ended March 31, 2018 operating (loss) income was $(259,070) compared to $13,193 in the prior period, a decrease of $272,263 primarily due to the impairment charges recorded in fiscal 2018.

 

Provision for Income Taxes

 

The effective tax rate for the three months ended March 31, 2018 was (1.9)% compared to expense of 34.4% for the prior period. During the three months ended March 31, 2018, the Company recorded a valuation allowance of $71,350 against its U.S. deferred tax assets. For additional information, see Notes 2 and 12 to the Company’s Condensed Consolidated Financial Statements. For the three months ended March 31, 2018, we recorded $1,189 of income tax benefit associated with the TCJA. In addition, we recorded $420 of additional income tax expense associated with net tax deficiencies under ASU 2016-09, which was adopted prospectively in the first quarter of fiscal 2018. We expect the substantially lower corporate tax rate associated with the TCJA to benefit our financial results and cash flow in future periods.

 

 42 

 

 

Liquidity and Capital Resources

 

Cash Flows

 

At March 31, 2018, we had $62,032 in cash, of which $17,293 was outside the United States, $3,059 in short-term investments, all of which is held outside the United States, and $319,420 in long-term debt (including the current portion), all of which is an obligation in the United States. Working capital was $52,446 at March 31, 2018 compared to $248,750 at June 30, 2017. The significant reduction in working capital at March 31, 2018 reflects the reclassification of our term debt and revolver debt into current liabilities. See Note 7 of the Notes to the Company’s Condensed Consolidated Financial Statements. The $17,293 of cash held outside of the United States is fully accessible to meet any liquidity needs of our business located in any of the countries in which we operate. The majority of the cash located outside of the United States is held by our European and Chinese operations and can be transferred into the United States. Although these amounts are fully accessible, transferring these amounts into the United States or any other countries could have certain local tax consequences. In accordance with the TCJA, we recorded $2,366 of additional income tax expense related to deferred tax liabilities for local tax authorities as we no longer assert permanent reinvestment of our undistributed non-U.S. subsidiaries' earnings. A portion of our cash is held in operating accounts that are with third party financial institutions. While we monitor daily the cash balances in our operating accounts and adjust the cash balances as appropriate, these cash balances could be impacted if the underlying financial institutions fail or are subject to other adverse conditions in the financial markets. To date, we have experienced no loss or lack of access to cash in our operating accounts.

 

Our cash position at March 31, 2018 increased $6,352 from the amount at June 30, 2017. Operating activities for the nine months ended March 31, 2018 provided cash of $56,415 for this period, as compared to cash provided of $31,551 for the comparable prior period. The $56,415 resulted from $281,395 in net loss, $301,178 derived from adjustments for non-cash items and a net $36,632 increase from changes in operating assets and liabilities. The non-cash items included $256,266 in goodwill and intangible asset impairment charges, $24,608 in depreciation and amortization expense, $11,714 of deferred income tax expense, a $902 environmental charge, $4,603 for amortization of debt issuance costs and debt discount, and $6,442 in non-cash stock compensation expense, offset in part by $1,990 of earnings on an equity investment in a joint venture and a $2,505 reversal of contingent consideration. Trade accounts receivable decreased $2,573 during the nine months ended March 31, 2018, due predominantly to a decrease in days sales outstanding, particularly at our Rising subsidiary. Inventories increased by $3,102 and accounts payable increased by $34,224 due primarily to increased inventories held in stock by our Agricultural Protection Products subsidiary for the anticipated shipments in the fourth quarter of fiscal 2018 as well as timing of payments processed at the end of the quarter. Inventories also increased as a result of a build-up of Specialty Chemicals inventory. Other receivables increased $3,662 due primarily to an increase in value added taxes receivables for our German subsidiaries, as well as income taxes due to the Company. Accrued expenses and other liabilities increased $9,728 due primarily to a rise in price concessions for our Rising business as well as the timing of income tax payments. Our cash position at March 31, 2017 decreased $6,866 from the amount at June 30, 2016. Operating activities for the nine months ended March 31, 2017 provided cash of $31,551 for this period. The $31,551 resulted from $9,409 in net income, $25,149 derived from net adjustments for non-cash items and a net $3,007 decrease from changes in operating assets and liabilities.

 

Investing activities for the nine months ended March 31, 2018 used cash of $6,469 primarily from purchases of property and equipment and intangible assets of $5,456 and purchases of investments in time deposits of $2,880, partially offset by sales of investments in time deposits of $1,867. Investing activities for the nine months ended March 31, 2017 used cash of $275,512 primarily from $270,000 of payments for the product acquisition and purchases of intangible assets and property and equipment of $4,463 and purchases of investments in time deposits of $1,824.

 

Financing activities for the nine months ended March 31, 2018 used cash of $44,727 primarily from $39,398 of repayments of bank loans and $5,924 in payment of cash dividends. Financing activities for the nine months ended March 31, 2017 provided cash of $237,852, primarily from bank borrowings of $265,000. Financing activities included $16,898 of repayments of bank loans, $5,944 in payment of cash dividends and $5,407 for payment of deferred financing costs offset in part by $550 of proceeds received from stock option exercises and $551 of excess income tax benefits on stock option exercises and restricted stock vestings.

 

 43 

 

 

Credit Facilities

 

We have available credit facilities with certain foreign financial institutions. At March 31, 2018, the Company had available lines of credit with foreign financial institutions totaling $7,929, all of which is available for borrowing by the respective foreign territories. We are not subject to any financial covenants under these arrangements.

 

On December 21, 2016 the Company entered into a Second Amended and Restated Credit Agreement (the “A&R Credit Agreement”), with eleven banks, which amended and restated in its entirety the Amended and Restated Credit Agreement, dated as of October 28, 2015, as amended by Amendment No. 1 to Amended and Restated Credit Agreement, dated as of November 10, 2015, and Amendment No. 2 to Amended and Restated Credit Agreement, dated as of August 26, 2016 (collectively, the “First Amended Credit Agreement”). The A&R Credit Agreement increased the aggregate available revolving commitment under the First Amended Credit Agreement from $150,000 to an initial aggregate available revolving commitment of $225,000 (the “Initial Revolving Commitment”). Under the A&R Credit Agreement, the Company may borrow, repay and reborrow from and as of December 21, 2016, to but excluding December 21, 2021 (the “Maturity Date”) provided, that if any of the Notes remain outstanding on the date that is 91 days prior to the maturity date of the Notes (the “2015 Convertible Maturity Date”), then the Maturity Date shall mean the date that is 91 days prior to the 2015 Convertible Maturity Date. The A&R Credit Agreement provides for (i) Eurodollar Loans (as such terms are defined in the A&R Credit Agreement), (ii) ABR Loans (as such terms are defined in the A&R Credit Agreement) or (iii) a combination thereof. As of March 31, 2018, the Company borrowed Revolving Loans (as defined under the A&R Credit Agreement) aggregating $62,000 which loans are Eurodollar Loans at interest rates ranging from 3.57% to 3.63% at March 31, 2018. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company’s senior secured net leverage ratio.

 

Under the A&R Credit Agreement, the Company also borrowed $150,000 in term loans (the “Initial Term Loan). Subject to certain conditions, including obtaining commitments from existing or prospective lenders, the Company had the right to increase the amount of the Initial Revolving Commitment (each, a “Revolving Facility Increase” and, together with the Initial Revolving Commitment, the “Revolving Commitment”) and/or the Initial Term Loan in an aggregate amount not to exceed $100,000 pursuant to an incremental loan feature in the A&R Credit Agreement. As of March 31, 2018, the remaining amount outstanding under the Initial Term Loan was $131,250 and was payable as a Eurodollar Loan at an interest rate of 4.05%. The proceeds of the Initial Revolving Commitment and Initial Term Loan were used to partially finance the acquisition of generic products and related assets of Citron and its affiliate Lucid, and pay fees and expenses related thereto. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company’s senior secured net leverage ratio.

 

The Initial Term Loan is payable as to principal in nineteen consecutive, equal quarterly installments of $3,750, which commenced on March 31, 2017 and will continue on each March 31, June 30, September 30 and December 31 thereafter. To the extent not previously paid, the final payment on the Term Loan Maturity Date (as defined in the A&R Credit Agreement) shall be in an amount equal to the then outstanding unpaid principal amount of the Initial Term Loan.

 

The A&R Credit Agreement, provides that commercial letters of credit shall be issued to provide the primary payment mechanism in connection with the purchase of any materials, goods or services in the ordinary course of business. The Company had no open letters of credit at March 31, 2018 and June 30, 2017.

 

In accordance with generally accepted accounting principles, deferred financing costs associated with the Initial Term Loan are presented as a direct deduction from the carrying value of the debt liability rather than showing the deferred financing costs as a deferred charge on the balance sheet. In addition, deferred financing costs associated with the Revolving Commitment have been recorded as a deferred charge on the balance sheet.

 

The A&R Credit Agreement provides for a security interest in substantially all of the personal property of the Company and certain of its subsidiaries. The A&R Credit Agreement contains several financial covenants including, among other things, maintaining a minimum level of debt service and certain leverage ratios. Under the A&R Credit Agreement, the Company and its subsidiaries are also subject to certain restrictive covenants, including, among other things, covenants governing liens, limitations on indebtedness, limitations on guarantees, limitations on sales of assets and sales of receivables, and limitations on loans and investments.

 

 44 

 

 

On December 13, 2017, the Company entered into a First Amendment to the Second Amended and Restated Credit Agreement (the “2017 Amendment”), which amended the A&R Credit Agreement. The 2017 Amendment, among other things, contained several amendments to the financial covenants in the A&R Credit Agreement.

 

As of March 31, 2018, the Company was in compliance with all of its financial covenants except for the maximum total net leverage ratio and the minimum debt service coverage ratio. On May 3, 2018, the Company entered into a Second Amendment and Waiver to the Second Amended and Restated Credit Agreement (the “2018 Amendment”). The 2018 Amendment, among other things, contains a waiver of any event of default under the A&R Credit Agreement arising as a result of the non-compliance by the Company with the Total Net Leverage Ratio and Debt Service Coverage Ratio financial covenants, in each case, solely for the fiscal quarter ended March 31, 2018. The Amendment also contains several amendments to the A&R Credit Agreement including, among other things, (a) reducing the available revolving commitment thereunder to $100,000, and (b) during the period commencing on the closing of the 2018 Amendment and ending on the date the Company demonstrates compliance with each financial covenant set forth in the A&R Credit Agreement for the fiscal quarter ending June 30, 2018 (the “Limitation Period”; provided that if the Company is not in compliance with any of the financial covenants set forth in the A&R Credit Agreement for the fiscal quarter ending June 30, 2018, then the Limitation Period shall continue indefinitely): (i) fixing the applicable margin with respect to all loans under the A&R Credit Agreement to the highest level provided under the A&R Credit Agreement, which is 1.50% in the case of ABR Loans (as defined in the A&R Credit Agreement) and 2.50% in the case of Eurodollar Loans (as defined in the A&R Credit Agreement), (ii) fixing the commitment fee on the undrawn revolving commitments under the A&R Credit Agreement to the highest level provided under the A&R Credit Agreement which is 0.40% per annum, (iii) requiring the prior written consent of the Required Lenders (as defined in the A&R Credit Agreement) as a condition precedent to the lenders extending any Loans (as defined in the A&R Credit Agreement) or the issuing banks issuing, amending, renewing or extending any Letter of Credit (as defined in the A&R Credit Agreement), (iv) restricting the amount of dividends or distributions the Company may make to its shareholders to no more than $0.01 per share for the fiscal quarter ending on June 30, 2018 and, during the Limitation Period, restricting the Company from making any other dividends or distributions to its shareholders thereafter and (v) restricting the incurrence of certain indebtedness, limiting acquisitions and other investments and imposing certain other restrictions.

 

In accordance with GAAP, we have classified the indebtedness outstanding under the Company’s credit facility as a current liability as of March 31, 2018. This differs from the customary treatment heretofore applicable to indebtedness outstanding under the Company’s credit facility, in which only the portion of such indebtedness payable within one year from the balance sheet date has been recorded as a current liability.  The waiver that the Company has received from its lenders under the credit facility applies solely to the non-compliance with certain financial covenants as of March 31, 2018 and thus does not waive non-compliance with any financial covenants as of June 30, 2018. It is probable that the Company will not comply with certain financial covenants as of June 30, 2018 in the absence of a material change in the Company’s operating results.  That probability is the factor that has caused the Company to reclassify its indebtedness. While the Company believes that if the Company cooperates with its lenders during the next 90 days, it is probable that the lenders will amend the financial covenants prior to June 30, 2018 or grant comparable waivers as of June 30, 2018, that probability is not sufficient to enable the Company to avoid reclassifying its indebtedness under current circumstances.

 

In conjunction with the Credit Agreement, the Company entered into an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is December 21, 2021. The remaining notional balance of this derivative as of March 31, 2018 is $87,500.

 

Working Capital Outlook

 

As a result of the above-mentioned reclassification of certain of the Company’s debt, working capital was $52,446 at March 31, 2018. At June 30, 2017, the Company’s working capital was $248,750. The reclassification adversely impacts the calculation of the Company’s working capital. As of March 31, 2018, the Company had current assets of $487,641 and, after giving effect to the reclassification, current liabilities of $435,195, resulting in working capital of $52,446.   If the lenders’ waiver applied to June 30, 2018 as well as March 31, 2018, the Company’s current liabilities as of March 31, 2018 would have been $258,937 and the Company’s working capital would have been $228,704.

 

 45 

 

 

In connection with the acquisition of certain products and related assets from Citron and Lucid, Aceto committed to make a $50,000 unsecured deferred payment that will bear interest at a rate of 5% per annum to the sellers on December 21, 2021 and to issue 5,122 shares of Aceto common stock beginning on December 21, 2019. The product purchase agreement also provides for a 5-year potential earn-out of up to an additional $50,000 in cash, based on the financial performance of four pre-specified pipeline products that are currently in development. As of March 31, 2018, the Company accrued $663 related to this contingent consideration.

 

In October 2015, we filed a universal shelf registration statement with the SEC to allow us to potentially offer an indeterminate principal amount and number of securities in the future with a proposed maximum aggregate offering price of up to $200,000. Under the shelf registration statement, we have the flexibility to publicly offer and sell from time to time common stock, debt securities, preferred stock, warrants and units or any combination of such securities.

 

In November 2015, we offered $125,000 aggregate principal amount of 2% Convertible Senior Notes due 2020 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In addition, we granted the initial purchasers for the offering an option to purchase up to an additional $18,750 aggregate principal amount pursuant to the initial purchasers’ option to purchase additional notes, which was exercised in November 2015. Therefore, the total offering was $143,750 aggregate principal amount. The remaining net proceeds received from the offering, after paying down our credit facilities and costs associated with the offering and a related hedge transaction, were used for general corporate purposes.

 

In connection with our agricultural protection business, we plan to continue to acquire product registrations and related data filed with the United States Environmental Protection Agency as well as payments to various task force groups, which could approximate $2,299 over the next twelve months.

 

In connection with our environmental remediation obligation for Arsynco, we anticipate paying $4,112 towards remediation of the property in the next twelve months, which is included in accrued expenses in our Condensed Consolidated Balance Sheet as of March 31, 2018.

 

As noted above, in order to obtain a waiver with respect to certain financial covenants under its credit facilities, the Company entered into the 2018 Amendment. The 2018 Amendment substantially restricts the Company’s borrowing capacity and does not provide covenant waivers with respect to any date or period after March 31, 2018. The significant decline in the market price of the Company’s common stock, and the uncertainties associated with pending legal proceedings, render it difficult for the Company to access the equity markets at the present time. The Company is also incurring substantial expenses to address the business and financial challenges previously discussed. As announced by the Company in its April 18, 2019 press release, the Company will pay a flat monthly fee of $250 for the services of its interim chief financial officer, Rebecca Roof. The Company has also retained financial and legal advisors to assist it in dealing with the various challenges that the Company is currently facing. While the Company had over $60,000 in cash as of March 31, 2018, and while its operating businesses continue to generate substantial cash, the current demands upon the Company and its liquidity are significant. As a result, the Company also announced on April 18, 2018 that it is exploring a range of strategic alternatives, including the sale of a key business segment(s), a merger or other business combination with another party, continuing as a standalone entity or other potential alternatives. We believe that our cash, liquid assets and operating cash flows will provide us with adequate resources to fund our working capital needs for the next twelve months.

 

Impact of Recent Accounting Pronouncements

 

In February 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which gives entities the option to reclassify the disproportionate income tax effects ("stranded tax effects") caused by the newly-enacted U.S. Tax Cuts and Jobs Act from accumulated other comprehensive income to retained earnings. The update also requires new disclosures, some of which are applicable for all entities. The guidance in ASU 2018-02 is effective for annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact of the provisions of ASU 2018-02.

 

 46 

 

 

In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which has the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. In addition to that main objective, the amendments in ASU 2017-12 make certain targeted improvements to simplify the application of the hedge accounting guidance in current GAAP. The amendments in ASU 2017-12 are effective for public business entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of the provisions of ASU 2017-12.

 

In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company does not believe this new accounting standard update will have a material impact on its consolidated financial statements.

 

In January 2017, the FASB issued ASU 2017-04 Intangibles - Goodwill and Other (Topic 350) which would eliminate the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, the amount of an impairment charge would be recognized if the carrying amount of a reporting unit is greater than its fair value. ASU 2017-04 is effective for public companies for fiscal years beginning after December 15, 2019. The Company elected to early adopt this ASU in the third quarter of fiscal 2018. (See Note 9 to the Condensed Consolidated Financial Statements- Fair Value Measurements).

 

In January 2017, the FASB issued ASU 2017-01 Business Combinations (Topic 805): Clarifying the Definition of a Business, with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU 2017-01 is effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated financial statements.

 

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which addresses eight specific cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact of the provisions of ASU 2016-15.

 

In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which changes certain aspects of accounting for share-based payments to employees. The Company adopted ASU 2016-09 as of July 1, 2017. ASU 2016-09 requires that all tax benefits and deficiencies related to share-based payments be recognized and recorded through the statement of income for all awards settled or expiring after the adoption of ASU 2016-09. Under prior guidance, tax benefits in excess of compensation costs ("windfalls") were recorded in equity, and any tax deficiencies ("shortfalls") were recorded in equity to the extent of previous windfalls and then to the statement of income. For the three months and nine months ended March 31, 2018, the Company recorded additional tax expense of $420 and $1,521, respectively, associated with net tax deficiencies. ASU 2016-09 also requires, either prospectively or retrospectively, that all tax-related cash flows resulting from share-based payments be reported as operating activities on the statement of cash flows, a change from prior guidance that required windfall tax benefits to be presented as an inflow from financing activities and an outflow from operating activities on the statement of cash flows. The Company has elected to adopt such presentation on a prospective basis. Additionally, ASU 2016-09 allows entities to make an accounting policy election for the impact of most types of forfeitures on the recognition of expense for share-based payment awards by allowing the forfeitures to be either estimated, as was required under prior guidance, or recognized when they actually occur. Under ASU 2016-09, the Company recognizes forfeitures when they actually occur.

 

 47 

 

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) that replaces existing lease guidance. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. ASU 2016-02 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2018. The Company is currently evaluating the impact of the provisions of ASU 2016-02.

 

In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Assets. This ASU is intended to simplify the presentation of deferred taxes on the balance sheet and requires an entity to present all deferred tax assets and deferred tax liabilities as non-current on the balance sheet. Under the prior guidance, entities were required to separately present deferred taxes as current or non-current. Netting deferred tax assets and deferred tax liabilities by tax jurisdiction will still be required under the new guidance. The Company prospectively adopted the provisions of ASU 2015-17, as of July 1, 2017. The Company's prospective adoption of ASU 2015-17 impacts the classification of deferred tax assets and liabilities on any balance sheet that reports the Company's financial position for any date after June 30, 2017. Balance sheets for prior periods have not been adjusted. The adoption of ASU 2015-17 has no impact on the Company's results of operations or cash flows.

 

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. This ASU requires that an entity measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted this standard in the first quarter of fiscal year 2018. The adoption of this standard did not have any impact on the condensed consolidated financial statements of the Company.

 

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which is the new comprehensive revenue recognition standard that will supersede all existing revenue recognition guidance under U.S. GAAP. The standard's core principle is that a company will recognize revenue when it transfers promised goods or services to a customer in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB subsequently issued ASU 2015-14, Revenue from Contracts with Customers - Deferral of the Effective Date, which approved a one-year deferral of ASU 2014-09 for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. In March 2016 and April 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers - Principal versus Agent Considerations (Reporting Revenue Gross versus Net), and ASU 2016-10, Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing, respectively, which further clarify the guidance related to those specific topics within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients, to reduce the risk of diversity in practice for certain aspects in ASU 2014-09, including collectibility, noncash consideration, presentation of sales tax and transition. Additionally, in December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers. ASU 2016-20 makes minor corrections or minor improvements to the standard that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. The Company has made progress in its evaluation of the amended guidance, including identification of revenue streams. The Company recognizes revenue from product sales at the time of shipment and passage of title and risk of loss and control of the goods is transferred to the customer. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to its customers. Although the Company is continuing to assess the impact of the amended guidance, Aceto generally anticipates that the timing of recognition of revenue will be substantially unchanged under the amended guidance. The amended guidance will be effective for Aceto in the first quarter of fiscal 2019 and permits adoption under either the full retrospective approach (recognize effects of the amended guidance in each prior reporting period presented) or the modified retrospective approach (recognize the cumulative effect of adoption as an adjustment to retained earnings at the date of initial application). The Company anticipates adopting this amended standard on a modified retrospective basis.

 

 48 

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Market Risk Sensitive Instruments

 

The market risk inherent in our market-risk-sensitive instruments and positions is the potential loss arising from adverse changes in investment market prices, foreign currency exchange-rates and interest rates.

 

Investment Market Price Risk

 

We had short-term investments of $3,059 at March 31, 2018 and $2,046 at June 30, 2017. Those short-term investments consisted of time deposits. Time deposits are short-term in nature and are accordingly valued at cost plus accrued interest, which approximates fair value.

 

Foreign Currency Exchange Risk

 

In order to reduce the risk of foreign currency exchange rate fluctuations, we hedge some of our transactions denominated in a currency other than the functional currencies applicable to each of our various entities. The instruments used for hedging are short-term foreign currency contracts (futures). The changes in market value of such contracts have a high correlation to price changes in the currency of the related hedged transactions. At March 31, 2018, we had foreign currency contracts outstanding that had a notional amount of $62,350. At June 30, 2017 our outstanding foreign currency contracts had a notional amount of $62,187. The difference between the fair market value of the foreign currency contracts and the related commitments at inception and the fair market value of the contracts and the related commitments at March 31, 2018 was not material.

 

We are subject to risk from changes in foreign exchange rates for our subsidiaries that use a foreign currency as their functional currency and are translated into U.S. dollars. These changes result in cumulative translation adjustments, which are included in accumulated other comprehensive loss. On March 31, 2018, we had translation exposure to various foreign currencies, with the most significant being the Euro. The potential loss as of March 31, 2018, resulting from a hypothetical 10% adverse change in quoted foreign currency exchange rates amounted to $6,588. On June 30, 2017 such potential loss amounted to $8,869. Actual results may differ.

 

Interest rate risk

 

Due to our financing, investing and cash-management activities, we are subject to market risk from exposure to changes in interest rates. We utilize a balanced mix of debt maturities along with both fixed-rate and variable-rate debt to manage our exposure to changes in interest rates. Our financial instrument holdings were analyzed to determine their sensitivity to interest rate changes. In this sensitivity analysis, we used the same change in interest rate for all maturities. All other factors were held constant. If there were an adverse change in interest rates of 10%, the expected effect on net income related to our financial instruments would be immaterial. However, there can be no assurances that interest rates will not significantly affect our results of operations.

 

In conjunction with the Company’s credit facilities, the Company entered into an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is December 21, 2021. The remaining notional balance of this derivative as of March 31, 2018 is $87,500. The unrealized gain to date associated with this derivative, which is recorded in accumulated other comprehensive income in the consolidated balance sheet at March 31, 2018, is $1,539.

 

 49 

 

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are designed to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. Our disclosure controls and procedures are also designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officer, to allow timely decisions regarding required disclosure. Our chief executive officer and chief financial officer, with assistance from other members of our management, have reviewed the effectiveness of our disclosure controls and procedures as of March 31, 2018, the end of the period covered by this report. Previously, based on that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2018. However, due to the material weakness in internal control over financial reporting described below, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures were not effective as of March 31, 2018.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company's annual or interim financial statements will not be prevented or detected on a timely basis. In completing our work with respect to the condensed consolidated financial statements presented in this report, we evaluated the deficiencies in our internal controls over financial reporting and determined that our internal control over financial reporting was not effective due to a material weakness in our controls over income tax accounting.  Specifically, the execution of the controls over the application of the accounting literature to the measurement of deferred taxes did not operate effectively in relation to the assessment of the realizability of our deferred tax assets, and the need for a valuation allowance.

 

Changes in Internal Control Over Financial Reporting

 

There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during our fiscal quarter ended March 31, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

As previously described in our 2017 10-K, we are subject to various environmental proceedings for which there were no material changes during the nine months ended March 31, 2018. 

 

The Company incorporates by reference into this Item 1 the disclosures made with respect to pending legal proceedings set forth in Note 8 (Commitments, Contingencies and Other Matters) and Note 13 (Subsequent Events) to the Company’s Condensed Consolidated Financial Statements presented elsewhere herein.

 

 50 

 

 

Item 1A. Risk Factors.

 

In addition to the other information discussed in this report, the factors described in Part I, Item 1A. “Risk Factors” in our 2017 Annual Report on Form 10-K for the fiscal year ended June 30, 2017, as amended, should be considered as they could materially adversely affect our business, financial condition, liquidity or future results.

 

The risk factors set forth below update and, to the extent inconsistent, supersede the risk factors associated with our business previously disclosed in Part I, Item 1A. "Risk Factors" in our 2017 Annual Report on Form 10-K for the fiscal year ended June 30, 2017, as amended.

 

The risk factors identified by the Company in this and other filings may not describe all of the risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may adversely affect our business, financial condition or operating results.

 

The material impairment charge that we recorded as of March 31, 2018 was based on several adverse factors, certain of which could materially adversely impact the Company in subsequent fiscal quarters.

 

In the third quarter of fiscal 2018, we recorded impairment charges for goodwill and intangible assets of $256,266, all of which related to the Rising Pharmaceuticals reporting unit which is part of the Human Health segment. During the third quarter of fiscal 2018, our Rising Pharmaceuticals reporting unit had a decline in actual and forecasted revenue and earnings due to the persistent adverse conditions in the generics market. In addition, the U.S. government made a determination (which we are appealing) that 11 generic drug products we acquired through our Acetris Health subsidiary (part of the Rising Pharmaceuticals reporting unit) in a product purchase agreement with Lucid are not in compliance with the TAA country-of-origin provisions of a clause contained in the government supply contracts acquired from Lucid. As a result of the foregoing, we conducted an impairment test and recognized a significant goodwill and intangible asset impairment charge.

 

Many of the market and industry factors that led to the March 31, 2018 impairment charges could continue to impact us in future fiscal periods. Such factors could materially and adversely impact our business, financial condition, results of operations, liquidity and cash flows and could lead to additional impairment charges in the future.

 

We have been named in legal proceedings alleging securities law violations, which could be expensive and could divert our management’s attention.  There may be additional class action and/or derivative claims filed in the future.

 

We and certain of our former and current executive officers have been named as defendants in securities actions filed in the United States District Court for the Eastern District of New York. While we plan to vigorously defend these actions, we may be unable to defend or settle these claims on favorable terms, and there can be no assurance that additional claims will not be made by other stockholders, or stockholders as a class. We expect to incur significant expenses associated with the defense of the pending and any future securities laws claims or derivative suits (including, without limitation, substantial attorneys’ fees and other fees of professional advisors and potential obligations to indemnify individuals who are or may become parties to such actions). An adverse determination, if one were to occur, could harm our reputation and have a material and negative affect on our business. We currently maintain “directors and officers” insurance policies; however, our insurance coverage may not be adequate or available for us to avoid or limit our exposure in the pending actions or in future claims and adequate insurance coverage may not be available in sufficient amounts or at a reasonable cost in the future. Additionally, securities and derivative claims may divert our management’s attention from other business concerns, which could seriously harm our business, financial condition, results of operations, liquidity and cash flows.

 

 51 

 

 

We were not in compliance with certain covenants under our A&R Credit Facility as of March 31, 2018 and, although a waiver was obtained with respect to such non-compliance, in the event we are in violation of such covenants for subsequent periods, and we are unable to obtain a waiver, our business, financial condition, results of operations, liquidity and cash flows could be materially and adversely affected.

 

As of March 31, 2018, we were not in compliance with financial covenants under our A&R Credit Facility related to the maximum total net leverage ratio and the minimum debt service coverage ratio. On May 3, 2018, we entered into a Second Amendment and Waiver to the A&R Credit Agreement (the “2018 Amendment”). The 2018 Amendment, among other things, contains a waiver of any event of default under the A&R Credit Agreement arising as a result of our non-compliance with the Total Net Leverage Ratio and Debt Service Coverage Ratio financial covenants, in each case, solely for the fiscal quarter ended March 31, 2018. We could again be in breach of these covenants or other covenants with respect to subsequent periods while our credit facility remains outstanding. In the event of any future breach and resulting default, there is no guarantee that we could obtain an additional waiver on satisfactory terms, or at all, and any such waiver could result in higher borrowing costs and/or more restrictive covenants in future periods. Our failure to comply with these covenants or others could result in a default that, if not cured or waived, could result in our outstanding indebtedness becoming immediately due and payable, which in turn would have a material and adverse effect on our business, financial condition, results of operations, liquidity and cash flows.

 

In addition, during the period commencing on the closing of the 2018 Amendment and ending on the date we demonstrate compliance with each financial covenant set forth in the A&R Credit Agreement, the 2018 Amendment also amends the A&R Credit Facility to, among other things, restrict the incurrence of certain indebtedness, limit our ability to pay dividends, limit acquisitions and other investments and imposes certain other restrictions. Such restrictions limit our flexibility and thus could have a material and adverse effect on our business, financial condition, results of operations, liquidity and cash flows.

 

Because the waiver that we have received does not extend to fiscal periods beyond March 31, 2018 and because it is probable that we will not comply with certain financial covenants as of June 30, 2018 in the absence of a material change in our operating results, it was necessary for us to reclassify indebtedness under our credit facility, which lowered our working capital significantly as compared with our working capital as of December 31, 2017. Our ability to access the capital markets may be adversely affected by the additional restrictions contained in the 2018 Amendment and the reduction to our working capital, and we may be subject to higher borrowing costs, or, in some cases, unable to obtain financing on terms that are acceptable to us. If adequate funds are not available to us, or are not available on acceptable terms, we may not have sufficient liquidity to fund our operations, make future investments, take advantage of acquisitions or other opportunities, or respond to competitive challenges and this, in turn, could materially adversely affect our ability to advance our strategic plans.

 

We have experienced turnover in our senior management, and the loss of key personnel or an ability to attract, retain and motivate qualified personnel may result in operational inefficiencies that could negatively affect our business.

 

Our success depends upon the continued service of our talented management, as well as our key operational and technical employees, as well as upon our ability to continue to attract additional highly qualified personnel. We have recently experienced significant turnover in our senior management. In October 2017, William C. Kennally III replaced Salvatore Guccione as our chief executive officer. In October 2017, our chief financial officer, Douglas Roth, announced that he was retiring. He was replaced by Edward J. Borkowski, who served only briefly before accepting employment elsewhere. We have named Rebecca Roof to serve as our interim chief financial officer at a cost of two hundred fifty thousand dollars per month, payable to Ms. Roof’s employer AP Services LLC, an affiliate of AlixPartners LLP. In light of the significant challenges we are facing, we have also retained financial advisors to assist us at considerable expense.

 

 52 

 

 

Our business may be adversely affected if we encounter complications in connection with the upgrade and implementation of our enterprise resource planning (“ERP”) system, our information technology systems and infrastructure. Upgrading and integrating our business systems could result in implementation issues and business disruptions.

 

In recent years, we have implemented or planned implementations of a new ERP system at all our global locations. The implementation of a new ERP system at our Rising subsidiary is scheduled to commence during May 2018. In general, the process of planning and preparing for these types of implementations is extremely complex and we will be required to address a number of challenges, including data conversion, system cutover and user training during the Rising implementation. Problems in any of these areas could cause operational problems during implementation, including delayed shipments, missed sales, billing and accounting errors and other operational issues. While we have invested significantly in the operation and protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions, or identify breaches in our systems. Prolonged interruptions or significant breaches could materially adversely affect our business, financial condition, operating results and cash flows. In addition, in automating processes that heretofore have been undertaken manually, we may be required to reassess certain of our estimates, especially with respect to our rebates, returns and chargebacks approaches.

 

Our business, products or product pricing could be subject to negative publicity arising from the subpoena we recently received, which could have a material adverse effect on our business, financial position, results of operations, liquidity and cash flows.

 

In recent years, the generic pharmaceutical industry has been the subject of significant publicity regarding the pricing of pharmaceutical products, including publicity and pressure resulting from prices charged by competitors and peer companies for new products as well as price increases by competitors and peer companies on older products that the public has deemed excessive. Any downward pricing pressure on the price of our products arising from social or political pressure to lower the cost of pharmaceutical products could have a material adverse impact on our business, financial position, results of operations, liquidity and cash flows.

 

Accompanying the press and media coverage of pharmaceutical pricing practices and public complaints about the same, there has been increasing U.S. federal and state legislative and enforcement interest with respect to drug pricing. For instance, the United States Department of Justice has issued subpoenas to pharmaceutical companies, including us, seeking information about the sales, marketing and pricing of certain generic drugs. In addition to the effects of any investigations or claims brought against us, our business, financial position, results of operations, liquidity and cash flows could also be materially adversely affected if any such inquiries, of us or of other pharmaceutical companies or the industry more generally, were to result in legislative or regulatory proposals that limit our ability to increase the prices of our products.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

Not Applicable.

 

Item 3. Defaults Upon Senior Securities

 

Not Applicable.

 

Item 4. Mine Safety Disclosures

 

Not Applicable.

 

Item 5. Other Information

 

On May 3, 2018, the Company entered into a Second Amendment and Waiver to Second Amended and Restated Credit Agreement (the “Amendment”), by and among the Company, certain other loan parties party thereto (the “Loan Parties”), the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent (the “Administrative Agent”), which amended that certain Second Amended and Restated Credit Agreement, dated as of December 21, 2016, by and among the Company, the Loan Parties, the lenders party thereto and the Administrative Agent (as amended by that certain First Amendment to Second Amended and Restated Credit Agreement, dated as of December 13, 2017, the “A&R Credit Agreement”).

 

 53 

 

 

The Amendment, among other things, contains a waiver of any event of default under the A&R Credit Agreement arising as a result of the non-compliance by the Company with the Total Net Leverage Ratio and Debt Service Coverage Ratio financial covenants, in each case, solely for the fiscal quarter ended March 31, 2018. The Amendment also contains several amendments to the A&R Credit Agreement including, among other things, (a) reducing the available revolving commitment thereunder to $100,000,000, and (b) during the period commencing on the closing of the Amendment and ending on the date the Company demonstrates compliance with each financial covenant set forth in the A&R Credit Agreement for the fiscal quarter ending June 30, 2018 (the “Limitation Period”; provided that if the Company is not in compliance with any of the financial covenants set forth in the A&R Credit Agreement for the fiscal quarter ending June 30, 2018, then the Limitation Period shall continue indefinitely): (i) fixing the applicable margin with respect to all loans under the A&R Credit Agreement to the highest level provided under the A&R Credit Agreement, which is 1.50% in the case of ABR Loans (as defined in the A&R Credit Agreement) and 2.50% in the case of Eurodollar Loans (as defined in the A&R Credit Agreement), (ii) fixing the commitment fee on the undrawn revolving commitments under the A&R Credit Agreement to the highest level provided under the A&R Credit Agreement which is 0.40% per annum, (iii) requiring the prior written consent of the Required Lenders (as defined in the A&R Credit Agreement) as a condition precedent to the lenders extending any Loans (as defined in the A&R Credit Agreement) or the issuing banks issuing, amending, renewing or extending any Letter of Credit (as defined in the A&R Credit Agreement), (iv) restricting the amount of dividends or distributions the Company may make to its shareholders to no more than $0.01 per share for the fiscal quarter ending on June 30, 2018 and, during the Limitation Period, restricting the Company from making any other dividends or distributions to its shareholders thereafter and (v) restricting the incurrence of certain indebtedness, limiting acquisitions and other investments and imposing certain other restrictions.

 

The foregoing description of the Amendment is a summary only, and is qualified in its entirety by reference to the complete text thereof, a copy of which is attached as Exhibit 10.3 to this Quarterly Report on Form 10-Q, and which is incorporated herein.

 

Item 6.Exhibits

 

15.1Letter from BDO USA, LLP regarding unaudited interim financial information

 

31.1Certifications of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

31.2Certifications of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

32.1*Certifications of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

32.2*Certifications of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

101.INSXBRL Instance Document

 

101.SCHXBRL Taxonomy Extension Schema Document

 

101.CALXBRL Taxonomy Extension Calculation Linkbase Document

 

101.DEFXBRL Taxonomy Extension Definition Linkbase Document

 

101.LABXBRL Taxonomy Extension Label Linkbase Document

 

101.PREXBRL Taxonomy Extension Presentation Linkbase Document

 

*Furnished, not filed

 

 54 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

      ACETO CORPORATION
         
DATE October 12, 2018   BY /s/ William C. Kennally, III
      William C. Kennally, President and Chief Executive Officer
      (Principal Executive Officer)
         
DATE October 12, 2018   BY /s/ Rebecca Roof
      Rebecca Roof, Interim Chief Financial Officer
      (Principal Financial Officer)

  

 55 

 

 EX-15.1 2 tv504330_ex15-1.htm EXHIBIT 15.1

 

Exhibit 15.1

 

October 12, 2018

 

 

Securities and Exchange Commission

100 F Street N.E.

Washington, D.C. 20549

 

We are aware that Aceto Corporation and subsidiaries has incorporated by reference in its Registration Statements on Form S-3 (No. 333-207394) and Form S-8 (No. 333-209693, No. 333-187353, No. 333-174834, No. 333-149586, No. 333-90929, and No. 333-110653) our report dated May 7, 2018, except for Notes 2 and 12 which are dated October 12, 2018, relating to the Company’s unaudited interim condensed consolidated financial statements appearing in its quarterly report on Form 10-Q for the quarter ended March 31, 2018. Our report on the unaudited interim condensed consolidated financial statements contains an emphasis of a matter regarding the Company’s restatement of the consolidated financial statements for the quarter ended March 31, 2018. Pursuant to Regulation C under the Securities Act of 1933, that report is not considered a part of the registration statement prepared or certified by our firm or a report prepared or certified by our firm within the meaning of Sections 7 and 11 of the Act. It should be noted that we have not performed any procedures subsequent to May 7, 2018, except for the information contained in Notes 2 and 12 which are dated October 12, 2018.

 

 

/s/ BDO USA, LLP

 

Melville, New York

 

 

 EX-31.1 3 tv504330_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

CERTIFICATION

 

I, William C. Kennally, III, certify that:

 

1.I have reviewed this Amendment No. 1 to quarterly report on Form 10-Q of Aceto Corporation (the “Registrant”);

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

 

4.The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

 

a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

 

5.The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

 

a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

 

b)any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

Dated: October 12, 2018

 

/s/   William C. Kennally, III  
President and Chief Executive Officer  

(Principal Executive Officer)

  

 

 

 EX-31.2 4 tv504330_ex31-2.htm EXHIBIT 31.2

 

Exhibit 31.2

 

CERTIFICATION

 

I, Rebecca Roof, certify that:

 

1.I have reviewed this Amendment No. 1 to quarterly report on Form 10-Q of Aceto Corporation (the “Registrant”);

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

 

4.The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

 

a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

 

5.The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

 

a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

 

b)any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

Dated: October 12, 2018

 

/s/   Rebecca Roof  
Interim Chief Financial Officer  
(Principal Financial Officer)  

 

 
 EX-32.1 5 tv504330_ex32-1.htm EXHIBIT 32.1

 

Exhibit 32.1

 

CERTIFICATION

 

In connection with Amendment No. 1 to the Quarterly Report of Aceto Corporation, a New York corporation (the “Company”), on Form 10-Q for the period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, William C. Kennally, III, President and Chief Executive Officer, certify, pursuant to Section 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ William C. Kennally, III  
President and Chief Executive Officer  
 (Principal Executive Officer)  
October 12, 2018  

 

 
 EX-32.2 6 tv504330_ex32-2.htm EXHIBIT 32.2

 

Exhibit 32.2

 

CERTIFICATION

 

In connection with Amendment No. 1 to the Quarterly Report of Aceto Corporation, a New York corporation (the “Company”), on Form 10-Q for the period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Rebecca Roof, Interim Chief Financial Officer of the Company, certify, pursuant to Section 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Rebecca Roof  
Interim Chief Financial Officer  
(Principal Financial Officer)  
October 12, 2018  

 

 

 

 EX-101.INS 7 acet-20180331.xml XBRL INSTANCE DOCUMENT 0000002034 acet:BASFCorporationMember 2008-07-01 2009-06-30 0000002034 us-gaap:MortgagesMember 2011-06-30 0000002034 us-gaap:MortgagesMember 2011-06-01 2011-06-30 0000002034 acet:Plan2010Member 2012-12-06 0000002034 2015-11-30 0000002034 us-gaap:SeniorNotesMember 2015-11-30 0000002034 us-gaap:SeniorNotesMember 2015-11-01 2015-11-30 0000002034 acet:Plan2015Member 2015-12-15 0000002034 2016-06-30 0000002034 us-gaap:RevolvingCreditFacilityMember acet:AmendedCreditAgreementMember 2016-08-26 0000002034 us-gaap:RevolvingCreditFacilityMember acet:AmendedCreditAgreementMember 2016-12-21 0000002034 acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2016-12-21 0000002034 us-gaap:RevolvingCreditFacilityMember acet:AmendedCreditAgreementMember 2016-12-01 2016-12-21 0000002034 acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2016-12-01 2016-12-21 0000002034 acet:AmendedCreditAgreementMember 2016-12-01 2016-12-21 0000002034 acet:RisingPharmaceuticalsIncMember 2016-12-01 2016-12-21 0000002034 acet:ExpirationDateDecember212021Member us-gaap:CashFlowHedgingMember us-gaap:InterestRateSwapMember 2017-03-21 0000002034 acet:ExpirationDateDecember212021Member us-gaap:CashFlowHedgingMember us-gaap:InterestRateSwapMember 2017-03-01 2017-03-21 0000002034 2017-01-01 2017-03-31 0000002034 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-03-31 0000002034 us-gaap:OperatingSegmentsMember acet:HumanHealthMember 2017-01-01 2017-03-31 0000002034 us-gaap:OperatingSegmentsMember acet:PharmaceuticalIngredientsMember 2017-01-01 2017-03-31 0000002034 us-gaap:OperatingSegmentsMember acet:PerformanceChemicalsMember 2017-01-01 2017-03-31 0000002034 acet:RestrictedCommonStockAndRestrictedStockUnitsMember 2017-01-01 2017-03-31 0000002034 us-gaap:ForeignExchangeContractMember 2017-01-01 2017-03-31 0000002034 2016-07-01 2017-03-31 0000002034 us-gaap:CorporateNonSegmentMember 2016-07-01 2017-03-31 0000002034 us-gaap:OperatingSegmentsMember acet:HumanHealthMember 2016-07-01 2017-03-31 0000002034 us-gaap:OperatingSegmentsMember acet:PharmaceuticalIngredientsMember 2016-07-01 2017-03-31 0000002034 us-gaap:OperatingSegmentsMember acet:PerformanceChemicalsMember 2016-07-01 2017-03-31 0000002034 acet:RestrictedCommonStockAndRestrictedStockUnitsMember 2016-07-01 2017-03-31 0000002034 us-gaap:ForeignExchangeContractMember 2016-07-01 2017-03-31 0000002034 2017-03-31 0000002034 acet:ShareRepurchaseProgramMember 2017-05-04 0000002034 us-gaap:PerformanceSharesMember 2016-07-01 2017-06-30 0000002034 us-gaap:RestrictedStockMember acet:NonEmployeeDirectorMember 2016-07-01 2017-06-30 0000002034 us-gaap:RestrictedStockMember acet:EmployeeMember 2016-07-01 2017-06-30 0000002034 us-gaap:RestrictedStockUnitsRSUMember acet:EmployeeMember 2016-07-01 2017-06-30 0000002034 2017-06-30 0000002034 acet:BASFCorporationMember 2017-06-30 0000002034 us-gaap:SeniorNotesMember 2017-06-30 0000002034 acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2017-06-30 0000002034 acet:FranceCompanyMember 2017-06-30 0000002034 us-gaap:MediumTermNotesMember 2017-06-30 0000002034 acet:ArsyncoIncMember 2017-06-30 0000002034 us-gaap:RevolvingCreditFacilityMember 2017-06-30 0000002034 us-gaap:FairValueInputsLevel1Member us-gaap:BankTimeDepositsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-06-30 0000002034 us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-06-30 0000002034 us-gaap:FairValueInputsLevel3Member us-gaap:BankTimeDepositsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-06-30 0000002034 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-06-30 0000002034 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-06-30 0000002034 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-06-30 0000002034 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-06-30 0000002034 us-gaap:BankTimeDepositsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-06-30 0000002034 us-gaap:AccruedLiabilitiesMember 2017-06-30 0000002034 us-gaap:LongTermDebtMember 2017-06-30 0000002034 2017-08-01 2017-08-24 0000002034 acet:RestrictedCommonStockAndRestrictedStockUnitsMember us-gaap:ChiefExecutiveOfficerMember 2017-09-01 2017-09-30 0000002034 2017-12-01 2017-12-07 0000002034 2017-07-01 2017-12-31 0000002034 2018-01-31 2018-02-01 0000002034 2018-01-01 2018-03-31 0000002034 acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2018-01-01 2018-03-31 0000002034 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-03-31 0000002034 us-gaap:OperatingSegmentsMember acet:HumanHealthMember 2018-01-01 2018-03-31 0000002034 us-gaap:OperatingSegmentsMember acet:PharmaceuticalIngredientsMember 2018-01-01 2018-03-31 0000002034 us-gaap:OperatingSegmentsMember acet:PerformanceChemicalsMember 2018-01-01 2018-03-31 0000002034 acet:RestrictedCommonStockAndRestrictedStockUnitsMember 2018-01-01 2018-03-31 0000002034 us-gaap:ForeignExchangeContractMember 2018-01-01 2018-03-31 0000002034 us-gaap:InterestExpenseMember 2018-01-01 2018-03-31 0000002034 us-gaap:AccountingStandardsUpdate201609Member 2018-01-01 2018-03-31 0000002034 acet:HumanHealthSegmentAcetrisHealthMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-03-31 0000002034 acet:HumanHealthSegmentRisingReportingUnitMember 2018-01-01 2018-03-31 0000002034 acet:HumanHealthSegmentRisingPharmaMember 2018-01-01 2018-03-31 0000002034 us-gaap:ScenarioPreviouslyReportedMember 2018-01-01 2018-03-31 0000002034 us-gaap:RestatementAdjustmentMember 2018-01-01 2018-03-31 0000002034 2017-07-01 2018-03-31 0000002034 us-gaap:SeniorNotesMember 2017-07-01 2018-03-31 0000002034 acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2017-07-01 2018-03-31 0000002034 us-gaap:CorporateNonSegmentMember 2017-07-01 2018-03-31 0000002034 us-gaap:OperatingSegmentsMember acet:HumanHealthMember 2017-07-01 2018-03-31 0000002034 us-gaap:OperatingSegmentsMember acet:PharmaceuticalIngredientsMember 2017-07-01 2018-03-31 0000002034 us-gaap:OperatingSegmentsMember acet:PerformanceChemicalsMember 2017-07-01 2018-03-31 0000002034 acet:RestrictedCommonStockAndRestrictedStockUnitsMember 2017-07-01 2018-03-31 0000002034 us-gaap:ForeignExchangeContractMember 2017-07-01 2018-03-31 0000002034 us-gaap:PerformanceSharesMember 2017-07-01 2018-03-31 0000002034 us-gaap:RestrictedStockMember acet:NonEmployeeDirectorMember 2017-07-01 2018-03-31 0000002034 us-gaap:RestrictedStockMember acet:EmployeeMember 2017-07-01 2018-03-31 0000002034 us-gaap:MediumTermNotesMember 2017-07-01 2018-03-31 0000002034 us-gaap:InterestExpenseMember 2017-07-01 2018-03-31 0000002034 us-gaap:AccountingStandardsUpdate201609Member 2017-07-01 2018-03-31 0000002034 acet:HumanHealthSegmentAcetrisHealthMember us-gaap:CustomerRelationshipsMember 2017-07-01 2018-03-31 0000002034 acet:HumanHealthSegmentRisingReportingUnitMember 2017-07-01 2018-03-31 0000002034 acet:HumanHealthSegmentRisingPharmaMember 2017-07-01 2018-03-31 0000002034 us-gaap:ScenarioPreviouslyReportedMember 2017-07-01 2018-03-31 0000002034 us-gaap:RestatementAdjustmentMember 2017-07-01 2018-03-31 0000002034 acet:PulvairSiteGroupMember 2017-07-01 2018-03-31 0000002034 acet:ArsyncoIncMember us-gaap:MinimumMember 2017-07-01 2018-03-31 0000002034 acet:ArsyncoIncMember us-gaap:MaximumMember 2017-07-01 2018-03-31 0000002034 2018-03-31 0000002034 acet:BASFCorporationMember 2018-03-31 0000002034 us-gaap:MortgagesMember 2018-03-31 0000002034 us-gaap:SeniorNotesMember 2018-03-31 0000002034 acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2018-03-31 0000002034 acet:ExpirationDateDecember212021Member us-gaap:CashFlowHedgingMember us-gaap:InterestRateSwapMember 2018-03-31 0000002034 us-gaap:ForeignExchangeContractMember 2018-03-31 0000002034 acet:FranceCompanyMember 2018-03-31 0000002034 us-gaap:MediumTermNotesMember 2018-03-31 0000002034 acet:ArsyncoIncMember 2018-03-31 0000002034 us-gaap:RevolvingCreditFacilityMember 2018-03-31 0000002034 us-gaap:FairValueInputsLevel1Member us-gaap:BankTimeDepositsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-03-31 0000002034 us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-03-31 0000002034 us-gaap:FairValueInputsLevel3Member us-gaap:BankTimeDepositsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-03-31 0000002034 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-03-31 0000002034 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-03-31 0000002034 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-03-31 0000002034 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-03-31 0000002034 us-gaap:BankTimeDepositsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-03-31 0000002034 us-gaap:AccruedLiabilitiesMember 2018-03-31 0000002034 us-gaap:LongTermDebtMember 2018-03-31 0000002034 us-gaap:ScenarioPreviouslyReportedMember 2018-03-31 0000002034 us-gaap:RestatementAdjustmentMember 2018-03-31 0000002034 us-gaap:MediumTermNotesMember acet:AmendedCreditAgreementMember 2018-03-31 0000002034 us-gaap:SubsidiariesMember 2018-03-31 0000002034 acet:ArsyncoIncMember acet:BerrysCreekStudyAreaMember 2018-03-31 0000002034 us-gaap:MediumTermNotesMember acet:AmendedCreditAgreementMember us-gaap:EurodollarMember 2018-03-31 0000002034 us-gaap:MinimumMember us-gaap:EurodollarMember acet:AmendedCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2018-03-31 0000002034 us-gaap:MaximumMember us-gaap:EurodollarMember acet:AmendedCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2018-03-31 0000002034 us-gaap:StateAndLocalJurisdictionMember 2018-03-31 0000002034 us-gaap:ChiefFinancialOfficerMember acet:RestrictedCommonStockAndRestrictedStockUnitsMember 2018-03-01 2018-03-31 0000002034 2018-05-01 0000002034 us-gaap:SubsequentEventMember acet:SecondAmendedAndRestatedCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2018-05-03 0000002034 us-gaap:SubsequentEventMember us-gaap:BaseRateMember acet:SecondAmendedAndRestatedCreditAgreementMember 2018-05-03 0000002034 us-gaap:SubsequentEventMember us-gaap:EurodollarMember acet:SecondAmendedAndRestatedCreditAgreementMember 2018-05-03 0000002034 us-gaap:SubsequentEventMember acet:SecondAmendedAndRestatedCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2018-04-01 2018-05-03 0000002034 us-gaap:SubsequentEventMember us-gaap:BaseRateMember acet:SecondAmendedAndRestatedCreditAgreementMember acet:UndrawnRevolvingCommitmentMember 2018-04-01 2018-05-03 0000002034 us-gaap:SubsequentEventMember 2018-05-01 2018-05-03 xbrli:shares iso4217:USD iso4217:USDxbrli:shares acet:Contract xbrli:pure acet:Subsidiary acet:Share acet:Day acet:Entity acet:Installment acet:Segment ACETO CORP 0000002034 acet --06-30 Large Accelerated Filer 30788044 10-Q/A 2018-03-31 true 2018 Q3 66828000 59962000 55680000 62032000 2046000 3059000 260889000 260168000 12066000 15771000 136387000 141669000 3941000 4942000 546000 471555000 487641000 10428000 14002000 7152000 6250000 236970000 1939000 285081000 241513000 19453000 7546000 9846000 1038185000 761191000 831280000 -70089000 14466000 190723000 90011000 125083000 118328000 119389000 222805000 435195000 339200000 128697000 61449000 63623000 2339000 383000 7325000 1261000 0 1261000 633118000 629159000 627898000 1261000 301000 308000 214198000 221253000 195680000 -91704000 -20354000 -71350000 -5112000 2175000 405067000 132032000 203382000 -71350000 1038185000 761191000 831280000 -70089000 485000 805000 2000000 2000000 0 0 0 0 0.01 0.01 75000000 75000000 30094000 30839000 30094000 30839000 147809000 339735000 158302000 440833000 42319000 0 25300000 7255000 9764000 103963000 0 56424000 19867000 27672000 27696000 0 9535000 7038000 11123000 101649000 0 57080000 17259000 27310000 26519000 75614000 28029000 87241000 256266000 256266000 256266000 256266000 2607000 4998000 2471000 6208000 13193000 23351000 -259070000 -248066000 5321000 10223000 5040000 15443000 640000 1230000 1073000 2111000 -4681000 -8993000 -3967000 -13332000 8512000 -4565000 5007000 3036000 5034000 14358000 -20452000 13912000 7299000 13599000 -263037000 -7237000 -265486000 2987000 6699000 -261398000 -23142000 -258172000 5795000 14121000 2924000 4949000 4948000 420000 -66402000 71350000 19997000 1521000 -51353000 71350000 5588000 9409000 -267985000 -196635000 -71350000 -281395000 -210045000 -71350000 0.16 0.30 -7.59 -5.57 -2.02 -8.00 -5.97 -2.03 0.16 0.30 -7.59 -5.57 -2.02 -8.00 -5.97 -2.03 34769000 31453000 35304000 35162000 35121000 31792000 35304000 35162000 947000 -2201000 1941000 5167000 -249000 -249000 1138000 2120000 6286000 6959000 -264906000 -193556000 -71350000 -274108000 -202758000 -71350000 15301000 24608000 4355000 4603000 300000 833000 -18000 305000 1506000 5239000 5213000 2017000 1931000 6442000 6426000 431000 627000 11714000 -80207000 91921000 903000 902000 1558000 1990000 2505000 -2505000 14839000 -2573000 -1664000 3662000 3778000 3102000 424000 927000 -215000 2202000 18857000 34224000 -4702000 9728000 30299000 -20571000 31551000 56415000 56415000 0 270000000 270000000 1824000 2880000 775000 1867000 3077000 779000 1386000 4677000 -275512000 -6469000 5944000 5924000 550000 595000 551000 265000000 5407000 16898000 39398000 237852000 -44727000 -757000 1133000 -6866000 6352000 5122000 5122000 5122000 5122000 90400000 <div><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(1) Basis of Presentation</b></p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The condensed consolidated financial statements of Aceto Corporation and subsidiaries (&#8220;Aceto&#8221; or the &#8220;Company&#8221;) included herein have been prepared by the Company and reflect all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for all periods presented. Interim results are not necessarily indicative of results which may be achieved for the full year.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements and the disclosure of contingent assets and liabilities at the date of the financial statements. These judgments can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company&#8217;s most critical accounting policies relate to revenue recognition; allowance for doubtful accounts; inventory; goodwill and other indefinite-life intangible assets; long-lived assets; environmental matters and other contingencies; income taxes; stock-based compensation; and purchase price allocation.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">These condensed consolidated financial statements do not include all disclosures associated with consolidated financial statements prepared in accordance with GAAP. Accordingly, these statements should be read in conjunction with the Company&#8217;s consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2017, as amended (the &#8220;2017 10-K&#8221;).</div></div> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>(2) Restatement of Previously Issued Financial Statements</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As previously disclosed, the Company determined that it incorrectly accounted for a valuation allowance related to U.S. net deferred tax assets. At the time of the March 31, 2018 Form 10-Q filing, the Company believed that the carrying value of its&#160;deferred tax assets&#160;was appropriate based on its view that it was more likely than not that this&#160;deferred tax asset&#160;would be realized in future periods. In preparing its consolidated financial statements for the year ended June 30, 2018, the Company determined, in consultation with BDO USA, LLP (&#8220;BDO&#8221;), based on management's review of current and historical performance, internal projections and industry data and applicable accounting literature, that it should recognize a valuation allowance equal to the entire carrying value of the Company&#8217;s U.S. deferred tax assets. However, upon further review of the negative and positive objective evidence and applicable accounting literature, the Company determined, in consultation with BDO, that a full valuation allowance on domestic net deferred tax assets should have been recorded as of the end of its third fiscal quarter rather than as of the end of its fourth fiscal quarter. As a result, the Company has determined to record a valuation allowance of approximately $71,350 on its U.S. deferred tax assets at March 31, 2018.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As a result, the Company is restating its condensed consolidated financial statements for the three and nine months ended March 31, 2018. The following financial tables reconcile the previously reported amounts to the restated amounts for each condensed consolidated financial statement.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The table below sets forth the condensed consolidated balance sheet, including the balances originally reported, corrections and the as restated balances for March 31, 2018 (in thousands):</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Reported</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Adjustment</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Restated</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Assets</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; width: 851px;">Deferred income tax asset, net</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">70,089</td> <td style="text-align: left; width: 14px;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(70,089</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">-</td> <td style="text-align: left; width: 14px;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Total assets</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">831,280</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(70,089</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">761,191</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Liabilities and Shareholders&#8217; Equity</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Deferred income tax liability</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,261</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,261</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Total liabilities</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">627,898</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,261</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">629,159</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Retained deficit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(20,354</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(71,350</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(91,704</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Total shareholders&#8217; equity</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">203,382</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(71,350</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">132,032</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Total liabilities and shareholders&#8217; equity</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">831,280</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(70,089</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">761,191</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The tables below set forth the condensed consolidated statements of loss, including the balances originally reported, corrections and the as restated balances for the three and nine months ended March 31, 2018 (in thousands, except per share data):</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>As Reported</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Adjustment</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>As Restated</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Three months ended March 31, 2018</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; width: 851px;">Income tax (benefit) provision</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(66,402</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">71,350</td> <td style="text-align: left; width: 14px;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">4,948</td> <td style="text-align: left; width: 14px;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Net loss</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(196,635</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(71,350</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(267,985</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Basic loss per common share</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(5.57</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(2.02</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(7.59</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Diluted loss per common share</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(5.57</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(2.02</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(7.59</td> <td style="text-align: left;">)</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Reported</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Adjustment</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Restated</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Nine months ended March 31, 2018</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; width: 851px;">Income tax (benefit) provision</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(51,353</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">71,350</td> <td style="text-align: left; width: 14px;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">19,997</td> <td style="text-align: left; width: 14px;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Net loss</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(210,045</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(71,350</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(281,395</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Basic loss per common share</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(5.97</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(2.03</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(8.00</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Diluted loss per common share</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(5.97</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(2.03</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(8.00</td> <td style="text-align: left;">)</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The tables below set forth the condensed consolidated statements of comprehensive income, including the balances originally reported, corrections and the as restated balances for the three and nine months ended March 31, 2018 (in thousands):</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Reported</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Adjustment</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Restated</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Three months ended March 31, 2018</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 861px;">Net loss</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(196,635</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(71,350</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(267,985</td> <td style="text-align: left; width: 14px;">)</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Comprehensive loss</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(193,556</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(71,350</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(264,906</td> <td style="text-align: left;">)</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Reported</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Adjustment</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Restated</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Nine months ended March 31, 2018</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; width: 851px;">Net loss</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(210,045</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(71,350</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(281,395</td> <td style="text-align: left; width: 14px;">)</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Comprehensive loss</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(202,758</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(71,350</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(274,108</td> <td style="text-align: left;">)</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The table below sets forth the condensed consolidated statements of cash flows from operating activities, including the balances originally reported, corrections and the as restated balances for the nine months ended March 31, 2018 (in thousands):</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Reported</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Adjustment</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Restated</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Nine months ended March 31, 2018</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; width: 851px;">Net loss</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(210,045</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(71,350</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(281,395</td> <td style="text-align: left; width: 14px;">)</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Deferred income taxes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(80,207</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">91,921</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">11,714</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Accrued expenses and other liabilities</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">30,299</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(20,571</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,728</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Net cash provided by operating activities</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">56,415</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">56,415</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As indicated above, there was no impact on net cash provided by operating activities as the valuation allowance is a non-cash item. In addition, the restatement had no impact on cash flows from investing activities or financing activities.</p> <div><div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(3) Business Combinations</b></div><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">On December 21, 2016, wholly owned subsidiaries of Rising Pharmaceuticals, Inc. (&#8220;Rising&#8221;), a wholly owned subsidiary of Aceto, completed the acquisition of certain generic products and related assets of entities formerly known as Citron Pharma LLC (&#8220;Citron&#8221;) and its affiliate Lucid Pharma LLC (&#8220;Lucid&#8221;). Citron was a privately-held New Jersey-based pharmaceutical company focused on developing and marketing generic pharmaceutical products in partnership with leading generic pharmaceutical manufacturers based in India and the United States. Lucid was a privately-held New Jersey-based generic pharmaceutical distributor specializing in providing cost-effective products to various agencies of the U.S. Federal Government including the Veterans Administration and the Defense Logistics Agency. Lucid serviced 18 national contracts with the Federal Government, nearly all of which had 5-year terms.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Aceto and Citron possess complementary asset-light business models, drug development and manufacturing partnerships and product portfolios. The Company believes consistent with its strategy of expanding Rising&#8217;s portfolio of finished dosage form generic products through product development partnerships and acquisitions of late stage assets, abbreviated new drug applications (&#8220;ANDAs&#8221;) and complementary generic drug businesses, this transaction significantly expanded its roster of commercialized products and pipeline of products under development. In addition, the Company believes that this product acquisition greatly enhanced its size and stature within the generic pharmaceutical industry, expanded its partnership network and offers the Company opportunities to realize meaningful cost and tax efficiencies.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">At closing, Aceto paid the sellers $270,000 in cash, committed to make a $50,000 unsecured deferred payment that will bear interest at a rate of 5% per annum to the sellers on December 21, 2021 and agreed to issue 5,122 shares of Aceto common stock beginning on December 21, 2019. The product purchase agreement also provides the sellers with a 5-year potential earn-out of up to an additional $50,000 in cash, based on the financial performance of four pre-specified pipeline products that are currently in development. In the third quarter of fiscal 2018, the Company reversed $2,505 of contingent consideration due to management&#8217;s evaluation and assessment of the financial performance of these products. As of March 31, 2018, the Company accrued $663 related to this contingent consideration.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Rising formed two subsidiaries to consummate the product acquisition &#8211; Rising Health, LLC (which acquired certain products and related assets of Citron) and Acetris Health, LLC (which acquired certain products and related assets of Lucid).</div></div> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: times new roman,times;" size="2"><b>(4) Stock-Based Compensation</b></font></p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: times new roman,times;" size="2"><b>&#160;</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: times new roman,times;" size="2">Under the Aceto Corporation 2015 Equity Participation Plan (the &#8220;2015 Plan&#8221;), grants of stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards (&#8220;Stock Awards&#8221;) may be offered to employees, non-employee directors, consultants and advisors of the Company, including the chief executive officer, chief financial officer and other named executive officers. The maximum number of shares of common stock of the Company that may be issued pursuant to Stock Awards granted under the 2015 Plan will not exceed, in the aggregate, 4,250 shares.&#160;Performance-based awards may be granted, vested and paid based on the attainment of specified performance goals.</font></p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: times new roman,times;" size="2"><b>&#160;</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: times new roman,times;" size="2">Under the Aceto Corporation 2010 Equity Participation Plan (as amended and restated in 2012, the &#8220;2010 Plan&#8221;), grants of stock options, restricted stock, restricted stock units, stock appreciation rights, and stock bonuses may be made to employees, non-employee directors and consultants of the Company. The maximum number of shares of common stock of the Company that may be issued pursuant to awards granted under the 2010 Plan will not exceed, in the aggregate, 5,250 shares. In addition, restricted stock may be granted to an eligible participant in lieu of a portion of any annual cash bonus earned by such participant. Such award may include additional shares of restricted stock (premium shares) greater than the portion of bonus paid in restricted stock. The restricted stock award is vested at issuance and the restrictions lapse ratably over a period of years as determined by the Board of Directors, generally three years. The premium shares vest when all the restrictions lapse, provided that the participant remains employed by the Company at that time.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: times new roman,times;" size="2">During the nine months ended March 31, 2018, the Company granted 490 shares of restricted common stock to its employees that vest over three years and 27 shares of restricted stock to its non-employee directors, which vest over approximately one year. In addition, the Company also issued a target grant of 203 performance-vested restricted stock units, which grant could be as much as 355 units if certain performance criteria and market conditions are met. These performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: times new roman,times;" size="2">During the year ended June 30, 2017, the Company granted 277 shares of restricted common stock to its employees that vest over three years and 22 shares of restricted common stock to its non-employee directors, which vest over approximately one year as well as 42 restricted stock units that have varying vest dates through July 2017. In addition, the Company also issued a target grant of 160 performance-vested restricted stock units, which grant could be as much as 280 if certain performance criteria and market conditions are met. These performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt;"><font style="font-family: times new roman,times;" size="2">For the three and nine months ended March 31, 2018, the Company recorded stock-based compensation expense of approximately $1,931 and $6,426, respectively, related to restricted common stock and restricted stock units. Included in the $6,426 for the nine months ended March 31, 2018 is $431 in stock-based compensation expense associated with the retirement of a Chief Financial Officer in March 2018 and $2,017 in stock-based compensation expense associated with the&#160;<font style="color: black;">separation of the Company&#8217;s former Chief Executive Officer</font>&#160;in September 2017. For the three and nine months ended March 31, 2017, the Company recorded stock-based compensation expense of approximately $1,506 and $5,213, respectively, related to restricted common stock and restricted stock units. As of March 31, 2018, the total unrecognized stock-based compensation cost is approximately $7,864.</font></p> <div><div style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(5) Capital Stock</b></div><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>&#160;</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">On May 3, 2018, the Company&#8217;s Board of Directors declared a quarterly dividend of $0.01 per share which will be paid on June 22, 2018 to shareholders of record as of June 8, 2018.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">On February 1, 2018, the Company&#8217;s Board of Directors declared a regular quarterly dividend of $0.065 per share which was paid on March 23, 2018 to shareholders of record as of March 9, 2018.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">On December 7, 2017, the Company's Board of Directors declared a regular quarterly dividend of $0.065 per share which was paid on December 28, 2017 to shareholders of record as of December 18, 2017.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">On August 24, 2017, the Company's Board of Directors declared a regular quarterly dividend of $0.065 per share which was paid on September 21, 2017 to shareholders of record as of September 8, 2017.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">On May 4, 2017, the Board of Directors of the Company authorized the continuation of the Company&#8217;s stock repurchase program, expiring in May 2020. Under the stock repurchase program, the Company is authorized to purchase up to 5,000 shares of common stock in open market or private transactions, at prices not to exceed the market value of the common stock at the time of such purchase.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company is authorized to issue 75,000 shares of Common Stock and 2,000 shares of Preferred Stock. The Board of Directors has authority under the Company&#8217;s Restated Certificate of Incorporation to issue shares of preferred stock with voting and other relative rights to be determined by the Board of Directors.</div></div> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(6) Net (Loss) Income Per Common Share</b></p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>&#160;</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Basic income per common share is based on the weighted average number of common shares outstanding during the period. Diluted income per common share includes the dilutive effect of potential common shares outstanding. The following table sets forth the reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding:</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 76%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Nine Months Ended<br />March 31,</td> <td style="font-weight: bold;">&#160;</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Three Months Ended<br />March 31,</td> <td style="font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2018</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2018</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -10pt; padding-left: 10pt; width: 527px;">Weighted average shares outstanding</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="text-align: right; width: 113px;">35,162</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 11px;">&#160;</td> <td style="text-align: right; width: 112px;">31,453</td> <td style="text-align: left; width: 11px;">&#160;</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 11px;">&#160;</td> <td style="text-align: right; width: 112px;">35,304</td> <td style="text-align: left; width: 11px;">&#160;</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 11px;">&#160;</td> <td style="text-align: right; width: 112px;">34,769</td> <td style="text-align: left; width: 11px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt;">Dilutive effect of stock options and restricted stock awards and units</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">339</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">352</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -10pt; padding-left: 10pt;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt;">Diluted weighted average shares outstanding</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: right;">35,162</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: right;">31,792</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: right;">35,304</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: right;">35,121</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The effect of approximately 100 and 181 common equivalent shares for the three and nine months ended March 31, 2018, respectively, was excluded from the diluted weighted average shares outstanding due to a net loss for the periods. There were 170 and 143 common equivalent shares outstanding for the three and nine months ended March 31, 2018, respectively, that were not included in the calculation of diluted net income per common share because their effect would have been anti-dilutive.</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>&#160;</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The weighted average shares outstanding for the three and nine months ended March 31, 2018 includes the effect of 5,122 shares to be issued beginning on December 21, 2019 in connection with the acquisition of certain products and related assets from Citron and Lucid (see Note 3).</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Convertible Senior Notes (see Note 7) will only be included in the dilutive net income per share calculations using the treasury stock method during periods in which the average market price of Aceto&#8217;s common stock is above the applicable conversion price of the Convertible Senior Notes, or $33.215 per share, and the impact would not be anti-dilutive.</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>(7) Debt</b></p><div style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></div><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>Long-term debt</i></p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>&#160;</i></p><table style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 1pt;" nowrap="nowrap"><b>&#160;</b></td><td style="padding-bottom: 1pt;"><b>&#160;</b></td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>March 31,</b></p><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>2018</b></p></td><td style="padding-bottom: 1pt;"><b>&#160;</b></td><td style="padding-bottom: 1pt;"><b>&#160;</b></td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>June 30,</b></p><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>2017</b></p></td><td style="padding-bottom: 1pt;"><b>&#160;</b></td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 703px;">Convertible Senior Notes, net</td><td style="width: 10px;">&#160;</td><td style="text-align: left; width: 10px;">$</td><td style="text-align: right; width: 123px;">126,279</td><td style="text-align: left; width: 10px;">&#160;</td><td style="width: 10px;">&#160;</td><td style="text-align: left; width: 9px;">$</td><td style="text-align: right; width: 122px;">121,676</td><td style="text-align: left; width: 9px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Revolving Bank Loans</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">62,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">90,000</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Term Bank Loans</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">128,526</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">139,227</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt;">Mortgage</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">2,615</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">2,763</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-indent: -10pt; padding-left: 10pt;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">319,420</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">353,666</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt;">Less current portion</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">190,723</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">14,466</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">128,697</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">339,200</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr></table><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>Convertible Senior Notes</i></p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In November 2015, Aceto offered $125,000 aggregate principal amount of Convertible Senior Notes due 2020 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In addition, Aceto granted the initial purchasers for the offering an option to purchase up to an additional $18,750 aggregate principal amount pursuant to the initial purchasers&#8217; option to purchase additional Notes, which was exercised in November 2015. Therefore, the total offering was $143,750 aggregate principal amount. The Notes are unsecured obligations of Aceto and rank senior in right of payment to any of Aceto&#8217;s subordinated indebtedness, equal in right of payment to all of Aceto&#8217;s unsecured indebtedness that is not subordinated, effectively junior in right of payment to any of Aceto&#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness and structurally junior in right of payment to all indebtedness and other liabilities (including trade payables) of Aceto&#8217;s subsidiaries. The Notes will be convertible into cash, shares of Aceto common stock or a combination thereof, at Aceto&#8217;s election, upon the satisfaction of specified conditions and during certain periods. The Notes will mature in November 2020. The Notes pay 2.0% interest semi-annually in arrears on May 1 and November 1 of each year, which commenced on May 1, 2016. The Notes are convertible into 4,328 shares of common stock, based on an initial conversion price of $33.215 per share.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Holders may convert all or any portion of their notes, in multiples of one thousand dollar principal amount, at their option at any time prior to the close of business on the business day immediately preceding May 1, 2020 only under the following circumstances: (i) during any calendar quarter (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the five consecutive business day period after any five consecutive trading day period (which is referred to as the &#8220;measurement period&#8221;) in which the trading price per one thousand dollar principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of Aceto&#8217;s common stock and the conversion rate on each such trading day; or (iii) upon the occurrence of specified corporate events.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="color: black;">Upon conversion by the holders, the Company may elect to settle such conversion in shares of its common stock, cash, or a combination thereof. As a result of its cash conversion option, the Company separately accounted for the value of the embedded conversion option as a debt discount (with an offset to capital in excess of par value). The debt discount is being amortized as additional non-cash interest expense using the effective interest method over the term of the Notes. Debt issuance costs are being amortized as additional non-cash interest expense.&#160;</font>The Company presents debt issuance costs as a direct deduction from the carrying value of the debt liability rather than showing the debt issuance costs as a deferred charge on the balance sheet.</p><p style="text-align: justify; widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In connection with the offering of the Notes, Aceto entered into privately negotiated convertible note hedge transactions with option counterparties, which are affiliates of certain of the initial purchasers. The convertible note hedge transactions are expected generally to reduce the potential dilution to Aceto&#8217;s common stock and/or offset any cash payments Aceto is required to make in excess of the principal amount of converted Notes upon any conversion of Notes. Aceto also entered into privately negotiated warrant transactions with the option counterparties. The warrant transactions could separately have a dilutive effect to the extent that the market price per share of Aceto&#8217;s common stock as measured over the applicable valuation period at the maturity of the warrants exceeds the applicable strike price of the warrants. By entering into these transactions with the option counterparties, the Company issued convertible debt and a freestanding &#8220;call-spread.&#8221;</p><p style="text-align: justify; widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The carrying value of the Notes is as follows:</p><p style="text-align: justify; widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>March 31,</b></p><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>2018</b></p></td><td style="padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>June 30,</b></p><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>2017</b></p></td><td style="padding-bottom: 1pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 751px;">Principal amount</td><td style="width: 11px;">&#160;</td><td style="text-align: left; width: 11px;">$</td><td style="text-align: right; width: 130px;">143,750</td><td style="text-align: left; width: 10px;">&#160;</td><td style="width: 10px;">&#160;</td><td style="text-align: left; width: 10px;">$</td><td style="text-align: right; width: 130px;">143,750</td><td style="text-align: left; width: 10px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Unamortized debt discount</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(15,278</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(19,255</td><td style="text-align: left;">)</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt;">Unamortized debt issuance costs</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(2,193</td><td style="text-align: left; padding-bottom: 1pt;">)</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(2,819</td><td style="text-align: left; padding-bottom: 1pt;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt;">Net carrying value</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">126,279</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">121,676</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr></table><p style="text-align: justify; widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following table sets forth the components of total &#8220;interest expense&#8221; related to the Notes recognized in the accompanying consolidated statements of operations for the three and nine months ended March 31:</p><p style="text-align: justify; widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><b>Nine Months Ended</b><br /><b>March 31, 2018</b></td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><b>Three Months Ended&#160;</b><br /><b>March 31, 2018</b></td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 751px;">Contractual coupon</td><td style="width: 11px;">&#160;</td><td style="text-align: left; width: 11px;">$</td><td style="text-align: right; width: 130px;">2,127</td><td style="text-align: left; width: 10px;">&#160;</td><td style="width: 10px;">&#160;</td><td style="text-align: left; width: 10px;">$</td><td style="text-align: right; width: 130px;">709</td><td style="text-align: left; width: 10px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Amortization of debt discount</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">3,977</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,347</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt;">Amortization of debt issuance costs</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">626</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">208</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">6,730</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">2,264</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr></table><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>&#160;</i></p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>Credit Facilities</i></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On December 21, 2016 the Company entered into a Second Amended and Restated Credit Agreement (the &#8220;A&amp;R Credit Agreement&#8221;), with eleven banks, which amended and restated in its entirety the Amended and Restated Credit Agreement, dated as of October 28, 2015, as amended by Amendment No. 1 to Amended and Restated Credit Agreement, dated as of November 10, 2015, and Amendment No. 2 to Amended and Restated Credit Agreement, dated as of August 26, 2016 (collectively, the &#8220;First Amended Credit Agreement&#8221;). The A&amp;R Credit Agreement increased the aggregate available revolving commitment under the First Amended Credit Agreement from $150,000 to an initial aggregate available revolving commitment of $225,000 (the &#8220;Initial Revolving Commitment&#8221;). Under the A&amp;R Credit Agreement, the Company may borrow, repay and reborrow from and as of December 21, 2016, to but excluding December 21, 2021 (the &#8220;Maturity Date&#8221;) provided, that if any of the Notes remain outstanding on the date that is 91 days prior to the maturity date of the Notes (the &#8220;2015 Convertible Maturity Date&#8221;), then the Maturity Date shall mean the date that is 91 days prior to the 2015 Convertible Maturity Date. The A&amp;R Credit Agreement provides for (i) Eurodollar Loans (as such terms are defined in the A&amp;R Credit Agreement), (ii) ABR Loans (as such terms are defined in the A&amp;R Credit Agreement) or (iii) a combination thereof. As of March 31, 2018, the Company borrowed Revolving Loans (as defined under the A&amp;R Credit Agreement) aggregating $62,000 which loans are Eurodollar Loans at interest rates ranging from 3.57% to 3.63% at March 31, 2018. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company&#8217;s senior secured net leverage ratio.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Under the A&amp;R Credit Agreement, the Company also borrowed $150,000 in term loans (the &#8220;Initial Term Loan). Subject to certain conditions, including obtaining commitments from existing or prospective lenders, the Company had the right to increase the amount of the Initial Revolving Commitment (each, a &#8220;Revolving Facility Increase&#8221; and, together with the Initial Revolving Commitment, the &#8220;Revolving Commitment&#8221;) and/or the Initial Term Loan in an aggregate amount not to exceed $100,000 pursuant to an incremental loan feature in the A&amp;R Credit Agreement. As of March 31, 2018, the remaining amount outstanding under the Initial Term Loan was $131,250 and was payable as a Eurodollar Loan at an interest rate of 4.05%. The proceeds of the Initial Revolving Commitment and Initial Term Loan were used to partially finance the acquisition of generic products and related assets of Citron and its affiliate Lucid, and pay fees and expenses related thereto. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company&#8217;s senior secured net leverage ratio.</p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Initial Term Loan is payable as to principal in nineteen consecutive, equal quarterly installments of $3,750, which commenced on March 31, 2017 and will continue each March 31, June 30, September 30 and December 31 thereafter. To the extent not previously paid, the final payment on the Term Loan Maturity Date (as defined in the A&amp;R Credit Agreement) shall be in an amount equal to the then outstanding unpaid principal amount of the Initial Term Loan.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The A&amp;R Credit Agreement provides that commercial letters of credit shall be issued to provide the primary payment mechanism in connection with the purchase of any materials, goods or services in the ordinary course of business. The Company had no open letters of credit at March 31, 2018 and June 30, 2017.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In accordance with generally accepted accounting principles, deferred financing costs associated with the Initial Term Loan are presented as a direct deduction from the carrying value of the debt liability rather than showing the deferred financing costs as a deferred charge on the balance sheet. In addition, deferred financing costs associated with the Revolving Commitment have been recorded as a deferred charge on the balance sheet.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The A&amp;R Credit Agreement provides for a security interest in substantially all the personal property of the Company and certain of its subsidiaries. The A&amp;R Credit Agreement contains several financial covenants including, among other things, maintaining a minimum level of debt service and certain leverage ratios. Under the A&amp;R Credit Agreement, the Company and its subsidiaries are also subject to certain restrictive covenants, including, among other things, covenants governing liens, limitations on indebtedness, limitations on guarantees, limitations on sales of assets and sales of receivables, and limitations on loans and investments.</p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: green; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font size="+0">&#160;</font></p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On December 13, 2017, the Company entered into a First Amendment to the Second Amended and Restated Credit Agreement (the &#8220;2017 Amendment&#8221;), which amended the A&amp;R Credit Agreement. The 2017 Amendment, among other things, contained several amendments to the financial covenants in the A&amp;R Credit Agreement.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of March 31, 2018, the Company was in compliance with all of its financial covenants except for the maximum total net leverage ratio and the minimum debt service coverage ratio. On May 3, 2018, the Company entered into a Second Amendment and Waiver to the Second Amended and Restated Credit Agreement (the &#8220;2018 Amendment&#8221;). The 2018 Amendment, among other things, contains a waiver of any event of default under the A&amp;R Credit Agreement arising as a result of the non-compliance by the Company with the Total Net Leverage Ratio and Debt Service Coverage Ratio financial covenants, in each case, solely for the fiscal quarter ended March 31, 2018. The Amendment also contains several amendments to the A&amp;R Credit Agreement including, among other things, (a) reducing the available revolving commitment thereunder to $100,000, and (b) during the period commencing on the closing of the 2018 Amendment and ending on the date the Company demonstrates compliance with each financial covenant set forth in the A&amp;R Credit Agreement for the fiscal quarter ending June 30, 2018 (the &#8220;Limitation Period&#8221;; provided that if the Company is not in compliance with any of the financial covenants set forth in the A&amp;R Credit Agreement for the fiscal quarter ending June 30, 2018, then the Limitation Period shall continue indefinitely): (i) fixing the applicable margin with respect to all loans under the A&amp;R Credit Agreement to the highest level provided under the A&amp;R Credit Agreement, which is 1.50% in the case of ABR Loans (as defined in the A&amp;R Credit Agreement) and 2.50% in the case of Eurodollar Loans (as defined in the A&amp;R Credit Agreement), (ii) fixing the commitment fee on the undrawn revolving commitments under the A&amp;R Credit Agreement to the highest level provided under the A&amp;R Credit Agreement which is 0.40% per annum, (iii) requiring the prior written consent of the Required Lenders (as defined in the A&amp;R Credit Agreement) as a condition precedent to the lenders extending any Loans (as defined in the A&amp;R Credit Agreement) or the issuing banks issuing, amending, renewing or extending any Letter of Credit (as defined in the A&amp;R Credit Agreement), (iv) restricting the amount of dividends or distributions the Company may make to its shareholders to no more than $0.01 per share for the fiscal quarter ending on June 30, 2018 and, during the Limitation Period, restricting the Company from making any other dividends or distributions to its shareholders thereafter and (v) restricting the incurrence of certain indebtedness, limiting acquisitions and other investments and imposing certain other restrictions.</p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In accordance with GAAP, we have classified the&#160;<font style="color: black;">indebtedness outstanding under the Company&#8217;s credit facility as a current liability as of March 31, 2018. This differs from the customary treatment heretofore applicable to indebtedness outstanding under the Company&#8217;s credit facility, in which only the portion of such indebtedness payable within one year from the balance sheet date has been recorded as a current liability.&#160; The waiver that the Company has received from its lenders under the credit facility applies solely to the non-compliance with certain financial covenants as of March 31, 2018 and thus does not waive non-compliance with any financial covenants as of June 30, 2018. It is probable that the Company will not comply with certain financial covenants as of June 30, 2018 in the absence of a material change in the Company&#8217;s operating results.&#160; That probability is the factor that has caused the Company to reclassify its indebtedness</font>. The Company believes it will work cooperatively with its lenders over the next 120 days and anticipates that the financial covenants for the June 30, 2018 reporting date will be amended.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>Mortgage</i></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>&#160;</i></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On June 30, 2011, the Company entered into a mortgage payable for $3,947 on its corporate headquarters, in Port Washington, New York. This mortgage payable is secured by the land and building and is being amortized over a period of 20 years. The mortgage payable, which was modified in October 2013, bears interest at 4.92% per annum as of March 31, 2018 and matures on June 30, 2021.</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;"><b>(8) Commitments, Contingencies and Other Matters</b></font></p><div style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">&#160;</font></div><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">The Company and its subsidiaries are subject to various claims which have arisen in the normal course of business. The Company provides for costs related to contingencies when a loss from such claims is probable and the amount is reasonably determinable. In determining whether it is possible to provide an estimate of loss, or range of possible loss, the Company reviews and evaluates its litigation and regulatory matters on a quarterly basis in light of potentially relevant factual and legal developments. If the Company determines an unfavorable outcome is not probable or reasonably estimable, the Company does not accrue for a potential litigation loss. While the Company has determined that there is a reasonable possibility that a loss has been incurred, no amounts have been recognized in the financial statements, other than what has been discussed below, because the amount of the liability cannot be reasonably estimated at this time.</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">In fiscal years 2011, 2009, 2008 and 2007, the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State had begun administrative proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly contributed to the contamination of the environment and thus believes that, at most, it is a de minimis contributor to the site contamination. Accordingly, the Company believes that the settlement offer is unreasonable. Management believes that the ultimate outcome of this matter will not have a material adverse effect on the Company's financial condition or liquidity.</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">The Company has environmental remediation obligations in connection with Arsynco, Inc. (&#8220;Arsynco&#8221;), a subsidiary formerly involved in manufacturing chemicals located in Carlstadt, New Jersey, which was closed in 1993 and is currently held for sale. Based on continued monitoring of the contamination at the site and the approved plan of remediation, Arsynco received an estimate from an environmental consultant stating that the costs of remediation could be between $21,500 and $23,300. Remediation commenced in fiscal 2010, and as of March 31, 2018 and June 30, 2017, a liability of $4,495 and $8,451, respectively, is included in the accompanying consolidated balance sheets for this matter. For the nine months ended March 31, 2018, the Company recorded an environmental charge of $902, which is included in selling, general and administrative expenses in the accompanying condensed consolidated statement of operations for the nine months ended March 31, 2018. In accordance with GAAP, management believes that the majority of costs incurred to remediate the site will be capitalized in preparing the property which is currently classified as held for sale. An estimate of the fair value of the property has been determined by a third party real estate professional and supports the assumption that the expected fair value after the remediation is in excess of the amount required to be capitalized. However, these matters, if resolved in a manner different from those assumed in current estimates, could have a material adverse effect on the Company&#8217;s financial condition, operating results and cash flows when resolved in a future reporting period.</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">&#160;&#160;</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new;"><font style="font-family: times new roman,times;" size="2">In connection with the environmental remediation obligation for Arsynco, in July 2009, Arsynco entered into a settlement agreement with BASF Corporation (&#8220;BASF&#8221;), the former owners of the Arsynco property. In accordance with the settlement agreement, BASF paid for a portion of the prior remediation costs and going forward, will co-remediate the property with the Company. The contract requires that BASF pay $550 related to past response costs and pay a proportionate share of the future remediation costs. Accordingly, the Company had recorded a gain of $550 in fiscal 2009. This $550 gain relates to the partial reimbursement of costs of approximately $1,200 that the Company had previously expensed. The Company also recorded an additional receivable from BASF, with an offset against property held for sale, representing its estimated portion of the future remediation costs. The balance of this receivable for future remediation costs as of March 31, 2018 and June 30, 2017 is $2,023 and $3,803, respectively, which is included in the accompanying consolidated balance sheets.</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">In March 2006, Arsynco received notice from the EPA of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for a site described as the Berry&#8217;s Creek Study Area (&#8220;BCSA&#8221;). Arsynco is one of over 150 PRPs which have potential liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. In July 2014, Arsynco received notice from the U.S. Department of Interior (&#8220;USDOI&#8221;) regarding the USDOI&#8217;s intent to perform a Natural Resource Damage (NRD) Assessment at the BCSA. Arsynco has to date declined to participate in the development and performance of the NRD assessment process. Based on prior practice in similar situations, it is possible that the State may assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State (or both) may assert claims against Arsynco for natural resource damages in connection with Berry's Creek; any such claim with respect to Berry's Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the former owners of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et al., Docket No. ESX-L-9868-05 (the "NJDEP Litigation") and were considering impleading Arsynco into the same proceeding. Arsynco entered into an agreement to avoid impleader. Pursuant to the agreement, Arsynco agreed to (1) a tolling period that would not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation; (2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against Arsynco. In July 2015, Arsynco was contacted by an allocation consultant retained by a group of the named PRPs, inviting Arsynco to participate in the allocation among the PRPs&#8217; investigation and remediation costs relating to the BCSA. Arsynco declined that invitation. Since an amount of the liability cannot be reasonably estimated at this time, no accrual is recorded for these potential future costs. The impact of the resolution of this matter on the Company&#8217;s results of operations in a particular reporting period is not currently known.</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">A subsidiary of the Company markets certain agricultural protection products which are subject to the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). FIFRA requires that test data be provided to the EPA to register, obtain and maintain approved labels for pesticide products. The EPA requires that follow-on registrants of these products compensate the initial registrant for the cost of producing the necessary test data on a basis prescribed in the FIFRA regulations. Follow-on registrants do not themselves generate or contract for the data. However, when FIFRA requirements mandate that new test data be generated to enable all registrants to continue marketing a pesticide product, often both the initial and follow-on registrants establish a task force to jointly undertake the testing effort. The Company is presently a member of several such task force groups, which requires payments for such memberships. In addition, in connection with our agricultural protection business, the Company plans to acquire product registrations and related data filed with the United States Environmental Protection Agency to support such registrations and other supporting data for several products. The acquisition of these product registrations and related data filed with the United States Environmental Protection Agency as well as payments to various task force groups could approximate $2,299 through the remainder of fiscal 2018.</font></p><p style="text-align: center; widows: 2; text-transform: none; margin-top: 0pt; text-indent: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">The Company has been notified by the U.S. government that 11 generic drug products it acquired through its Acetris Health subsidiary in a product purchase agreement with Lucid are not in compliance with the federal Trade Agreement Act (&#8220;TAA&#8221;) country-of-origin provisions of a clause contained in the government supply contracts acquired from Lucid (the &#8220;TAA Notification&#8221;). The 11 finished dosage form products purchased by the U.S. government are manufactured by Aurolife Pharma LLC which is located in Dayton, New Jersey using APIs sourced from India. In conjunction with this finding, the U.S. Department of Veterans Affairs (&#8220;VA&#8221;) requested that Aceto supply new TAA-compliant sources for the referenced products by March 9, 2018 and supply new TAA-compliant drugs to the government purchasers under the contracts by March 26, 2018. The Company was not able to meet these deadlines and thereafter Acetris and the government entered into agreements that provided for a no-cost termination of each of the 11 supply contracts.</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">Under current longstanding law, the government, under the Buy America Act, is permitted to buy domestic end products, including commercial off-the-shelf (&#8220;COTS&#8221;) products like generic drugs that are manufactured in the U.S. even if their components are not all manufactured in the US. The Company believes that the government was and is permitted to buy Acetris&#8217; products, because they are COTS items manufactured in the U.S. As a result, the Company has disputed the determination that the 11 products sold pursuant to novated contracts with the VA originate in India rather than the United States and has appealed the decision that it is not currently compliant with contract sourcing requirements. To further pursue remedies, Aceto has asserted an indemnification claim against the sellers under the product purchase agreement dated December 21, 2016. In addition, the U.S. Defense Logistics Agency, by letter dated April 25, 2018 to Acetris, requested that Acetris seek a ruling from U.S. Customs and Border Protection that seven products specified therein, each of which have APIs sourced from India, are TAA compliant.</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">In March 2018, Sigmapharm Laboratories, LLC (&#8220;SigmaPharm&#8221;) commenced an action against Rising and the Company in the United States District Court for the Eastern District of Pennsylvania.&#160; The complaint arises out of an agreement, effective as of June 22, 2006 (the &#8220;SigmaPharm Agreement&#8221;), pursuant to which SigmaPharm agreed to supply certain generic pharmaceutical products (the &#8220;Products&#8221;) to Rising, and Rising in turn agreed to market and distribute the Products in the United States and pay SigmaPharm a share of the profits pursuant to a formula specified in the Agreement.&#160; The complaint alleges that Rising and Aceto breached the Agreement by failing to pay or timely make payments due under the Agreement and to disclose certain information to SigmaPharm.&#160; The complaint seeks, among other relief, a declaration that the Agreement has been terminated and that SigmaPharm has exclusive marketing and distribution rights to the Products; injunctive relief; and an unspecified amount of damages.&#160; The Company intends to vigorously defend the action and assert counterclaims against SigmaPharm in the course of this litigation.</font></p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(9) Fair Value Measurements</b></p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly fashion between market participants at the measurement date. GAAP establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s assumptions (unobservable inputs). The hierarchy consists of three levels:</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 0.25in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Level 1 &#8211; Quoted market prices in active markets for identical assets or liabilities;</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 0.25in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 0.25in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Level 2 &#8211; Inputs other than Level 1 inputs that are either directly or indirectly observable; and</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 0.25in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;&#160;</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 0.25in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Level 3 &#8211; Unobservable inputs that are not corroborated by market data.</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">On a recurring basis, Aceto measures at fair value certain financial assets and liabilities, which consist of cash equivalents, investments and foreign currency contracts. The Company classifies cash equivalents and investments within Level 1 if quoted prices are available in active markets. Level 1 assets include instruments valued based on quoted market prices in active markets which generally include corporate equity securities publicly traded on major exchanges. Time deposits are very short-term in nature and are accordingly valued at cost plus accrued interest, which approximates fair value, and are classified within Level 2 of the valuation hierarchy. The Company uses foreign currency futures contracts to minimize the risk caused by foreign currency fluctuation on its foreign currency receivables and payables by purchasing futures with one of its financial institutions. Futures are traded on regulated U.S. and international exchanges and represent commitments to purchase or sell a foreign currency at a future date and at a specific price. Aceto&#8217;s foreign currency derivative contracts are classified within Level 2 as the fair value of these hedges is primarily based on observable futures foreign exchange rates. At March 31, 2018, the Company had foreign currency contracts outstanding that had a notional amount of $62,350. Unrealized (losses) gains on hedging activities for the three and nine months ended March 31, 2018 was ($34) and $227, respectively. Unrealized gains (losses) on hedging activities for the three and nine months ended March 31, 2017 was $353 and ($230), respectively, and are included in interest and other income, net, in the consolidated statements of operations. The contracts have varying maturities of less than one year.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In conjunction with its existing credit agreement (see Note 7), the Company entered an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is December 21, 2021. The remaining notional balance of this derivative as of March 31, 2018 is $87,500. The unrealized gain to date associated with this derivative, which is recorded in accumulated other comprehensive income in the consolidated balance sheet at March 31, 2018, is $1,539. Aceto&#8217;s interest rate swaps are classified within Level 2 as the fair value of this hedge is primarily based on observable interest rates.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">At March 31, 2018, the Company had accrued $752 of contingent consideration, $663 of which related to the acquisition of certain products and related assets of Citron and Lucid, which was completed in December 2016 (see Note 3) and $89 of contingent consideration related to a previously acquired company in France. At June 30, 2017, the Company had accrued $2,952 of contingent consideration, $2,807 of which related to the acquisition of certain products and related assets of Citron and Lucid and $145 of contingent consideration related to a previously acquired company in France. The contingent consideration was calculated using the present value of a probability weighted income approach.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company accounts for goodwill and intangible assets in accordance with ASC 350, Intangibles &#8211; Goodwill and Other (&#8220;ASC 350&#8221;). ASC 350 requires that goodwill and other intangibles with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value. During the third quarter of fiscal 2018<font style="font-size: 10pt;">,&#160;</font>the Company&#8217;s Rising Pharmaceuticals reporting unit (which is part of the Human Health segment) had a decline in actual and forecasted revenue and earnings due to the persistent adverse conditions in the generics market. In addition, as noted above, the Company was notified by the U.S. government that 11 generic drug products it acquired through its Acetris Health subsidiary (part of the Rising reporting unit which is part of the Human Health segment) in a product purchase agreement with an entity formerly known as Lucid Pharma LLC are not in compliance with the federal Trade Agreement Act country-of-origin provisions of a clause contained in the government supply contracts acquired from Lucid. Based on these indicators, the Company determined that it was necessary to perform an interim goodwill impairment analysis at March 31, 2018 for its Rising reporting unit. The Company elected to early adopt Accounting Standards Update (&#8220;ASU&#8221;) 2017-04,&#160;<i>Intangibles- Goodwill and Other (Topic 350),&#160;</i>during the third quarter of fiscal 2018 which eliminated the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, the amount of an impairment charge is recognized if the carrying amount of a reporting unit is greater than its fair value.&#160;<font style="color: black;">The fair value of the Rising reporting unit was estimated using many assumptions and estimates and a market participant approach that directly impacts the results of the testing. In making these assumptions and estimates, the Company used industry accepted valuation models and set criteria that were reviewed and approved by various levels of management. Accordingly, with respect to the third quarter of fiscal 2018, the Company recognized a pre-tax non-cash goodwill impairment charge of $235,110 related to the Rising reporting unit.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Long-lived assets and certain identifiable intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;&#160;If it is determined such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization periods, their carrying values are reduced to estimated fair value.&#160;&#160;Measurements based on undiscounted cash flows are Level 3 inputs.&#160;&#160;As noted above, during the third quarter of fiscal 2018<font style="font-size: 10pt;">,&#160;</font>the Company&#8217;s Rising Pharmaceuticals subsidiary had a decline in actual and forecasted revenue and earnings and therefore the Company performed an impairment test on the related intangibles. The projected undiscounted cash flows for certain intangibles were determined to be less than the carrying value, and as a result, the Company recognized an impairment charge of $5,745 in the third quarter of fiscal 2018. Additionally, as noted above, the Company was notified by the U.S. government that 11 generic drug products it acquired through its Acetris Health subsidiary in a product purchase agreement with an entity formerly known as Lucid Pharma LLC are not in compliance with the federal Trade Agreement Act country-of-origin provisions of a clause contained in the government supply contracts acquired from Lucid. Based on this, the Company performed an impairment test on the related intangible asset and recognized an impairment charge of $15,411 on the customer relationships intangible asset in the third quarter of fiscal 2018.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The total impairment charges for goodwill and intangibles recorded in the third quarter of fiscal 2018 was $256,266, all of which related to the Rising reporting unit which is part of the Human Health segment.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In connection with the acquisition of certain products and related assets of Citron and Lucid (see Note 3), the Company will issue 5,122 shares of Aceto common stock beginning on December 21, 2019. The preliminary fair value of the future issuance of these shares was determined to be $90,400 at the time of the product acquisition after taking into effect that the shares won&#8217;t be issued until the third and fourth anniversary of the closing and the present value calculation of dividends.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In November 2015, the Company issued $143,750 aggregate principal amount of Notes (see Note 7). Since Aceto has the option to settle the potential conversion of the Notes in cash, the Company separated the embedded conversion option feature from the debt feature and accounts for each component separately, based on the fair value of the debt component assuming no conversion option. The calculation of the fair value of the debt component required the use of Level 3 inputs, and was determined by calculating the fair value of similar non-convertible debt, using a theoretical borrowing rate of 6.5%.&#160;<font style="color: black;">The value of the embedded conversion option was determined using an expected present value technique (income approach) to estimate the fair value of similar non-convertible debt</font>&#160;and included utilization of c<font style="color: black;">onvertible investors&#8217; credit assumptions and high yield bond indices. The Notes approximate a full fair value of $126,600 at March 31, 2018 giving effect to certain factors, including the term of the Notes, current stock price of Aceto stock and effective interest rate.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The carrying values of all financial instruments classified as a current asset or current liability are deemed to approximate fair value because of the short maturity of these instruments. The fair values of the Company&#8217;s notes receivable and short-term and long-term bank loans were based upon current rates offered for similar financial instruments to the Company.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;&#160;</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The following tables summarize the valuation of the Company&#8217;s financial assets and liabilities which were determined by using the following inputs at March 31, 2018 and June 30, 2017:</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="14" nowrap="nowrap">Fair Value Measurements at March 31, 2018 Using</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Quoted Prices&#160;<br />in Active&#160;<br />Markets&#160;<br />(Level 1)</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant&#160;<br />Other&#160;<br />Observable&#160;<br />Inputs (Level 2)</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"> <p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>Significant</b></p> <p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>Unobservable</b><br /><b>Inputs</b></p> <p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>(Level 3)</b></p> </td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Total</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Cash equivalents:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt; width: 577px;">Time deposits</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="text-align: right; width: 123px;">-</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">2,746</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="text-align: right; width: 122px;">-</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">2,746</td> <td style="text-align: left; width: 12px;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Investments:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Time deposits</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">3,059</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">3,059</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Foreign currency contracts-assets&#160;<font style="font-size: 10pt;">(1)</font></td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">285</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">285</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Foreign currency contracts-liabilities&#160;<font style="font-size: 10pt;">(2)</font></td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">318</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">318</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Derivative asset for interest rate swap&#160;<font style="font-size: 10pt;">(3)</font></td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,539</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,539</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Contingent consideration&#160;<font style="font-size: 10pt;">(4)</font></td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">752</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">752</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <table style="widows: 2; text-transform: none; margin-top: 0pt; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0px;"></td> <td style="text-align: left; width: 0.5in;">(1)</td> <td>Included in &#8220;Other receivables&#8221; in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.</td> </tr> </table> <table style="widows: 2; text-transform: none; margin-top: 0pt; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0px;"></td> <td style="text-align: left; width: 0.5in;">(2)</td> <td>Included in &#8220;Accrued expenses&#8221; in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.</td> </tr> </table> <table style="widows: 2; text-transform: none; margin-top: 0pt; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0px;"></td> <td style="text-align: left; width: 0.5in;">(3)</td> <td>Included in &#8220;Other assets&#8221; in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.</td> </tr> </table> <table style="widows: 2; text-transform: none; margin-top: 0pt; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0px;"></td> <td style="width: 0.5in;">(4)</td> <td>$89 included in &#8220;Accrued expenses&#8221; and $663 included in &#8220;Long-term liabilities&#8221; in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.</td> </tr> </table> <p style="widows: 2; text-transform: none; text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"></p> <table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="14" nowrap="nowrap">Fair Value Measurements at June 30, 2017 Using</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Quoted Prices&#160;<br />in Active&#160;<br />Markets&#160;<br />(Level 1)</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant&#160;<br />Other&#160;<br />Observable&#160;<br />Inputs (Level 2)</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"> <p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>Significant</b></p> <p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>Unobservable<br />Inputs</b></p> <p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>(Level 3)</b></p> </td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Total</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Cash equivalents:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt; width: 577px;">Time deposits</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="text-align: right; width: 123px;">-</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">5,781</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="text-align: right; width: 122px;">-</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">5,781</td> <td style="text-align: left; width: 12px;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Investments:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Time deposits</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,046</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,046</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Foreign currency contracts-assets (5)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">486</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">486</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Foreign currency contracts-liabilities (6)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">137</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">137</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Derivative liability for interest rate swap (7)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">581</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">581</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Contingent consideration (8)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">2,952</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,952</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <table style="widows: 2; text-transform: none; margin-top: 0pt; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0px;"></td> <td style="width: 0.5in;">(5)</td> <td>Included in &#8220;Other receivables&#8221; in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.</td> </tr> </table> <table style="widows: 2; text-transform: none; margin-top: 0pt; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0px;"></td> <td style="text-align: left; width: 0.5in;">(6)</td> <td>Included in &#8220;Accrued expenses&#8221; in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.</td> </tr> </table> <table style="widows: 2; text-transform: none; margin-top: 0pt; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0px;"></td> <td style="width: 0.5in;">(7)</td> <td>Included in &#8220;Long-term liabilities&#8221; in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.</td> </tr> </table> <table style="widows: 2; text-transform: none; margin-top: 0pt; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0px;"></td> <td style="width: 0.5in;">(8)</td> <td>$145 included in &#8220;Accrued expenses&#8221; and $2,807 included in &#8220;Long-term liabilities&#8221; in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.</td> </tr> </table> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(10) Recent Accounting Pronouncements</b></p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In February 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU&#160;2018-02,&#160;<i>Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income,&#160;</i>which gives entities the option to reclassify the disproportionate income tax effects ("stranded tax effects") caused by the newly-enacted U.S. Tax Cuts and Jobs Act from accumulated other comprehensive income to retained earnings. The update also requires new disclosures, some of which are applicable for all entities. The guidance in ASU 2018-02 is effective for annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact of the provisions of ASU 2018-02.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In August 2017, the FASB issued ASU 2017-12,&#160;<i>Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities,</i>&#160;which has the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity&#8217;s risk management activities in its financial statements. In addition to that main objective, the amendments in ASU 2017-12 make certain targeted improvements to simplify the application of the hedge accounting guidance in current GAAP. The amendments in ASU 2017-12 are effective for public business entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of the provisions of ASU 2017-12.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In May 2017, the FASB issued ASU 2017-09,&#160;<i>Compensation &#8211; Stock Compensation (Topic 718): Scope of Modification Accounting,</i>&#160;which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company does not believe this new accounting standard update will have a material impact on its consolidated financial statements.</p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In January 2017, the FASB issued ASU 2017-01&#160;<i>Business Combinations (Topic 805): Clarifying the Definition of a Business,&#160;</i>with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU 2017-01 is effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated financial statements.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In August 2016, the FASB issued ASU 2016-15,&#160;<i>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,</i>&#160;which addresses eight specific cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact of the provisions of ASU 2016-15.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In March 2016, the FASB issued ASU 2016-09,&#160;<i>Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</i>, which changes certain aspects of accounting for share-based payments to employees. The Company adopted ASU 2016-09 as of July 1, 2017. ASU 2016-09 requires that all tax benefits and deficiencies related to share-based payments be recognized and recorded through the statement of income for all awards settled or expiring after the adoption of ASU 2016-09. Under prior guidance, tax benefits in excess of compensation costs ("windfalls") were recorded in equity, and any tax deficiencies ("shortfalls") were recorded in equity to the extent of previous windfalls and then to the statement of income. For the three months and nine months ended March 31, 2018, the Company recorded additional tax expense of $420 and $1,521, respectively, associated with net tax deficiencies. ASU 2016-09 also requires, either prospectively or retrospectively, that all tax-related cash flows resulting from share-based payments be reported as operating activities on the statement of cash flows, a change from prior guidance that required windfall tax benefits to be presented as an inflow from financing activities and an outflow from operating activities on the statement of cash flows. The Company has elected to adopt such presentation on a prospective basis. Additionally, ASU 2016-09 allows entities to make an accounting policy election for the impact of most types of forfeitures on the recognition of expense for share-based payment awards by allowing the forfeitures to be either estimated, as was required under prior guidance, or recognized when they actually occur. Under ASU 2016-09, the Company recognizes forfeitures when they occur.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><br class="apple-interchange-newline" />&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In February 2016, the FASB issued ASU 2016-02,&#160;<i>Leases (Topic 842)</i>&#160;that replaces existing lease guidance. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. ASU 2016-02 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2018. The Company is currently evaluating the impact of the provisions of ASU 2016-02.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In November 2015, the FASB issued ASU 2015-17,&#160;<i>Income Taxes (Topic 740): Balance Sheet Classification of Deferred Assets.&#160;</i>This ASU is intended to simplify the presentation of deferred taxes on the balance sheet and requires an entity to present all deferred tax assets and deferred tax liabilities as non-current on the balance sheet. Under the prior guidance, entities were required to separately present deferred taxes as current or non-current. Netting deferred tax assets and deferred tax liabilities by tax jurisdiction will still be required under the new guidance. The Company prospectively adopted the provisions of ASU 2015-17, as of July 1, 2017. The Company's prospective adoption of ASU 2015-17 impacts the classification of deferred tax assets and liabilities on any balance sheet that reports the Company's financial position for any date after June 30, 2017. Balance sheets for prior periods have not been adjusted. The adoption of ASU 2015-17 has no impact on the Company's results of operations or cash flows.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In July 2015, the FASB issued ASU 2015-11,&#160;<i>Inventory (Topic 330)</i>:&#160;<i>Simplifying the Measurement of Inventory.</i>&#160;This ASU requires that an entity measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted this standard in the first quarter of fiscal year 2018. The adoption of this standard did not have any impact on the condensed consolidated financial statements of the Company.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In May 2014, the FASB issued ASU 2014-09,&#160;<i>Revenue from Contracts with Customers (Topic 606),</i>&#160;which is the new comprehensive revenue recognition standard that will supersede all existing revenue recognition guidance under U.S. GAAP. The standard's core principle is that a company will recognize revenue when it transfers promised goods or services to a customer in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB subsequently issued ASU 2015-14,&#160;<i>Revenue from Contracts with Customers - Deferral of the Effective Date</i>, which approved a one-year deferral of ASU 2014-09 for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. In March 2016 and April 2016, the FASB issued ASU 2016-08,&#160;<i>Revenue from Contracts with Customers - Principal versus Agent Considerations (Reporting Revenue Gross versus Net)</i>, and ASU 2016-10,&#160;<i>Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing,</i>&#160;respectively, which further clarify the guidance related to those specific topics within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12,&#160;<i>Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients</i>, to reduce the risk of diversity in practice for certain aspects in ASU 2014-09, including collectibility, noncash consideration, presentation of sales tax and transition. Additionally, in December 2016, the FASB issued ASU 2016-20,&#160;<i>Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers</i>. ASU 2016-20 makes minor corrections or minor improvements to the standard that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. The Company has made progress in its evaluation of the amended guidance, including identification of revenue streams. The Company recognizes revenue from product sales at the time of shipment and passage of title and risk of loss and control of the goods is transferred to the customer. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to its customers. Although the Company is continuing to assess the impact of the amended guidance, Aceto generally anticipates that the timing of recognition of revenue will be substantially unchanged under the amended guidance. The amended guidance will be effective for Aceto in the first quarter of fiscal 2019 and permits adoption under either the full retrospective approach (recognize effects of the amended guidance in each prior reporting period presented) or the modified retrospective approach (recognize the cumulative effect of adoption as an adjustment to retained earnings at the date of initial application). The Company anticipates adopting this amended standard on a modified retrospective basis.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>(11) Segment Information</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company's business is organized along product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Human Health</b>&#160;- includes finished dosage form generic drugs and nutraceutical products.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Pharmaceutical Ingredients &#8211;&#160;</b>includes pharmaceutical intermediates and active pharmaceutical ingredients (&#8220;APIs&#8221;).</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Performance Chemicals&#160;</b>- The Performance Chemicals segment is made up of two product groups: Specialty Chemicals and Agricultural Protection Products. Specialty Chemicals include a variety of chemicals used in the manufacture of plastics, surface coatings, cosmetics and personal care, textiles, fuels and lubricants, perform to their designed capabilities. Dye and pigment intermediates are used in the color-producing industries such as textiles, inks, paper, and coatings. Organic intermediates are used in the production of agrochemicals.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Agricultural Protection Products include herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms that can severely damage plant growth.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company's chief operating decision maker evaluates performance of the segments based on net sales, gross profit and income before income taxes. Unallocated corporate amounts are deemed by the Company as administrative, oversight costs, not managed by the segment managers. The Company does not allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments' performance, as the assets are managed on an entity-wide basis. During all periods presented, our chief operating decision maker has been the Chief Executive Officer of the Company. In accordance with GAAP, the Company has aggregated certain operating segments into reportable segments because they have similar economic characteristics, and the operating segments are similar in all of the following areas: (a) the nature of the products and services; (b) the nature of the production processes; (c) the type or class of customer for their products and services; (d) the methods used to distribute their products or provide their services; and (e) the nature of the regulatory environment.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Nine months Ended March 31, 2018 and 2017</b>:</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.25in; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size-adjust: none;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><b>Human<br />Health</b></td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><b>Pharmaceutical&#160;<br />Ingredients</b></td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; font-stretch: normal;"><b>Performance</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; font-stretch: normal;"><b>Chemicals</b></p> </td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><b>Unallocated<br />Corporate</b></td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><b>Consolidated<br />Totals</b></td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; text-decoration: underline;">2018</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 527px; text-align: left;">Net sales</td> <td style="width: 16px;">&#160;</td> <td style="width: 16px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">301,407</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">113,406</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">127,669</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">-</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">542,482</td> <td style="width: 15px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">57,080</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">17,259</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">27,310</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">101,649</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">(Loss) income before income taxes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(258,172</td> <td style="text-align: left;" nowrap="nowrap">)*</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,795</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">14,121</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(23,142</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(261,398</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; text-decoration: underline;">2017</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Net sales</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">201,686</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">121,253</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">120,759</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">443,698</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">56,424</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">19,867</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">27,672</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">103,963</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Income (loss) before income taxes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">13,912</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7,299</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">13,599</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(20,452</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">14,358</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">* Includes goodwill impairment charge of $235,110. See Note 9 Fair Value Measurements for details.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Three months Ended March 31, 2018 and 2017</b>:</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.25in; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size-adjust: none;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><b>Human&#160;</b><br /><b>Health</b></td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><b>Pharmaceutical&#160;</b><br /><b>Ingredients</b></td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; font-stretch: normal;"><b>Performance</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; font-stretch: normal;"><b>Chemicals</b></p> </td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><b>Unallocated&#160;</b><br /><b>Corporate</b></td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><b>Consolidated&#160;</b><br /><b>Totals</b></td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; text-decoration: underline;">2018</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 527px; text-align: left;">Net sales</td> <td style="width: 16px;">&#160;</td> <td style="width: 16px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">91,926</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">43,201</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">50,871</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">-</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">185,998</td> <td style="width: 15px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,535</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7,038</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">11,123</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">27,696</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">(Loss) income before income taxes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(265,486</td> <td style="text-align: left;" nowrap="nowrap">)*</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,987</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">6,699</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(7,237</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(263,037</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; text-decoration: underline;">2017</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Net sales</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">99,816</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">43,821</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">46,491</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">190,128</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">25,300</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7,255</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,764</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">42,319</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Income (loss) before income taxes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,007</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">3,036</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,034</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(4,565</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">8,512</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">* Includes goodwill impairment charge of $235,110. See Note&#160;9 Fair Value Measurements for details.</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;"><b>(12) Income Taxes</b></font></p><div style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2"><b>&#160;</b></font></div><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (&#8220;the TCJA&#8221;) was signed by the U.S. President, which enacted various changes to the U.S. corporate tax law. Some of the most significant provisions impacting corporations include a reduced U.S. corporate income tax rate from 35% to 21% effective in 2018, a one-time "deemed repatriation" tax on unremitted earnings accumulated in non-U.S. jurisdictions, limitation on deductibility of interest, the transition of U.S. international taxation from a worldwide tax system to a territorial tax system and other provisions. U.S. GAAP accounting for income taxes requires that Aceto record the impacts of any tax law change on the Company&#8217;s deferred income taxes in the quarter that the tax law change is enacted. Due to the complexities involved in accounting for the enactment of the TCJA, SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) 118 allows Aceto to provide a provisional estimate of the impacts of the TCJA in its earnings for the fiscal year ended June 30, 2018. Accordingly, based on currently available information, the Company recorded additional income tax expense of $12,720 for the nine months ended March 31, 2018. This charge is comprised of $3,342 related to the remeasurement of Aceto&#8217;s deferred tax assets arising from a lower U.S. corporate tax rate, $7,012 related to the deemed repatriation of unremitted earnings of foreign subsidiaries and $2,366 related to deferred tax liabilities for local tax authorities as the Company no longer asserts permanent reinvestment of its undistributed non-U.S. subsidiaries' earnings. Additional impacts from the enactment of the TCJA will be recorded as they are identified during the measurement period ending no later than December 22, 2018 as provided for in SAB 118. The charge recorded in the nine months ended March 31, 2018 represents the Company&#8217;s best estimate of the impact of the TCJA. The Company will continue to evaluate the interpretations and assumptions made, guidance that may be issued and actions the Company may take as a result of the TCJA, which could materially change this estimate in 2018 as new information becomes available.</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: times new roman,times;" size="2">Deferred tax assets are recorded for net operating losses and temporary differences between the book and tax basis of assets and liabilities expected to produce tax deductions in future periods. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the tax periods in which those deferred tax assets would be deductible. A valuation allowance is taken when necessary to reduce deferred tax assets to the amount expected to be realized. When determining the amount of net deferred tax assets that are more likely than not to be realized, the Company assesses all available positive and negative evidence. This evidence includes, but is not limited to, scheduled reversal of deferred tax liabilities, prior earnings history, projected future earnings, carry-back and carry-forward periods and the feasibility of ongoing tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. The weight given to the positive and negative evidence is commensurate with the extent the evidence may be objectively verified. As such, it is generally difficult for positive evidence regarding projected future taxable income (exclusive of reversing taxable temporary differences and carryforwards) to outweigh objective negative evidence such as the Company&#8217;s recent financial reporting loss for the three and nine months ended March 31, 2018 that created a cumulative loss. Therefore, the Company recorded a valuation allowance of $71,350 against its net U.S. deferred tax assets during the three and nine months ended March 31, 2018.</font></p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(13) Subsequent Events</b></p><div style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</div><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">On April 18, 2018, the Company issued a press release announcing, among other things, that (i) it was negotiating with its bank lenders a waiver of its credit agreement with respect to its total net leverage and debt service coverage financial covenants in the fiscal third quarter, (ii) the financial guidance issued on February 1, 2018 should no longer be relied upon, (iii) the Company&#160;<font style="background-color: white;">anticipated recording substantial non-cash intangible asset impairment charges as described herein and (iv) the resignation of Edward Borkowski as its chief financial officer. Subsequently, the market price of the Company&#8217;s common stock declined significantly and several law firms publicly announced that they were investigating alleged violations of law associated with the matters described in the Company&#8217;s press release. Thereafter, Aceto and certain related individuals have been named as defendants in civil lawsuits&#160;</font>that allege, among other things, that Aceto made false and misleading statements to investors in public filings that preceded the April 18, 2018 press release. The Company is currently preparing its responses to these legal proceedings.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In connection with the Department of Justice&#8217;s ongoing investigation into marketing and pricing practices throughout the generic pharmaceutical industry, the Company has received a subpoena from the Antitrust Division of the U.S. Department of Justice (the &#8220;DOJ&#8221;). The Company is one of many operating companies in the generic pharmaceutical industry to receive a subpoena from the DOJ relating to its years-long investigation into the industry. The Company is currently preparing its response to the subpoena.</p> <div><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Basis of Presentation</b></p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The condensed consolidated financial statements of Aceto Corporation and subsidiaries (&#8220;Aceto&#8221; or the &#8220;Company&#8221;) included herein have been prepared by the Company and reflect all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for all periods presented. Interim results are not necessarily indicative of results which may be achieved for the full year.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements and the disclosure of contingent assets and liabilities at the date of the financial statements. These judgments can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company&#8217;s most critical accounting policies relate to revenue recognition; allowance for doubtful accounts; inventory; goodwill and other indefinite-life intangible assets; long-lived assets; environmental matters and other contingencies; income taxes; stock-based compensation; and purchase price allocation.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">These condensed consolidated financial statements do not include all disclosures associated with consolidated financial statements prepared in accordance with GAAP. Accordingly, these statements should be read in conjunction with the Company&#8217;s consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2017, as amended (the &#8220;2017 10-K&#8221;).</div></div> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Recent Accounting Pronouncements</b></p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In February 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU&#160;2018-02,&#160;<i>Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income,&#160;</i>which gives entities the option to reclassify the disproportionate income tax effects ("stranded tax effects") caused by the newly-enacted U.S. Tax Cuts and Jobs Act from accumulated other comprehensive income to retained earnings. The update also requires new disclosures, some of which are applicable for all entities. The guidance in ASU 2018-02 is effective for annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact of the provisions of ASU 2018-02.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In August 2017, the FASB issued ASU 2017-12,&#160;<i>Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities,</i>&#160;which has the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity&#8217;s risk management activities in its financial statements. In addition to that main objective, the amendments in ASU 2017-12 make certain targeted improvements to simplify the application of the hedge accounting guidance in current GAAP. The amendments in ASU 2017-12 are effective for public business entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of the provisions of ASU 2017-12.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In May 2017, the FASB issued ASU 2017-09,&#160;<i>Compensation &#8211; Stock Compensation (Topic 718): Scope of Modification Accounting,</i>&#160;which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company does not believe this new accounting standard update will have a material impact on its consolidated financial statements.</p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In January 2017, the FASB issued ASU 2017-01&#160;<i>Business Combinations (Topic 805): Clarifying the Definition of a Business,&#160;</i>with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU 2017-01 is effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated financial statements.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In August 2016, the FASB issued ASU 2016-15,&#160;<i>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,</i>&#160;which addresses eight specific cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact of the provisions of ASU 2016-15.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In March 2016, the FASB issued ASU 2016-09,&#160;<i>Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</i>, which changes certain aspects of accounting for share-based payments to employees. The Company adopted ASU 2016-09 as of July 1, 2017. ASU 2016-09 requires that all tax benefits and deficiencies related to share-based payments be recognized and recorded through the statement of income for all awards settled or expiring after the adoption of ASU 2016-09. Under prior guidance, tax benefits in excess of compensation costs ("windfalls") were recorded in equity, and any tax deficiencies ("shortfalls") were recorded in equity to the extent of previous windfalls and then to the statement of income. For the three months and nine months ended March 31, 2018, the Company recorded additional tax expense of $420 and $1,521, respectively, associated with net tax deficiencies. ASU 2016-09 also requires, either prospectively or retrospectively, that all tax-related cash flows resulting from share-based payments be reported as operating activities on the statement of cash flows, a change from prior guidance that required windfall tax benefits to be presented as an inflow from financing activities and an outflow from operating activities on the statement of cash flows. The Company has elected to adopt such presentation on a prospective basis. Additionally, ASU 2016-09 allows entities to make an accounting policy election for the impact of most types of forfeitures on the recognition of expense for share-based payment awards by allowing the forfeitures to be either estimated, as was required under prior guidance, or recognized when they actually occur. Under ASU 2016-09, the Company recognizes forfeitures when they occur.<br class="apple-interchange-newline" />&#160;&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In February 2016, the FASB issued ASU 2016-02,&#160;<i>Leases (Topic 842)</i>&#160;that replaces existing lease guidance. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. ASU 2016-02 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2018. The Company is currently evaluating the impact of the provisions of ASU 2016-02.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In November 2015, the FASB issued ASU 2015-17,&#160;<i>Income Taxes (Topic 740): Balance Sheet Classification of Deferred Assets.&#160;</i>This ASU is intended to simplify the presentation of deferred taxes on the balance sheet and requires an entity to present all deferred tax assets and deferred tax liabilities as non-current on the balance sheet. Under the prior guidance, entities were required to separately present deferred taxes as current or non-current. Netting deferred tax assets and deferred tax liabilities by tax jurisdiction will still be required under the new guidance. The Company prospectively adopted the provisions of ASU 2015-17, as of July 1, 2017. The Company's prospective adoption of ASU 2015-17 impacts the classification of deferred tax assets and liabilities on any balance sheet that reports the Company's financial position for any date after June 30, 2017. Balance sheets for prior periods have not been adjusted. The adoption of ASU 2015-17 has no impact on the Company's results of operations or cash flows.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In July 2015, the FASB issued ASU 2015-11,&#160;<i>Inventory (Topic 330)</i>:&#160;<i>Simplifying the Measurement of Inventory.</i>&#160;This ASU requires that an entity measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted this standard in the first quarter of fiscal year 2018. The adoption of this standard did not have any impact on the condensed consolidated financial statements of the Company.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In May 2014, the FASB issued ASU 2014-09,&#160;<i>Revenue from Contracts with Customers (Topic 606),</i>&#160;which is the new comprehensive revenue recognition standard that will supersede all existing revenue recognition guidance under U.S. GAAP. The standard's core principle is that a company will recognize revenue when it transfers promised goods or services to a customer in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB subsequently issued ASU 2015-14,&#160;<i>Revenue from Contracts with Customers - Deferral of the Effective Date</i>, which approved a one-year deferral of ASU 2014-09 for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. In March 2016 and April 2016, the FASB issued ASU 2016-08,&#160;<i>Revenue from Contracts with Customers - Principal versus Agent Considerations (Reporting Revenue Gross versus Net)</i>, and ASU 2016-10,&#160;<i>Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing,</i>&#160;respectively, which further clarify the guidance related to those specific topics within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12,&#160;<i>Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients</i>, to reduce the risk of diversity in practice for certain aspects in ASU 2014-09, including collectibility, noncash consideration, presentation of sales tax and transition. Additionally, in December 2016, the FASB issued ASU 2016-20,&#160;<i>Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers</i>. ASU 2016-20 makes minor corrections or minor improvements to the standard that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. The Company has made progress in its evaluation of the amended guidance, including identification of revenue streams. The Company recognizes revenue from product sales at the time of shipment and passage of title and risk of loss and control of the goods is transferred to the customer. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to its customers. Although the Company is continuing to assess the impact of the amended guidance, Aceto generally anticipates that the timing of recognition of revenue will be substantially unchanged under the amended guidance. The amended guidance will be effective for Aceto in the first quarter of fiscal 2019 and permits adoption under either the full retrospective approach (recognize effects of the amended guidance in each prior reporting period presented) or the modified retrospective approach (recognize the cumulative effect of adoption as an adjustment to retained earnings at the date of initial application). The Company anticipates adopting this amended standard on a modified retrospective basis.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The table below sets forth the condensed consolidated balance sheet, including the balances originally reported, corrections and the as restated balances for March 31, 2018 (in thousands):</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Reported</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Adjustment</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Restated</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Assets</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; width: 851px;">Deferred income tax asset, net</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">70,089</td> <td style="text-align: left; width: 14px;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(70,089</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">-</td> <td style="text-align: left; width: 14px;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Total assets</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">831,280</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(70,089</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">761,191</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Liabilities and Shareholders&#8217; Equity</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Deferred income tax liability</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,261</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,261</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Total liabilities</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">627,898</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,261</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">629,159</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Retained deficit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(20,354</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(71,350</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(91,704</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Total shareholders&#8217; equity</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">203,382</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(71,350</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">132,032</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Total liabilities and shareholders&#8217; equity</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">831,280</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(70,089</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">761,191</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The tables below set forth the condensed consolidated statements of loss, including the balances originally reported, corrections and the as restated balances for the three and nine months ended March 31, 2018 (in thousands, except per share data):</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>As Reported</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Adjustment</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>As Restated</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Three months ended March 31, 2018</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; width: 851px;">Income tax (benefit) provision</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(66,402</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">71,350</td> <td style="text-align: left; width: 14px;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">4,948</td> <td style="text-align: left; width: 14px;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Net loss</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(196,635</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(71,350</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(267,985</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Basic loss per common share</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(5.57</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(2.02</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(7.59</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Diluted loss per common share</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(5.57</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(2.02</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(7.59</td> <td style="text-align: left;">)</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Reported</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Adjustment</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Restated</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Nine months ended March 31, 2018</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; width: 851px;">Income tax (benefit) provision</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(51,353</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">71,350</td> <td style="text-align: left; width: 14px;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">19,997</td> <td style="text-align: left; width: 14px;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Net loss</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(210,045</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(71,350</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(281,395</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Basic loss per common share</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(5.97</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(2.03</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(8.00</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Diluted loss per common share</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(5.97</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(2.03</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(8.00</td> <td style="text-align: left;">)</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The tables below set forth the condensed consolidated statements of comprehensive income, including the balances originally reported, corrections and the as restated balances for the three and nine months ended March 31, 2018 (in thousands):</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Reported</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Adjustment</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Restated</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Three months ended March 31, 2018</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 861px;">Net loss</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(196,635</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(71,350</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(267,985</td> <td style="text-align: left; width: 14px;">)</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Comprehensive loss</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(193,556</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(71,350</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(264,906</td> <td style="text-align: left;">)</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Reported</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Adjustment</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Restated</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Nine months ended March 31, 2018</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; width: 851px;">Net loss</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(210,045</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(71,350</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(281,395</td> <td style="text-align: left; width: 14px;">)</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Comprehensive loss</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(202,758</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(71,350</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(274,108</td> <td style="text-align: left;">)</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The table below sets forth the condensed consolidated statements of cash flows from operating activities, including the balances originally reported, corrections and the as restated balances for the nine months ended March 31, 2018 (in thousands):</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Reported</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Adjustment</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">As Restated</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-indent: -0.1in; padding-left: 0.1in;">Nine months ended March 31, 2018</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; width: 851px;">Net loss</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(210,045</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(71,350</td> <td style="text-align: left; width: 14px;">)</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">(281,395</td> <td style="text-align: left; width: 14px;">)</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Deferred income taxes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(80,207</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">91,921</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">11,714</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Accrued expenses and other liabilities</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">30,299</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(20,571</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,728</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in;">Net cash provided by operating activities</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">56,415</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">56,415</td> <td style="text-align: left;">&#160;</td> </tr> </table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 76%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Nine Months Ended<br />March 31,</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Three Months Ended<br />March 31,</td><td style="font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2018</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2017</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2018</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2017</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-indent: -10pt; padding-left: 10pt; width: 527px;">Weighted average shares outstanding</td><td style="width: 12px;">&#160;</td><td style="text-align: left; width: 12px;">&#160;</td><td style="text-align: right; width: 113px;">35,162</td><td style="text-align: left; width: 12px;">&#160;</td><td style="width: 11px;">&#160;</td><td style="text-align: left; width: 11px;">&#160;</td><td style="text-align: right; width: 112px;">31,453</td><td style="text-align: left; width: 11px;">&#160;</td><td style="width: 11px;">&#160;</td><td style="text-align: left; width: 11px;">&#160;</td><td style="text-align: right; width: 112px;">35,304</td><td style="text-align: left; width: 11px;">&#160;</td><td style="width: 11px;">&#160;</td><td style="text-align: left; width: 11px;">&#160;</td><td style="text-align: right; width: 112px;">34,769</td><td style="text-align: left; width: 11px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt;">Dilutive effect of stock options and restricted stock awards and units</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">-</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">339</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">-</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">352</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-indent: -10pt; padding-left: 10pt;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt;">Diluted weighted average shares outstanding</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">35,162</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">31,792</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">35,304</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">35,121</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr></table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 1pt;" nowrap="nowrap"><b>&#160;</b></td><td style="padding-bottom: 1pt;"><b>&#160;</b></td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif;"><b>March 31,</b></p><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif;"><b>2018</b></p></td><td style="padding-bottom: 1pt;"><b>&#160;</b></td><td style="padding-bottom: 1pt;"><b>&#160;</b></td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif;"><b>June 30,</b></p><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif;"><b>2017</b></p></td><td style="padding-bottom: 1pt;"><b>&#160;</b></td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 809px;">Convertible Senior Notes, net</td><td style="width: 12px;">&#160;</td><td style="text-align: left; width: 12px;">$</td><td style="text-align: right; width: 142px;">126,279</td><td style="text-align: left; width: 12px;">&#160;</td><td style="width: 11px;">&#160;</td><td style="text-align: left; width: 11px;">$</td><td style="text-align: right; width: 141px;">121,676</td><td style="text-align: left; width: 11px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Revolving Bank Loans</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">62,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">90,000</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Term Bank Loans</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">128,526</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">139,227</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt;">Mortgage</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">2,615</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">2,763</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-indent: -10pt; padding-left: 10pt;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">319,420</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">353,666</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt;">Less current portion</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">190,723</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">14,466</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">128,697</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">339,200</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr></table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 76%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">March 31,<br />2018</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">June 30,<br />2017</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 819px;">Principal amount</td><td style="width: 12px;">&#160;</td><td style="text-align: left; width: 12px;">$</td><td style="text-align: right; width: 112px;">143,750</td><td style="text-align: left; width: 11px;">&#160;</td><td style="width: 11px;">&#160;</td><td style="text-align: left; width: 11px;">$</td><td style="text-align: right; width: 112px;">143,750</td><td style="text-align: left; width: 11px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Unamortized debt discount</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(15,278</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(19,255</td><td style="text-align: left;">)</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt;">Unamortized debt issuance costs</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(2,193</td><td style="text-align: left; padding-bottom: 1pt;">)</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(2,819</td><td style="text-align: left; padding-bottom: 1pt;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt;">Net carrying value</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">126,279</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">121,676</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr></table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 76%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Nine Months Ended<br />March 31, 2018</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Three Months Ended<br />March 31, 2018</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 819px;">Contractual coupon</td><td style="width: 12px;">&#160;</td><td style="text-align: left; width: 12px;">$</td><td style="text-align: right; width: 112px;">2,127</td><td style="text-align: left; width: 11px;">&#160;</td><td style="width: 11px;">&#160;</td><td style="text-align: left; width: 11px;">$</td><td style="text-align: right; width: 112px;">709</td><td style="text-align: left; width: 11px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Amortization of debt discount</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">3,977</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,347</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt;">Amortization of debt issuance costs</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">626</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">208</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">6,730</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">2,264</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr></table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="14" nowrap="nowrap">Fair Value Measurements at March 31, 2018 Using</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Quoted Prices<br />in Active<br />Markets<br />(Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant<br />Other<br />Observable<br />Inputs (Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant<br />Unobservable<br />Inputs<br />(Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Total</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left;">Cash equivalents:</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-left: 9pt; width: 664px;">Time deposits</td><td style="width: 15px;">&#160;</td><td style="text-align: left; width: 15px;">&#160;</td><td style="text-align: right; width: 141px;">-</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">$</td><td style="text-align: right; width: 140px;">2,746</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">&#160;</td><td style="text-align: right; width: 140px;">-</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">$</td><td style="text-align: right; width: 140px;">2,746</td><td style="text-align: left; width: 14px;">&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Investments:</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left; padding-left: 9pt;">Time deposits</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">3,059</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">3,059</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left;">Foreign currency contracts-assets&#160;<font style="font-size: 10pt;">(1)</font></td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">285</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">285</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Foreign currency contracts-liabilities&#160;<font style="font-size: 10pt;">(2)</font></td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">318</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">318</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left;">Derivative asset for interest rate swap&#160;<font style="font-size: 10pt;">(3)</font></td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,539</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,539</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Contingent consideration&#160;<font style="font-size: 10pt;">(4)</font></td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">752</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">752</td><td style="text-align: left;">&#160;</td></tr></table><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><table style="widows: 2; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0px;"></td><td style="text-align: left; width: 0.5in;">(1)</td><td style="text-align: justify;">Included in &#8220;Other receivables&#8221; in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.</td></tr></table><table style="widows: 2; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0px;"></td><td style="text-align: left; width: 0.5in;">(2)</td><td style="text-align: justify;">Included in &#8220;Accrued expenses&#8221; in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.</td></tr></table><table style="widows: 2; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0px;"></td><td style="text-align: left; width: 0.5in;">(3)</td><td style="text-align: justify;">Included in &#8220;Other assets&#8221; in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.</td></tr></table><table style="widows: 2; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0px;"></td><td style="width: 0.5in;">(4)</td><td>$89 included in &#8220;Accrued expenses&#8221; and $663 included in &#8220;Long-term liabilities&#8221; in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.</td></tr></table><p style="widows: 2; text-transform: none; text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="14" nowrap="nowrap">Fair Value Measurements at June 30, 2017 Using</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Quoted Prices<br />in Active<br />Markets<br />(Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant<br />Other<br />Observable<br />Inputs (Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant<br />Unobservable<br />Inputs<br />(Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Total</td><td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left;">Cash equivalents:</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-left: 9pt; width: 664px;">Time deposits</td><td style="width: 15px;">&#160;</td><td style="text-align: left; width: 15px;">&#160;</td><td style="text-align: right; width: 141px;">-</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">$</td><td style="text-align: right; width: 140px;">5,781</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">&#160;</td><td style="text-align: right; width: 140px;">-</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">$</td><td style="text-align: right; width: 140px;">5,781</td><td style="text-align: left; width: 14px;">&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Investments:</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left; padding-left: 9pt;">Time deposits</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,046</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,046</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left;">Foreign currency contracts-assets&#160;<font style="font-size: 10pt;">(5)</font></td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">486</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">486</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Foreign currency contracts-liabilities&#160;<font style="font-size: 10pt;">(6)</font></td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">137</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">137</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="text-align: left;">Derivative liability for interest rate swap (<font style="font-size: 10pt;">7</font>)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">581</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">581</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Contingent consideration&#160;<font style="font-size: 10pt;">(8)</font></td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">2,952</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,952</td><td style="text-align: left;">&#160;</td></tr></table><p style="widows: 2; text-transform: none; text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><table style="widows: 2; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0px;"></td><td style="width: 0.5in;">(5)</td><td>Included in &#8220;Other receivables&#8221; in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.</td></tr></table><table style="widows: 2; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="text-align: justify; vertical-align: top;"><td style="width: 0px;"></td><td style="text-align: left; width: 0.5in;">(6)</td><td style="text-align: justify;">Included in &#8220;Accrued expenses&#8221; in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.</td></tr></table><table style="widows: 2; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0px;"></td><td style="width: 0.5in;">(7)</td><td>Included in &#8220;Long-term liabilities&#8221; in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.</td></tr></table><table style="widows: 2; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0px;"></td><td style="width: 0.5in;">(8)</td><td>$145 included in &#8220;Accrued expenses&#8221; and $2,807 included in &#8220;Long-term liabilities&#8221; in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.</td></tr></table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Nine months Ended March 31, 2018 and 2017</b>:</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.25in; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size-adjust: none;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><b>Human<br />Health</b></td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><b>Pharmaceutical&#160;<br />Ingredients</b></td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; font-stretch: normal;"><b>Performance</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; font-stretch: normal;"><b>Chemicals</b></p> </td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><b>Unallocated<br />Corporate</b></td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><b>Consolidated<br />Totals</b></td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; text-decoration: underline;">2018</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 527px; text-align: left;">Net sales</td> <td style="width: 16px;">&#160;</td> <td style="width: 16px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">301,407</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">113,406</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">127,669</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">-</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">542,482</td> <td style="width: 15px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">57,080</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">17,259</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">27,310</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">101,649</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">(Loss) income before income taxes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(258,172</td> <td style="text-align: left;" nowrap="nowrap">)*</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,795</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">14,121</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(23,142</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(261,398</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; text-decoration: underline;">2017</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Net sales</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">201,686</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">121,253</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">120,759</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">443,698</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">56,424</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">19,867</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">27,672</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">103,963</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Income (loss) before income taxes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">13,912</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7,299</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">13,599</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(20,452</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">14,358</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">* Includes goodwill impairment charge of $235,110. See Note&#160;9 Fair Value Measurements for details.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Three months Ended March 31, 2018 and 2017</b>:</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.25in; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size-adjust: none;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><b>Human&#160;</b><br /><b>Health</b></td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><b>Pharmaceutical&#160;</b><br /><b>Ingredients</b></td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; font-stretch: normal;"><b>Performance</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; font-stretch: normal;"><b>Chemicals</b></p> </td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><b>Unallocated&#160;</b><br /><b>Corporate</b></td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><b>Consolidated&#160;</b><br /><b>Totals</b></td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; text-decoration: underline;">2018</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 527px; text-align: left;">Net sales</td> <td style="width: 16px;">&#160;</td> <td style="width: 16px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">91,926</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">43,201</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">50,871</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">-</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 150px; text-align: right;">185,998</td> <td style="width: 15px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,535</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7,038</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">11,123</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">27,696</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">(Loss) income before income taxes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(265,486</td> <td style="text-align: left;" nowrap="nowrap">)*</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,987</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">6,699</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(7,237</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(263,037</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; text-decoration: underline;">2017</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Net sales</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">99,816</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">43,821</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">46,491</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">190,128</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">25,300</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7,255</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,764</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">42,319</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Income (loss) before income taxes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,007</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">3,036</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,034</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(4,565</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">8,512</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">* Includes goodwill impairment charge of $235,110. See Note&#160;9 Fair Value Measurements for details.</p> 0 70089000 -70089000 71350000 18 P5Y 50000000 0.0500 P5Y 50000000 2952000 2807000 145000 752000 663000 89000 2 5250000 4250000 160000 22000 277000 42000 203000 27000 490000 P3Y P1Y P3Y P3Y P1Y P3Y 280000 355000 1.00 1.00 7864000 0.065 0.065 0.065 0.01 2017-08-24 2017-12-07 2018-02-01 2018-05-03 2018-09-21 2017-12-28 2018-03-23 2018-06-22 2017-09-08 2017-12-18 2018-03-09 2018-06-08 5000000 352000 339000 0 0 33.215 100000 181000 170000 143000 3947000 2763000 2615000 353666000 121676000 139227000 90000000 319420000 126279000 128526000 62000000 150000000 143750000 143750000 131250000 19255000 15278000 2819000 2193000 709000 2127000 1347000 3977000 208000 626000 2264000 6730000 143750000 125000000 18750000 143750000 0.020 0.0492 0.0405 0.0357 0.0363 0.015 0.025 4328000 1000000 20 30 1.30 0.98 11 150000000 225000000 100000000 100000000 Maturity Date shall mean the date that is 91 days prior to the 2015 Convertible Maturity Date 19 Quarterly 3750000 <div><font style="font-family: times new roman,times;" size="2">Restricting the amount of dividends or distributions the Company may make to its shareholders to no more than $0.01 per share for the fiscal quarter ending on June 30, 2018 and, during the Limitation Period, restricting the Company from making any other dividends or distributions to its shareholders thereafter</font></div> 0.004 P20Y 1700000 21500000 23300000 8451000 4495000 550000 550000 1200000 3803000 2023000 150 2299000 0 5781000 0 5781000 0 2746000 0 2746000 0 2046000 0 2046000 0 3059000 0 3059000 0 486000 0 486000 0 285000 0 285000 0 137000 0 137000 0 318000 0 318000 0 1539000 0 1539000 0 581000 0 581000 0 0 2952000 2952000 145000 2807000 0 0 752000 752000 89000 663000 0.02005 100000000 62350000 2021-12-21 87500000 353000 -230000 -34000 227000 1539000 235110000 235110000 15411000 5745000 15411000 5745000 0.065 126600000 Yes 3 0.3500 0.2100 12720000 3342000 7012000 2366000 190128000 0 99816000 43821000 46491000 443698000 0 201686000 121253000 120759000 185998000 0 91926000 43201000 50871000 542482000 0 301407000 113406000 127669000 (as restated) Includes goodwill impairment charge of $235,110. See Note 8 Fair Value Measurements for details. Included in "Other receivables" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017. Included in "Other receivables" in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018. Included in "Accrued expenses" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017. Included in "Accrued expenses" in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018. Included in "Other assets" in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018. Included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017. $145 included in "Accrued expenses" and $2,807 included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017. $89 included in "Accrued expenses" and $663 included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018. <p style="text-align: center; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Explanatory Note</b></p> <p style="text-align: center; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">(all dollar amounts in this Explanatory Note are expressed in thousands)</p> <p style="text-align: center; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Aceto Corporation (the &#8220;Company&#8221;)&#160;<font style="color: black;">is filing this Amendment No.&#160;1 (&#8220;Amendment No.&#160;1&#8221;) to its Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2018, which was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on May&#160;7, 2018 (the &#8220;Original Filing&#8221;), to amend and restate the Company&#8217;s unaudited consolidated condensed financial statements and related notes for the three and nine months ended March&#160;31, 2018 and 2017, as discussed below and in Notes 2 and 12 to the accompanying restated consolidated condensed financial statements, as well as to amend certain other Items within the Original Filing as listed in &#8220;Items Amended in this Filing&#8221; below, as a result of the restatement of the Company&#8217;s consolidated condensed financial statements.</font>&#160;Certain reclassifications between trade receivables and accrued expenses to the June 30, 2017 consolidated balance sheet, which have been reflected in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2018 are not reflected in the June 30, 2017 consolidated balance sheet presented herein.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Background of the Restatement</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On September 26, 2018, the Audit Committee (the &#8220;Audit Committee&#8221;) of the Board of Directors of the Company, in consultation with management and the Company's independent registered public accounting firm, BDO USA, LLP (&#8220;BDO&#8221;), determined that the Company&#8217;s unaudited<font style="color: black;">consolidated condensed&#160;</font>financial statements for the three and nine months ended March 31, 2018 (the &#8220;Relevant Financial Statements&#8221;) incorrectly accounted for a valuation allowance related to deferred tax assets and should be restated to reflect this allowance (the &#8220;Restatement&#8221;). This incorrect valuation allowance has no effect on the Company's cash position or operating expenses and is solely related to the appropriate timing of the recording of a valuation allowance reserved against U.S. deferred tax assets.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">At the time of the March 31, 2018 Form 10-Q filing, the Company believed that the carrying value of its&#160;deferred tax assets&#160;was appropriate based on its view that it was more likely than not that this&#160;deferred tax asset&#160;would be realized in future periods. In preparing its consolidated financial statements for the year ended June 30, 2018, the Company determined, in consultation with BDO, based on management's review of current and historical performance, internal projections and industry data and applicable accounting literature, that it should recognize a valuation allowance equal to the entire carrying value of the Company&#8217;s U.S. deferred tax assets. However, upon further review of the negative and positive objective evidence and applicable accounting literature, the Company determined, in consultation with BDO, that a full valuation allowance on domestic net deferred tax assets should have been recorded as of the end of its third fiscal quarter rather than as of the end of its fourth fiscal quarter. As a result, the Company has determined to record a valuation allowance of approximately $71,350 on its U.S. deferred tax assets at March 31, 2018.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The impact of this Restatement on the Company&#8217;s consolidated statements of operations for the three and nine months ended March 31, 2018 is to increase income tax expense and net loss by approximately $71,350.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>As reported</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Adjustment</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>As restated</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: justify;" nowrap="nowrap"><b>For the quarter ended March 31, 2018</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="text-align: right;" colspan="2" nowrap="nowrap"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="text-align: right;" colspan="2" nowrap="nowrap"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="text-align: right;" colspan="2" nowrap="nowrap"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; width: 956px;">Loss before income taxes</td> <td style="width: 16px;">&#160;</td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">(263,037</td> <td style="text-align: left; width: 16px;">)</td> <td style="width: 16px;">&#160;</td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">-</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">(263,037</td> <td style="text-align: left; width: 15px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Income tax (benefit) provision</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(66,402</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">71,350</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">4,948</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Net loss</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(196,635</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(71,350</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(267,985</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Loss per diluted share</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(5.57</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(2.02</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(7.59</td> <td style="text-align: left;">)</td> </tr> </table> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>As reported</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Adjustment</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>As restated</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: justify;" nowrap="nowrap"><b>For the nine months ended March 31, 2018</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="text-align: right;" colspan="2" nowrap="nowrap"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="text-align: center; padding-bottom: 1pt;" colspan="2" nowrap="nowrap"><b>$</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> <td style="text-align: right;" colspan="2" nowrap="nowrap"><b>&#160;</b></td> <td style="padding-bottom: 1pt;"><b>&#160;</b></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; width: 956px;">Loss before income taxes</td> <td style="width: 16px;">&#160;</td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">(261,398</td> <td style="text-align: left; width: 16px;">)</td> <td style="width: 16px;">&#160;</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="text-align: right; width: 157px;">-</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">(261,398</td> <td style="text-align: left; width: 15px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Income tax (benefit) provision</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(51,353</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">71,350</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">19,997</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Net loss</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(210,045</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(71,350</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(281,395</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td>Loss per diluted share</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(5.97</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(2.03</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(8.00</td> <td style="text-align: left;">)</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For additional information regarding the impact of the Restatement on the Company&#8217;s financial statements, see Note 2 of the notes to the Company&#8217;s consolidated financial statements.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On September 26, 2018, the Audit Committee concluded that the Relevant Financial Statements and related disclosures included in the Company&#8217;s Quarterly Report on&#160;Form 10-Q&#160;for the quarter ended March 31, 2018, should no longer be relied upon. This Amendment No. 1 reflects the Restatement. The Restatement has no effect on the Company&#8217;s consolidated balance sheet as of June 30, 2018 and consolidated statement of operations for the year ended June 30, 2018, which financial statements were filed on September 28, 2018 with the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2018. The Annual Report reflected the results of the Restatement in Note 20 to the Company&#8217;s consolidated financial statements, entitled &#8220;Unaudited Quarterly Financial Data.&#8221;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Internal Control Considerations</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company&#8217;s management determined that there was a control deficiency in its internal control that constitutes a material weakness, as discussed in Part&#160;I &#8212; Item&#160;4 of this Amendment No.&#160;1. A material weakness is a deficiency, or combination of control deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim consolidated financial statements will not be prevented or detected on a timely basis.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Items Amended in This Filing</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the convenience of the reader, this Amendment No.&#160;1 sets forth the Original Filing, as modified and superseded where necessary to reflect the Restatement. The following items have been amended as a result of, and to reflect, the Restatement:</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="text-align: justify; vertical-align: top;"> <td style="width: 1in;"></td> <td style="text-align: left; width: 0.5in;"><font style="font-family: symbol;">&#183;</font></td> <td style="text-align: justify;">Part&#160;I &#8212; Item&#160;1. Financial Statements;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="text-align: justify; vertical-align: top;"> <td style="width: 1in;"></td> <td style="text-align: left; width: 0.5in;"><font style="font-family: symbol;">&#183;</font></td> <td style="text-align: justify;">Part&#160;I &#8212; Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations; and</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="widows: 2; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="text-align: justify; vertical-align: top;"> <td style="width: 1in;"></td> <td style="text-align: left; width: 0.5in;"><font style="font-family: symbol;">&#183;</font></td> <td style="text-align: justify;">Part&#160;I &#8212; Item&#160;4. Controls and Procedures.</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In accordance with applicable SEC rules, this Amendment No.&#160;1 includes new certifications required by Rule&#160;13a-14 under the Securities and Exchange Act of 1934 (&#8220;Exchange Act&#8221;) from our Chief Executive Officer and Chief Financial Officer dated as of the date of filing of this Amendment No.&#160;1.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Except for the items noted above, no other information included in the Original Filing is being amended or updated by this Amendment No.&#160;1. This Amendment No. 1 continues to describe the conditions as of the date of the Original Filing, and, except as contained herein, the Company has not updated or modified the disclosures contained in the Original Filing. Accordingly, this Amendment No.&#160;1 should be read in conjunction with the Company&#8217;s filings made with the SEC subsequent to the filing of the Original Filing, including the Company&#8217;s Annual Report on Form 10-K.</p> EX-101.SCH 8 acet-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Restatement of Previously Issued Financial Statements link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Business Combinations link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Capital Stock link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Net (Loss) Income Per Common Share link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Debt link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Commitments, Contingencies and Other Matters link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Segment Information link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Restatement of Previously Issued Financial Statements (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Net (Loss) Income Per Common Share (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Segment Information (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Restatement of Previously Issued Financial Statements (Condensed consolidated balance sheet, including balances originally reported, corrections and restated balances) (Detail) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Restatement of Previously Issued Financial Statements (Condensed consolidated statements of (loss) income, including balances originally reported, corrections and restated balances (Detail 1) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Restatement of Previously Issued Financial Statements (Condensed consolidated statements of comprehensive income, including balances originally reported, corrections and restated balances) (Detail 2) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Restatement of Previously Issued Financial Statements (Condensed consolidated statements of cash flows from operating activities, including balances originally reported, corrections and restated balances) (Detail 3) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Restatement of Previously Issued Financial Statements (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Business Combinations (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Stock Based Compensation (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Capital Stock (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Net (Loss) Income Per Common Share (Reconciliation of Weighted Average Shares Outstanding and Diluted Weighted Average Shares Outstanding) (Detail) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Net (Loss) Income Per Common Share (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Debt (Summary of Long-term Debt) (Detail) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Debt (Summary carrying value of Notes) (Detail 1) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Debt (Summary interest expense related to notes recognized) (Detail 2) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Debt (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Debt (Narrative) (Detail 1) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Debt (Narrative) (Detail 2) link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Debt (Narrative) (Detail 3) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Commitments, Contingencies and Other Matters (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Fair Value Measurements (Summary of Valuation of Financial Assets and Liabilities) (Detail 1) link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Fair Value Measurements (Parentheticals) (Summary of Valuation of Financial Assets and Liabilities) (Detail 1) link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Fair Value Measurements (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - Recent Accounting Pronouncements (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - Segment Information (Summary of Segment Perfomance Measures by Segment) (Detail) link:presentationLink link:definitionLink link:calculationLink 049 - Disclosure - Segment Information (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 050 - Disclosure - Income Taxes (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 acet-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 acet-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 acet-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 12 acet-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
 9 Months Ended
Mar. 31, 2018
May 01, 2018
Document and Entity Information [Abstract]    
Entity Registrant Name ACETO CORP  
Entity Central Index Key 0000002034  
Trading Symbol acet  
Current Fiscal Year End Date --06-30  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock Shares Outstanding   30,788,044
Document Type 10-Q/A  
Document Period End Date Mar. 31, 2018  
Amendment Flag true  
Amendment Description <p style="text-align: center; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Explanatory Note</b></p> <p style="text-align: center; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">(all dollar amounts in this Explanatory Note are expressed in thousands)</p> <p style="text-align: center; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Aceto Corporation (the “Company”) <font style="color: black;">is filing this Amendment No. 1 (“Amendment No. 1”) to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, which was filed with the Securities and Exchange Commission (“SEC”) on May 7, 2018 (the “Original Filing”), to amend and restate the Company’s unaudited consolidated condensed financial statements and related notes for the three and nine months ended March 31, 2018 and 2017, as discussed below and in Notes 2 and 12 to the accompanying restated consolidated condensed financial statements, as well as to amend certain other Items within the Original Filing as listed in “Items Amended in this Filing” below, as a result of the restatement of the Company’s consolidated condensed financial statements.</font> Certain reclassifications between trade receivables and accrued expenses to the June 30, 2017 consolidated balance sheet, which have been reflected in the Company’s Annual Report on Form 10-K for the year ended June 30, 2018 are not reflected in the June 30, 2017 consolidated balance sheet presented herein.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Background of the Restatement</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On September 26, 2018, the Audit Committee (the “Audit Committee”) of the Board of Directors of the Company, in consultation with management and the Company's independent registered public accounting firm, BDO USA, LLP (“BDO”), determined that the Company’s unaudited<font style="color: black;">consolidated condensed </font>financial statements for the three and nine months ended March 31, 2018 (the “Relevant Financial Statements”) incorrectly accounted for a valuation allowance related to deferred tax assets and should be restated to reflect this allowance (the “Restatement”). This incorrect valuation allowance has no effect on the Company's cash position or operating expenses and is solely related to the appropriate timing of the recording of a valuation allowance reserved against U.S. deferred tax assets.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">At the time of the March 31, 2018 Form 10-Q filing, the Company believed that the carrying value of its deferred tax assets was appropriate based on its view that it was more likely than not that this deferred tax asset would be realized in future periods. In preparing its consolidated financial statements for the year ended June 30, 2018, the Company determined, in consultation with BDO, based on management's review of current and historical performance, internal projections and industry data and applicable accounting literature, that it should recognize a valuation allowance equal to the entire carrying value of the Company’s U.S. deferred tax assets. However, upon further review of the negative and positive objective evidence and applicable accounting literature, the Company determined, in consultation with BDO, that a full valuation allowance on domestic net deferred tax assets should have been recorded as of the end of its third fiscal quarter rather than as of the end of its fourth fiscal quarter. As a result, the Company has determined to record a valuation allowance of approximately $71,350 on its U.S. deferred tax assets at March 31, 2018.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The impact of this Restatement on the Company’s consolidated statements of operations for the three and nine months ended March 31, 2018 is to increase income tax expense and net loss by approximately $71,350.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>As reported</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Adjustment</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>As restated</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: justify;" nowrap="nowrap"><b>For the quarter ended March 31, 2018</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="text-align: right;" colspan="2" nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="text-align: right;" colspan="2" nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="text-align: right;" colspan="2" nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; width: 956px;">Loss before income taxes</td> <td style="width: 16px;"> </td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">(263,037</td> <td style="text-align: left; width: 16px;">)</td> <td style="width: 16px;"> </td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">-</td> <td style="text-align: left; width: 16px;"> </td> <td style="width: 15px;"> </td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">(263,037</td> <td style="text-align: left; width: 15px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Income tax (benefit) provision</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(66,402</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">71,350</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">4,948</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Net loss</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(196,635</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(71,350</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(267,985</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Loss per diluted share</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">(5.57</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">(2.02</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">(7.59</td> <td style="text-align: left;">)</td> </tr> </table> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>As reported</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Adjustment</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>As restated</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: justify;" nowrap="nowrap"><b>For the nine months ended March 31, 2018</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="text-align: right;" colspan="2" nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="text-align: center; padding-bottom: 1pt;" colspan="2" nowrap="nowrap"><b>$</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="text-align: right;" colspan="2" nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; width: 956px;">Loss before income taxes</td> <td style="width: 16px;"> </td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">(261,398</td> <td style="text-align: left; width: 16px;">)</td> <td style="width: 16px;"> </td> <td style="text-align: left; width: 16px;"> </td> <td style="text-align: right; width: 157px;">-</td> <td style="text-align: left; width: 16px;"> </td> <td style="width: 15px;"> </td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">(261,398</td> <td style="text-align: left; width: 15px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Income tax (benefit) provision</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(51,353</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">71,350</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">19,997</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Net loss</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(210,045</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(71,350</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(281,395</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td>Loss per diluted share</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">(5.97</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">(2.03</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">(8.00</td> <td style="text-align: left;">)</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For additional information regarding the impact of the Restatement on the Company’s financial statements, see Note 2 of the notes to the Company’s consolidated financial statements.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On September 26, 2018, the Audit Committee concluded that the Relevant Financial Statements and related disclosures included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, should no longer be relied upon. This Amendment No. 1 reflects the Restatement. The Restatement has no effect on the Company’s consolidated balance sheet as of June 30, 2018 and consolidated statement of operations for the year ended June 30, 2018, which financial statements were filed on September 28, 2018 with the Company’s Annual Report on Form 10-K for the year ended June 30, 2018. The Annual Report reflected the results of the Restatement in Note 20 to the Company’s consolidated financial statements, entitled “Unaudited Quarterly Financial Data.”</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b> </b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Internal Control Considerations</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company’s management determined that there was a control deficiency in its internal control that constitutes a material weakness, as discussed in Part I — Item 4 of this Amendment No. 1. A material weakness is a deficiency, or combination of control deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim consolidated financial statements will not be prevented or detected on a timely basis.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b> </b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Items Amended in This Filing</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the convenience of the reader, this Amendment No. 1 sets forth the Original Filing, as modified and superseded where necessary to reflect the Restatement. The following items have been amended as a result of, and to reflect, the Restatement:</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p> <table style="widows: 2; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="text-align: justify; vertical-align: top;"> <td style="width: 1in;"></td> <td style="text-align: left; width: 0.5in;"><font style="font-family: symbol;">·</font></td> <td style="text-align: justify;">Part I — Item 1. Financial Statements;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p> <table style="widows: 2; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="text-align: justify; vertical-align: top;"> <td style="width: 1in;"></td> <td style="text-align: left; width: 0.5in;"><font style="font-family: symbol;">·</font></td> <td style="text-align: justify;">Part I — Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations; and</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p> <table style="widows: 2; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="text-align: justify; vertical-align: top;"> <td style="width: 1in;"></td> <td style="text-align: left; width: 0.5in;"><font style="font-family: symbol;">·</font></td> <td style="text-align: justify;">Part I — Item 4. Controls and Procedures.</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In accordance with applicable SEC rules, this Amendment No. 1 includes new certifications required by Rule 13a-14 under the Securities and Exchange Act of 1934 (“Exchange Act”) from our Chief Executive Officer and Chief Financial Officer dated as of the date of filing of this Amendment No. 1.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Except for the items noted above, no other information included in the Original Filing is being amended or updated by this Amendment No. 1. This Amendment No. 1 continues to describe the conditions as of the date of the Original Filing, and, except as contained herein, the Company has not updated or modified the disclosures contained in the Original Filing. Accordingly, this Amendment No. 1 should be read in conjunction with the Company’s filings made with the SEC subsequent to the filing of the Original Filing, including the Company’s Annual Report on Form 10-K.</p>  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q3  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2018
 [1]
Jun. 30, 2017
Current assets:    
Cash and cash equivalents $ 62,032 $ 55,680
Investments 3,059 2,046
Trade receivables, less allowance for doubtful accounts (March 31, 2018, $805; June 30, 2017, $485) 260,168 260,889
Other receivables 15,771 12,066
Inventory 141,669 136,387
Prepaid expenses and other current assets 4,942 3,941
Deferred income tax asset, net   546
Total current assets 487,641 471,555
Property and equipment, net 14,002 10,428
Property held for sale 6,250 7,152
Goodwill 1,939 236,970
Intangible assets, net 241,513 285,081
Deferred income tax asset, net   19,453
Other assets 9,846 7,546
TOTAL ASSETS 761,191 1,038,185
Current liabilities:    
Current portion of long-term debt 190,723 14,466
Accounts payable 125,083 90,011
Accrued expenses 119,389 118,328
Total current liabilities 435,195 222,805
Long-term debt, net 128,697 339,200
Long-term liabilities 63,623 61,449
Environmental remediation liability 383 2,339
Deferred income tax liability 1,261 7,325
Total liabilities 629,159 633,118
Commitments and contingencies (Note 8)
Shareholders' equity:    
Preferred stock, 2,000 shares authorized; no shares issued and outstanding
Common stock, $.01 par value, 75,000 shares authorized; 30,839 and 30,094 shares issued and outstanding at March 31, 2018 and June 30, 2017, respectively 308 301
Capital in excess of par value 221,253 214,198
Retained (deficit) earnings (91,704) 195,680
Accumulated other comprehensive income (loss) 2,175 (5,112)
Total shareholders' equity 132,032 405,067
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 761,191 $ 1,038,185
[1] (as restated)
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)
shares in Thousands, $ in Thousands
Mar. 31, 2018
 [1]
Jun. 30, 2017
Statement Of Financial Position [Abstract]    
Allowance for doubtful accounts (in dollars) $ 805 $ 485
Preferred stock, shares authorized 2,000 2,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized 75,000 75,000
Common stock, shares issued 30,839 30,094
Common stock, shares outstanding 30,839 30,094
[1] (as restated)
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
Income Statement [Abstract]        
Net sales $ 185,998 [1] $ 190,128 $ 542,482 [1] $ 443,698
Cost of sales 158,302 [1] 147,809 440,833 [1] 339,735
Gross profit 27,696 [1] 42,319 101,649 [1] 103,963
Selling, general and administrative expenses 28,029 [1] 26,519 87,241 [1] 75,614
Impairment charges [1] 256,266   256,266  
Research and development expenses 2,471 [1] 2,607 6,208 [1] 4,998
Operating (loss) income (259,070) [1] 13,193 (248,066) [1] 23,351
Other (expense) income:        
Interest expense (5,040) [1] (5,321) (15,443) [1] (10,223)
Interest and other income, net 1,073 [1] 640 2,111 [1] 1,230
Other (expense) income, Total (3,967) [1] (4,681) (13,332) [1] (8,993)
(Loss) income before income taxes (263,037) [1] 8,512 (261,398) [1] 14,358
Income tax provision 4,948 [1] 2,924 19,997 [1] 4,949
Net (loss) income $ (267,985) [1] $ 5,588 $ (281,395) [1] $ 9,409
Basic (loss) income per common share (in dollars per share) $ (7.59) [1] $ 0.16 $ (8.00) [1] $ 0.30
Diluted (loss) income per common share (in dollars per share) $ (7.59) [1] $ 0.16 $ (8.00) [1] $ 0.30
Weighted average shares outstanding:        
Basic (in shares) 35,304 [1] 34,769 35,162 [1] 31,453
Diluted (in shares) 35,304 [1] 35,121 35,162 [1] 31,792
[1] (as restated)
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2018
 [1]
Mar. 31, 2017
Mar. 31, 2018
 [1]
Mar. 31, 2017
Statement of Comprehensive (loss) Income [Abstract]        
Net (loss) income $ (267,985) $ 5,588 $ (281,395) $ 9,409
Other comprehensive (loss) income:        
Foreign currency translation adjustments 1,941 947 5,167 (2,201)
Change in fair value of interest rate swaps 1,138 (249) 2,120 (249)
Comprehensive (loss) income $ (264,906) $ 6,286 $ (274,108) $ 6,959
[1] (as restated)
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
shares in Thousands, $ in Thousands
 9 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Operating activities:    
Net (loss) income $ (281,395) [1] $ 9,409
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Depreciation and amortization 24,608 [1] 15,301
Amortization of debt issuance costs and debt discount 4,603 [1] 4,355
Amortization of deferred financing costs 833 [1] 300
Provision for doubtful accounts 305 [1] (18)
Non-cash stock compensation 6,442 [1] 5,239
Deferred income taxes 11,714 [1] 627
Environmental charge 902 [1] 903
Earnings on equity investment in joint venture (1,990) [1] (1,558)
Contingent consideration [1] (2,505)  
Impairment charges [1] 256,266  
Changes in assets and liabilities:    
Trade accounts receivable 2,573 [1] (14,839)
Other receivables (3,662) [1] 1,664
Inventory (3,102) [1] (3,778)
Prepaid expenses and other current assets (927) [1] (424)
Other assets (2,202) [1] 215
Accounts payable 34,224 [1] 18,857
Accrued expenses and other liabilities 9,728 [1] (4,702)
Net cash provided by operating activities 56,415 [1] 31,551
Investing activities:    
Payment for net assets of business acquired   (270,000)
Purchases of investments (2,880) [1] (1,824)
Sales of investments 1,867 [1] 775
Payments for intangible assets (779) [1] (3,077)
Purchases of property and equipment, net (4,677) [1] (1,386)
Net cash used in investing activities (6,469) [1] (275,512)
Financing activities:    
Payment of cash dividends (5,924) [1] (5,944)
Proceeds from exercise of stock options 595 [1] 550
Excess tax benefit on stock option exercises and restricted stock   551
Borrowings of bank loans   265,000
Payment for deferred financing costs   (5,407)
Repayment of bank loans (39,398) [1] (16,898)
Net cash (used in) provided by financing activities (44,727) [1] 237,852
Effect of exchange rate changes on cash 1,133 [1] (757)
Net increase (decrease) in cash 6,352 [1] (6,866)
Cash and cash equivalents at beginning of period 55,680 66,828
Cash and cash equivalents at end of period $ 62,032 [1] $ 59,962
Noncash Investing and Financing Items [Abstract]    
Number of shares to be issued [1] 5,122  
Fair value of future issuance of shares $ 90,400  
[1] (as restated)
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation
 9 Months Ended
Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation

(1) Basis of Presentation

 

The condensed consolidated financial statements of Aceto Corporation and subsidiaries (“Aceto” or the “Company”) included herein have been prepared by the Company and reflect all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for all periods presented. Interim results are not necessarily indicative of results which may be achieved for the full year.

 

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements and the disclosure of contingent assets and liabilities at the date of the financial statements. These judgments can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition; allowance for doubtful accounts; inventory; goodwill and other indefinite-life intangible assets; long-lived assets; environmental matters and other contingencies; income taxes; stock-based compensation; and purchase price allocation.

 

These condensed consolidated financial statements do not include all disclosures associated with consolidated financial statements prepared in accordance with GAAP. Accordingly, these statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended June 30, 2017, as amended (the “2017 10-K”).
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restatement of Previously Issued Financial Statements
 9 Months Ended
Mar. 31, 2018
Accounting Changes and Error Corrections [Abstract]  
Restatement of Previously Issued Financial Statements

(2) Restatement of Previously Issued Financial Statements

 

As previously disclosed, the Company determined that it incorrectly accounted for a valuation allowance related to U.S. net deferred tax assets. At the time of the March 31, 2018 Form 10-Q filing, the Company believed that the carrying value of its deferred tax assets was appropriate based on its view that it was more likely than not that this deferred tax asset would be realized in future periods. In preparing its consolidated financial statements for the year ended June 30, 2018, the Company determined, in consultation with BDO USA, LLP (“BDO”), based on management's review of current and historical performance, internal projections and industry data and applicable accounting literature, that it should recognize a valuation allowance equal to the entire carrying value of the Company’s U.S. deferred tax assets. However, upon further review of the negative and positive objective evidence and applicable accounting literature, the Company determined, in consultation with BDO, that a full valuation allowance on domestic net deferred tax assets should have been recorded as of the end of its third fiscal quarter rather than as of the end of its fourth fiscal quarter. As a result, the Company has determined to record a valuation allowance of approximately $71,350 on its U.S. deferred tax assets at March 31, 2018.

 

As a result, the Company is restating its condensed consolidated financial statements for the three and nine months ended March 31, 2018. The following financial tables reconcile the previously reported amounts to the restated amounts for each condensed consolidated financial statement.

 

The table below sets forth the condensed consolidated balance sheet, including the balances originally reported, corrections and the as restated balances for March 31, 2018 (in thousands):

 

    As Reported     Adjustment     As Restated  
Assets                        
Deferred income tax asset, net   $ 70,089     $ (70,089 )   $ -  
Total assets     831,280       (70,089 )     761,191  
Liabilities and Shareholders’ Equity                        
Deferred income tax liability     -       1,261       1,261  
Total liabilities     627,898       1,261       629,159  
Retained deficit     (20,354 )     (71,350 )     (91,704 )
Total shareholders’ equity     203,382       (71,350 )     132,032  
Total liabilities and shareholders’ equity   $ 831,280     $ (70,089 )   $ 761,191  

  

The tables below set forth the condensed consolidated statements of loss, including the balances originally reported, corrections and the as restated balances for the three and nine months ended March 31, 2018 (in thousands, except per share data):

 

    As Reported     Adjustment     As Restated  
Three months ended March 31, 2018                        
Income tax (benefit) provision   $ (66,402 )   $ 71,350     $ 4,948  
Net loss   $ (196,635 )   $ (71,350 )   $ (267,985 )
Basic loss per common share   $ (5.57 )   $ (2.02 )   $ (7.59 )
Diluted loss per common share   $ (5.57 )   $ (2.02 )   $ (7.59 )

 

    As Reported     Adjustment     As Restated  
Nine months ended March 31, 2018                        
Income tax (benefit) provision   $ (51,353 )   $ 71,350     $ 19,997  
Net loss   $ (210,045 )   $ (71,350 )   $ (281,395 )
Basic loss per common share   $ (5.97 )   $ (2.03 )   $ (8.00 )
Diluted loss per common share   $ (5.97 )   $ (2.03 )   $ (8.00 )

 

The tables below set forth the condensed consolidated statements of comprehensive income, including the balances originally reported, corrections and the as restated balances for the three and nine months ended March 31, 2018 (in thousands):

 

    As Reported     Adjustment     As Restated  
Three months ended March 31, 2018                        
Net loss   $ (196,635 )   $ (71,350 )   $ (267,985 )
Comprehensive loss   $ (193,556 )   $ (71,350 )   $ (264,906 )

 

    As Reported     Adjustment     As Restated  
Nine months ended March 31, 2018                        
Net loss   $ (210,045 )   $ (71,350 )   $ (281,395 )
Comprehensive loss   $ (202,758 )   $ (71,350 )   $ (274,108 )

 

The table below sets forth the condensed consolidated statements of cash flows from operating activities, including the balances originally reported, corrections and the as restated balances for the nine months ended March 31, 2018 (in thousands):

 

    As Reported     Adjustment     As Restated  
Nine months ended March 31, 2018                        
Net loss   $ (210,045 )   $ (71,350 )   $ (281,395 )
Deferred income taxes     (80,207 )     91,921       11,714  
Accrued expenses and other liabilities     30,299       (20,571 )     9,728  
Net cash provided by operating activities     56,415       -       56,415  

 

As indicated above, there was no impact on net cash provided by operating activities as the valuation allowance is a non-cash item. In addition, the restatement had no impact on cash flows from investing activities or financing activities.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations
 9 Months Ended
Mar. 31, 2018
Business Combinations [Abstract]  
Business Combinations
(3) Business Combinations

 

On December 21, 2016, wholly owned subsidiaries of Rising Pharmaceuticals, Inc. (“Rising”), a wholly owned subsidiary of Aceto, completed the acquisition of certain generic products and related assets of entities formerly known as Citron Pharma LLC (“Citron”) and its affiliate Lucid Pharma LLC (“Lucid”). Citron was a privately-held New Jersey-based pharmaceutical company focused on developing and marketing generic pharmaceutical products in partnership with leading generic pharmaceutical manufacturers based in India and the United States. Lucid was a privately-held New Jersey-based generic pharmaceutical distributor specializing in providing cost-effective products to various agencies of the U.S. Federal Government including the Veterans Administration and the Defense Logistics Agency. Lucid serviced 18 national contracts with the Federal Government, nearly all of which had 5-year terms.

 

Aceto and Citron possess complementary asset-light business models, drug development and manufacturing partnerships and product portfolios. The Company believes consistent with its strategy of expanding Rising’s portfolio of finished dosage form generic products through product development partnerships and acquisitions of late stage assets, abbreviated new drug applications (“ANDAs”) and complementary generic drug businesses, this transaction significantly expanded its roster of commercialized products and pipeline of products under development. In addition, the Company believes that this product acquisition greatly enhanced its size and stature within the generic pharmaceutical industry, expanded its partnership network and offers the Company opportunities to realize meaningful cost and tax efficiencies.

 

At closing, Aceto paid the sellers $270,000 in cash, committed to make a $50,000 unsecured deferred payment that will bear interest at a rate of 5% per annum to the sellers on December 21, 2021 and agreed to issue 5,122 shares of Aceto common stock beginning on December 21, 2019. The product purchase agreement also provides the sellers with a 5-year potential earn-out of up to an additional $50,000 in cash, based on the financial performance of four pre-specified pipeline products that are currently in development. In the third quarter of fiscal 2018, the Company reversed $2,505 of contingent consideration due to management’s evaluation and assessment of the financial performance of these products. As of March 31, 2018, the Company accrued $663 related to this contingent consideration.

 

Rising formed two subsidiaries to consummate the product acquisition – Rising Health, LLC (which acquired certain products and related assets of Citron) and Acetris Health, LLC (which acquired certain products and related assets of Lucid).
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-Based Compensation
 9 Months Ended
Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation

(4) Stock-Based Compensation

 

Under the Aceto Corporation 2015 Equity Participation Plan (the “2015 Plan”), grants of stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards (“Stock Awards”) may be offered to employees, non-employee directors, consultants and advisors of the Company, including the chief executive officer, chief financial officer and other named executive officers. The maximum number of shares of common stock of the Company that may be issued pursuant to Stock Awards granted under the 2015 Plan will not exceed, in the aggregate, 4,250 shares. Performance-based awards may be granted, vested and paid based on the attainment of specified performance goals.

 

Under the Aceto Corporation 2010 Equity Participation Plan (as amended and restated in 2012, the “2010 Plan”), grants of stock options, restricted stock, restricted stock units, stock appreciation rights, and stock bonuses may be made to employees, non-employee directors and consultants of the Company. The maximum number of shares of common stock of the Company that may be issued pursuant to awards granted under the 2010 Plan will not exceed, in the aggregate, 5,250 shares. In addition, restricted stock may be granted to an eligible participant in lieu of a portion of any annual cash bonus earned by such participant. Such award may include additional shares of restricted stock (premium shares) greater than the portion of bonus paid in restricted stock. The restricted stock award is vested at issuance and the restrictions lapse ratably over a period of years as determined by the Board of Directors, generally three years. The premium shares vest when all the restrictions lapse, provided that the participant remains employed by the Company at that time.

 

During the nine months ended March 31, 2018, the Company granted 490 shares of restricted common stock to its employees that vest over three years and 27 shares of restricted stock to its non-employee directors, which vest over approximately one year. In addition, the Company also issued a target grant of 203 performance-vested restricted stock units, which grant could be as much as 355 units if certain performance criteria and market conditions are met. These performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.

 

During the year ended June 30, 2017, the Company granted 277 shares of restricted common stock to its employees that vest over three years and 22 shares of restricted common stock to its non-employee directors, which vest over approximately one year as well as 42 restricted stock units that have varying vest dates through July 2017. In addition, the Company also issued a target grant of 160 performance-vested restricted stock units, which grant could be as much as 280 if certain performance criteria and market conditions are met. These performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.

 

For the three and nine months ended March 31, 2018, the Company recorded stock-based compensation expense of approximately $1,931 and $6,426, respectively, related to restricted common stock and restricted stock units. Included in the $6,426 for the nine months ended March 31, 2018 is $431 in stock-based compensation expense associated with the retirement of a Chief Financial Officer in March 2018 and $2,017 in stock-based compensation expense associated with the separation of the Company’s former Chief Executive Officer in September 2017. For the three and nine months ended March 31, 2017, the Company recorded stock-based compensation expense of approximately $1,506 and $5,213, respectively, related to restricted common stock and restricted stock units. As of March 31, 2018, the total unrecognized stock-based compensation cost is approximately $7,864.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Capital Stock
 9 Months Ended
Mar. 31, 2018
Equity [Abstract]  
Capital Stock
(5) Capital Stock

 

On May 3, 2018, the Company’s Board of Directors declared a quarterly dividend of $0.01 per share which will be paid on June 22, 2018 to shareholders of record as of June 8, 2018.

 

On February 1, 2018, the Company’s Board of Directors declared a regular quarterly dividend of $0.065 per share which was paid on March 23, 2018 to shareholders of record as of March 9, 2018.

 

On December 7, 2017, the Company's Board of Directors declared a regular quarterly dividend of $0.065 per share which was paid on December 28, 2017 to shareholders of record as of December 18, 2017.

 

On August 24, 2017, the Company's Board of Directors declared a regular quarterly dividend of $0.065 per share which was paid on September 21, 2017 to shareholders of record as of September 8, 2017.

 

On May 4, 2017, the Board of Directors of the Company authorized the continuation of the Company’s stock repurchase program, expiring in May 2020. Under the stock repurchase program, the Company is authorized to purchase up to 5,000 shares of common stock in open market or private transactions, at prices not to exceed the market value of the common stock at the time of such purchase.

 

The Company is authorized to issue 75,000 shares of Common Stock and 2,000 shares of Preferred Stock. The Board of Directors has authority under the Company’s Restated Certificate of Incorporation to issue shares of preferred stock with voting and other relative rights to be determined by the Board of Directors.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net (Loss) Income Per Common Share
 9 Months Ended
Mar. 31, 2018
Earnings Per Share [Abstract]  
Net (Loss) Income Per Common Share

(6) Net (Loss) Income Per Common Share

 

Basic income per common share is based on the weighted average number of common shares outstanding during the period. Diluted income per common share includes the dilutive effect of potential common shares outstanding. The following table sets forth the reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding:

 

    Nine Months Ended
March 31,		     Three Months Ended
March 31,		  
    2018     2017     2018     2017  
                         
Weighted average shares outstanding     35,162       31,453       35,304       34,769  
Dilutive effect of stock options and restricted stock awards and units     -       339       -       352  
                                 
Diluted weighted average shares outstanding     35,162       31,792       35,304       35,121  

 

The effect of approximately 100 and 181 common equivalent shares for the three and nine months ended March 31, 2018, respectively, was excluded from the diluted weighted average shares outstanding due to a net loss for the periods. There were 170 and 143 common equivalent shares outstanding for the three and nine months ended March 31, 2018, respectively, that were not included in the calculation of diluted net income per common share because their effect would have been anti-dilutive.

 

The weighted average shares outstanding for the three and nine months ended March 31, 2018 includes the effect of 5,122 shares to be issued beginning on December 21, 2019 in connection with the acquisition of certain products and related assets from Citron and Lucid (see Note 3).

 

The Convertible Senior Notes (see Note 7) will only be included in the dilutive net income per share calculations using the treasury stock method during periods in which the average market price of Aceto’s common stock is above the applicable conversion price of the Convertible Senior Notes, or $33.215 per share, and the impact would not be anti-dilutive.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt
 9 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
Debt

(7) Debt

 

Long-term debt

 

  

March 31,

2018

  

June 30,

2017

 
       
Convertible Senior Notes, net $126,279  $121,676 
Revolving Bank Loans  62,000   90,000 
Term Bank Loans  128,526   139,227 
Mortgage  2,615   2,763 
   319,420   353,666 
Less current portion  190,723   14,466 
  $128,697  $339,200 

 

Convertible Senior Notes

 

In November 2015, Aceto offered $125,000 aggregate principal amount of Convertible Senior Notes due 2020 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In addition, Aceto granted the initial purchasers for the offering an option to purchase up to an additional $18,750 aggregate principal amount pursuant to the initial purchasers’ option to purchase additional Notes, which was exercised in November 2015. Therefore, the total offering was $143,750 aggregate principal amount. The Notes are unsecured obligations of Aceto and rank senior in right of payment to any of Aceto’s subordinated indebtedness, equal in right of payment to all of Aceto’s unsecured indebtedness that is not subordinated, effectively junior in right of payment to any of Aceto’s secured indebtedness to the extent of the value of the assets securing such indebtedness and structurally junior in right of payment to all indebtedness and other liabilities (including trade payables) of Aceto’s subsidiaries. The Notes will be convertible into cash, shares of Aceto common stock or a combination thereof, at Aceto’s election, upon the satisfaction of specified conditions and during certain periods. The Notes will mature in November 2020. The Notes pay 2.0% interest semi-annually in arrears on May 1 and November 1 of each year, which commenced on May 1, 2016. The Notes are convertible into 4,328 shares of common stock, based on an initial conversion price of $33.215 per share.

 

Holders may convert all or any portion of their notes, in multiples of one thousand dollar principal amount, at their option at any time prior to the close of business on the business day immediately preceding May 1, 2020 only under the following circumstances: (i) during any calendar quarter (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the five consecutive business day period after any five consecutive trading day period (which is referred to as the “measurement period”) in which the trading price per one thousand dollar principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of Aceto’s common stock and the conversion rate on each such trading day; or (iii) upon the occurrence of specified corporate events.

 

Upon conversion by the holders, the Company may elect to settle such conversion in shares of its common stock, cash, or a combination thereof. As a result of its cash conversion option, the Company separately accounted for the value of the embedded conversion option as a debt discount (with an offset to capital in excess of par value). The debt discount is being amortized as additional non-cash interest expense using the effective interest method over the term of the Notes. Debt issuance costs are being amortized as additional non-cash interest expense. The Company presents debt issuance costs as a direct deduction from the carrying value of the debt liability rather than showing the debt issuance costs as a deferred charge on the balance sheet.

  

In connection with the offering of the Notes, Aceto entered into privately negotiated convertible note hedge transactions with option counterparties, which are affiliates of certain of the initial purchasers. The convertible note hedge transactions are expected generally to reduce the potential dilution to Aceto’s common stock and/or offset any cash payments Aceto is required to make in excess of the principal amount of converted Notes upon any conversion of Notes. Aceto also entered into privately negotiated warrant transactions with the option counterparties. The warrant transactions could separately have a dilutive effect to the extent that the market price per share of Aceto’s common stock as measured over the applicable valuation period at the maturity of the warrants exceeds the applicable strike price of the warrants. By entering into these transactions with the option counterparties, the Company issued convertible debt and a freestanding “call-spread.”

 

The carrying value of the Notes is as follows:

 

  

March 31,

2018

  

June 30,

2017

 
       
Principal amount $143,750  $143,750 
Unamortized debt discount  (15,278)  (19,255)
Unamortized debt issuance costs  (2,193)  (2,819)
Net carrying value $126,279  $121,676 

 

The following table sets forth the components of total “interest expense” related to the Notes recognized in the accompanying consolidated statements of operations for the three and nine months ended March 31:

 

  Nine Months Ended
March 31, 2018		  Three Months Ended 
March 31, 2018		 
       
Contractual coupon $2,127  $709 
Amortization of debt discount  3,977   1,347 
Amortization of debt issuance costs  626   208 
  $6,730  $2,264 

 

Credit Facilities

 

On December 21, 2016 the Company entered into a Second Amended and Restated Credit Agreement (the “A&R Credit Agreement”), with eleven banks, which amended and restated in its entirety the Amended and Restated Credit Agreement, dated as of October 28, 2015, as amended by Amendment No. 1 to Amended and Restated Credit Agreement, dated as of November 10, 2015, and Amendment No. 2 to Amended and Restated Credit Agreement, dated as of August 26, 2016 (collectively, the “First Amended Credit Agreement”). The A&R Credit Agreement increased the aggregate available revolving commitment under the First Amended Credit Agreement from $150,000 to an initial aggregate available revolving commitment of $225,000 (the “Initial Revolving Commitment”). Under the A&R Credit Agreement, the Company may borrow, repay and reborrow from and as of December 21, 2016, to but excluding December 21, 2021 (the “Maturity Date”) provided, that if any of the Notes remain outstanding on the date that is 91 days prior to the maturity date of the Notes (the “2015 Convertible Maturity Date”), then the Maturity Date shall mean the date that is 91 days prior to the 2015 Convertible Maturity Date. The A&R Credit Agreement provides for (i) Eurodollar Loans (as such terms are defined in the A&R Credit Agreement), (ii) ABR Loans (as such terms are defined in the A&R Credit Agreement) or (iii) a combination thereof. As of March 31, 2018, the Company borrowed Revolving Loans (as defined under the A&R Credit Agreement) aggregating $62,000 which loans are Eurodollar Loans at interest rates ranging from 3.57% to 3.63% at March 31, 2018. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company’s senior secured net leverage ratio.

  

Under the A&R Credit Agreement, the Company also borrowed $150,000 in term loans (the “Initial Term Loan). Subject to certain conditions, including obtaining commitments from existing or prospective lenders, the Company had the right to increase the amount of the Initial Revolving Commitment (each, a “Revolving Facility Increase” and, together with the Initial Revolving Commitment, the “Revolving Commitment”) and/or the Initial Term Loan in an aggregate amount not to exceed $100,000 pursuant to an incremental loan feature in the A&R Credit Agreement. As of March 31, 2018, the remaining amount outstanding under the Initial Term Loan was $131,250 and was payable as a Eurodollar Loan at an interest rate of 4.05%. The proceeds of the Initial Revolving Commitment and Initial Term Loan were used to partially finance the acquisition of generic products and related assets of Citron and its affiliate Lucid, and pay fees and expenses related thereto. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company’s senior secured net leverage ratio.

 

The Initial Term Loan is payable as to principal in nineteen consecutive, equal quarterly installments of $3,750, which commenced on March 31, 2017 and will continue each March 31, June 30, September 30 and December 31 thereafter. To the extent not previously paid, the final payment on the Term Loan Maturity Date (as defined in the A&R Credit Agreement) shall be in an amount equal to the then outstanding unpaid principal amount of the Initial Term Loan.

 

The A&R Credit Agreement provides that commercial letters of credit shall be issued to provide the primary payment mechanism in connection with the purchase of any materials, goods or services in the ordinary course of business. The Company had no open letters of credit at March 31, 2018 and June 30, 2017.

 

In accordance with generally accepted accounting principles, deferred financing costs associated with the Initial Term Loan are presented as a direct deduction from the carrying value of the debt liability rather than showing the deferred financing costs as a deferred charge on the balance sheet. In addition, deferred financing costs associated with the Revolving Commitment have been recorded as a deferred charge on the balance sheet.

 

The A&R Credit Agreement provides for a security interest in substantially all the personal property of the Company and certain of its subsidiaries. The A&R Credit Agreement contains several financial covenants including, among other things, maintaining a minimum level of debt service and certain leverage ratios. Under the A&R Credit Agreement, the Company and its subsidiaries are also subject to certain restrictive covenants, including, among other things, covenants governing liens, limitations on indebtedness, limitations on guarantees, limitations on sales of assets and sales of receivables, and limitations on loans and investments.

 

On December 13, 2017, the Company entered into a First Amendment to the Second Amended and Restated Credit Agreement (the “2017 Amendment”), which amended the A&R Credit Agreement. The 2017 Amendment, among other things, contained several amendments to the financial covenants in the A&R Credit Agreement.

 

As of March 31, 2018, the Company was in compliance with all of its financial covenants except for the maximum total net leverage ratio and the minimum debt service coverage ratio. On May 3, 2018, the Company entered into a Second Amendment and Waiver to the Second Amended and Restated Credit Agreement (the “2018 Amendment”). The 2018 Amendment, among other things, contains a waiver of any event of default under the A&R Credit Agreement arising as a result of the non-compliance by the Company with the Total Net Leverage Ratio and Debt Service Coverage Ratio financial covenants, in each case, solely for the fiscal quarter ended March 31, 2018. The Amendment also contains several amendments to the A&R Credit Agreement including, among other things, (a) reducing the available revolving commitment thereunder to $100,000, and (b) during the period commencing on the closing of the 2018 Amendment and ending on the date the Company demonstrates compliance with each financial covenant set forth in the A&R Credit Agreement for the fiscal quarter ending June 30, 2018 (the “Limitation Period”; provided that if the Company is not in compliance with any of the financial covenants set forth in the A&R Credit Agreement for the fiscal quarter ending June 30, 2018, then the Limitation Period shall continue indefinitely): (i) fixing the applicable margin with respect to all loans under the A&R Credit Agreement to the highest level provided under the A&R Credit Agreement, which is 1.50% in the case of ABR Loans (as defined in the A&R Credit Agreement) and 2.50% in the case of Eurodollar Loans (as defined in the A&R Credit Agreement), (ii) fixing the commitment fee on the undrawn revolving commitments under the A&R Credit Agreement to the highest level provided under the A&R Credit Agreement which is 0.40% per annum, (iii) requiring the prior written consent of the Required Lenders (as defined in the A&R Credit Agreement) as a condition precedent to the lenders extending any Loans (as defined in the A&R Credit Agreement) or the issuing banks issuing, amending, renewing or extending any Letter of Credit (as defined in the A&R Credit Agreement), (iv) restricting the amount of dividends or distributions the Company may make to its shareholders to no more than $0.01 per share for the fiscal quarter ending on June 30, 2018 and, during the Limitation Period, restricting the Company from making any other dividends or distributions to its shareholders thereafter and (v) restricting the incurrence of certain indebtedness, limiting acquisitions and other investments and imposing certain other restrictions.

  

In accordance with GAAP, we have classified the indebtedness outstanding under the Company’s credit facility as a current liability as of March 31, 2018. This differs from the customary treatment heretofore applicable to indebtedness outstanding under the Company’s credit facility, in which only the portion of such indebtedness payable within one year from the balance sheet date has been recorded as a current liability.  The waiver that the Company has received from its lenders under the credit facility applies solely to the non-compliance with certain financial covenants as of March 31, 2018 and thus does not waive non-compliance with any financial covenants as of June 30, 2018. It is probable that the Company will not comply with certain financial covenants as of June 30, 2018 in the absence of a material change in the Company’s operating results.  That probability is the factor that has caused the Company to reclassify its indebtedness. The Company believes it will work cooperatively with its lenders over the next 120 days and anticipates that the financial covenants for the June 30, 2018 reporting date will be amended.

 

Mortgage

 

On June 30, 2011, the Company entered into a mortgage payable for $3,947 on its corporate headquarters, in Port Washington, New York. This mortgage payable is secured by the land and building and is being amortized over a period of 20 years. The mortgage payable, which was modified in October 2013, bears interest at 4.92% per annum as of March 31, 2018 and matures on June 30, 2021.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments, Contingencies and Other Matters
 9 Months Ended
Mar. 31, 2018
Commitments And Contingencies Disclosure [Abstract]  
Commitments, Contingencies and Other Matters

(8) Commitments, Contingencies and Other Matters

 

The Company and its subsidiaries are subject to various claims which have arisen in the normal course of business. The Company provides for costs related to contingencies when a loss from such claims is probable and the amount is reasonably determinable. In determining whether it is possible to provide an estimate of loss, or range of possible loss, the Company reviews and evaluates its litigation and regulatory matters on a quarterly basis in light of potentially relevant factual and legal developments. If the Company determines an unfavorable outcome is not probable or reasonably estimable, the Company does not accrue for a potential litigation loss. While the Company has determined that there is a reasonable possibility that a loss has been incurred, no amounts have been recognized in the financial statements, other than what has been discussed below, because the amount of the liability cannot be reasonably estimated at this time.

 

In fiscal years 2011, 2009, 2008 and 2007, the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State had begun administrative proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly contributed to the contamination of the environment and thus believes that, at most, it is a de minimis contributor to the site contamination. Accordingly, the Company believes that the settlement offer is unreasonable. Management believes that the ultimate outcome of this matter will not have a material adverse effect on the Company's financial condition or liquidity.

 

The Company has environmental remediation obligations in connection with Arsynco, Inc. (“Arsynco”), a subsidiary formerly involved in manufacturing chemicals located in Carlstadt, New Jersey, which was closed in 1993 and is currently held for sale. Based on continued monitoring of the contamination at the site and the approved plan of remediation, Arsynco received an estimate from an environmental consultant stating that the costs of remediation could be between $21,500 and $23,300. Remediation commenced in fiscal 2010, and as of March 31, 2018 and June 30, 2017, a liability of $4,495 and $8,451, respectively, is included in the accompanying consolidated balance sheets for this matter. For the nine months ended March 31, 2018, the Company recorded an environmental charge of $902, which is included in selling, general and administrative expenses in the accompanying condensed consolidated statement of operations for the nine months ended March 31, 2018. In accordance with GAAP, management believes that the majority of costs incurred to remediate the site will be capitalized in preparing the property which is currently classified as held for sale. An estimate of the fair value of the property has been determined by a third party real estate professional and supports the assumption that the expected fair value after the remediation is in excess of the amount required to be capitalized. However, these matters, if resolved in a manner different from those assumed in current estimates, could have a material adverse effect on the Company’s financial condition, operating results and cash flows when resolved in a future reporting period.

  

In connection with the environmental remediation obligation for Arsynco, in July 2009, Arsynco entered into a settlement agreement with BASF Corporation (“BASF”), the former owners of the Arsynco property. In accordance with the settlement agreement, BASF paid for a portion of the prior remediation costs and going forward, will co-remediate the property with the Company. The contract requires that BASF pay $550 related to past response costs and pay a proportionate share of the future remediation costs. Accordingly, the Company had recorded a gain of $550 in fiscal 2009. This $550 gain relates to the partial reimbursement of costs of approximately $1,200 that the Company had previously expensed. The Company also recorded an additional receivable from BASF, with an offset against property held for sale, representing its estimated portion of the future remediation costs. The balance of this receivable for future remediation costs as of March 31, 2018 and June 30, 2017 is $2,023 and $3,803, respectively, which is included in the accompanying consolidated balance sheets.

 

In March 2006, Arsynco received notice from the EPA of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for a site described as the Berry’s Creek Study Area (“BCSA”). Arsynco is one of over 150 PRPs which have potential liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. In July 2014, Arsynco received notice from the U.S. Department of Interior (“USDOI”) regarding the USDOI’s intent to perform a Natural Resource Damage (NRD) Assessment at the BCSA. Arsynco has to date declined to participate in the development and performance of the NRD assessment process. Based on prior practice in similar situations, it is possible that the State may assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State (or both) may assert claims against Arsynco for natural resource damages in connection with Berry's Creek; any such claim with respect to Berry's Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the former owners of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et al., Docket No. ESX-L-9868-05 (the "NJDEP Litigation") and were considering impleading Arsynco into the same proceeding. Arsynco entered into an agreement to avoid impleader. Pursuant to the agreement, Arsynco agreed to (1) a tolling period that would not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation; (2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against Arsynco. In July 2015, Arsynco was contacted by an allocation consultant retained by a group of the named PRPs, inviting Arsynco to participate in the allocation among the PRPs’ investigation and remediation costs relating to the BCSA. Arsynco declined that invitation. Since an amount of the liability cannot be reasonably estimated at this time, no accrual is recorded for these potential future costs. The impact of the resolution of this matter on the Company’s results of operations in a particular reporting period is not currently known.

 

A subsidiary of the Company markets certain agricultural protection products which are subject to the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). FIFRA requires that test data be provided to the EPA to register, obtain and maintain approved labels for pesticide products. The EPA requires that follow-on registrants of these products compensate the initial registrant for the cost of producing the necessary test data on a basis prescribed in the FIFRA regulations. Follow-on registrants do not themselves generate or contract for the data. However, when FIFRA requirements mandate that new test data be generated to enable all registrants to continue marketing a pesticide product, often both the initial and follow-on registrants establish a task force to jointly undertake the testing effort. The Company is presently a member of several such task force groups, which requires payments for such memberships. In addition, in connection with our agricultural protection business, the Company plans to acquire product registrations and related data filed with the United States Environmental Protection Agency to support such registrations and other supporting data for several products. The acquisition of these product registrations and related data filed with the United States Environmental Protection Agency as well as payments to various task force groups could approximate $2,299 through the remainder of fiscal 2018.

 

The Company has been notified by the U.S. government that 11 generic drug products it acquired through its Acetris Health subsidiary in a product purchase agreement with Lucid are not in compliance with the federal Trade Agreement Act (“TAA”) country-of-origin provisions of a clause contained in the government supply contracts acquired from Lucid (the “TAA Notification”). The 11 finished dosage form products purchased by the U.S. government are manufactured by Aurolife Pharma LLC which is located in Dayton, New Jersey using APIs sourced from India. In conjunction with this finding, the U.S. Department of Veterans Affairs (“VA”) requested that Aceto supply new TAA-compliant sources for the referenced products by March 9, 2018 and supply new TAA-compliant drugs to the government purchasers under the contracts by March 26, 2018. The Company was not able to meet these deadlines and thereafter Acetris and the government entered into agreements that provided for a no-cost termination of each of the 11 supply contracts.

 

Under current longstanding law, the government, under the Buy America Act, is permitted to buy domestic end products, including commercial off-the-shelf (“COTS”) products like generic drugs that are manufactured in the U.S. even if their components are not all manufactured in the US. The Company believes that the government was and is permitted to buy Acetris’ products, because they are COTS items manufactured in the U.S. As a result, the Company has disputed the determination that the 11 products sold pursuant to novated contracts with the VA originate in India rather than the United States and has appealed the decision that it is not currently compliant with contract sourcing requirements. To further pursue remedies, Aceto has asserted an indemnification claim against the sellers under the product purchase agreement dated December 21, 2016. In addition, the U.S. Defense Logistics Agency, by letter dated April 25, 2018 to Acetris, requested that Acetris seek a ruling from U.S. Customs and Border Protection that seven products specified therein, each of which have APIs sourced from India, are TAA compliant.

 

In March 2018, Sigmapharm Laboratories, LLC (“SigmaPharm”) commenced an action against Rising and the Company in the United States District Court for the Eastern District of Pennsylvania.  The complaint arises out of an agreement, effective as of June 22, 2006 (the “SigmaPharm Agreement”), pursuant to which SigmaPharm agreed to supply certain generic pharmaceutical products (the “Products”) to Rising, and Rising in turn agreed to market and distribute the Products in the United States and pay SigmaPharm a share of the profits pursuant to a formula specified in the Agreement.  The complaint alleges that Rising and Aceto breached the Agreement by failing to pay or timely make payments due under the Agreement and to disclose certain information to SigmaPharm.  The complaint seeks, among other relief, a declaration that the Agreement has been terminated and that SigmaPharm has exclusive marketing and distribution rights to the Products; injunctive relief; and an unspecified amount of damages.  The Company intends to vigorously defend the action and assert counterclaims against SigmaPharm in the course of this litigation.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements
 9 Months Ended
Mar. 31, 2018
Fair Value Disclosures [Abstract]  
Fair Value Measurements

(9) Fair Value Measurements

 

GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly fashion between market participants at the measurement date. GAAP establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s assumptions (unobservable inputs). The hierarchy consists of three levels:

 

Level 1 – Quoted market prices in active markets for identical assets or liabilities;

 

Level 2 – Inputs other than Level 1 inputs that are either directly or indirectly observable; and

  

Level 3 – Unobservable inputs that are not corroborated by market data.

 

On a recurring basis, Aceto measures at fair value certain financial assets and liabilities, which consist of cash equivalents, investments and foreign currency contracts. The Company classifies cash equivalents and investments within Level 1 if quoted prices are available in active markets. Level 1 assets include instruments valued based on quoted market prices in active markets which generally include corporate equity securities publicly traded on major exchanges. Time deposits are very short-term in nature and are accordingly valued at cost plus accrued interest, which approximates fair value, and are classified within Level 2 of the valuation hierarchy. The Company uses foreign currency futures contracts to minimize the risk caused by foreign currency fluctuation on its foreign currency receivables and payables by purchasing futures with one of its financial institutions. Futures are traded on regulated U.S. and international exchanges and represent commitments to purchase or sell a foreign currency at a future date and at a specific price. Aceto’s foreign currency derivative contracts are classified within Level 2 as the fair value of these hedges is primarily based on observable futures foreign exchange rates. At March 31, 2018, the Company had foreign currency contracts outstanding that had a notional amount of $62,350. Unrealized (losses) gains on hedging activities for the three and nine months ended March 31, 2018 was ($34) and $227, respectively. Unrealized gains (losses) on hedging activities for the three and nine months ended March 31, 2017 was $353 and ($230), respectively, and are included in interest and other income, net, in the consolidated statements of operations. The contracts have varying maturities of less than one year.

 

In conjunction with its existing credit agreement (see Note 7), the Company entered an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is December 21, 2021. The remaining notional balance of this derivative as of March 31, 2018 is $87,500. The unrealized gain to date associated with this derivative, which is recorded in accumulated other comprehensive income in the consolidated balance sheet at March 31, 2018, is $1,539. Aceto’s interest rate swaps are classified within Level 2 as the fair value of this hedge is primarily based on observable interest rates.

 

At March 31, 2018, the Company had accrued $752 of contingent consideration, $663 of which related to the acquisition of certain products and related assets of Citron and Lucid, which was completed in December 2016 (see Note 3) and $89 of contingent consideration related to a previously acquired company in France. At June 30, 2017, the Company had accrued $2,952 of contingent consideration, $2,807 of which related to the acquisition of certain products and related assets of Citron and Lucid and $145 of contingent consideration related to a previously acquired company in France. The contingent consideration was calculated using the present value of a probability weighted income approach.

 

The Company accounts for goodwill and intangible assets in accordance with ASC 350, Intangibles – Goodwill and Other (“ASC 350”). ASC 350 requires that goodwill and other intangibles with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value. During the third quarter of fiscal 2018, the Company’s Rising Pharmaceuticals reporting unit (which is part of the Human Health segment) had a decline in actual and forecasted revenue and earnings due to the persistent adverse conditions in the generics market. In addition, as noted above, the Company was notified by the U.S. government that 11 generic drug products it acquired through its Acetris Health subsidiary (part of the Rising reporting unit which is part of the Human Health segment) in a product purchase agreement with an entity formerly known as Lucid Pharma LLC are not in compliance with the federal Trade Agreement Act country-of-origin provisions of a clause contained in the government supply contracts acquired from Lucid. Based on these indicators, the Company determined that it was necessary to perform an interim goodwill impairment analysis at March 31, 2018 for its Rising reporting unit. The Company elected to early adopt Accounting Standards Update (“ASU”) 2017-04, Intangibles- Goodwill and Other (Topic 350), during the third quarter of fiscal 2018 which eliminated the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, the amount of an impairment charge is recognized if the carrying amount of a reporting unit is greater than its fair value. The fair value of the Rising reporting unit was estimated using many assumptions and estimates and a market participant approach that directly impacts the results of the testing. In making these assumptions and estimates, the Company used industry accepted valuation models and set criteria that were reviewed and approved by various levels of management. Accordingly, with respect to the third quarter of fiscal 2018, the Company recognized a pre-tax non-cash goodwill impairment charge of $235,110 related to the Rising reporting unit.

  

Long-lived assets and certain identifiable intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  If it is determined such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization periods, their carrying values are reduced to estimated fair value.  Measurements based on undiscounted cash flows are Level 3 inputs.  As noted above, during the third quarter of fiscal 2018, the Company’s Rising Pharmaceuticals subsidiary had a decline in actual and forecasted revenue and earnings and therefore the Company performed an impairment test on the related intangibles. The projected undiscounted cash flows for certain intangibles were determined to be less than the carrying value, and as a result, the Company recognized an impairment charge of $5,745 in the third quarter of fiscal 2018. Additionally, as noted above, the Company was notified by the U.S. government that 11 generic drug products it acquired through its Acetris Health subsidiary in a product purchase agreement with an entity formerly known as Lucid Pharma LLC are not in compliance with the federal Trade Agreement Act country-of-origin provisions of a clause contained in the government supply contracts acquired from Lucid. Based on this, the Company performed an impairment test on the related intangible asset and recognized an impairment charge of $15,411 on the customer relationships intangible asset in the third quarter of fiscal 2018.

 

The total impairment charges for goodwill and intangibles recorded in the third quarter of fiscal 2018 was $256,266, all of which related to the Rising reporting unit which is part of the Human Health segment.

 

In connection with the acquisition of certain products and related assets of Citron and Lucid (see Note 3), the Company will issue 5,122 shares of Aceto common stock beginning on December 21, 2019. The preliminary fair value of the future issuance of these shares was determined to be $90,400 at the time of the product acquisition after taking into effect that the shares won’t be issued until the third and fourth anniversary of the closing and the present value calculation of dividends.

 

In November 2015, the Company issued $143,750 aggregate principal amount of Notes (see Note 7). Since Aceto has the option to settle the potential conversion of the Notes in cash, the Company separated the embedded conversion option feature from the debt feature and accounts for each component separately, based on the fair value of the debt component assuming no conversion option. The calculation of the fair value of the debt component required the use of Level 3 inputs, and was determined by calculating the fair value of similar non-convertible debt, using a theoretical borrowing rate of 6.5%. The value of the embedded conversion option was determined using an expected present value technique (income approach) to estimate the fair value of similar non-convertible debt and included utilization of convertible investors’ credit assumptions and high yield bond indices. The Notes approximate a full fair value of $126,600 at March 31, 2018 giving effect to certain factors, including the term of the Notes, current stock price of Aceto stock and effective interest rate.

 

The carrying values of all financial instruments classified as a current asset or current liability are deemed to approximate fair value because of the short maturity of these instruments. The fair values of the Company’s notes receivable and short-term and long-term bank loans were based upon current rates offered for similar financial instruments to the Company.

  

The following tables summarize the valuation of the Company’s financial assets and liabilities which were determined by using the following inputs at March 31, 2018 and June 30, 2017:

 

    Fair Value Measurements at March 31, 2018 Using  
    Quoted Prices 
in Active 
Markets 
(Level 1)		     Significant 
Other 
Observable 
Inputs (Level 2)		    

Significant

Unobservable
Inputs

(Level 3)

     Total  
                         
Cash equivalents:                                
Time deposits     -     $ 2,746       -     $ 2,746  
                                 
Investments:                                
Time deposits     -       3,059       -       3,059  
                                 
Foreign currency contracts-assets (1)     -       285       -       285  
Foreign currency contracts-liabilities (2)     -       318       -       318  
Derivative asset for interest rate swap (3)     -       1,539       -       1,539  
Contingent consideration (4)     -       -     $ 752       752  

 

(1) Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.
(2) Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.
(3) Included in “Other assets” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.
(4) $89 included in “Accrued expenses” and $663 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.

 

    Fair Value Measurements at June 30, 2017 Using  
    Quoted Prices 
in Active 
Markets 
(Level 1)		     Significant 
Other 
Observable 
Inputs (Level 2)		    

Significant

Unobservable
Inputs

(Level 3)

     Total  
                         
Cash equivalents:                                
Time deposits     -     $ 5,781       -     $ 5,781  
                                 
Investments:                                
Time deposits     -       2,046       -       2,046  
                                 
Foreign currency contracts-assets (5)     -       486       -       486  
Foreign currency contracts-liabilities (6)     -       137       -       137  
Derivative liability for interest rate swap (7)     -       581       -       581  
Contingent consideration (8)     -       -     $ 2,952       2,952  

 

(5) Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.
(6) Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.
(7) Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.
(8) $145 included in “Accrued expenses” and $2,807 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Recent Accounting Pronouncements
 9 Months Ended
Mar. 31, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]  
Recent Accounting Pronouncements

(10) Recent Accounting Pronouncements

 

In February 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which gives entities the option to reclassify the disproportionate income tax effects ("stranded tax effects") caused by the newly-enacted U.S. Tax Cuts and Jobs Act from accumulated other comprehensive income to retained earnings. The update also requires new disclosures, some of which are applicable for all entities. The guidance in ASU 2018-02 is effective for annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact of the provisions of ASU 2018-02.

 

In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which has the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. In addition to that main objective, the amendments in ASU 2017-12 make certain targeted improvements to simplify the application of the hedge accounting guidance in current GAAP. The amendments in ASU 2017-12 are effective for public business entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of the provisions of ASU 2017-12.

 

In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company does not believe this new accounting standard update will have a material impact on its consolidated financial statements.

 

In January 2017, the FASB issued ASU 2017-01 Business Combinations (Topic 805): Clarifying the Definition of a Business, with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU 2017-01 is effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated financial statements.

 

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which addresses eight specific cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact of the provisions of ASU 2016-15.

 

In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which changes certain aspects of accounting for share-based payments to employees. The Company adopted ASU 2016-09 as of July 1, 2017. ASU 2016-09 requires that all tax benefits and deficiencies related to share-based payments be recognized and recorded through the statement of income for all awards settled or expiring after the adoption of ASU 2016-09. Under prior guidance, tax benefits in excess of compensation costs ("windfalls") were recorded in equity, and any tax deficiencies ("shortfalls") were recorded in equity to the extent of previous windfalls and then to the statement of income. For the three months and nine months ended March 31, 2018, the Company recorded additional tax expense of $420 and $1,521, respectively, associated with net tax deficiencies. ASU 2016-09 also requires, either prospectively or retrospectively, that all tax-related cash flows resulting from share-based payments be reported as operating activities on the statement of cash flows, a change from prior guidance that required windfall tax benefits to be presented as an inflow from financing activities and an outflow from operating activities on the statement of cash flows. The Company has elected to adopt such presentation on a prospective basis. Additionally, ASU 2016-09 allows entities to make an accounting policy election for the impact of most types of forfeitures on the recognition of expense for share-based payment awards by allowing the forfeitures to be either estimated, as was required under prior guidance, or recognized when they actually occur. Under ASU 2016-09, the Company recognizes forfeitures when they occur.


 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) that replaces existing lease guidance. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. ASU 2016-02 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2018. The Company is currently evaluating the impact of the provisions of ASU 2016-02.

 

In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Assets. This ASU is intended to simplify the presentation of deferred taxes on the balance sheet and requires an entity to present all deferred tax assets and deferred tax liabilities as non-current on the balance sheet. Under the prior guidance, entities were required to separately present deferred taxes as current or non-current. Netting deferred tax assets and deferred tax liabilities by tax jurisdiction will still be required under the new guidance. The Company prospectively adopted the provisions of ASU 2015-17, as of July 1, 2017. The Company's prospective adoption of ASU 2015-17 impacts the classification of deferred tax assets and liabilities on any balance sheet that reports the Company's financial position for any date after June 30, 2017. Balance sheets for prior periods have not been adjusted. The adoption of ASU 2015-17 has no impact on the Company's results of operations or cash flows.

 

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. This ASU requires that an entity measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted this standard in the first quarter of fiscal year 2018. The adoption of this standard did not have any impact on the condensed consolidated financial statements of the Company.

 

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which is the new comprehensive revenue recognition standard that will supersede all existing revenue recognition guidance under U.S. GAAP. The standard's core principle is that a company will recognize revenue when it transfers promised goods or services to a customer in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB subsequently issued ASU 2015-14, Revenue from Contracts with Customers - Deferral of the Effective Date, which approved a one-year deferral of ASU 2014-09 for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. In March 2016 and April 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers - Principal versus Agent Considerations (Reporting Revenue Gross versus Net), and ASU 2016-10, Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing, respectively, which further clarify the guidance related to those specific topics within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients, to reduce the risk of diversity in practice for certain aspects in ASU 2014-09, including collectibility, noncash consideration, presentation of sales tax and transition. Additionally, in December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers. ASU 2016-20 makes minor corrections or minor improvements to the standard that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. The Company has made progress in its evaluation of the amended guidance, including identification of revenue streams. The Company recognizes revenue from product sales at the time of shipment and passage of title and risk of loss and control of the goods is transferred to the customer. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to its customers. Although the Company is continuing to assess the impact of the amended guidance, Aceto generally anticipates that the timing of recognition of revenue will be substantially unchanged under the amended guidance. The amended guidance will be effective for Aceto in the first quarter of fiscal 2019 and permits adoption under either the full retrospective approach (recognize effects of the amended guidance in each prior reporting period presented) or the modified retrospective approach (recognize the cumulative effect of adoption as an adjustment to retained earnings at the date of initial application). The Company anticipates adopting this amended standard on a modified retrospective basis.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information
 9 Months Ended
Mar. 31, 2018
Segment Reporting [Abstract]  
Segment Information

(11) Segment Information

 

The Company's business is organized along product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.

 

Human Health - includes finished dosage form generic drugs and nutraceutical products.

 

Pharmaceutical Ingredients – includes pharmaceutical intermediates and active pharmaceutical ingredients (“APIs”).

 

Performance Chemicals - The Performance Chemicals segment is made up of two product groups: Specialty Chemicals and Agricultural Protection Products. Specialty Chemicals include a variety of chemicals used in the manufacture of plastics, surface coatings, cosmetics and personal care, textiles, fuels and lubricants, perform to their designed capabilities. Dye and pigment intermediates are used in the color-producing industries such as textiles, inks, paper, and coatings. Organic intermediates are used in the production of agrochemicals.

 

Agricultural Protection Products include herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms that can severely damage plant growth.

 

The Company's chief operating decision maker evaluates performance of the segments based on net sales, gross profit and income before income taxes. Unallocated corporate amounts are deemed by the Company as administrative, oversight costs, not managed by the segment managers. The Company does not allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments' performance, as the assets are managed on an entity-wide basis. During all periods presented, our chief operating decision maker has been the Chief Executive Officer of the Company. In accordance with GAAP, the Company has aggregated certain operating segments into reportable segments because they have similar economic characteristics, and the operating segments are similar in all of the following areas: (a) the nature of the products and services; (b) the nature of the production processes; (c) the type or class of customer for their products and services; (d) the methods used to distribute their products or provide their services; and (e) the nature of the regulatory environment.

 

Nine months Ended March 31, 2018 and 2017:

 

    Human
Health		     Pharmaceutical 
Ingredients		    

Performance

Chemicals

     Unallocated
Corporate		     Consolidated
Totals		  
2018                                        
Net sales   $ 301,407     $ 113,406     $ 127,669     $ -     $ 542,482  
Gross profit     57,080       17,259       27,310       -       101,649  
(Loss) income before income taxes     (258,172 )*     5,795       14,121       (23,142 )     (261,398 )
                                         
2017                                        
Net sales   $ 201,686     $ 121,253     $ 120,759     $ -     $ 443,698  
Gross profit     56,424       19,867       27,672       -       103,963  
Income (loss) before income taxes     13,912       7,299       13,599       (20,452 )     14,358  

 

* Includes goodwill impairment charge of $235,110. See Note 9 Fair Value Measurements for details.

 

 

Three months Ended March 31, 2018 and 2017:

 

    Human 
Health		     Pharmaceutical 
Ingredients		    

Performance

Chemicals

     Unallocated 
Corporate		     Consolidated 
Totals		  
2018                                        
Net sales   $ 91,926     $ 43,201     $ 50,871     $ -     $ 185,998  
Gross profit     9,535       7,038       11,123       -       27,696  
(Loss) income before income taxes     (265,486 )*     2,987       6,699       (7,237 )     (263,037 )
                                         
2017                                        
Net sales   $ 99,816     $ 43,821     $ 46,491     $ -     $ 190,128  
Gross profit     25,300       7,255       9,764       -       42,319  
Income (loss) before income taxes     5,007       3,036       5,034       (4,565 )     8,512  

 

* Includes goodwill impairment charge of $235,110. See Note 9 Fair Value Measurements for details.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes
 9 Months Ended
Mar. 31, 2018
Income Tax Disclosure [Abstract]  
Income Taxes

(12) Income Taxes

 

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (“the TCJA”) was signed by the U.S. President, which enacted various changes to the U.S. corporate tax law. Some of the most significant provisions impacting corporations include a reduced U.S. corporate income tax rate from 35% to 21% effective in 2018, a one-time "deemed repatriation" tax on unremitted earnings accumulated in non-U.S. jurisdictions, limitation on deductibility of interest, the transition of U.S. international taxation from a worldwide tax system to a territorial tax system and other provisions. U.S. GAAP accounting for income taxes requires that Aceto record the impacts of any tax law change on the Company’s deferred income taxes in the quarter that the tax law change is enacted. Due to the complexities involved in accounting for the enactment of the TCJA, SEC Staff Accounting Bulletin (“SAB”) 118 allows Aceto to provide a provisional estimate of the impacts of the TCJA in its earnings for the fiscal year ended June 30, 2018. Accordingly, based on currently available information, the Company recorded additional income tax expense of $12,720 for the nine months ended March 31, 2018. This charge is comprised of $3,342 related to the remeasurement of Aceto’s deferred tax assets arising from a lower U.S. corporate tax rate, $7,012 related to the deemed repatriation of unremitted earnings of foreign subsidiaries and $2,366 related to deferred tax liabilities for local tax authorities as the Company no longer asserts permanent reinvestment of its undistributed non-U.S. subsidiaries' earnings. Additional impacts from the enactment of the TCJA will be recorded as they are identified during the measurement period ending no later than December 22, 2018 as provided for in SAB 118. The charge recorded in the nine months ended March 31, 2018 represents the Company’s best estimate of the impact of the TCJA. The Company will continue to evaluate the interpretations and assumptions made, guidance that may be issued and actions the Company may take as a result of the TCJA, which could materially change this estimate in 2018 as new information becomes available.

 

Deferred tax assets are recorded for net operating losses and temporary differences between the book and tax basis of assets and liabilities expected to produce tax deductions in future periods. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the tax periods in which those deferred tax assets would be deductible. A valuation allowance is taken when necessary to reduce deferred tax assets to the amount expected to be realized. When determining the amount of net deferred tax assets that are more likely than not to be realized, the Company assesses all available positive and negative evidence. This evidence includes, but is not limited to, scheduled reversal of deferred tax liabilities, prior earnings history, projected future earnings, carry-back and carry-forward periods and the feasibility of ongoing tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. The weight given to the positive and negative evidence is commensurate with the extent the evidence may be objectively verified. As such, it is generally difficult for positive evidence regarding projected future taxable income (exclusive of reversing taxable temporary differences and carryforwards) to outweigh objective negative evidence such as the Company’s recent financial reporting loss for the three and nine months ended March 31, 2018 that created a cumulative loss. Therefore, the Company recorded a valuation allowance of $71,350 against its net U.S. deferred tax assets during the three and nine months ended March 31, 2018.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events
 9 Months Ended
Mar. 31, 2018
Subsequent Events [Abstract]  
Subsequent Events

(13) Subsequent Events

 

On April 18, 2018, the Company issued a press release announcing, among other things, that (i) it was negotiating with its bank lenders a waiver of its credit agreement with respect to its total net leverage and debt service coverage financial covenants in the fiscal third quarter, (ii) the financial guidance issued on February 1, 2018 should no longer be relied upon, (iii) the Company anticipated recording substantial non-cash intangible asset impairment charges as described herein and (iv) the resignation of Edward Borkowski as its chief financial officer. Subsequently, the market price of the Company’s common stock declined significantly and several law firms publicly announced that they were investigating alleged violations of law associated with the matters described in the Company’s press release. Thereafter, Aceto and certain related individuals have been named as defendants in civil lawsuits that allege, among other things, that Aceto made false and misleading statements to investors in public filings that preceded the April 18, 2018 press release. The Company is currently preparing its responses to these legal proceedings.

 

In connection with the Department of Justice’s ongoing investigation into marketing and pricing practices throughout the generic pharmaceutical industry, the Company has received a subpoena from the Antitrust Division of the U.S. Department of Justice (the “DOJ”). The Company is one of many operating companies in the generic pharmaceutical industry to receive a subpoena from the DOJ relating to its years-long investigation into the industry. The Company is currently preparing its response to the subpoena.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accounting Policies (Policies)
 9 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The condensed consolidated financial statements of Aceto Corporation and subsidiaries (“Aceto” or the “Company”) included herein have been prepared by the Company and reflect all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for all periods presented. Interim results are not necessarily indicative of results which may be achieved for the full year.

 

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements and the disclosure of contingent assets and liabilities at the date of the financial statements. These judgments can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition; allowance for doubtful accounts; inventory; goodwill and other indefinite-life intangible assets; long-lived assets; environmental matters and other contingencies; income taxes; stock-based compensation; and purchase price allocation.

 

These condensed consolidated financial statements do not include all disclosures associated with consolidated financial statements prepared in accordance with GAAP. Accordingly, these statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended June 30, 2017, as amended (the “2017 10-K”).
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In February 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which gives entities the option to reclassify the disproportionate income tax effects ("stranded tax effects") caused by the newly-enacted U.S. Tax Cuts and Jobs Act from accumulated other comprehensive income to retained earnings. The update also requires new disclosures, some of which are applicable for all entities. The guidance in ASU 2018-02 is effective for annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact of the provisions of ASU 2018-02.

 

In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which has the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. In addition to that main objective, the amendments in ASU 2017-12 make certain targeted improvements to simplify the application of the hedge accounting guidance in current GAAP. The amendments in ASU 2017-12 are effective for public business entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of the provisions of ASU 2017-12.

 

In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company does not believe this new accounting standard update will have a material impact on its consolidated financial statements.

 

In January 2017, the FASB issued ASU 2017-01 Business Combinations (Topic 805): Clarifying the Definition of a Business, with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU 2017-01 is effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated financial statements.

 

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which addresses eight specific cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact of the provisions of ASU 2016-15.

 

In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which changes certain aspects of accounting for share-based payments to employees. The Company adopted ASU 2016-09 as of July 1, 2017. ASU 2016-09 requires that all tax benefits and deficiencies related to share-based payments be recognized and recorded through the statement of income for all awards settled or expiring after the adoption of ASU 2016-09. Under prior guidance, tax benefits in excess of compensation costs ("windfalls") were recorded in equity, and any tax deficiencies ("shortfalls") were recorded in equity to the extent of previous windfalls and then to the statement of income. For the three months and nine months ended March 31, 2018, the Company recorded additional tax expense of $420 and $1,521, respectively, associated with net tax deficiencies. ASU 2016-09 also requires, either prospectively or retrospectively, that all tax-related cash flows resulting from share-based payments be reported as operating activities on the statement of cash flows, a change from prior guidance that required windfall tax benefits to be presented as an inflow from financing activities and an outflow from operating activities on the statement of cash flows. The Company has elected to adopt such presentation on a prospective basis. Additionally, ASU 2016-09 allows entities to make an accounting policy election for the impact of most types of forfeitures on the recognition of expense for share-based payment awards by allowing the forfeitures to be either estimated, as was required under prior guidance, or recognized when they actually occur. Under ASU 2016-09, the Company recognizes forfeitures when they occur.
  

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) that replaces existing lease guidance. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. ASU 2016-02 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2018. The Company is currently evaluating the impact of the provisions of ASU 2016-02.

 

In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Assets. This ASU is intended to simplify the presentation of deferred taxes on the balance sheet and requires an entity to present all deferred tax assets and deferred tax liabilities as non-current on the balance sheet. Under the prior guidance, entities were required to separately present deferred taxes as current or non-current. Netting deferred tax assets and deferred tax liabilities by tax jurisdiction will still be required under the new guidance. The Company prospectively adopted the provisions of ASU 2015-17, as of July 1, 2017. The Company's prospective adoption of ASU 2015-17 impacts the classification of deferred tax assets and liabilities on any balance sheet that reports the Company's financial position for any date after June 30, 2017. Balance sheets for prior periods have not been adjusted. The adoption of ASU 2015-17 has no impact on the Company's results of operations or cash flows.

 

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. This ASU requires that an entity measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted this standard in the first quarter of fiscal year 2018. The adoption of this standard did not have any impact on the condensed consolidated financial statements of the Company.

 

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which is the new comprehensive revenue recognition standard that will supersede all existing revenue recognition guidance under U.S. GAAP. The standard's core principle is that a company will recognize revenue when it transfers promised goods or services to a customer in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB subsequently issued ASU 2015-14, Revenue from Contracts with Customers - Deferral of the Effective Date, which approved a one-year deferral of ASU 2014-09 for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. In March 2016 and April 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers - Principal versus Agent Considerations (Reporting Revenue Gross versus Net), and ASU 2016-10, Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing, respectively, which further clarify the guidance related to those specific topics within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients, to reduce the risk of diversity in practice for certain aspects in ASU 2014-09, including collectibility, noncash consideration, presentation of sales tax and transition. Additionally, in December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers. ASU 2016-20 makes minor corrections or minor improvements to the standard that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. The Company has made progress in its evaluation of the amended guidance, including identification of revenue streams. The Company recognizes revenue from product sales at the time of shipment and passage of title and risk of loss and control of the goods is transferred to the customer. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to its customers. Although the Company is continuing to assess the impact of the amended guidance, Aceto generally anticipates that the timing of recognition of revenue will be substantially unchanged under the amended guidance. The amended guidance will be effective for Aceto in the first quarter of fiscal 2019 and permits adoption under either the full retrospective approach (recognize effects of the amended guidance in each prior reporting period presented) or the modified retrospective approach (recognize the cumulative effect of adoption as an adjustment to retained earnings at the date of initial application). The Company anticipates adopting this amended standard on a modified retrospective basis.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restatement of Previously Issued Financial Statements (Tables)
 9 Months Ended
Mar. 31, 2018
Accounting Changes and Error Corrections [Abstract]  
Schedule of restated amounts for each condensed consolidated financial statement

The table below sets forth the condensed consolidated balance sheet, including the balances originally reported, corrections and the as restated balances for March 31, 2018 (in thousands):

 

    As Reported     Adjustment     As Restated  
Assets                        
Deferred income tax asset, net   $ 70,089     $ (70,089 )   $ -  
Total assets     831,280       (70,089 )     761,191  
Liabilities and Shareholders’ Equity                        
Deferred income tax liability     -       1,261       1,261  
Total liabilities     627,898       1,261       629,159  
Retained deficit     (20,354 )     (71,350 )     (91,704 )
Total shareholders’ equity     203,382       (71,350 )     132,032  
Total liabilities and shareholders’ equity   $ 831,280     $ (70,089 )   $ 761,191  

  

The tables below set forth the condensed consolidated statements of loss, including the balances originally reported, corrections and the as restated balances for the three and nine months ended March 31, 2018 (in thousands, except per share data):

 

    As Reported     Adjustment     As Restated  
Three months ended March 31, 2018                        
Income tax (benefit) provision   $ (66,402 )   $ 71,350     $ 4,948  
Net loss   $ (196,635 )   $ (71,350 )   $ (267,985 )
Basic loss per common share   $ (5.57 )   $ (2.02 )   $ (7.59 )
Diluted loss per common share   $ (5.57 )   $ (2.02 )   $ (7.59 )

 

    As Reported     Adjustment     As Restated  
Nine months ended March 31, 2018                        
Income tax (benefit) provision   $ (51,353 )   $ 71,350     $ 19,997  
Net loss   $ (210,045 )   $ (71,350 )   $ (281,395 )
Basic loss per common share   $ (5.97 )   $ (2.03 )   $ (8.00 )
Diluted loss per common share   $ (5.97 )   $ (2.03 )   $ (8.00 )

 

The tables below set forth the condensed consolidated statements of comprehensive income, including the balances originally reported, corrections and the as restated balances for the three and nine months ended March 31, 2018 (in thousands):

 

    As Reported     Adjustment     As Restated  
Three months ended March 31, 2018                        
Net loss   $ (196,635 )   $ (71,350 )   $ (267,985 )
Comprehensive loss   $ (193,556 )   $ (71,350 )   $ (264,906 )

 

    As Reported     Adjustment     As Restated  
Nine months ended March 31, 2018                        
Net loss   $ (210,045 )   $ (71,350 )   $ (281,395 )
Comprehensive loss   $ (202,758 )   $ (71,350 )   $ (274,108 )

 

The table below sets forth the condensed consolidated statements of cash flows from operating activities, including the balances originally reported, corrections and the as restated balances for the nine months ended March 31, 2018 (in thousands):

 

    As Reported     Adjustment     As Restated  
Nine months ended March 31, 2018                        
Net loss   $ (210,045 )   $ (71,350 )   $ (281,395 )
Deferred income taxes     (80,207 )     91,921       11,714  
Accrued expenses and other liabilities     30,299       (20,571 )     9,728  
Net cash provided by operating activities     56,415       -       56,415  
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net (Loss) Income Per Common Share (Tables)
 9 Months Ended
Mar. 31, 2018
Earnings Per Share [Abstract]  
Schedule of reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding
  Nine Months Ended
March 31,		  Three Months Ended
March 31,		 
  2018  2017  2018  2017 
             
Weighted average shares outstanding  35,162   31,453   35,304   34,769 
Dilutive effect of stock options and restricted stock awards and units  -   339   -   352 
                 
Diluted weighted average shares outstanding  35,162   31,792   35,304   35,121 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt (Tables)
 9 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
Schedule of long-term debt
  

March 31,

2018

  

June 30,

2017

 
       
Convertible Senior Notes, net $126,279  $121,676 
Revolving Bank Loans  62,000   90,000 
Term Bank Loans  128,526   139,227 
Mortgage  2,615   2,763 
   319,420   353,666 
Less current portion  190,723   14,466 
  $128,697  $339,200 
Schedule of carrying value of notes
  March 31,
2018		  June 30,
2017		 
       
Principal amount $143,750  $143,750 
Unamortized debt discount  (15,278)  (19,255)
Unamortized debt issuance costs  (2,193)  (2,819)
Net carrying value $126,279  $121,676 
Schedule of components of total interest expense related to notes
  Nine Months Ended
March 31, 2018		  Three Months Ended
March 31, 2018		 
       
Contractual coupon $2,127  $709 
Amortization of debt discount  3,977   1,347 
Amortization of debt issuance costs  626   208 
  $6,730  $2,264 
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements (Tables)
 9 Months Ended
Mar. 31, 2018
Fair Value Disclosures [Abstract]  
Schedule of valuation of financial assets and liabilities
  Fair Value Measurements at March 31, 2018 Using 
  Quoted Prices
in Active
Markets
(Level 1)		  Significant
Other
Observable
Inputs (Level 2)		  Significant
Unobservable
Inputs
(Level 3)		  Total 
             
Cash equivalents:                
Time deposits  -  $2,746   -  $2,746 
                 
Investments:                
Time deposits  -   3,059   -   3,059 
                 
Foreign currency contracts-assets (1)  -   285   -   285 
Foreign currency contracts-liabilities (2)  -   318   -   318 
Derivative asset for interest rate swap (3)  -   1,539   -   1,539 
Contingent consideration (4)  -   -  $752   752 

 

(1)Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.
(2)Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.
(3)Included in “Other assets” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.
(4)$89 included in “Accrued expenses” and $663 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.

 

  Fair Value Measurements at June 30, 2017 Using 
  Quoted Prices
in Active
Markets
(Level 1)		  Significant
Other
Observable
Inputs (Level 2)		  Significant
Unobservable
Inputs
(Level 3)		  Total 
             
Cash equivalents:                
Time deposits  -  $5,781   -  $5,781 
                 
Investments:                
Time deposits  -   2,046   -   2,046 
                 
Foreign currency contracts-assets (5)  -   486   -   486 
Foreign currency contracts-liabilities (6)  -   137   -   137 
Derivative liability for interest rate swap (7)  -   581   -   581 
Contingent consideration (8)  -   -  $2,952   2,952 

 

(5)Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.
(6)Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.
(7)Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.
(8)$145 included in “Accrued expenses” and $2,807 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information (Tables)
 9 Months Ended
Mar. 31, 2018
Segment Reporting [Abstract]  
Schedule of segment performance measures

Nine months Ended March 31, 2018 and 2017:

 

    Human
Health		     Pharmaceutical 
Ingredients		    

Performance

Chemicals

     Unallocated
Corporate		     Consolidated
Totals		  
2018                                        
Net sales   $ 301,407     $ 113,406     $ 127,669     $ -     $ 542,482  
Gross profit     57,080       17,259       27,310       -       101,649  
(Loss) income before income taxes     (258,172 )*     5,795       14,121       (23,142 )     (261,398 )
                                         
2017                                        
Net sales   $ 201,686     $ 121,253     $ 120,759     $ -     $ 443,698  
Gross profit     56,424       19,867       27,672       -       103,963  
Income (loss) before income taxes     13,912       7,299       13,599       (20,452 )     14,358  

 

* Includes goodwill impairment charge of $235,110. See Note 9 Fair Value Measurements for details.

 

Three months Ended March 31, 2018 and 2017:

 

    Human 
Health		     Pharmaceutical 
Ingredients		    

Performance

Chemicals

     Unallocated 
Corporate		     Consolidated 
Totals		  
2018                                        
Net sales   $ 91,926     $ 43,201     $ 50,871     $ -     $ 185,998  
Gross profit     9,535       7,038       11,123       -       27,696  
(Loss) income before income taxes     (265,486 )*     2,987       6,699       (7,237 )     (263,037 )
                                         
2017                                        
Net sales   $ 99,816     $ 43,821     $ 46,491     $ -     $ 190,128  
Gross profit     25,300       7,255       9,764       -       42,319  
Income (loss) before income taxes     5,007       3,036       5,034       (4,565 )     8,512  

 

* Includes goodwill impairment charge of $235,110. See Note 9 Fair Value Measurements for details.
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restatement of Previously Issued Financial Statements (Condensed consolidated balance sheet, including balances originally reported, corrections and restated balances) (Detail) - USD ($)
$ in Thousands
Mar. 31, 2018
Jun. 30, 2017
Assets    
Deferred income tax asset, net $ 0  
Total assets 761,191 [1] $ 1,038,185
Liabilities and Shareholders' Equity    
Deferred income tax liability 1,261 [1] 7,325
Total liabilities 629,159 [1] 633,118
Retained deficit (91,704) [1] 195,680
Total shareholders' equity 132,032 [1] 405,067
Total liabilities and shareholders' equity 761,191 [1] $ 1,038,185
As Reported    
Assets    
Deferred income tax asset, net 70,089  
Total assets 831,280  
Liabilities and Shareholders' Equity    
Deferred income tax liability 0  
Total liabilities 627,898  
Retained deficit (20,354)  
Total shareholders' equity 203,382  
Total liabilities and shareholders' equity 831,280  
Adjustment    
Assets    
Deferred income tax asset, net (70,089)  
Total assets (70,089)  
Liabilities and Shareholders' Equity    
Deferred income tax liability 1,261  
Total liabilities 1,261  
Retained deficit (71,350)  
Total shareholders' equity (71,350)  
Total liabilities and shareholders' equity $ (70,089)  
[1] (as restated)
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restatement of Previously Issued Financial Statements (Condensed consolidated statements of (loss) income, including balances originally reported, corrections and restated balances (Detail 1) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Income tax (benefit) provision $ 4,948 [1] $ 2,924 $ 19,997 [1] $ 4,949
Net loss $ (267,985) [1] $ 5,588 $ (281,395) [1] $ 9,409
Basic loss per common share (in dollars per share) $ (7.59) [1] $ 0.16 $ (8.00) [1] $ 0.30
Diluted loss per common share (in dollars per share) $ (7.59) [1] $ 0.16 $ (8.00) [1] $ 0.30
As Reported        
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Income tax (benefit) provision $ (66,402)   $ (51,353)  
Net loss $ (196,635)   $ (210,045)  
Basic loss per common share (in dollars per share) $ (5.57)   $ (5.97)  
Diluted loss per common share (in dollars per share) $ (5.57)   $ (5.97)  
Adjustment        
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Income tax (benefit) provision $ 71,350   $ 71,350  
Net loss $ (71,350)   $ (71,350)  
Basic loss per common share (in dollars per share) $ (2.02)   $ (2.03)  
Diluted loss per common share (in dollars per share) $ (2.02)   $ (2.03)  
[1] (as restated)
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restatement of Previously Issued Financial Statements (Condensed consolidated statements of comprehensive income, including balances originally reported, corrections and restated balances) (Detail 2) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Net loss $ (267,985) [1] $ 5,588 $ (281,395) [1] $ 9,409
Comprehensive loss (264,906) [1] $ 6,286 (274,108) [1] $ 6,959
As Reported        
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Net loss (196,635)   (210,045)  
Comprehensive loss (193,556)   (202,758)  
Adjustment        
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Net loss (71,350)   (71,350)  
Comprehensive loss $ (71,350)   $ (71,350)  
[1] (as restated)
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restatement of Previously Issued Financial Statements (Condensed consolidated statements of cash flows from operating activities, including balances originally reported, corrections and restated balances) (Detail 3) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Net loss $ (267,985) [1] $ 5,588 $ (281,395) [1] $ 9,409
Deferred income taxes     11,714 [1] 627
Accrued expenses and other liabilities     9,728 [1] (4,702)
Net cash provided by operating activities     56,415 [1] $ 31,551
As Reported        
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Net loss (196,635)   (210,045)  
Deferred income taxes     (80,207)  
Accrued expenses and other liabilities     30,299  
Net cash provided by operating activities     56,415  
Adjustment        
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Net loss $ (71,350)   (71,350)  
Deferred income taxes     91,921  
Accrued expenses and other liabilities     (20,571)  
Net cash provided by operating activities     $ 0  
[1] (as restated)
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restatement of Previously Issued Financial Statements (Narrative) (Detail)
$ in Thousands
Mar. 31, 2018
USD ($)
Accounting Changes and Error Corrections [Abstract]  
Valuation allowance against net U.S.deferred tax assets $ 71,350
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations (Narrative) (Detail)
shares in Thousands, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Dec. 21, 2016
USD ($)
Contract
Subsidiary
shares
Mar. 31, 2018
USD ($)
shares
Mar. 31, 2018
USD ($)
shares
Mar. 31, 2017
USD ($)
Jun. 30, 2017
USD ($)
Business Acquisition [Line Items]          
Cash paid       $ 270,000  
Number of shares to be issued | shares [1]     5,122    
Amount of contingent consideration reversed [1]     $ (2,505)    
Contingent consideration   $ 752 $ 752   $ 2,952
Citron and Lucid          
Business Acquisition [Line Items]          
Number of national contracts with the Federal Government | Contract 18        
Term of national contracts 5 years        
Cash paid $ 270,000        
Deferred payment $ 50,000        
Interest rate 5.00%        
Number of shares to be issued | shares 5,122 5,122 5,122    
Purchase price, earn-out period 5 years        
Purchase price, earn-out amount $ 50,000        
Amount of contingent consideration reversed   $ 2,505      
Contingent consideration   $ 663 $ 663   $ 2,807
Rising Pharmaceuticals, Inc.          
Business Acquisition [Line Items]          
Number of subsidiary | Subsidiary 2        
[1] (as restated)
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Based Compensation (Narrative) (Detail) - USD ($)
shares in Thousands, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2018
Sep. 30, 2017
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
Jun. 30, 2017
Dec. 15, 2015
Dec. 06, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Stock-based compensation expense         $ 6,442 [1] $ 5,239      
Total unrecognized stock-based compensation cost $ 7,864   $ 7,864   $ 7,864        
2015 Equity Participation Plan (the "2015 Plan")                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Maximum number of shares of common stock that may be issued               4,250  
2010 Equity Participation Plan (as amended and restated in 2012, the "2010 Plan")                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Maximum number of shares of common stock that may be issued                 5,250
Restricted stock | Employees                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Common stock granted, shares         490   277    
Restricted stock, vesting period         3 years   3 years    
Restricted stock | Non-employee directors                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Common stock granted, shares         27   22    
Restricted stock, vesting period         1 year   1 year    
Restricted stock units | Employees                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Common stock granted, shares             42    
Performance-vested restricted stock units                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Common stock granted, shares         203   160    
Restricted stock, vesting period         3 years   3 years    
Upper limit of target grant, shares         355   280    
Performance-vested restricted stock units, vesting percentage at the end of third year         100.00%   100.00%    
Restricted common stock and restricted stock units                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Stock-based compensation expense     $ 1,931 $ 1,506 $ 6,426 $ 5,213      
Restricted common stock and restricted stock units | Chief financial officer                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Stock-based compensation expense $ 431                
Restricted common stock and restricted stock units | Chief executive officer                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Stock-based compensation expense   $ 2,017              
[1] (as restated)
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Capital Stock (Narrative) (Detail) - $ / shares
shares in Thousands
 1 Months Ended
May 03, 2018
Feb. 01, 2018
Dec. 07, 2017
Aug. 24, 2017
Mar. 31, 2018
 [1]
Jun. 30, 2017
May 04, 2017
Dividends Payable [Line Items]              
Common stock, shares authorized         75,000 75,000  
Preferred stock, shares authorized         2,000 2,000  
Dividends declared, per share amount   $ 0.065 $ 0.065 $ 0.065      
Dividends declared, date of declaration   Feb. 01, 2018 Dec. 07, 2017 Aug. 24, 2017      
Dividend paid, date   Mar. 23, 2018 Dec. 28, 2017 Sep. 21, 2018      
Dividends declared, date of record   Mar. 09, 2018 Dec. 18, 2017 Sep. 08, 2017      
Subsequent event              
Dividends Payable [Line Items]              
Dividends declared, per share amount $ 0.01            
Dividends declared, date of declaration May 03, 2018            
Dividends payable, date to be paid Jun. 22, 2018            
Dividends declared, date of record Jun. 08, 2018            
Stock repurchase program              
Dividends Payable [Line Items]              
Number of shares authorized to be repurchased             5,000
[1] (as restated)
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net (Loss) Income Per Common Share (Reconciliation of Weighted Average Shares Outstanding and Diluted Weighted Average Shares Outstanding) (Detail) - shares
shares in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
Earnings Per Share [Abstract]        
Weighted average shares outstanding 35,304 [1] 34,769 35,162 [1] 31,453
Dilutive effect of stock options and restricted stock awards and units 0 352 0 339
Diluted weighted average shares outstanding 35,304 [1] 35,121 35,162 [1] 31,792
[1] (as restated)
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net (Loss) Income Per Common Share (Narrative) (Detail) - $ / shares
shares in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Dec. 21, 2016
Mar. 31, 2018
Mar. 31, 2018
Nov. 30, 2015
Net Income Per Common Share [Line Items]        
Number of shares issued in connection with acquisition included in weighted average shares outstanding [1]     5,122  
Common equivalent shares excluded from computation of earnings per share due to net loss   100 181  
Antidilutive securities excluded from computation of earnings per share   170 143  
Citron and Lucid        
Net Income Per Common Share [Line Items]        
Number of shares issued in connection with acquisition included in weighted average shares outstanding 5,122 5,122 5,122  
Convertible Senior Notes        
Net Income Per Common Share [Line Items]        
Senior notes, initial conversion price per share       $ 33.215
[1] (as restated)
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt (Summary of Long-term Debt) (Detail) - USD ($)
$ in Thousands
Mar. 31, 2018
Jun. 30, 2017
Debt Instrument [Line Items]    
Mortgage $ 2,615 $ 2,763
Long-term debt including current portion 319,420 353,666
Less current portion 190,723 [1] 14,466
Long-term debt, net 128,697 [1] 339,200
Convertible Senior Notes, net    
Debt Instrument [Line Items]    
Long-term debt including current portion 126,279 121,676
Revolving Bank Loans    
Debt Instrument [Line Items]    
Long-term debt including current portion 62,000 90,000
Term Bank Loans    
Debt Instrument [Line Items]    
Long-term debt including current portion $ 128,526 $ 139,227
[1] (as restated)
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt (Summary carrying value of Notes) (Detail 1) - USD ($)
$ in Thousands
Mar. 31, 2018
Jun. 30, 2017
Debt Instrument [Line Items]    
Net carrying value $ 319,420 $ 353,666
Convertible Senior Notes, net    
Debt Instrument [Line Items]    
Principal amount 143,750 143,750
Unamortized debt discount (15,278) (19,255)
Unamortized debt issuance costs (2,193) (2,819)
Net carrying value $ 126,279 $ 121,676
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt (Summary interest expense related to notes recognized) (Detail 2) - Interest expense - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2018
Mar. 31, 2018
Debt Instrument [Line Items]    
Contractual coupon $ 709 $ 2,127
Amortization of debt discount 1,347 3,977
Amortization of debt issuance costs 208 626
Interest expense $ 2,264 $ 6,730
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt (Narrative) (Detail)
$ / shares in Units, Share in Thousands, $ in Thousands
 1 Months Ended 9 Months Ended
Nov. 30, 2015
USD ($)
Share
$ / shares
Mar. 31, 2018
USD ($)
Day
Debt Instrument [Line Items]    
Aggregate principal amount of notes $ 143,750  
Convertible Senior Notes due 2020 (the "Notes")    
Debt Instrument [Line Items]    
Aggregate principal amount of notes 125,000  
Aggregate principal amount of additional convertible debt 18,750  
Aggregate proceeds from convertible senior notes $ 143,750  
Debt interest rate 2.00%  
Number of common stock issue in conversion debt | Share 4,328  
Senior notes, initial conversion price per share | $ / shares $ 33.215  
Threshold multiple for debt conversion of notes   $ 1,000
Threshold trading days for convertible debt | Day   20
Threshold consecutive trading days for convertible debt | Day   30
Percentage of minimum stock price trigger for conversion   130.00%
Maximum calculated percentage to which trading price of notes is compared in order to trigger conversion feature of notes   98.00%
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt (Narrative) (Detail 1)
$ in Thousands
 1 Months Ended 9 Months Ended
Dec. 21, 2016
USD ($)
Entity
Mar. 31, 2018
USD ($)
Installment
Jun. 30, 2017
USD ($)
Aug. 26, 2016
USD ($)
Debt Instrument [Line Items]        
Borrowed loans   $ 319,420 $ 353,666  
Amended and Restated Credit Agreement        
Debt Instrument [Line Items]        
Number of banks | Entity 11      
Revolving Bank Loans        
Debt Instrument [Line Items]        
Borrowed loans   $ 62,000 90,000  
Revolving Bank Loans | Amended and Restated Credit Agreement        
Debt Instrument [Line Items]        
Aggregate revolving commitment $ 225,000     $ 150,000
Maturity date description Maturity Date shall mean the date that is 91 days prior to the 2015 Convertible Maturity Date      
Revolving Bank Loans | Amended and Restated Credit Agreement | Eurodollar Loan | Minimum        
Debt Instrument [Line Items]        
Debt interest rate   3.57%    
Revolving Bank Loans | Amended and Restated Credit Agreement | Eurodollar Loan | Maximum        
Debt Instrument [Line Items]        
Debt interest rate   3.63%    
Initial Term Loan        
Debt Instrument [Line Items]        
Borrowed loans   $ 128,526 $ 139,227  
Number of installments | Installment   19    
Frequency of periodic payment   Quarterly    
Principal payment   $ 3,750    
Initial Term Loan | Amended and Restated Credit Agreement        
Debt Instrument [Line Items]        
Borrowed loans   150,000    
Aggregate amount increase   100,000    
Remaining amount outstanding   $ 131,250    
Initial Term Loan | Amended and Restated Credit Agreement | Eurodollar Loan        
Debt Instrument [Line Items]        
Debt interest rate   4.05%    
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt (Narrative) (Detail 2) - 2018 Amendment - Subsequent event
$ in Thousands
 1 Months Ended
May 03, 2018
USD ($)
ABR Loans  
Line of Credit Facility [Line Items]  
Debt interest rate 1.50%
Eurodollar Loan  
Line of Credit Facility [Line Items]  
Debt interest rate 2.50%
Revolving Bank Loans  
Line of Credit Facility [Line Items]  
Available revolving commitment $ 100,000
Dividend restrictions <div><font style="font-family: times new roman,times;" size="2">Restricting the amount of dividends or distributions the Company may make to its shareholders to no more than $0.01 per share for the fiscal quarter ending on June 30, 2018 and, during the Limitation Period, restricting the Company from making any other dividends or distributions to its shareholders thereafter</font></div>
Undrawn revolving commitments | ABR Loans  
Line of Credit Facility [Line Items]  
Commitment fee percentage 0.40%
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt (Narrative) (Detail 3) - USD ($)
$ in Thousands
 1 Months Ended
Jun. 30, 2011
Mar. 31, 2018
Jun. 30, 2017
Debt Instrument [Line Items]      
Mortgage payable   $ 2,615 $ 2,763
Mortgage payable      
Debt Instrument [Line Items]      
Mortgage payable $ 3,947    
Mortgage payable, amortization period 20 years    
Debt interest rate   4.92%  
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments, Contingencies and Other Matters (Narrative) (Detail)
$ in Thousands
 9 Months Ended 12 Months Ended
Mar. 31, 2018
USD ($)
Entity
Mar. 31, 2017
USD ($)
Jun. 30, 2009
USD ($)
Jun. 30, 2017
USD ($)
Commitments and Contingencies Disclosure [Line Items]        
Environmental charge $ 902 [1] $ 903    
PRP Group        
Commitments and Contingencies Disclosure [Line Items]        
Loss contingency, damages sought 1,700      
Arsynco        
Commitments and Contingencies Disclosure [Line Items]        
Accrual for environmental loss contingencies 4,495     $ 8,451
Arsynco | Minimum        
Commitments and Contingencies Disclosure [Line Items]        
Estimated cost of environmental remediation obligations 21,500      
Arsynco | Maximum        
Commitments and Contingencies Disclosure [Line Items]        
Estimated cost of environmental remediation obligations 23,300      
BASF        
Commitments and Contingencies Disclosure [Line Items]        
Partial reimbursement of environmental remediation costs previously expensed     $ 550  
Gain related to partial reimbursement     550  
Environmental remediation costs expensed in prior years     $ 1,200  
Future remediation costs receivable 2,023     $ 3,803
Subsidiary        
Commitments and Contingencies Disclosure [Line Items]        
Amount expected to be paid for product registrations and various task force groups $ 2,299      
Berry's Creek Study Area | Arsynco        
Commitments and Contingencies Disclosure [Line Items]        
Number of potentially responsible parties | Entity 150      
[1] (as restated)
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements (Summary of Valuation of Financial Assets and Liabilities) (Detail 1) - Fair Value Measurement - USD ($)
$ in Thousands
Mar. 31, 2018
Jun. 30, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign currency contracts-assets $ 285 [1] $ 486 [2]
Foreign currency contracts-liabilities 318 [3] 137 [4]
Derivative asset for interest rate swap [5] 1,539  
Derivative liability for interest rate swap [6]   581
Contingent consideration 752 [7] 2,952 [8]
Time deposits    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 2,746 5,781
Investments 3,059 2,046
Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign currency contracts-assets 0 [1] 0 [2]
Foreign currency contracts-liabilities 0 [3] 0 [4]
Derivative asset for interest rate swap [5] 0  
Derivative liability for interest rate swap [6]   0
Contingent consideration 0 [7] 0 [8]
Quoted Prices in Active Markets (Level 1) | Time deposits    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Investments 0 0
Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign currency contracts-assets 285 [1] 486 [2]
Foreign currency contracts-liabilities 318 [3] 137 [4]
Derivative asset for interest rate swap [5] 1,539  
Derivative liability for interest rate swap [6]   581
Contingent consideration 0 [7] 0 [8]
Significant Other Observable Inputs (Level 2) | Time deposits    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 2,746 5,781
Investments 3,059 2,046
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign currency contracts-assets 0 [1] 0 [2]
Foreign currency contracts-liabilities 0 [3] 0 [4]
Derivative asset for interest rate swap [5] 0  
Derivative liability for interest rate swap [6]   0
Contingent consideration 752 [7] 2,952 [8]
Significant Unobservable Inputs (Level 3) | Time deposits    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Investments $ 0 $ 0
[1] Included in "Other receivables" in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.
[2] Included in "Other receivables" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.
[3] Included in "Accrued expenses" in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.
[4] Included in "Accrued expenses" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.
[5] Included in "Other assets" in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.
[6] Included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.
[7] $89 included in "Accrued expenses" and $663 included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2018.
[8] $145 included in "Accrued expenses" and $2,807 included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2017.
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements (Parentheticals) (Summary of Valuation of Financial Assets and Liabilities) (Detail 1) - USD ($)
$ in Thousands
Mar. 31, 2018
Jun. 30, 2017
Accrued expenses    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration $ 89 $ 145
Long-term liabilities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration $ 663 $ 2,807
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements (Narrative) (Detail) - USD ($)
shares in Thousands, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Mar. 21, 2017
Dec. 21, 2016
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
Jun. 30, 2017
Nov. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Unrealized gain on interest rate swap         $ 1,539      
Accrued contingent consideration     $ 752   752   $ 2,952  
Impairment charges for goodwill and intangibles [1]     256,266   $ 256,266      
Number of shares to be issued [1]         5,122      
Aggregate principal amount of notes               $ 143,750
Theoretical borrowing rate used to calculate fair value of debt               6.50%
Fair value of the notes     126,600   $ 126,600      
Fair value of future issuance of shares     90,400   90,400      
Human Health Segment - Rising Reporting Unit                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Goodwill impairment charge     235,110   235,110      
Impairment charges for goodwill and intangibles     256,266   256,266      
Human Health Segment - Rising Pharma                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Intangible asset and recognized an impairment charge     5,745   5,745      
Customer relationships | Human Health Segment - Acetris Health                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Intangible asset and recognized an impairment charge     15,411   15,411      
Foreign currency contract                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Derivative, notional amount     62,350   62,350      
Unrealized gains (losses) on hedging activities     (34) $ 353 227 $ (230)    
Cash flow hedging | December 21, 2021 | Interest rate swap                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Additional interest cost rate of derivative 2.005%              
Derivative, notional amount $ 100,000              
Derivative, expiration date Dec. 21, 2021              
Notional balance of derivative     87,500   87,500      
France Company                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Accrued contingent consideration     89   89   145  
Citron and Lucid                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Accrued contingent consideration     $ 663   $ 663   $ 2,807  
Number of shares to be issued   5,122 5,122   5,122      
[1] (as restated)
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.10.0.1
Recent Accounting Pronouncements (Narrative) (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Income tax provision $ 4,948 [1] $ 2,924 $ 19,997 [1] $ 4,949
ASU 2016-09 Adjustment        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Income tax provision $ 420   $ 1,521  
Effect on financial statements     Yes  
[1] (as restated)
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information (Summary of Segment Perfomance Measures by Segment) (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
Segment Reporting Information [Line Items]        
Net sales $ 185,998 [1] $ 190,128 $ 542,482 [1] $ 443,698
Gross profit 27,696 [1] 42,319 101,649 [1] 103,963
(Loss) income before income taxes (263,037) [1] 8,512 (261,398) [1] 14,358
Operating Segments | Human Health        
Segment Reporting Information [Line Items]        
Net sales 91,926 99,816 301,407 201,686
Gross profit 9,535 25,300 57,080 56,424
(Loss) income before income taxes (265,486) [2] 5,007 (258,172) [2] 13,912
Operating Segments | Pharmaceutical Ingredients        
Segment Reporting Information [Line Items]        
Net sales 43,201 43,821 113,406 121,253
Gross profit 7,038 7,255 17,259 19,867
(Loss) income before income taxes 2,987 3,036 5,795 7,299
Operating Segments | Performance Chemicals        
Segment Reporting Information [Line Items]        
Net sales 50,871 46,491 127,669 120,759
Gross profit 11,123 9,764 27,310 27,672
(Loss) income before income taxes 6,699 5,034 14,121 13,599
Unallocated Corporate        
Segment Reporting Information [Line Items]        
Net sales 0 0 0 0
Gross profit 0 0 0 0
(Loss) income before income taxes $ (7,237) $ (4,565) $ (23,142) $ (20,452)
[1] (as restated)
[2] Includes goodwill impairment charge of $235,110. See Note 8 Fair Value Measurements for details.
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information (Narrative) (Detail)
$ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2018
USD ($)
Mar. 31, 2018
USD ($)
Segment
Segment Reporting [Abstract]    
Number of operating segments | Segment   3
Human Health Segment - Rising Reporting Unit    
Segment Reporting Information [Line Items]    
Goodwill impairment charge | $ $ 235,110 $ 235,110
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes (Narrative) (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 9 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Mar. 31, 2018
Income Tax [Line Items]      
US corporate income tax rate 21.00% 35.00%  
Tax Cuts and Jobs Act, net tax expense (benefit)     $ 12,720
Income tax expense due to remeasurement of deferred tax assets     3,342
Tax Cuts and Jobs Act one-time transition tax expense     7,012
Valuation allowance against net U.S.deferred tax assets $ 71,350   71,350
Local tax authorities      
Income Tax [Line Items]      
Deferred tax liabilities, undistributed foreign earnings $ 2,366   $ 2,366
EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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� M:,M S7"%'3!FB8R,7Q-G/)>TBF MG\3X"28_>1Q-YK_ %9B!6R6F1B.8N=^/H=_)B2@LG MX"D!SPDX^6=".B6D;PEK9]XKB623FL-L;-"=G=LS M;I6)7NN,9"6Z6J()L_48O,"0XCUD=P])9@0R F85.*1BB^_2,<8W)>XQ&L;OK;W#?=KY2>>YZ%1V$-B_&W>N3$!J,FM6#.=O6=+IYP>"D[928N?3O MW2^T&*96AN9^6O\!4$L#!!0 ( (F(3$U\\*OH7@( +D' 9 >&PO M=V]R:W-H965T?;2@#XW3]$W]PSCWG7CN^>*XNI=0;8).W^$*^$_FC/7"U F.44U631E2L M\3@YK_VG\'$?&H)!_*Q()R9S3Z=R9.Q%+[Z"+%% 'TJIC9[+/$FYZSS>'^\+=:W*'R,5?4+O6F*;;ZI\@BU>]O$ M*,O!30<:,-L> R<8E,XANR4D1JLY9K_$A","*).C4^ARNH4+.K1,+!%Q%E@F MWHLR,Q$YRQ49>C23N)-%[ P0FP#Q+("5Q]:%B:Q<79C8;21Q&DD< 1*K6#T& M&4S3GQA$,'#+I$Z9U"%C79Y]CTDF,E$4WSD6Y%1!#A5DJ:"%"@K".RJ94R5; MJ$!HGXJ F,4OL2_ _5VP&3=ZTF_&)ZAO *=FU,PYKLCGWI"9IW\1^\;VK?,+]4 MC?".3*K7U;R!9\8D46:"!W4TI>JCXX*2L]13I.:\;R;]0K)V:)1@[-:;OU!+ M P04 " ")B$Q-E'DG)-!N !3#0( % 'AL+W-H87)E9%-T&UL[7WK<]O(L>_GH[\"Y:-DI5N0E@^1%.UDJVC)WFB/UU8L.[FG4O<#2((4 MUB# *1DI?+'WW[-"QB0E"SO*TI5UA0)S*-GIKNG'[_^4UFN@G66_',=G^7K M;/7G9R?#UK/@\R+-RC\_NUZMEL^__;:<7,>+J#S.EW$&O\SR8A&MX,]B_FVY M+.)H6E['\6J1?MMIM?K?+J(D>_;=G\KDNS^MOCO/)^M%G*V"*)L&K[)5LKH+ M+C)N(J[/WV+[_![P^#'/%M=E_#.-)Y6?_TQ*HZ#;CL, M.JWV:?W'NZ#5\-NVX?QC-"Y71319_;_JF_+P^WB>X!/0Q-MH$5>?&IV]^O N M.'OW_K+A_3/HO(A2Z'0:?P[^)[ZK/O>AB*9)-@^N[A;C/*W^&DWB5?6[LW51 MX)1>)^4$6O[?."J0:L%YM*J-[^BHU3_JMAH&]SI)XR(X@_?F>5$;V9NHF,?! M:#*)X2EX9LK/-TTT7RR H%>K?/(IN*(U#MZM5^4** _S:UR8#W?+VJC;K:._ M?CMJ?.4R+I)\VCAGM5GV_NN_?%MB!&U,J9W7:50;UZI8UQ=9OW$>EY,B6>+6 MJ3[TQVBQ?)&N7BR#)N?!YD>1;+MPGLE6SU/&@M/[\(%K *289_K/B+68Z_M?'O;U;) LB< MQ;=!D2^B[)LPH&_"H 02S:"_ZV05'Y5+V$;8 ^SZ]$60%\MKZ)9&D<8K&!@] M 8MDGIGD:5X\#_Z[1?^#AO)B:IZB<1S=QN-/"KS\LTRJ(5;-7@;;Z* MU8_?CNU'OUWB7WM/R_$5EN,@2M-@FJ*CA >"U74"?+NR.@%P@"#^ M#.*B+(%UT&/YN@1N4!X^K=7/='3^N]UOW>MD_+0N5\GL[HG<]R7W" 1U#D*P M6,I3P<'J.@YX%4X[G=8+$)#+*+O3W[1?'-;7"$FFUD6Z&:?1Y!-W L=LEJ2H M+="1,W+I;7YLVFH'!U:W30_9XPA@Z FG7FC!5^!HW/]#C@#FOT?E@^:V) MK8[C-+^E'X'!OJ5>.O1GNX-SQ-ZBR83GA/M&IGJOF5"7MS&P?OA7$VX2%RM0 M_(,<^BB""WBVI"4F1A\'%>KCJRDHTBP)K%7B%VF3*BD!.[NV9#Q1&DF$DUBG ML#EGU)-,B;:X?.5;Q'M,^%AS3#R.+C,]DVD7\22-8+/.D@D=]Q)&N+J-8Y@ M*/0XJDFC7=X?V#RVX,Y)0$.&[?>T:YC M#E#XH_B>!K!'XB0[?A)%3Y+_=TEN=4=Y";)Z7H!F/%6\Z+UA3P^_L#PMSM-9 M^"V0^UT&VMT2=OL8=().7ZF"> Y&J$*QC@=3B&OJ6N5W5^7CH_0RCPHZ5^<) MB%>X:985@1^BA$)Y!.H!*^&D= *EHWFLS8#6"]_@_74:+V-:09!T:.P#434- MENMQFDQ(>8)K+FHPLZ18A,'+\W?!QZM1&+QY<^FHJ?"#JV).8VAI 0H>]ABM MMFN7N]T!_'J,9Y\KW<6KG.ZLBFJK:VW!WL=I?!.1'5)U<*4[<)8OR6#3X(K! MQ4((BIH7#"$*;J)TS4L5I:#AD?*@M&90D:;Q+"YP/5;19U#^RE@4Z_(Z7Z>H M_AJ-%IX6385U2-->?>0N2Y9Q'@!K"*,1#$FBQIZ\MED2^+A.XCR0)?U'HNC&LJ M7S01#OC(#306S4%'+5?!Q^.K8Q\-GQ2Q)^'SNR/WB'DL3DJ=F0H+LVP9=,$, M[=.+5\PDOK'9]20J"KHVXV&C1A/%VG!5/0?+_(B&#_LPCR.\;L)Q14/+30*K M0-V S,,G%SE,(]G8I=6C88FPE?[%][79>K6&II?D,BF/ M@XL,;V7+J,!IX5 <>;)15C1=%%TJ&K'7((U!4(:&&D8V _C%$L""SG6= Q 9.&_\3K]7"LV&@H)!X=DN3R&]DR\%? M\EO8@D48K)F7N+ '],<.,L*%*@L7GF%N-#9-F>@>$/9I;6ZF&]1N$OA%!2X/>TX&!DCDCM]%.ZVVI;+J!HV E>9E&8SO_ ?\Z;C^ M*H[KBL2:D/P!U)4!MUNM/[P(QBA]"AQ(&BU+&*OZ=#^B[T+?7X">,KT_/VL] M"R9QFDKO^N]E-)W*WRZ)"T5?T$I6J(.I;3W.5ZM\\:+R^'2#"_\9$."VB)9_ M?L;_UJVGGA5W3:6K:4-W,OXC'A4LUG+ELK;2".^SU08>DU][0M2:>H;G1W'[B^'+D>/,IK[3$Z/X7$I MTWLDRO0?<\?TMNZ8^W NKE_^?FG!R^,C>-@'&?Q+%D=HL7\)L%(R^8Y?_&" M?=&2"\^GY>GWPY-6YZ$CV'"$?S539*O2UQS KV:J)^'PY/3K]?^+R%EZ\*T8 M#7\#:W#0'O;#?K?W>SY2!U]VIGX34^ST!^'P]/&7\>N)*JV"+N'N.TW2-1GX M,5GP:]/[0?QG**= " M;Y_WHN?^KVV:3QOPL?C4D^?GT3T_[; [?(AU\5?I^7EHX@+YXZ_R2 M+J!=2?LXMIDOVYA?O@]^>UZ/I^G^CCP]OWV/:@]](]V'CN"WX!OY#_*HMH?A M(#40J_ M&=CQ(IY'C.6RJB3)QKOFR/J1&LLX9O3=CD8+(%!(02K8FFR[&0[Q:;<\'<[? M";GO@50&!V22KJKTB<;!/ 7&OHB[AX2?,T*)Z]>[+1>?-20QV9#FKU^'JVB8_UT M^XEC_>PXHQYIX7HAGU;B9UJ)"X5"=084*'+ZMTRFBC,]+<^3)O7[)O>'!LEC MH:YZH%!!XA)"'@HH.C;3>)9,DCB;W*%D2ZBRB)PL]0B]BP(-Y-4:;S51@+@\ M!8JDVSCZE,5E6<''AZ8N07Z9+7&AI5P;2(OH\^:W$XU3U%0TX3@8U;M$5*'( M&G^(N)^3?#$&> _=R5JY2T^5,I;/*W-DVKPNR6W M"H(&N0*2(HD%-),OMM$4<4XW%S(BM$P@L%R_*T5E2-8O\FDR0T,&P8*OEW$! MK3*E_88FQ/+'IH])OVHL&-J^'>5 M4>;=Z%7W-I"Y,4!$D1DVM"-B'Q"FR30ZA02?W?UN EN:]<6^\T\Z<%_C3$U][XFM/ M?.V)K_UL?.WD6'EPV(%_6>23>(I^^^-?"R_ZC[@1A\ZUA]T3IR"?_8 5JW 8S&"U@GQ=!&?723R#AJ!A*ISS;@8# M@]ZP>?[-Z"WJ-_:-F&HS^#=^EKK<6QU(3QOWB4_\WL@-)RV&>:IH)[:?8MPI M')1Q?A.'&!O&=<+M(-AJ.%RU9'B"^>I4.UP,L-#^>BFA8W?;'+7>B#9TLB;9 MF@-B@25-BF0<*Q,UWTM*S^'VVYZS:1C$//6( JVP,+BN=5VO+(5N4S5^F(HV M7%-/5IB@:ZJGJM=U4/CPJ(/:_]C&5'*5@2/Z!,O8E2M ]6'[S(;F)&2*K]]*%:MSX$ MOE/:=53Q@$_S]7@U6Z>JFEP9'%2#3?=/6[T7;I%X^/+DM'=8[?*=5+?37?J& MFZWRXJ[ZPR76,$RF;E%59C$3AU2U3:#*L5FUG^C)$,L^U6B2KS T8V.+<%%8 M@E)S1T- TB^1O-[F]*/7<P59MV6)I$%$,">E9]F\DS%)+"@2T83WR$T3W 3L>UP8S4 M)EE&=[C GM^+=6R6<3/]K:%5'WSC#,-+&//(AG9>93=)D6>X@A1\LXBG"4LK M]5)M*_IV5./#/*$- ^"P9$^)_WAS\^64@3X MV7=!M>TKS J\SE/0J,MO:*NN[FIK#"=+YE.N\LDG.+\AZ!:<40A#6J^N\P*+ MB[Y H2[?)F6Y%@]LOEZ5L$V1U_NF!H249O>/6VW8%@57RPR#0:^I'V BI]TA MM0X?6\.3S=W6JRO2$Q5^!.\ON5YF6ENDLVB9K"ACA^1[2?J 'FKUZ?>Q2.L# M#NY:'08@@C(4G9[MOEZL.3% F!6(0E@3V/QX 9$==(!ISS5FR5NG]*RA_YB_ MN1B]O'AS\>'BU54P>GL.$FKT_M5?WKTY?_7^ZIO@U5\_7GSXW^J;!Y&!>:L- M8#<)>' 9X6&]CLGX5!Y:(E$MFR47PRUR4GNZX )FW<8N587M?XS&H-1&DU5- MG(ZVB:T$JY2F:53425T[ [5=N>L;O$5W?7KGPZ,WHST-R@"FENI+Y[R]=3;> MQ_U3\3ZZ:1[^373U ?[Y\=5;V$#O7@?O+E^]'WVX@ >"@[7*1/C"G=0-?F04 MOE=XEZC^"@SC6/&+FO(E@!]F+S;O.@0M0)GNX>LEF2F\/WY?4 )WD<^2FMBZ MBE/6H4$&Q 7L?:KJ.UW #0S'P!5_&\3G!>C924%#G@#%YO4GWH.P(%Z)K4YC MX(8YJ2^-3;[3]>R92PG/\FLA!]**>JHF;"AX'OB-ZJ[Q=Z/><4L;5)]JIV% MG+/&ZMY8P_KX.#-NZNKPP;^L*M0@0-YYDA@(::L=?,Y?^>1WLY"U*@%]UF@<2;*[.0N M(*M2*C6E-7!MG7&P$1-+N<-9MBK1JZ-1H)&BO(V6/EVR:7@/6X?1U5^"UV_> M_?T1V;+A)Q%J8_Y[A\'U+551;M #TI@J];K['W[&+^D>3,=TRM:B?)=^SF.@ MUT04?N*S"[SI_(N^J W*^@T7!"\>)"1)Z9@ OR^%J\+W:-]!O6-[(Z(82/0] MC)=:\MPDF0/YM9L:7T++'9*$Y#3M6]@5WFEYKC/;KDDL6VK/B!*,QAS64Z%) M97W /?%3#GLXP O^NJAO2'7OX8P/G5#E/QZTYU1Q=:#YIDLLVSFT'FBL#]LN MIY80VG"!>[OK[O.;9K;LT,OHCLB'JY[%RB2!.V>\+A/*1HDF[%*IO;H&.1_A M/(A[--J!KE!#V?*,#(/S;I.J76)CS\O=S26:E&M)Y4D\)*KQ67UP=B C9N9@ M!],$E\K#GL@+'$]+=AK%G^-BDI3$?_DDY4NR&=?V/E\;45<0A+A *U3NV]\>NO.1]O#3D:&Y:K\:!+,>A ML\5G'KK7R"+YX3.\5[-<(^DUD4,,9,$>?#WKFNUPR^9/AV3,]CS>: Q%R\ X MGB=9)K;J)5F [_5^C#R@Z4U@L_2.=93A<;,C.1MDP^UA37GGN+M8DH(T&\<- M-Z_7CCHP6R,7-?)'M^'3VF@37:*A"(ZNCZN^*^91)F(II(Q63@M3Z0CP;OCR8QD.DL+Y;BHY),@#$(C20JR&SV M1W8)TZ-_9#]P(-XJ^4GY))236#NGV)MCI0,LT?1<*!^48,@RA-;9TN M." 9QEL"9H2Y<3!R=N.A! *=D':+>>7035U8,I%(!TSOQ.6BZ+$4:TAHPP58 MX AZ+\_2_)9Y-@Z0]W"IVHZGQ\&%) *J=O "@6XK-98D12$^)??]#6TR]23# M*RRB.]RPT>0Z@;OD5+L$03=)"06!%>6/57H+43-@=Q/'X^OCM4U M& 8"(ARA&J9*EB,%ET#'2;)$"7;P_6AT>:@B#)Q\5"#H(OH$]V98$4R19!*! M\%HOF)]+_B2S*TY7X9(=J!&N9>,I([RE#. *@$*SEA:UYJ!?)X]>7L;^.5-& MB>,-5+FCH@KY59Q 4$EL=Z47R >)#WW_M)[.N<-)E.%ZP6'YB8VA8G-> 4_ MAQI^@WU]1/+5FG8L+_J$?(O3!.A4L(3DR372E9??.FN<*8RVD0G&=J!;SEY- M./QD]V8T%=;]B;YT!YAGM.U?;'-1O2#%@?Q(+X*Y>%<=?L%"_F@<,9IWCD# M&2SQ8E/@00KX6.>,8G"3Q+=Z^K>4L AL/4T^Q23'@0'CZ91>$U\'P:UU7E*T MUY,UB!4^$>(HNN5@<@KC+N=E.VB2?S5#.;,H!")S:%^>OPL^7HW"X,V;2ZUR MP9?J&(2&,$86?X/,G6B$DDXYVF$? RV 89-$@#E2U!!LB- )@"]?U);'%\ M+@[*$ZA+,..(!8\)5K2$"LA,U(R >*%>%V%)(E3^%3?L1I"#T+&$O"!L4N'; M)CX^0YO7NW'_DM_"OBM" N*"52TD)D+1A##\XGFDI3-K>ZA]::$=T^UU$N\\ MZ_NM:JC@)$B-\Q$F1QOS L7^I.F(*AH;11JI74R=:$JY726$.984N&\I5$>A MF\$,KBD<-,K\;\UR)&#EM6-D5RIUMQZ79;.I7$;5L %0Z\.#_IG4&SC ^XR* MK Y[TS+7?=(;QI0H'ZQUDG>6]NI,KZZ+F/?#M@I4U?1GTRR%LY>6N77%NKMB M^S6E6$Z&\B#K[W%0,5P*[C$3'A7GDP!OSF^KN> -33F8.]C@<0+;7*0RD<]JR'AGTVV%[V-Y[8U\38%)V#(AP MI^ 566>](]&!+,%1 %WTV_S?O5H<2]#O#,+3X:D\U>\,PW9ON*>#(R0V(CCH MM.# G, (!5 V$K6[',R(R S0W MM:^IYI)6*&?V7VDVX/;]Y]HFT#7Q%3?A_0ZZNTEU[*IV"I+@W&WO?J!.-_2U MM[E(!I*\WP]/6ATF.2_F?D#5X?<4\C\^):7*Z3&SZ/!9BE_#IF$_9*HPT!WO M)SR(Y9OEE6/ICTH$PYO*0?F0=W>@TMLM"[(#D;A2ATLD+OC@4$GJ#WBHQ(CV MNU!I:&;*'1+J]VY4:GKW40Z1+T;J5WJH'NOTW/,$N(Y>\V(W[/7ZOA?AG+7Z MC[2)[[D/_6/MM#KAH'?J>7%P$K9;I_96NI<^4-E*EA64LH \?KFOO+6^QH9Z M[#7R^H#A3+?"3@M/.LCK80=4 1#;[9.]W?RD>*OL#(>D /0&;6PE''1X:#OY M2X,>"(QV#Q01^3 JE2W:))H89,$LU[CJV>XA ;AVN$H^Y9_P]C+E2<YAX'_G M71:4 S4"B.9'-X2#XIG/"Y0YV1' 8@\6/+I>E*!Y39^-&.$M6!;3)XP_>O#G3@^9?M+.(S _8PPQ-2V@">K.>)%/? MF_2#-@RJ+A@*1A9(9CB<\3?D74"$PS>Y'/T]TW@0>SG3LT=8_.3"4P/.#T?+87]&4T(7U/$ M67T@>!^,<'^B!1_&S!XWY#&]([+@H14#+:'D#Z4<5MYS/Q(XL\FF,)W1:K.=.."CO)K7@Y)LQVX6/EM"8DD-F(']SU]NC+*QL MF 3:8+,T73PY1,=X?L>Q 4N)Y#>\@8QHNF5Q&B9PR8>;95YBP"(>W_J9!T4N M7\^O]>#L.=5F8#$2OKU19-T*6U>^OF@\1OL'\1!,Z"1"B<6-W].^YK?GH]+A M$"[]U5"I!;4 .IF:@@,C]HB4R3RCE&ERP3%U8F8X!6QS#AA G1P#2L1 [#"] M9;($VF>QA-_P#YQ8;='#(\QJ2V?,U(J@-O.=%W%$0\RN46#R$$LRIV:LB:'% M&M=?6-5 ]V/I##A?XEY99\S9R:I'A D6<83! M'^@=1!;!QQ:N7_',X/*2,P']&>0DX.-$R6;80QFG*?:VWT&3 =QQ) B%A!(5 MC)AJ]W(4[/?XH36PA,FZ8#L(JU8JYH9(2@[),1YB'=9)!M="/+J]/]#%"Q%[ M%\K*ID:2UP0SJ&:TG6$]>#040!+TPG:GHP-[5>#$Q K@MZ-CZN)^J)SWH#C5,L?3C_8^S)0YRM?D>EHO V)<=M$<14!-9>U" MJ(1 &!U/_:]ENO%@OSV MUK:Q&09-N/U"-?87.*2KZY#U)19O*IA1:W5;M#D6>T5>_)>T)<\VQ=0Z\1SVDUA)AOK"_!!@_F2>%05(!UEN4-=/#H.F08#NI: S MZB%2L ]Z8OVO.B#+7'2P401-.;I,P+K1;*.:E:!2:$#Q)K[)"<\4%"^<$%I9=&";LN55T5=6D2?DP5P^:P:"RA"WL21.N-C;B84D,1(X- 8#4CQ3C;! M>/W@ 0.NHA?9(+RC>5B\@G3+FL^Q:MD*+MDG8:>G,C6/,8U><2!WK60PTED8 MX%TWYG1-$J<.*X]6> X5C[/8ML7?YCD(F.-M^[JU:5];(1LJ[#:2N"QXM1,& M[L9O[;KQ=]W=&X\(:TDDA_-L7<::A(3 L,MVUA%;:D>[F^2K[K!HP]YJ[;RW M>L[>^LN-EA70U+[ZV38\B^N+,CC5WET<--J)C'*YXP#J?3ZMH, M^$@V51-KX]'PVQ,5LX013W1FRJ#;ZXF,3XR9SF;P& .*]4HLXY4#S%/@!6ZE M@B!W'AGSG4F:S&9,*X235$&S$CQBU'RZH9AP")Z.)]21=J,U^ 5JFY/2\G I M[F8"B'=7I'E'KP>6CW6X]Y'C#VX.DDW/,DO+ZWB[9Z M0Y>HLZ80;.7'\@1[M<-AEVTK^_WP!*N&VC BH7U];CH4OF0O7AOR MN^<0Q/[^21H1U=0ATIDE*@?*1 MLAU1K#2G&N*C^RT"P=$!.,PPQ!C(JA^0A+A\IR.+O,J=H"9FP!RR: JHGJK0 M/ACYZWAY<7(:>D1N*FY M[5<7406I!&<:^9?F@K%OQFZC!VP&LG1!DEA:W.0ZK3:70/F40^/9B"(9L[O< M5FO67 )O>6/C?URBR!&"X;@:(0[P07IBDUCI'P;;NP@X3J\)S24I7;/9;16W MQ1AU[/<<()=@:BX3?-.'^X7$^#7VJS"<\:4I/DQY!SJ?VWAT&KNMQIE+K0 W MBDO%FB>:,=1FZ)D0P6S(#'9X_CD'3-EX4 ''Y-E?[9&D(B:I/^WM@),#U]RP MW>^@6G;2Z^)?W=9)T#T)!_TAQU*ZI',LB7[]4$QK^!NK\4=!MSO$__8Z.CQS M%T*9H0V&'3TT= QRO+,9E:OYPC6!>F^?MM4"F[QXU=']@R>K^C/**F"/K 1+ M/FE\GY55/K6((KXHXDV-2B=*?> 0,?Q/>R#3.NDV3\MN_LNGR.[>6/*JJQ#( MDRB=K%.#!B,SSQ@ P7LRQ_$D6I?D8TL*M8"WE50;N#DE1^K8\D'$M)I>;1P2$KZ7F6LC6\LHR:0586CE?,6N0R6)>*%:\0U6(- M>KH8MV.0K5/%JU6N/G3 :AT1059.U A.%E:.?2MOUM9:2HZ4K%['J4)C05'G MNIG5!F)0C>/];O>XT[94SE#;F"7FD?>AU MV-V$==Z@.'XO?!9;S=(-PA26A MIUT@V.KN= QF&R;'F3=MN.%W!D/ZU [[@SXH,S=Y>H,+\A)Q4MX@3DK09Q5J MR)$*'[!OZ]ZW.ZPI:E>,@E+ )"-*XV+ML:%]Y+NHA+/G^!E]^8P06G2@'_=%NSW' M*TS*#KY$RGFS\V2\OL-;B.U7PK(0,.>3D;\6A"G_T+4SLBLV/IZM]A3A#F4$ M>ZU.%T94Z(%&F4+KJ5\.*G$JP.D'O8WDL^?D'X!*4/+T:74E6]3<[A22$+$? M9Y5%V"&T(=]\5I0DI>>';^^#\-LR=.:+O-#(P$PT4SY.DWFD ^9,Z&&!!Z#D M'9*(AY/T1!7UE)/OK<:LRO68D /$*8MG.)YR77=.OFUJC&,BW<;,..V66 0G M?!^S^PL#'3 *;/VG]?T'[^U-LH4_KZSX'>?&I_)C:4\C0 S>\IPVV#%^SMH&Q5$XLQ)!E&_U"TUL9@ M,TKZGY@8\X""]ZFR[JK2?9RR B!9TG3%AW?*F81(.B$#MIT\TQ+4LK)K/="> MQ(*C$]TCA%8%\]P2+0W'K3^8(+TR7B1'[$#FZ+$(6';$07EHEV!CL6ZP3>&M MF B+IG5UABETD^(EU5L<75\]=C4:GX3=SFF#?<**E(LRS6M\8KXFQ3$GG8U! MZ.&67OF$%;3Q+2EM! RKY7"?RYR@>2D* % MJ>CL(N'7+, P2S-7S?/D\&3MI*#'ABH'8MN,B@8J[IGJ,I:846I34##:CWD\QBD0RG8+-)%E1-LLB!:= - M8*B0U0,S+G=DXM**:S@W-?&/HF$Z9;GEML@5YQW\6-BE%$F-S'>&_E42M9O* M%HQ^22ZO$#,24DJ+F23O[F&]I M59AY+EHJ7N*#P)*.>X\1T4EAI6RH47ZU= HX5!N+6[K%QI (9"JW(*W0^PZF7 ML&MMF.6;-]\K-A_V;_-";2\6?)@XJ8*1F8")5;I/I3LX^X^Y3YV_R<3BJ7 Z M8A#4B[7[9VJSR(4"@S*V+]DM*%]TOZJM$>T'WSJ)*8K&E1S?CM MZOS(HZUP5'$+.@5Z5&Y M1'BX8P772:?"B[7$&RFA,$56YD!YVVCXN:QNS/U W8+-IX^98485'MSNA9T! MYJ0?M(=AIX>YU+6G*RSNH!.VAXB- !].VX@TPHG/SH1\)J<=G"889P'ZA8KW MI3N^4++*+A4UG40/14(-?Z4-F2BZ:!$YI[(QK]X"&[V/S?AY4'?$5!:N[I>I M/G$FR9,4Q)L3/]D/@-J= 8'G# ,O4+M>S&XX' S@;M ]&?B?K"QDO].'?D^A M[7XXZ+:HKT[_)#B#0YNL@M?11-VO?1G3SL%P6%J$1JTUATS<.AU74)1 Q2*$9R.@&H+A*1J0 ,Y6K'[M-*K0*8_Z;K+* MK9")G@.8"%I=M3@CRJ7[]V(NURW=C:*B;KSSP,95N$9?5N]@ B?1=N;H-7B= M%/"@ZJ)I)5C>-*V7!KF6O'9MD(MNHB2EDU]H _1$%PJS[K*;1\$ND/VVY-2Q M$5-I(#OWAB:#CEB+[5UX(0T9&_F9?LG,WTK>:*!"7<,?$_@Y>M+0 L-;E;_C M&7&.G!-T8Q *T-FT7HE;$4=53Y:T9_&C$J7G0 I]N5-QZ HQ<*8,@#;S7)!> M9[G/Y.HSY10X-CH.VWSM=BP;6G[;"+[4[%XM$\LVP7L'2_3CGIW?40-!.U<< M[3JLS?UMV]S\M_BZ>@>]P9_P"7M'O>[?_ A$7YPM4.WL@Q7-D:%P84/9R\M7'XLPD/>+^?(+N"'H=-(_#Q:>2 MC[P<'G9%_CHDY"$F]^AIJ7N:,2;;&8#Y&']T&:.N$2$X[Q01EBO??X"6LIK] M M$;*.R%K/AXKU)E#D@ Z%L3_K6)OP8':(A!\!2%JJ(?$H7D#@..J&FE D98 MOWB5S]F2J!7Z3=TX$F\3GU>W2+M!36BRDV>VP.%YNO%Q^^T6+Z&38Y8QA01T M&UXN#FW]9FP PUA!'L<2<+1EG>,OHK6F\II M9>MVY8C!J$Z.6[T_Z/QZOK3MLN[8IV=8&%]"F# $75#@SZDJT1'[ BAV!,NQ MPB<\>#>AY'9"3W$= 5\N'(S,_>MD.A_\V]594K8^R/41QHBWFQ7&V%CF9>6L M-&-#+S>L@;XP[=,=L\$#9&W0 >\JRMJ0VN5LX*!_-%6Q2^9T;(A8Z4Q+I25:X'A]8I0 MBQC+V23EHBEV23OU)0$58^R*A)"QL#@!(8 )3%"I:,E.Z@+-9, .'2^8&P"2Q!E213=@N>DG68SQM(BQ46B[PX#(7O'4NW%4-[,^FME6;,']JT0*- M Y,*#;PCPRB G3.!FGT5<"T84KQ!//>I6LJ88?!T&*+R5/A8%",N%Z>W( MW%-MQ9$#M6>/UF7_Y0.43I&##O0)V?Q1&RWKVJ3.<29WI$POW#8_0X@YH8$Q MGGN<4>T9V#PJ ">K1,Q4?IR#-,+XI[C^4ZEJOED%9O1WID*>8!147I:K"4'P MZXIQ;M).N^O+4:W8ORSCA8IDP:*/6YKU>&W*K M7LEZG.7.[Y[UIV =AN2/$&A!BI+I>EUNV87FL@'6NB'+JW'S^BG89/S5 W$E?22\RD MC]D8:ZB/V7R5&5EVSMI\1&?75R93X2N].^3(KEGR6>\DLAFK#;&U 2"LC=/NY1N*&HNZSXNU;/G2]=E.SG:\]K MF+VG)=:BIG4&9[%65F':172;><_JST)50]36\4G+PE,,Q?K+\0R:)Y A_+9 M1$>YVYO+YGL5^O"&C7KW7(B2+,UB5Y1P.FN*8BGD^_E4A1\^8,7E+.&U%5LA MQY_Z*V363)\*N-W=BLFRTBG=(,GRPZW?=VO<'!J=5YTV?6_757>Q8XWK*_47 M71<0!9@(H(B3KXSUOG.NJ457O&I*_6:&HK+K-9*FAF7*K3&6GCGM2X5L]4=Y&I12"U M57'I"#H 1\QT3Y@M8LY#+LN)2TCIGU-G-ES&C$_C':VJL^5T"MH[E_VU-][4 M%NHMM6-GE (8#D\&JOR9">:]CJ.I\%J^:UQB?^__FQ2BE/S\\/_Q.DEUWK$CZAP)?!) M$HCJ"\JFDZ2,A'D-])2(6%'N H2GE-+(."NN#I87Y*]G=';U$O]DGT:N""E> M-0X$1?< I 0Q+7)4ZO8F2(KB"VW7P?9&OEQB',,'+.\D08GO5JMH(4FDVFT!"V+>Q@AC$9IJ M_* E2TR3'A&#W,"3<[5M." =2Q L8P18^%=43)&CB>]D$FL[%S:G! MN-3Q6 M4B-%%Y#5!<2Y7YXE>O#&<(;1MV1*C-SHP "G(GF:&:3Z&^RL>MX 3-Z!8*> MU^P9;-R*HXS7J$H&S01=2O"HX'72#5=X)9-&JG0CX1WS54CR809"% >-B:0E7T,KX-&4 M2C-H4!)'$?_&]9(HVTR.&=-P@Y[JRY0M4RS:PEMJA])[5EZ\)PI@5)1WV22O M5,*2;^U26%;U*UV>"N[N>7K#$L8MR3.YCA=48@N$UD1%*G2BI5Q=8JQ_0G6ZC:6JIH.1%P6, M^8MJV1V52PK8QXIOSD!IXCQ,"@Q84W4ER2HKR_5"\$JT\%-)B=8PV*:)O]IG MD*\A;M:@:+EV>J%+.L0GN$7_(FW2,E;7'$JTA[.CN2,R?V"\A1@%=08$Z FE MC)P?5(8S14;R_6H$K5UEB &KK4N2L&[AX< 94Q&2;JCN\&=KBFSEC&T# ]68 M\[J+0**-HP50DBE8;-3_%=NM6'XLB6UJ/5&G+T=7KYWZ&TJ6X0].0H)"\,6J MCD9751VJW>D]D16E(3)^,NJ>P@+5K= &IA ?CLOS2R'\/!> ,X36"U6$Y9%[ M>,V15.,XLPMIJ+)]:J\*BY!1@7+;Z[5LB\22T^_I#A1;8Z&L%NJ,QR_)&H4Y MSFH?5&:R0>_"6X1AV\%_S#E(*67<=%;W)'X8ODX68S3( M*(ZKI6I-I46K'F0K#G[IJ%441V.+&R@$W<4A\C)'.85#)AU<7(\/O M;&9).40<7DC9K1@(H^_)E=W33/0/EE5>:9_VX/ "T?#RCEH"07EWPE:'];'] M;GC:ZM;0$GVR]C[J 9TVA>3=ZGO4+M"C,9Y$7\]>78YTC!^6\Y-H2;SXN1X2 M4^'YE<.3WLON#]U2583'I[4BA/0Z.'OU_NS-Z% %+*(8G<;E!.XB+ 2QIY=Q M41BV>P9\X1-&W8_C /QRII6YG4 MX)1RH>63%/%U+' 6XYUI-8 W3E54^_H00]D_,>T!I+[>59$%[\H7IEJU:A1U MR03DBQ2S,^9)ELPK?7@=#5VT\C3.YHAI,&/X'7LBZ(65.5<"7\E78)LU]3P6 MF#RI H.H>ASK97H2; \%"N A7@;$187;NA\74#?Y]$" M?0H';]^?'P8C4[%/N"#N0;/WKCF1@)QY"/#-=LG<5+=9:4]1M0IKO>!? %W: M-0+)3H264'U58T&X1%F%9$*5'"[W&/ !^Y(1!+60-O12ONAZIH>+ PSE%%V]XAKP11MF@&+V_NI+S=/0(-LMC9=UHJEHTAHX*$W"%T64!O%=PY5!U2(^#F^/@ MW61"](<'SL2@8JNXZM$P.,\G"/&!^>6OKO[OT9NCX6G_]*C54QB8/YR_N@2I MID3#,P[!(F.P8H>DA/#8\:,63^;/)EJFL"M_[("/6FI MT*I!4RSVH(V9L*N<[NS*B4DPQZ*>+J'8T^9,V1C+"MB"5RG MX6BW#:0)C/4(%M9GGUL496LO\ \2-P84Z#BZW4VIX\20FOB(KAZ,#D7(M*,K;-L91\$4I*ML1;<#Z0,3*GT3A.V3"XQ/6F M 9@JR1^D0;=_1MTY0K0[ZD77_EPY198#7>:(C08*4,.\I.\,5'(\5T78%;<$ MX0[J&D6HZ1F3QY[]]'A?E6N/'#)%K+E"$4>[KF^LTYR3JD&,@7Q'&R9;8%?D M>]?F"S4\[-DRKB%CWW,6AJ-+0/H8/FV/2T=GK!50 MED*LK*P-+.L,XV]1X7.(B\OL7Q^T6H[3I+RF^FTE(6E.2)[\E"=T*(SW$EO$ MP6/O\0PCU&M%5<1:@ EQXFBE,#Y);V#("=,+L4\-KJ.WDP9/(SL$OB,^V^MD M6:URZE'XL)AYT[%4D3&N]0>=*D1F*72M@2 5I>QB$VR?HO6;):F=I?@1(^:G MK'B7CEY1UYH<8+!([I7Q7)JA[)BM)ZLZY^ZI3L8H. MZK6SXI=J*ZZT?Z/@H_FF,QP&JOB@6+ZCA,PDN5-"ONY9)*46+[5T!Y#X-[K4 M6M%*R#2 2_SU1%MP6#@+4S=0WRN*N:<]6$2->O MJ*6"V'>X#P0K;4+PB>7+]?O#2-MD&#VNN#O*9T=YD5:M)K.Y[EM3V/[G24I-QD M&'AS='F!D;=XO9.)762P?,HE\-,Z;:C'84#!,<)0"04L?GKF1XI64J(^_+A*-QF'I "Z?(F_8L>5O$ MK:V5:8O$%GB_%:^L=X#N1 "\*B<-E62*+),PO04&6#.3F<+-*958-@&M8 ^6 M.C[*8F8-QKV3J4TORH367\2.EQ^1,B#AA(K#44J8*&BP :M;6F4HZT!OT+!U MB'H:W8:5(84655ZN"7$-&$6$YY#\RDOL?26R>KS&8+L%B6"J!:K6RC8Q6D ) M^6QV! T?P0E)9WK3G+W[<&7#9O%JIP@W:?,IH4KMB,BQIFU*:'6)PABW0 X5 M]R$X*]_;5^XZUSVXUJKA)I"8AQHY9+'5W<40Q(K*NZ/AX+2!O8*>U3P?"TFX MZJO!O(5RN5:U*728J>M7A1VA*0H7"K?\>I;?*.!:V?V:'?]M%#!;E8L:<0P' M&*$N(9$D%/VV7(*@T..:$%,.5"15[<)ACBQ'T"L5DU@".S^-)DE()#.X_]*- M&>>B3,X&J9?&H$U1G.>RR#3/%NN7;67#: .7(6R0:>P6J<'&>2H$"^=DZ\2; M''4/K''+"D.(K(8C(Z7)T;)(0+KW3,%+V4RACYD6$C"'&V2=:N@NZO.,$EAX M15[B';2P%18V!M)1,7M#HVL3XTK09B6,Q7)N-$B2D/8SRD:]EHZ?"&-#KI+Y M(EJB! O>1&,TC.4%K1F*,\4)Z"$2$GG":BE>R_IT9F;RI#X-N=Y MPGE)\!1:3Y2<>17A53 S/\.$+^,L*^_2FRA#(6Y@6WA YZ)SR?-A29=O% M#+BUE>G!15A;?4>-,//T(6_:1Y2);SUOC&Z*T\LE7,,QD98PB=V1+-#F3FF$6J/'HD56XJBQT65$GRGG3,16CAUY7A2(MIE_==QXE$LWC;U M&83>#BGH6F'MIG.M_BL1$$_E4,"C%LFO5:T\\K):MVA[.0FJ7Q?&M)<6+7&L M+-[$,C@VAU+LOEDB*UN3G0F5&S*ZQJ9\.4KF><$V>3*\2IS?1!OZE*^&H:(K M+AMK9BH]66=_D!IKXOQK:3.O,,^DPY:9\F.%AT- V MA8E))FSIQ#F5<@*226Q;S/67N$4%-:ZLL:0BJ=!P4RMB2IB=-&YM(\'3;(_^.H&K /!Y MY>;&W8_+4ZS%]*/0R=$\9EZC>4X9]W#-S:K!F?@PJW*IC)CNZ0?Y&&%$! 0. M=*#RL"H$M%G4;NQ@G=7?Y,UI9D%^EE)9[="I1'GCY7."T$B#-C'1=OM%\-=U MOJ*0< /;S@97/B'*2DIQZ6S#1"N4 .,Y=95>2-L=W?8%#U-_:7GRT>56^GJ?C[6*6*:YN3&HLA)7O-MU%H' FU!]11U.=-G&N0 MS8)T;&19:[0*2J22;#7Y9\$_>=UEP0F[2>.*U);_6+\I\Q0GF'-&B#13L]G_ MN=O.8@H9H#75M%4@A0O7EZ;VW7(-IWB".;@%.3_I:/U$6?R<;HJDPD".:8SY MW7)U@JO/':8C%"LNE(@@A@RA25RZB"4"CZ+*U'0() _CJE(,^J%4K*G.AM28 M2L;^93/%4#=LQ;$Z2]%1FH.I<* /L;O:ZY(-"^[68 =,:5U^<--2"L._6*4! M5>^32I4=WWE:2+&ZFES$.9NU]HP%A*64(/X#&I2[!:GN,ABVW7*(D0O#9-4\ M1-N]/$^9+GHAQ;P/?] M@'1A,/I-1;;IUBJ'5R-E55"D*RL*'7J$Z-$ M-W%BD6F?U@N_%$5@POOVN%*\HM80NK1O(H$WTW:XC0L?J:SF2L1R*35/)#L3 M,183#?))$:V:U2F"J^$HRC :,@RZBGI8#Y5L9C8.#( .0(C(.LLAT5I#0L3F M;H\*T6, -85Y'V#^();4(ST'!XZS8F@&H!.?XP?4V46SQ<%^]^10TA4Z S<\ MT!D$]ZV'\DB#&##\;;?'08H'^YUNZ[ :I*A.OAVC:)*H+4 *S.6APJNA40!W MJ#?A1N)*+N9-Q+B0@JN>,(Z=J9"E0!;\5E.*"E4HS@HXTP",656 _?GR-7S? M\C9:&F37CJ(>60*="%?]FG(4=HY;K=X?V!OHVW :U4K=ZW5L/V:+J4(&D0DS MYS,ED8B?EXG<0PSN?%+Z!@_?UF#SN1$#G:S'5PV-M9B"-_H58UU/!YAZPTVN MW8VK ^7J.)I.XU9 K';6DYB=K!?"27FO39SX5"G/[-MS+O)N53*C[[;#7 M'5898YV$#V2#22F5G[8R01<"?B>FI\3X_J#743&AE#&_T@%*$O*TW^]WC?FH M4CSF ;6X72AI 8^V4M+P)ATK5XC>>%2!PZK7+4E3PTUCMP<;V7%CVCLT,9:F MUP6N-]&NDK352+I..-Q*O$YXVAI\9?(Q+=HGO4.;QNBL,I M;43OY883:XKV0",,P%CH1D]^S0L;YBTI\B#,@)<9,1RQ+-/ ^0EZ8=\"=HC$ ^$Y0>?GJ?L M>B:8:0WDXL+6.C*+]]6"]H1E Z#0896SQ:J&QQJB-Y>R4\AUFF.T2A6AI0*N MK* 0T@\$THM5TL;>71:QYHS:Z1JNA19FMKG=+/(I!B21TQ/K@(&6@AEF8C%B MO #$^Q#CGPYD&M_I( 2V9."(3;)B)2'(%_>[:4'K69\"9D',XF@5?3:%&/7N MM_:PE0W:Z?;"=KM597;>Q89K=9[-CU+.]#46!&UWE7!H)>A.6LE&GJQ/8QWG@83D/W:Y5[7F>JMED\M8Z0E6FH2PLZ=2],Y3,I MD1TJSZO#'12]L<(DQWCI+LS9/G:-I?ZQ62/")I4UBPU7Y"[-R'(2C7/4[J8[ M,R7D,PQD7-N;&T6)JSAN[8AN/YU>/^ST^Z'"6_:*^ 86I]15Y%6*\_QE#:=9 M!^?$CZ0ZV#I5!5N:#CC%5<-Q[G0V%W0?QW"GS 17L>I3':KJ)C'& M@%,M@[HL$!N$+KFG30'2[VT%R8?7)I1D(C-7 MIU@-5E*DTIG>:2TO:]585*&Q<[MBZE/%>ZDC(- M6 [J[-2LR5J_I@H\^)C+V-@D4MG(XSO3F_ X MMRN5K\5 B&XAU5#4(]0>XKR(V3?!M;"([<$X^? MHMF=9\_;UH[5C$B@5L:TC[58^\Q7*A:+>7(C(<.5^@Z,S5A+RJR5P0YU"!=S M3K<*NU5VW5-CNXA4*FE5,*-ZDJ85.[-R2[@0$@8L5'L@/3"K5$4/ W+HPF@1 MS**4"H52B:[H5Z@6)':]B,>5BX#6NJONODQ5I569U:0N&\<%>9E0=[KE?JB*KH#D[ZYM/>A7';U1_OAJW>4/V[][K1>'\D-,:< MMJ.@<]KC_VYZPUX*S#6#3H B]-^]<]N2*:#V/G,III0=!6095/_NG3694 Y. M\&&<.)KAX/][.-H+RUXN9HEW$DBBG5"JDI\O[?],0^:0]G[>E^)"8OA=3SM7KO;I@\+^?7ZAD6 JV)R>YS)Z,;VD8][[S1G,G:4E]I MZ!N.MHLK\>"3_9 CW0L'IVWS:?.1[H0M.O_T[RY'NH?'YN2TS__=^4CWZ6AV M!_Q?^TB[& ^^8SW =WLT)_COAB-]JHXTFX?IOWLXXI_Q6+M5W?9PXC_?J:YV M/O!V_C6/2'4$L"1D'K_OZ6;C_<]\OMW!5^/2WL<3SJ;1%?@NX4(/GR?^P#=, M(FE\F&9Y9FQBSH.JKM^F(+EVZS#8-B*\S[Z.Q\4:K\;&TOA:ZT+6FU?H;(^* M:1F\S.$?;95_/;IZJ6-!&ORE_$22_#/&WW8)@?T(R%W5XLR":L-56+A,B_U,LC[>$/.8S[;MM0 M$ G,0>=1+I,KNI8X/\G0!NU3&-K5)%_21>!'0E$7,IIQT0!^B#*U"S8.HAV\ ME-1&[%%5Y2XU,5I(C#/0W9/9G=*+S]G7(HL7Z18JZ]!O[+=_A*:6*QM7D 3= M:[)2JNW2;7'7#9N%WL 3D2S5\<)O+B7L.'2BZ3>-I;801UN7H+HI7BV6:7X7 M(W>!V]P1(\+(2.P=4SF?&T<%._4->I#,6IR0QNBS6'E:Z!WAPLL)A(-EVAF< M(&%=?E@G\[FJACDB1:"*@-#<:QM[13< 0J,KQQ2L)2A F.A@MI&E0C%RD+QT M;!V@D\:>3FC=WJ/#82UVK3,W)X[:S*4V%:+59\VI+"N235J3@1$:%JH:_KY 2'1YZ6V\.MRYRPMVY!"A+RT< MHW<67"Y#@4V0CR+'V+7IMQ&:NX0%.:< &[QDZ".8ZRN0\=.$?OA YBJ!=RG8 MMLZ/5T^17J4=QU.5D5=LQX?MHQ,(FAXQY-XD)O!- F3!6]E05D)*QPU"Q)Y3$@"P&YG"H)"Q0-K> I=_1F6,4^# M6TR,F<,V0EN^R0!7/Y-Y"V1\1#5%N!D[KQW&6.1,Z'*AFL:JP^B Q.P3SJ"@ MY/R5]'-<6;/)=1+/+*Q0G7&'F2N%5?C! P.F%LQ8PK&.)Y5Q#;&[LI3$'"$# M,>!Q3&60Y*\5LF,,'10<%[(*J_AC5>[ ,@M62E6B8=&!]0W)UU@2Q@^AHX3D MP62'M7Y=!BY?%Y7X;E, 0L:D#&?C._VF725A"PEU<^)PM3RL5H-H[R1$-8>R MW]AD#U7,EN6&5A/C YD=JN[HUL$M* @#AU9@69:\;*: =8O^QH]*Q6S;"'+MA3:5Q)%DEG?5(]/XB=L'.3+(-F(UGI\4* M:#W;5[&$:PX'A-RP"$I4C9"3^[NELR: KJ(^1L%6:OXF:3HK&[*3>Q MB%?7N.!%_Y0HFYX$=[ ML,<\VF7.>WY&;',(^S:[ARWNO55\)]B'6VP[/($;]'[0;G?A4Q\_=09AOS^$ M3V0<.NF$)Z>=O>]M%M4;A*W35@"J8J;F!B MP4&G=QJV!YW@\/^@^6G8"T!G:W?:\$,W;)_ ]_"IWPZ[P]/@<(_F;P^[@QV= M\F#;,(8N?6J%@YX:]LE)-^P/3RO#[H]T>D+?5/84-"1NBBS9'6*=A?Z=-U>^%:'.$3=4) MAZ>#H ]OP@K!>G4'O*6ZT/; MZ6&L"G:,EQ0Q(AKV8)M]_8U4 MU5WM>U_S;SO6*VNSI\)<)-_9<2<=.W@7&SU;"V_^(1^7!$:#(?9H%E< RECUV4ETN0V125IJ*6XXR1]G2%,S&HB0>17C*:% ;2I=$M$#,W ML2I8@L4N\F)CX'"H(@-P:"1*H^U&.AZKTI'9#6S&IEM+M_<''%>G_0?'O2QV M.<0>BX\HB.:9:'E8I@ D%:-84F,4R@7+S6@9<51@U$_IQ-IC5EF>'=& ;$1# M59U4IUI-8Q*[IB*&R2HCP8L)L=JF0\VY>5 PGLA )498/"J=DLZ%(RWORE6\ MX(!G>*N@0B7\EOK-:/"&XL?<$V7+1JYAS3EA;D0P>^\YB(P&KT),!0A3UEW5 M@FP _YLJ X?3DUB452R:#E:JM)F4:B^BLJEQ-#FB_C/[0.P*,I7)44 (OJ^, M'^I$A,'5JS.TC,UFMMWHY3I-,>_K NZ44.IL>"DX*7 ,\?A)G!!OKFIPZ]8<0YU36GKYU!B]H_Z3:].B@KG% MA38$_!&CPL2DP6\C9U\B)*TQQMFQ78L(,47GZX1OLHP@'-U9X9D<,:@ AMTB MXH3Y&!D4)I>_J11U1&M0!5\0DH7Y*J5BZ4Z4DX_G4 S\$G<6[&B*P\(G M!1]4WI5^4(8S R:>:H=Z0WO*4I)D&BL]+_U]:K -I550@20K*HOD$6T>!/J% M#9$Q@+4%PIJ+-N7M0"5M<72M3]0"@]HL0"=H7T"O\]_DA)1O '4(R$' M-1Z-(PF Y#^E3H_>":6F.( )RCLS[') ),IXGQLB+.\.N1AIGU\)% MA-3)=<[UHEG(.IL\\JR7E%>G5#:,"8TS73-G(]E%S .G!X8?K2S@3*G/01_5 MP\+?D7D,K/Q4(>R92*_S"DXT, $49J<"B[M?/], M>MX=L-R4)1'(#88"@G*I.%W0W;I))?1R%U3>!FV$ ] 01ZAXX,$G5<-W^IT, MEUW'7[MA7X$2@PAS0*97-[YPD-H#&Z_8W<.@_@+'PA$95$ XXJLIL>27>?$);GB? M$FR UH"<$F;V.3LECJUMI(J5V9@X3?'23H:1QOYWB^&RO9T1I/$N/(.I6>@X MLN]B4_K[CN.KK6($[)2A0L\W22ZXZH0: >W5D0=TT4&+9HG_.N^< 6$GE(.D MP)7L5$=U*\*$!>"':[20FO+B7) A*@5@36W&"3Q*$R_7"<=:^9+%7-3?'];H M?XGU*)7H=.LSD*?'Q9;#Q6*QP=6$D$\3NC3"*&H%KXY=J+)AZTXG4^05-^\R MAU-FKE5P0K@*NWPZW.7I9GGQ4MT^+OGF:.(2&FJXVL6^;(07/AIV:4D& MB+:,"3I=7UD_,/!2Y+]"(S9GD<,&51BG\#=SM)B6'I.73O&2I]"G-ATKN*U&"=#5F_OQI(I7PH MHL=;R^$F^;HD&&B%GOXFGQO*&25.,H_.! M'*BN=KZ5Y>H&>%M.5%E-ADW7BJM.EKU"O42J_H4 M5Q$!+/,!7Z]4MJF93':2]9< M-HP6G6]*K,S;!7,;Z>JP*"U1R)^!P 8,E6BMIF(C+.R8?7)4E4 .2'$FK4R3 M0RE?CU>PXW0^*-<2HL"\%WXL#@6]<42(^S7@@!>_#(J6TB_8 P=2G%JAI56/9 MWJ!F@!X@%3QS]5JSF)9MWA<%E@T4JFY=M1R!3[W;-C"Z!.6,B !<6VK'.%4@ MJHV."$M%8NE(W<;*#>W6T?]HWM7@+AA05 ^H6?2+K4>0GQ";T-K$?"+DMK**;#7>0@K95:.JM!]\7J3/RR5<]O_\C&Y2Q4W\[+L/Y)!"#9*QTTJ! M!!?=IJ$W!T:R"@TA/Y:J0@OC.O&](B3 ;GM-R(M4F@GKMW'&%;OV =]*UB6\ M6!X^WQN5H@G@*=57TH"^YN;VF)GLG=<#4%@_)GQ63%1OA:U3C(,\D$^'&,.V M1W%ZZC9S"@/IG+:L1P;]=M@>MO?>V'<L\18NNPO5X15C7WI&8-%U, MK>_TV_Q?Z=V^0/4[@_!T>"I/]3O#L-T;[KU7!4_Q>C!)5A1>V>V=8/2>6.SA MT[ =#EKPG31;>L8H>-R=5C?LGG:LE]O=3MCJ=CPC8@"+QJ;V-=5 M.AC'&:S^ZM!$(2')^_WPI-5ADO-B[@P-YY5CZ.Q@<]V"Q]\Z3E&)2'O+N M#E1ZNV5!=B!2#V?<=8G4'H;#X<"A4J<-^_?$1Z53#+K>B4I#,U/N\.#TN-7: MC4I-[S[*(?)!"/]*#]5CG9Y[G@#W)FA>[(:]7M_W(IRS5O^1-O$]]Z%_K!W0 M\0>]4\^+@Y.PW3JUM]*]]('*5K),N*A.&3]$9%U:O^K6^AH;ZK'7R*,)X)WI MM!5V6GC2*1>@C2']@_;)7A71P3+@V>*XVZ(T"U0 >H,VMA(..CPT6A8=53>^ M\ZX+I7NT$51(/M21%T"]X*P"8:R7;"5!9D5ZSXX*+FR@"8Q:W_\T?G(D?FH% MS&@5*^!*4,PH=WA^)PV8LXE^M--"F'4X7]&F(8.9^?3W'4:,.0;]#NZ1$Y P M7QPKO]$I(PPUBCVAWQ!SD["C M")2IV^L$Y[L3QQK:8-C10^M11E%UZ"DTP(2=<-^OQ^\ M01N6PF&CRS1L9$QY&72ZF-9TTN=^MU4MK60K M'34)+ZO@F3 @0=@TGSYF@I4;2\B(0K0%Z=8#XJ)< #E'"3N']:E*NYQ4!]9O&X3?;J2\)QQ?T C:Y7SF.V<-G2O8"K@7V.A< MM<<=P+W@WH![F][8 +@7? '@7K [X%[PRP+N!;\HX%[PBP'N!;]=P+U-A]<# MN/?H9[>"K+?Y[#K(>KN<71=9;^>SZR+K!?="U@L&-K+>AK/K0]8+?E%DO>"7 M1-8+?G%DO>#WA*SG ]7913U0L"$V*HNJF5F[$S[A,3SA,3SA,3SA,?PJ\!@> MZ)4]NZ>K\WX6RYJI$A;RG": TO_CU7EPL(_V00Q*4F;)6MPR*3/5;VT79?6W M37[);\0C62>?ZTST][?)!?B-./_JX]^B5REZY MXVYW(='V)P<-Q(2;SK&^Z30\HRDUL@ID;6*&9)P ?:0V[[=K"GK$NQ"3E)/5 M)2KPWX%_'B.=$;^A9"D&V=4)7:UBUCP@C10T<2/5*'0QGE+6X/>8[TE1_S!6 MM5XU82YE?.H-5I_L<8)7?7/(WEUR\&E=U%B6D5J;QZW6'ZI?7CHY!2'ET1]A M)AZG >W\.#L\:LR!06/<.P3%[DYJBJ2U ?0V!UJ:/5^[/Y.#CH-QW5A>WT$U M_.PA1[:S\Q4MS4KP'&F-J,7[6^R-&1,*/G5JS%&T\KD]P!-/+)&EI?!?8 MS^FH9,JMW702KQIR392MQ:^)(EB/KNK9E*Y"?I7J^SA]48)AE%)@C_?E9C-3]&GY/%>A%D54;!JH/)\:V#NGB&TMHT%"N#PQ&4C-K2X:#E M9]2*?ZSOJV[D?^L8UG=]5VP^"&"\TV'->NGXUXAO;.%6[S^HMM:F]K<^PIWS!GRW)P=,/5C&N>=VJD^N+'Y9)",!8)@^]0&@=3 MK8EF._?E$!,S<2BQ7\ T,L'UP%1]'PW:K9:/O5JD R,M.W_D;GL MP,^?1^LY*%PG_A^IRX;?SE6U362Z%,2UB=V:IQ&# !/E0BM,U2\^?>^H;$[^ MQ@L%3[1HAWO_]5^-Q!C(KXW4:/A9C8A4.!Z,5[7L=#=VWSEMZH!$::=Y\!LH MPA 6WN$,-XZFO7DTS;\:6!.J#NW;/,UTT#-9\NZ1B;#:Z].021_O=)H:I)]/ MFW[E8PB70:/ Y< V%UO5< '-^U=L,*I4&W65>8=HM?>U4#0=V#62Z*DK[OE= M)11-V2]V>-YA,KLSF!U"S+Q&E2^.*FLRU=P_ZFZG-7@,9NS<4VN#R&^T0ES3 M>7&$34/;Q$%K6U/NADD=KL0NUVS[!Q] 3QF>\:>K=PC5BL#WT#2#ZN]ZI?>T M1BRS,A$8KC!KL.\A3LE4;:82L1\4W-Z]NJD/WQ_05^=T]%O&P7Z4_^F6;.:< M\\9^.&3QBDJ9$HJ%\<'B3P^POU.+%[J8ZL:MH2((:Q9Y)S[2LI15 @EK[WF" M#7>E+(5*UC6M>I2DUSK0_+-+X7KH(G5^V&0,WT3I>L1@38>N!#;6U/*FF,:M M#[JA>)OGO#4$,3!WTXJU]Z+ZZNX&X&HHHL<$U1R+N-/#N]# ;R_UN#B8C][' MN.$P:Z$*M6+:W\70>![575 ;R\K[HD8;3Q6QSTZKTQ)# 7U9OWAO[M$"7ZX6 M"=_44#Z)XVFI&+!YK[1XIG?5DDWFN([OOFADG',A(TDG@DXQ9-HZ_^;U_E)N M#NTT+S9&#I3H; P6B."Z3 5/A0O7FY+O#2MJ7H>#1,QW&MVQ3[E6J?W?@6<7 MF08(=$:NG0]L[-)<[1&X"TB#-B6[B#IH:O.YE&4QTZO=][O>^[XR4DVB="+ M%I8Q ?B4X,_*X#5P';,O0>]6*"H(#UD0&I<,R:+V+-:U6[Q4'Y[ZAM?$2U!: M;)/&=;?$*RI/M MO0#$>I:G/9,T7SK[3<,W+D&-:.KDN/8)Q9)GJ5/I0<,9 MCB,%Y-A\T! /DHQ5WMEXTQO^'3RH3\-3"MTJ'O/$ZXK_$1<8+91T+624P*5/ M$=$/$G !G.$TQ=BQS( _D444-M>PS<>%474%YHU,KC;;==I[3'H@D==%SEYF M>A6^^9&/8,UR>=P;>*QIC]TY']=ZY_UNK?,+X:*DIN'[S5LJ,=L=Q[=A][\N MR( P(969;;B($^CW[OR5(4+3.E/3LJ[1+U09^Y=O89&JT#$6T/+LDT7$P-5* M_#9?L1X\NOJ:5IL^.6[U=N>"I"I2+!QU+_!'53//5C^UL5(V\+/1R_=^'9^N M. B"PQ-]'4TXZGG3W:=]W*LS^BUDZ?C>&6G0[UW8D[8$*N,&6CNJ#_TQ6BQ? MI*L7T^3FC_/5"_7G+,=K].HNC?_\##\?S:)%DMX]#[!J#"/B@ZX592']_>)9 M4()*_^=GG6?8B#):UT'1I]JDANJ)JL_@1?(GG#^!TK2#J?@JP>CI!)N^#V*^ M;2E*E:(AJIJ*%%K(,[=V"&[?T(9E?F,JUW!$46CH)X^H89*Z">-D\]>=9)]N MFJ-O.AHL5M'^6R2XO1C?RN+4KVK3(KK-O)N!N&[3)C[3CX&6$EOZ3_7!UO') M/524>\2DV)$+[29;@;*[;ON=H*;-I#>G:=:K)9%WDEN)53 MNJ"3W;4"8-O3C5SM>CJY>UPB'[FGJ(UF,UT6I ZV:A\!)C4L3 MB"4VC]JF_=X&C$8T65]?-6)LZ5=UACN4]4SOP7C-I0+J[YML&Y^[Q1\),O(6 MTT ?"A/FJT=CNJEE9?V;G59J 4&:M%(K*+EB M'/2WOS.3-:^'#?VI9@FP_KV!,X:GWN:9P3=FS.=-[&-KSEGUA7]T[M-&<^KM M=__HUAKZQTG=N;M;FFFMI=ZFEK8EO=5:Z]>'.JA_=5K[RLGWJ['_2C9A_5)B M9R8F&4-EXBT20=]AM[X!I1EWW(-?A .R<81V!B3+SG=CS)$F5?8B6ZY-8YUZ M$M9]7K[/2#YF>5-#W8VCV/CBMA'8F7S/:NF+SQXYB_5G[GUSZIW3>35O\&>= M^:-W?H^)VUG7/^NDO3F77WGFU=QO#^6]^=Y?:;!;R%7+<6T:;CVO]1>A;J/^ M 3HI?+B..9KW\-$4DOOJ'95A/7K4+T,&H=&I&O+:44$U)(PWV><3Z_NL M1J^=UP@-S.>/<')*59;T42 !X@8>%[V8M7M*8R;C_7KA,/0Z%ZN4-N*('1WD M# UN[5=AUDJ9%EC2ZV2)FGW#@+#B2 $Z+_^PLZ;:K"R&2'7V;#9YZ)WM6G(V M'AY!V+C7@G)NLHJ\6B!F(NEG_VW5$:4CTFF3J7OK$; +X,K#=*TN=&"CFI3/ M8^JSYAHB "--).W#%YJHG%@4(]>I68;>*A*J+-2-HWE=<.(S<]ZZ_7L+EO\6 M=K4M8N-V0].8Q"C%G#/W,:F"LO&N90&G!\V)HJ\DW"WSUERH/OV_OH C#U*" M)4C4[Q2^S3GFPNY+RGG@GQ] .]6PX3GV$#91YIU.OY,VJB=\IQ>:$^IW>]V7 M=%\_[9X<_ ;U[0&9XJEZ68;C,F<+ TI&]YJ%C<8)N&AH@7! M_R6'NK\]+[#;H(R806S&POB M27"E=?TF")JL DZ:"UF#,)%"*DZT<549-+4"DC']^=8B?N< Y1I[C?9[@ M:/D2![]/>A'^F-?$#J@7?TC]4^Y#\J4E#_H-2N-"BOU]LH"I3CB@#6$)OB:, MKA6U607AE&T]/+= )IE42)L#,NHBBS0//AQYSYY=S\.ID,K5]A7\=]U//P@, MGA5(&1L%SK$'TK@F6H,2-\9QDQWX70CU]FI;&X6E(MMHOL!3@AM,D;54.:BQ M3(0'*(T9%%:.HF5E1RWKP :UEMP8.26E%,1I&#)ZP]!FP-B=O=B?BSWNKD!^ MCCV2$".K8C#-JGMS.K702=YE\]R[M.%1O*BF&ZG?M68YPOGV\L"M@H)VSN^* M48!A)W7-MF\9+04'OYA?%HR.+)C&9*B#*JGH@^&S5R4S "B,-J TS7:1KXK4 M*^CT<)VZXEC-\Q/4_*_WN00!BK!=T>;N/^5=_L^*+U_]O63W5SD4_+1V];$E MVDYZ B(7IR!R^<@B@[[I['2VO;XVHFC=4J:IZ.56-,_!Z[$/BP1_LJ\:MM== MIO9FZ#59F]?@'K_)S:$@+=.W=HDNF.#)_F"%1\MQUFJD2/!D?X2&PO=V]R:V)O;VLN M>&ULQ9I;C]HZ$(#_BI4G5FH+N<"VJU)IN]#3E2B+-JM]K4P8P-K$YM@.>_GU M=9)R<"B,SLN4I]Q,\F42S^=Q^/RL]--R/5YN,NP9;>.#S8= +&"^M^B9R"WK$+?RC5;D1LP&/3<";?"B+G(A7T=!O5Z#H&[BZYW&W4<=LLFB%?Z_X11+9*H(:^N+LU:;$S )"]@&.R:,"X7;"RMHV&WLCF5:UO=B[OT[:*Y+^LBMH=E M^DJX _IV$5;@=) W=]/1>)J.1\RMI7>3V]'U@]OX>CVYGMZ,F0<9(9#1&2%_ M1AYDC$#&9X%,']SBQWCJ028(9')&R%8D^PAD_YR0L0\3]@V^$\R2K.7THU"/$ M(IFZ\W8FRI@+)[E,% OL!W)2ZSBQ^7PTQ683$MKB' MK$ITUUFFRCJ$+N$IZ=:SFM/'Q'01$OLBA56=D$^, #%=A,2^^-U?'_@+M)XJ M9H>06 ]I.3?P;UE%;+P]?-TP-X3$$;$]CN2]HZ'$ M%!*1*P3K+7[!$6$*B8@5@F,F/B:FD^BQ K"]>WGS1A34$RL(!S3SYLQ9J&8V$+-*",MBX+KUZJO M3Y1@"W90M<:8A6)B"[4Q,_=JOE:#X6T]$E%+'Q.S4$QLH3:FD"Z.+I,R M>*GZ//C%=8Q9*":V4(-YV,%%[H^-8LP_,;%_3@&RT$=,,/.8D8MQ QYR34SL%FHUJU6((Y)SE7V=-T=1\3_;XVN\FYIR$V#E':]V]T'U,S#D)]=S:,_\"EJY064S=)8S;G_$\FVE6+9IO$TF_ MFEYS_LF[0LZIR[FQ#2JHZ'*EVT76R&.YNV/U1Y^-IO0U>M7JIM##J? M+T(_GE'Z[Z;)]NWH]Q";_4O&]H B_!^ETD-*#;#K(Z$$^'>3TH'(ZJ*0'+::# M%O2@R^F@2WK0U730%3WH>CKHFAXDNM0&_EZZU ;^7KK4!OY>NM0&_EZVU ;^/K;4!OX^MM0&\[ MPUD).BSAZVU ;^/K;4!OX^MM0&_CZVU ;^/K;4!OX^MM0&_CZ^U ;^?K[4!O MY^OM0&_GZ^U ;S_#631=]] E!+ P04 " ")B$Q-2I4EW<WO&Z:.JFZ-+TKK;^*"I/>\B5U\O#9)8M4G[(0)OV]L MS^-]KVMRKLSI7]',?%YFE)ML5<=;4F\=Z=P71*&N4E]H1_E;<&6SV.>=:1=> M=!T;LTW%?BQ(KYYK/N#^CI%U!+ 0(4 Q0 ( (F(3$T?(\\#P M !," + " 0 !?D !D;V-0&UL4$L! A0#% @ B8A,37R^B>;N *P( !$ M ( !F0$ &1O8U!R;W!S+V-O&UL4$L! A0#% @ B8A,39E&PO=V]R:W-H965T&UL4$L! A0#% @ B8A,38JLN$!> M!0 #!H !@ ( !F L 'AL+W=O&0 & @ $/% >&PO=V]R:W-H965T&UL4$L! A0#% @ B8A,3;WVD70 P U@H !@ M ( !4QD 'AL+W=O 8 " 8D< !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0# M% @ B8A,35DOIO:U 0 T@, !@ ( !:"0 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ B8A,3558E/2U 0 T@, !D M ( !%"P 'AL+W=O&PO=V]R:W-H965T MHO !X;"]W;W)K&UL4$L! A0# M% @ B8A,3;&[Q 6U 0 T@, !D ( !U3$ 'AL+W=O M&PO=V]R:W-H965T[1[M $ -(# 9 " :TU M !X;"]W;W)K&UL4$L! A0#% @ B8A,3:2< MILJT 0 T@, !D ( !F#< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ B8A,37VNQ#BS 0 T@, !D M ( !;3T 'AL+W=O&PO M=V]R:W-H965T_;TP$ M )P$ 9 " 4)! !X;"]W;W)K&UL4$L! A0#% @ B8A,3<3A#9NX 0 T@, !D ( ! M3$, 'AL+W=O&PO=V]R:W-H965TA , )00 9 M " 2=' !X;"]W;W)K&UL4$L! A0#% M @ B8A,3=\$NRB% P "Q !D ( !XDH 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ B8A,31*_]O1H P E X !D M ( !$E\ 'AL+W=O&PO=V]R M:W-H965TE ( %D) M 9 " 7UE !X;"]W;W)K&UL M4$L! A0#% @ B8A,32<$X!C% @ * H !D ( !2&@ M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MB8A,37"-P/:/ @ 30D !D ( !^6\ 'AL+W=O&UL4$L! A0#% @ B8A,32@&%.$@ @ M508 !D ( !OW@ 'AL+W=OP >&PO=V]R:W-H965T 9 " :9^ !X;"]W;W)K&UL4$L! A0#% @ B8A,38]I]0+? 0 &@4 !D M ( !(80 'AL+W=O&PO=V]R:W-H M965T* !X;"]W;W)K&UL4$L! M A0#% @ B8A,34WUDC*B! BA8 !D ( !L(T 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ B8A, M391Y)R30;@ 4PT" !0 ( !5Y< 'AL+W-H87)E9%-T&UL4$L! A0#% @ B8A,330:440Y @ ?PH T M ( !608! 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% M @ B8A,31;_3#;: 0 FQX !H ( !-@T! 'AL+U]R96QS M+W=O XML 64 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 137 216 1 true 56 0 false 11 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.aceto.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.aceto.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.aceto.com/role/CondensedConsolidatedBalanceSheetsParentheticals CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Sheet http://www.aceto.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Statements 4 false false R5.htm 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) Sheet http://www.aceto.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) Statements 5 false false R6.htm 006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Sheet http://www.aceto.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Statements 6 false false R7.htm 007 - Disclosure - Basis of Presentation Sheet http://www.aceto.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 008 - Disclosure - Restatement of Previously Issued Financial Statements Sheet http://www.aceto.com/role/RestatementOfPreviouslyIssuedFinancialStatements Restatement of Previously Issued Financial Statements Notes 8 false false R9.htm 009 - Disclosure - Business Combinations Sheet http://www.aceto.com/role/BusinessCombinations Business Combinations Notes 9 false false R10.htm 010 - Disclosure - Stock-Based Compensation Sheet http://www.aceto.com/role/StockBasedCompensation Stock-Based Compensation Notes 10 false false R11.htm 011 - Disclosure - Capital Stock Sheet http://www.aceto.com/role/CapitalStock Capital Stock Notes 11 false false R12.htm 012 - Disclosure - Net (Loss) Income Per Common Share Sheet http://www.aceto.com/role/NetLossIncomePerCommonShare Net (Loss) Income Per Common Share Notes 12 false false R13.htm 013 - Disclosure - Debt Sheet http://www.aceto.com/role/Debt Debt Notes 13 false false R14.htm 014 - Disclosure - Commitments, Contingencies and Other Matters Sheet http://www.aceto.com/role/CommitmentsContingenciesAndOtherMatters Commitments, Contingencies and Other Matters Notes 14 false false R15.htm 015 - Disclosure - Fair Value Measurements Sheet http://www.aceto.com/role/FairValueMeasurements Fair Value Measurements Notes 15 false false R16.htm 016 - Disclosure - Recent Accounting Pronouncements Sheet http://www.aceto.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 16 false false R17.htm 017 - Disclosure - Segment Information Sheet http://www.aceto.com/role/SegmentInformation Segment Information Notes 17 false false R18.htm 018 - Disclosure - Income Taxes Sheet http://www.aceto.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 019 - Disclosure - Subsequent Events Sheet http://www.aceto.com/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 020 - Disclosure - Accounting Policies (Policies) Sheet http://www.aceto.com/role/AccountingPoliciesPolicies Accounting Policies (Policies) Policies http://www.aceto.com/role/RecentAccountingPronouncements 20 false false R21.htm 021 - Disclosure - Restatement of Previously Issued Financial Statements (Tables) Sheet http://www.aceto.com/role/RestatementofPreviouslyIssuedFinancialStatementsTables Restatement of Previously Issued Financial Statements (Tables) Tables http://www.aceto.com/role/RestatementOfPreviouslyIssuedFinancialStatements 21 false false R22.htm 022 - Disclosure - Net (Loss) Income Per Common Share (Tables) Sheet http://www.aceto.com/role/NetLossIncomePerCommonShareTables Net (Loss) Income Per Common Share (Tables) Tables http://www.aceto.com/role/NetLossIncomePerCommonShare 22 false false R23.htm 023 - Disclosure - Debt (Tables) Sheet http://www.aceto.com/role/DebtTables Debt (Tables) Tables http://www.aceto.com/role/Debt 23 false false R24.htm 024 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.aceto.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.aceto.com/role/FairValueMeasurements 24 false false R25.htm 025 - Disclosure - Segment Information (Tables) Sheet http://www.aceto.com/role/Segmentinformationtables Segment Information (Tables) Tables http://www.aceto.com/role/SegmentInformation 25 false false R26.htm 026 - Disclosure - Restatement of Previously Issued Financial Statements (Condensed consolidated balance sheet, including balances originally reported, corrections and restated balances) (Detail) Sheet http://www.aceto.com/role/RestatementOfPreviouslyIssuedFinancialStatementsCondensedConsolidatedBalanceSheetIncludingBalancesOriginallyReportedCorrectionsAndRestatedBalancesDetail Restatement of Previously Issued Financial Statements (Condensed consolidated balance sheet, including balances originally reported, corrections and restated balances) (Detail) Details http://www.aceto.com/role/RestatementofPreviouslyIssuedFinancialStatementsTables 26 false false R27.htm 027 - Disclosure - Restatement of Previously Issued Financial Statements (Condensed consolidated statements of (loss) income, including balances originally reported, corrections and restated balances (Detail 1) Sheet http://www.aceto.com/role/RestatementOfPreviouslyIssuedFinancialStatementsCondensedConsolidatedStatementsOfLossIncomeIncludingBalancesOriginallyReportedCorrectionsAndRestatedBalancesDetail1 Restatement of Previously Issued Financial Statements (Condensed consolidated statements of (loss) income, including balances originally reported, corrections and restated balances (Detail 1) Details http://www.aceto.com/role/RestatementofPreviouslyIssuedFinancialStatementsTables 27 false false R28.htm 028 - Disclosure - Restatement of Previously Issued Financial Statements (Condensed consolidated statements of comprehensive income, including balances originally reported, corrections and restated balances) (Detail 2) Sheet http://www.aceto.com/role/RestatementOfPreviouslyIssuedFinancialStatementsCondensedConsolidatedStatementsOfComprehensiveIncomeIncludingBalancesOriginallyReportedCorrectionsAndRestatedBalancesDetail2 Restatement of Previously Issued Financial Statements (Condensed consolidated statements of comprehensive income, including balances originally reported, corrections and restated balances) (Detail 2) Details http://www.aceto.com/role/RestatementofPreviouslyIssuedFinancialStatementsTables 28 false false R29.htm 029 - Disclosure - Restatement of Previously Issued Financial Statements (Condensed consolidated statements of cash flows from operating activities, including balances originally reported, corrections and restated balances) (Detail 3) Sheet http://www.aceto.com/role/RestatementOfPreviouslyIssuedFinancialStatementsCondensedConsolidatedStatementsOfCashFlowsFromOperatingActivitiesIncludingBalancesOriginallyReportedCorrectionsAndRestatedBalancesDetail3 Restatement of Previously Issued Financial Statements (Condensed consolidated statements of cash flows from operating activities, including balances originally reported, corrections and restated balances) (Detail 3) Details http://www.aceto.com/role/RestatementofPreviouslyIssuedFinancialStatementsTables 29 false false R30.htm 030 - Disclosure - Restatement of Previously Issued Financial Statements (Narrative) (Detail) Sheet http://www.aceto.com/role/RestatementOfPreviouslyIssuedFinancialStatementsNarrativeDetail Restatement of Previously Issued Financial Statements (Narrative) (Detail) Details http://www.aceto.com/role/RestatementofPreviouslyIssuedFinancialStatementsTables 30 false false R31.htm 031 - Disclosure - Business Combinations (Narrative) (Detail) Sheet http://www.aceto.com/role/BusinessCombinationsNarrativeDetail Business Combinations (Narrative) (Detail) Details http://www.aceto.com/role/BusinessCombinations 31 false false R32.htm 032 - Disclosure - Stock Based Compensation (Narrative) (Detail) Sheet http://www.aceto.com/role/StockBasedCompensationNarrativeDetail Stock Based Compensation (Narrative) (Detail) Details 32 false false R33.htm 033 - Disclosure - Capital Stock (Narrative) (Detail) Sheet http://www.aceto.com/role/CapitalStockNarrativeDetail Capital Stock (Narrative) (Detail) Details http://www.aceto.com/role/CapitalStock 33 false false R34.htm 034 - Disclosure - Net (Loss) Income Per Common Share (Reconciliation of Weighted Average Shares Outstanding and Diluted Weighted Average Shares Outstanding) (Detail) Sheet http://www.aceto.com/role/NetLossIncomePerCommonShareReconciliationOfWeightedAverageSharesOutstandingAndDilutedWeightedAverageSharesOutstandingDetail Net (Loss) Income Per Common Share (Reconciliation of Weighted Average Shares Outstanding and Diluted Weighted Average Shares Outstanding) (Detail) Details http://www.aceto.com/role/NetLossIncomePerCommonShareTables 34 false false R35.htm 035 - Disclosure - Net (Loss) Income Per Common Share (Narrative) (Detail) Sheet http://www.aceto.com/role/NetLossIncomePerCommonShareNarrativeDetail Net (Loss) Income Per Common Share (Narrative) (Detail) Details http://www.aceto.com/role/NetLossIncomePerCommonShareTables 35 false false R36.htm 036 - Disclosure - Debt (Summary of Long-term Debt) (Detail) Sheet http://www.aceto.com/role/DebtSummaryOfLongTermDebtDetail Debt (Summary of Long-term Debt) (Detail) Details http://www.aceto.com/role/DebtTables 36 false false R37.htm 037 - Disclosure - Debt (Summary carrying value of Notes) (Detail 1) Notes http://www.aceto.com/role/DebtSummaryCarryingValueOfNotesDetail1 Debt (Summary carrying value of Notes) (Detail 1) Details http://www.aceto.com/role/DebtTables 37 false false R38.htm 038 - Disclosure - Debt (Summary interest expense related to notes recognized) (Detail 2) Notes http://www.aceto.com/role/DebtSummaryInterestExpenseRelatedToNotesRecognizedDetail2 Debt (Summary interest expense related to notes recognized) (Detail 2) Details http://www.aceto.com/role/DebtTables 38 false false R39.htm 039 - Disclosure - Debt (Narrative) (Detail) Sheet http://www.aceto.com/role/DebtNarrativeDetail Debt (Narrative) (Detail) Details http://www.aceto.com/role/DebtTables 39 false false R40.htm 040 - Disclosure - Debt (Narrative) (Detail 1) Sheet http://www.aceto.com/role/DebtNarrativeDetail1 Debt (Narrative) (Detail 1) Details http://www.aceto.com/role/DebtTables 40 false false R41.htm 041 - Disclosure - Debt (Narrative) (Detail 2) Sheet http://www.aceto.com/role/DebtNarrativeDetail2 Debt (Narrative) (Detail 2) Details http://www.aceto.com/role/DebtTables 41 false false R42.htm 042 - Disclosure - Debt (Narrative) (Detail 3) Sheet http://www.aceto.com/role/DebtNarrativeDetail3 Debt (Narrative) (Detail 3) Details http://www.aceto.com/role/DebtTables 42 false false R43.htm 043 - Disclosure - Commitments, Contingencies and Other Matters (Narrative) (Detail) Sheet http://www.aceto.com/role/CommitmentsContingenciesAndOtherMattersNarrativeDetail Commitments, Contingencies and Other Matters (Narrative) (Detail) Details http://www.aceto.com/role/CommitmentsContingenciesAndOtherMatters 43 false false R44.htm 044 - Disclosure - Fair Value Measurements (Summary of Valuation of Financial Assets and Liabilities) (Detail 1) Sheet http://www.aceto.com/role/FairValueMeasurementsSummaryOfValuationOfFinancialAssetsAndLiabilitiesDetail1 Fair Value Measurements (Summary of Valuation of Financial Assets and Liabilities) (Detail 1) Details http://www.aceto.com/role/FairValueMeasurementsTables 44 false false R45.htm 045 - Disclosure - Fair Value Measurements (Parentheticals) (Summary of Valuation of Financial Assets and Liabilities) (Detail 1) Sheet http://www.aceto.com/role/FairValueMeasurementsParentheticalsSummaryOfValuationOfFinancialAssetsAndLiabilitiesDetail1 Fair Value Measurements (Parentheticals) (Summary of Valuation of Financial Assets and Liabilities) (Detail 1) Details http://www.aceto.com/role/FairValueMeasurementsTables 45 false false R46.htm 046 - Disclosure - Fair Value Measurements (Narrative) (Detail) Sheet http://www.aceto.com/role/FairValueMeasurementsNarrativeDetail Fair Value Measurements (Narrative) (Detail) Details http://www.aceto.com/role/FairValueMeasurementsTables 46 false false R47.htm 047 - Disclosure - Recent Accounting Pronouncements (Narrative) (Detail) Sheet http://www.aceto.com/role/RecentAccountingPronouncementsNarrativeDetail Recent Accounting Pronouncements (Narrative) (Detail) Details 47 false false R48.htm 048 - Disclosure - Segment Information (Summary of Segment Perfomance Measures by Segment) (Detail) Sheet http://www.aceto.com/role/SegmentInformationSummaryOfSegmentPerfomanceMeasuresBySegmentDetail Segment Information (Summary of Segment Perfomance Measures by Segment) (Detail) Details http://www.aceto.com/role/Segmentinformationtables 48 false false R49.htm 049 - Disclosure - Segment Information (Narrative) (Detail) Sheet http://www.aceto.com/role/SegmentInformationNarrativeDetail Segment Information (Narrative) (Detail) Details http://www.aceto.com/role/Segmentinformationtables 49 false false R50.htm 050 - Disclosure - Income Taxes (Narrative) (Detail) Sheet http://www.aceto.com/role/IncomeTaxesNarrativeDetail Income Taxes (Narrative) (Detail) Details http://www.aceto.com/role/IncomeTaxes 50 false false All Reports Book All Reports acet-20180331.xml acet-20180331.xsd acet-20180331_cal.xml acet-20180331_def.xml acet-20180331_lab.xml acet-20180331_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 69 0001144204-18-053676-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-18-053676-xbrl.zip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end